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 Recently, phage lytic enzymes (also known as endolysins or, simply, 
lysins) have received considerable attention as potential antibacterial agents.  
During the infective cycle of double-stranded DNA phage, these peptidoglycan 
hydrolases are responsible for digesting the cell wall of the host bacterium and 
freeing newly-assembled viral particles.  At the same time, an increasing body of 
evidence has demonstrated that recombinantly-purified phage lysins—when 
added exogenously—can potently kill Gram-positive bacteria, whose 
peptidoglycan is accessible from the extracellular space.  Consequently, lysins 
have been proposed as novel enzybiotic (i.e. enzyme-antibiotic) molecules that 
could serve as novel weapons in the fight against drug-resistant bacteria.  Most 
lysins characterized to date were initially identified through either recombinant 
screening or DNA-sequencing of phage genomes.  Recent technological and 
methodological advances, however, have drastically increased the potential 
avenues for lysin identification.  The goal of the work presented here to exploit 
and expand upon these advances so that the identification of new lysins is 
increasingly rapid and straightforward. 
 This thesis is subdivided into four interrelated sections, each of which 
represents a distinct study into a novel approach/method for cloning phage 
lysins.  The first study (Chapter 2) addresses the issue of bacterial genomic 
sequencing and how the rapidly expanding database of bacterial genomes 
represents a vast source of proviral lysins.  Focusing on the anaerobic pathogen 
Clostridium perfringens, the genomes of 9 recently-sequenced strains were 
computationally mined for prophage lysins and lysin-like ORFs (open reading 
frames), revealing several dozen proteins of various enzymatic classes.  Of these 
lysins, a muramidase (termed PlyCM) from strain ATCC 13124 was chosen for 
recombinant analysis based on its dissimilarity to the only other previously-
characterized C. perfringens lysin.  Following expression and purification, various 
biochemical properties of PlyCM were determined in vitro, including pH/salt-
dependence and temperature stability.  The enzyme exhibited activity at low 
g/ml concentrations, and it was active against 23/24 strains of C. perfringens 
tested. 
Chapters 3 and 4 focus on the emerging field of viral metegenomics, a term 
which refers to the bulk extraction and analysis of DNA from environmental 
phage without prior laboratory culture of any particular virus.  Phage 
metagenomes have been shown to be incredibly complex and diverse, and the 
goal of these chapters was to tap into this diversity through functional 
metagenomic screens for lytic enzymes. Chapter 3 first addresses a preliminary 
methodological issue, namely the fact that uncultured phage samples generally 
do not provide sufficient quantities of DNA for ready screening.  A novel E-
LASL protocol (for expressed linker amplified shotgun library) was developed 
that combines linker amplification of enzyme-digested DNA with subsequent 
topoisomerase cloning into linearized expression plasmids.  As proof-of-
principle, genomic and metagenomic E-LASLs were constructed and screened 
for antibacterial and hemolytic activity in an Escherichia coli host.  Six Bacillus 
anthracis phage lysins were cloned in the process, along with a virulence factor of 
the aerolysin gene family. 
Chapter 4 proceeds to address an additional methodological issue 
surrounding metagenomic lysin identification: the question of how to identify 
lysin-encoding clones in a functional screen when the targeted bacteria are not 
pre-defined.  A novel two-step screening technique was devised for this purpose.  
It involves a primary screen in which transformed E. coli clones were identified 
that demonstrated colony lysis following exposure to nebulized inducing agent.  
This effect, which can be due to the expression of membrane-permeabilizing 
phage holins, was discerned by the development a hemolytic-effect in 
surrounding blood agar.  The selected clones were then overlaid with autoclaved 
Gram-negative bacteria (specifically Pseudomonas aeruginosa) to assay directly for 
recombinant expression of lytic enzymes, which are often encoded proximally to 
holins in phage genomes.  This method was combined with the aforementioned 
E-LASL technique and applied to a viral metagenomic library constructed from 
mixed animal feces.  Twenty-six lytic enzymes were cloned in this screen, 
including both Gram-positive-like and Gram-negative-like enzymes, as well as 
several atypical lysins whose predicted structures are less common among 
known phage.   
Finally, Chapter 5 takes the above techniques and reapplies them outside 
the context of metegenomics, returning to individual genomes as sources of lytic 
enzymes.  Specifically, 2 lysins were cloned from prophage of Streptococcus suis, 
an important veterinary and emerging zoonotic pathogen.  One of these S. suis 
enzymes (PlySs1) was identified by applying the two-step screen to the genome 
of an unsequenced clinical strain.  The other (PlySs2) was identified in a manner 
similar to the clostridial lysin PlyCM, by analyzing the published genomes of 
various sequenced strains.  Finally, PlySs1 was subject to chromatographic 
purification and in vitro analysis against numerous suis and non-suis strains of 
streptococci.  Currently, both PlySs1 and PlySs2 are involved in a collaborator’s 
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BACTERIOPHAGE AND THEIR BIOLOGY 
 Nearly a century has now passed since the initial discovery of 
bacteriophages, a term that has come to encompass any virus that infects a 
bacterial host.  In 1915, Frederick Twort reported that filtered suspensions of 
environmental samples were capable of producing ―glassy areas‖ on plates of 
Micrococcus, and he proposed a bacterial virus as one of several possible causes 
(Twort 1915).  Two years later, similar findings were reported for enteric bacilli 
by Felix d‘Herelle, who was more adamant of the viral nature of the 
2 
 
phenomenon (1917).  It was d‘Herelle, in fact, who originally coined the term 
bacteriophage, derived from Greek and signifying bacteria-eater.  At that time, it 
would have been difficult to predict the global significance of these viruses and 
the massive body of research that would go into studying their biology and 
applications.   Bacteriophages (or phages) are crucial players in bacterial ecology 
and pathogenesis; they were important experimental tools in the development of 
the modern field of molecular biology; and they—along with the proteins they 
produce—can be utilized for various biotechnological and biomedical purposes, 
many of which have become evident only recently.  It is this latter area of applied 
phagology that is the focus of the present thesis. 
 
Bacteriophage taxonomy.  Phages can be subdivided into several families (see 
Figure 1.1) based on their structural morphology and the nature of their genetic 
material (Fauquet et al. 2005).  The large majority of the 5000+ phages examined 
to date belongs to the order Caudovirales (Ackermann and Abedon 2001), defined 
as non-enveloped viruses with protein tails and linear, dsDNA genomes 
(ranging from tens to 100+ kb in length).  The caudoviruses are further 
subdivided into three families based on their specific tail-architecture:  
Siphoviridae—long, noncontractile tails; Myoviridae—intermediate length, 
contractile tails; and Podoviridae—short, noncontractile tails.  Outside the 
caudoviruses, there exist several non-tailed families of phages with more 




Figure 1.1a Phage Morphologies—Caudoviruses 
Phage in the order Caudovirales possess linear, dSDNA genomes and 
proteinacious tails.  The order is divided into the above three families 




Figure 1.1b Phage Morphologies—Lipidic dsDNA Phage 
The tectiviruses and corticoviruses both possess external icosehedral capsids with a 
lipid membrane lying directly beneath (not evident in the above images).  The two 
families differ in terms of capsid and genome organization.  Whereas the 
corticovirus genome is circular and highly supercoiled, the tectivirus genome is 
linear with terminal inverted repeats.  
 
By contrast, the plasmaviruses possess an external lipid envelope, a pleomorphic 
geometry, and a circular genome.  They are only known to infect the mycoplasmal 
genus Acholeplasma. 
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Inovirus (Filamentous Phage) 
Microvirus 
Figure 1.1c Phage Morphologies—ssDNA Phage 
The inoviruses consist of a non-enveloped rod of filaments surrounding a 
circular, ssDNA genome. The microviruses possess a linear, ssDNA genome 
and a non-enveloped, icosehedral capsid. 
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Figure 1.1d Phage Morphologies—RNA Phage 
The cystoviruses possess a linear, segmented, dsRNA genome.  They are 
charactarized by a double capsid with a surrounding lipid envelope.  The 
leviviruses possess a linear, positive-stranded, ssRNA genome and a non-
enveloped, spherical capsid. 
Cystovirus 
NOTE: The preceding images were taken, with permission, from the ViralZone 
website (www.expasy.org/viralzone, Swiss Institute of Bioinformatics).  It should 
also be noted that three other phage families are known to exist in addition to the 
ones pictures above (Lipothrixoviridae, Fuselloviridae, and Rudiviridae).  These 
viruses, however, are only known to infect archaea and are not considered here 






These include several other DNA phages: Tectiviridae and Corticoviridae—
dsDNA, possessing a lipid membrane internal to the capsid; Plasmaviridae—
dsDNA, possessing an external lipid envelope; Inoviridae—ssDNA with a 
filamentous morphology; and Microviridae—ssDNA with an icosahedral 
morphology.  Phage families with RNA genomes include: Cystoviridae—dsRNA 
with an enveloped capsid; and Levivirus—ssRNA with a non-enveloped capsid.   
The caudoviruses possess by far the broadest range of known hosts, and 
examples have been defined that infect virtually all bacterial phyla.  For any 
single caudovirus, however, the host range is often limited to a particular 
bacterial species or a subset of strains within that species.  Nonetheless, a number 
of phages have been observed that infect various species within a given genus or 
even across genera (Hyman and Abedon 2010).  For the non-caudoviral phage 
families, the taxonomic range of hosts (at least among phage isolated to date) is 
far narrower.  For example, the tectiviruses are the only non-caudoviral family 
known to infect Gram-positive bacteria, and several phage families 
(plasmaviruses, cystoviruses, corticoviruses) have only been defined for a single 
bacterial genus (Fauquet et al. 2005). 
 
Phage life-style.  In terms of the bacteriophage lifecycle, various examples have 
been observed among the above taxonomic families.  These range from 
replication and extrusion in the absence of host death (in the case of the 
filamentous inoviruses, Calendar and Inman 2005) to rapid and complete host 
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lysis.  For some of the rarer phage families, relatively few details are known on 
the molecular level.  And even for the ubiquitous caudoviruses, the majority of 
mechanistic information is defined for model viruses (often E. coli  phages), and 
these details do not necessarily apply universally.  Broadly speaking, though, the 
lifecycle of the tailed phages can be broken down into two possible categories: 
lytic and lysogenic.  The lytic (or virulent) phages co-opt the host‘s 
transcriptional apparatus following DNA injection, replicating and assembling 
within in the cytoplasm and inducing bacteriolysis from within.  Within 30 
minutes of initial infection, up to several hundred progeny viruses are released 
and the life-cycle begins anew (Karam 1994).  Macroscopically, the tell-tale sign 
of actively-lysing phages is the clearing zone, or plaque, that results on a lawn of 
host bacteria (Figure 1.2).  (The molecular mediators of host lysis—phage lytic 
enzymes—are the principle focus of this thesis and are described later in much 
greater detail). 
By contrast, lysogenic (or temperate) phages are faced with a decision 
following infection: either they can [1] begin the above lytic cycle or [2] enter into 
a proviral state in which their DNA is incorporated into the host genome (Figure 
1.3).  The latter pathway is possible because these phages encode regulators that 
repress transcription of lytic-pathway proteins (Little 2005).  Lysogenic phages 
also typically encode an integrase that is responsible for the site-specific 
recombination of their genome into the bacterial chromosome (van Duyne 2005).   
Figure 1.2 Phage Plaques 
In this image, purified lytic phage have been dropped onto a lawn of their host 
bacteria.  The resulting clearing zones are known as plaques.  The majority of the 
above plaques are considered macro-plaques; here, the initial titer of phage was so 
high that it is impossible to differentiate individual plaque-forming-units (PFUs).  
At the bottom of the image, however, several micro-plaques are evident (indicated 
with arrow).  Each one is derived an single ancestral phage (i.e. each micro-plaque 
is clonal).  NOTE: The above image originally appeared in Abshire et al. (2005).  It 
has been reproduced here with permission (American Society for Microbiology, 
Licensing Number 2482280006256). 
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Figure 1.3 Lysogeny Versus Lysis 
Upon initial infection, lysogenic phage may either begin the lytic cycle or enter 
into a proviral state (the lysogenic cycle).  These alternate pathways are depicted 
above for E. coli and its -phage.  In the image, the cos site of the phage genome is 
noted; this refers to the terminal portions of the linear DNA molecule that 
circularize prior to recombination with the host chromosome.  NOTE: The above 
image originally appeared in Campbell (2003).  It has been reproduced here with 




Alternatively, some lysogenic phages do not physically integrate their DNA; 
rather, their genomes independently propagate in the host cytoplasm as linear 
(Ravin 2003) or circularized (Bourhy et al. 2005) episomes.  It must be 
emphasized that the individual molecular steps governing lysogenization 
represent an expansive field onto itself (Ptashne 1994).  Very broadly stated, the 
lysogeny-versus-lysis decision is governed by a combination of probabilistic 
factors, the number of infecting viral particles, and the host bacterium‘s 
metabolic status at the time of infection (Zeng et al. 2010). 
Prophages can replicate for numerous generations within the host without 
synthesis of progeny viral particles.  At some point, however, reactivation may 
take place: the phage genome is excised from the chromosome and viral 
replication commences, culminating in host lysis.  The stimulus for reactivation is 
typically DNA damage (chemical or UV-induced) or other physiological 
stressors on the host.  The best-characterized molecular pathway involves the 
bacterial SOS system, a response to damage-induced ssDNA in the cell (Little 
and Mount 1982).  Even in the absence of stressors, some prophages will reactive 
spontaneously within their host, albeit at a far less frequent rate (~10-4 to 10-5 
cells, Little 2005).   
Conversely, other prophages may remain incorporated for such an 
extended period that they decay and lose their ability to reactivate, becoming 
defective (or cryptic) (Casjens 2003).  More recent research has indicated that 
prophage DNA, both intact and defective, may occasionally excise itself from the 
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chromosome without completion of the lytic pathway.  This phenomenon was 
exploited as an elegant experimental means of curing a polylysogenized bacterial 
strain of its prophages in vitro (Euler 2010). 
 
Phage ecology.  With the complex interplay between phage and host, it is hardly 
surprising that phages are crucial players in the field of microbial ecology.  In 
fact, the importance of phage in shaping the global microbiome cannot be 
understated, especially when one considers the ubiquity of these viruses within 
the environment.  The numbers that have been reported on the topic are truly 
staggering: it is thought that 1031 phage particles exist globally (the majority 
residing in the oceans); there are up to 10 phages for every single bacterium on 
earth; an estimated 1023 phage infections occur every second; and ~20% of the 
marine biomass is turned over every day by phages (Suttle 2007; Hatfull 2008).  
Resultantly, phages are major participants in biogeochemical pathways, 
particularly when it comes to the solubilization of biomass and the dynamics of 
carbon respiration/fixation (Abedon 2006). 
On the level of individual bacterial species and their genotypic and/or 
phenotypic properties, phages likewise serve crucial roles.  In general, the 
movement of genetic information between cells via phages, transduction, is one 
major modes of horizontal gene transfer that exist for bacteria (Birge 2006).  This 
includes both generalized transduction, in which bacterial DNA is mistakenly 
packaged into the phage capsid, as well as specialized transduction, in which a 
13 
 
prophage DNA excises itself from the bacterial genome but takes with it a stretch 
of adjacent chromosome.  Lysogenization in itself can also lead to the acquisition 
of important genetic material.  Although many viral genes are repressed in the 
proviral state (e.g. structural and lytic cassettes), this is not true for all prophage 
genes (Canchaya et al. 2004).  Various prophage transcripts are expressed, 
including ones that can affect the behavior of the host and its ability to survive, 
proliferate, and infect (Broudy and Fischetti 2003). 
  The relationship between lysogenization and bacterial phenotype is 
particularly characterized as it relates to the virulence of bacterial pathogens 
(Breitbart et al. 2005).  A number of pathogenic bacterial species have been 
identified for which a crucial virulence factor is prophage-encoded or included 
on chromosomal islands that have evolved from prophage (Novick et al. 2010).  
These include: shiga toxin for enterohemorrhagic E. coli, cholera toxin for Vibrio 
cholera, and superantigents for toxic shock-inducing Streptococcus pyogenes.  The 
preceding list is far from exhaustive, however, and new phage-encoded 
virulence factors are often identified  (for a more complete review of the topic, 
the reader is referred to Boyd and Brüssow 2002 or Chapters 7 - 18 of Waldor et 
al. 2005).  Prophages could likewise enhance the ability of bacterial pathogens to 
persist in environmental reservoirs, as was recently proposed for Bacillus 





PHAGE IN BIOTECHNOLOGY AND BIOMEDICINE 
 The field of phage biology is clearly diverse, incorporating aspects of 
molecular genetics, ecology, and infectious disease.  (The discussion to this point 
has not even touched upon the areas of bacteriophage evolution and interphage 
recombination, see Hendrix 2002 or 2005).  At the same time, the above topics are 
all connected in that each one attempts to study phages in their own right.  Basic 
phage research, however, is only one side of the coin as to why investigators are 
so interested in these microscopic juggernauts.  Since their discovery, phages 
have also been utilized as experimental tools for answering broader questions 
facing the scientific community.  Applied phage research is equally expansive, as 
phages and phage-products can serve in a variety of manners as industrial and 
biomedical agents.  Illustrated in the following section, these other aspects of 
phage science have their own rich histories, ones that are still actively unfolding. 
  
Phages and molecular biology.  First and foremost, any discussion of phage-as-
tools would be incomplete without mentioning their indispensible role in the 
development of the field of modern molecular biology.  A number of classic 
experiments establishing the molecular principles of genetics were dependent on 
bacteriophages as model ―organisms.‖  For instance, the nature of genetic 
mutations was revealed by experiments involving the de novo generation of 
phage resistance in E. coli (Luria and Delbruck 1943; Lederberg and Lederberg 
1952).  Following the initial identification of DNA as the heritable genetic 
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material (Avery et al. 1944), important confirmatory evidence was provided by 
Hershey and Chase using selective radiolabelling of the T2 phage (1952).  And 
the triplet nature of DNA code was subsequently established by Crick et al. by 
observing the altered plaque morphologies following mutagenesis of the T4 
phage (1961). 
 Moving ahead, while the discipline of molecular biology is now well-
established, phages are still intimately involved in day-to-day research efforts.  A 
variety of common laboratory reagents (primarily involved in nucleic acid 
modification) are recombinantly-expressed enzymes originating from phages.  
These include benchtop staples such T4 DNA ligase and polynucleotide kinase, 
as well as more recent additions such as Bacillus phage φ29 polymerase (a highly 
processive polymerase used in whole-genome amplification).  A review of 
phage-encoded proteins that could serve as applied tools was recently provided 
by Schoenfeld et al. (2010).  
 It is important to emphasize that a great deal of current research in 
molecular biology (including this thesis) involves the functional screening of 
DNA libraries to identity proteins with targeted properties.  Phage-based cloning 
systems are commonplace in this regard.  In fact, one of the first widespread 
cloning vectors was the E. coli -phage (Chauthaiwale et al. 1992).  By inserting a 
fragmented DNA library into a specific position in the -genome (followed by in 
vitro viral packaging and host infection), one could generate a large set of clonal 
plaques, each encoding and expressing a unique recombinant insert.   
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In large part, -libraries have given way to other generalized cloning 
methods (involving plasmids, cosmids, and artificial chromosomes).  
Nevertheless, a related screening technique is still widely used for elucidating 
protein-ligand and peptide-ligand interactions: phage display (Paschke 2006; 
Gupta et al. 2005).  Here, a DNA-library is ligated in-frame with a phage‘s coat 
protein (both filamentous and tailed phages have been used).  This generates a 
set of recombinant phages, which are exposed in bulk to a molecular target 
immobilized on a solid interface.  Phages that bind the target via their surface 
fusion-protein are isolated, enriched, and identified through subsequent rounds 
of infection and selection.  Outside of basic scientific discovery, applications of 
phage display include the identification of drugs and drug targets, as well as the 
development of molecular imaging agents (Newton and Deutscher 2008).  
 
Phage typing.  While -cloning and phage display involve the generation of 
genetically-modified viruses, other important applications utilize wild-type 
phages for generating information.  In the fields of epidemiology and clinical 
microbiology, susceptibility to phage infection is a classic method of typing 
bacterial strains on the sub-species level.  By analyzing which phages (from a 
predefined panel) are capable of infecting a bacterial isolate, it is possible to track 
the flow of pathogens within the human population.  Most notably, phage typing 
is used in the study of Salmonella strains (Threllfall and Frost 1990), although 
schemes for other bacteria have been reported (Engel 1978, Mokrousov 2009).  In 
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a related application, the specificity that a phage demonstrates for a particular 
host can be utilized to identify an unknown bacterial isolate.  For example, while 
clinical isolations are admittedly rare, a classic test for the positive identification 
of B. anthracis involves its susceptibility to infection by -phage (Brown and 
Cherry 1955; Abshire 2005).  More recently, culture-free methods for the rapid 
identification of bacterial pathogens have been developed that rely upon ELISA-
based detection of selectively-amplified phages (Rees and Dodd 2006; 
www.microphage.com). 
 
Phage therapy.  With these diverse applications, researchers have clearly 
exploited bacteriophages in creative and sophisticated ways.  At the same time, 
there exists another avenue of applied phage research that—while tremendous in 
its potential benefits—is theoretically quite straightforward.  Simply put, phages 
have the ability to kill bacteria, and bacteria have the ability to cause infections… 
therefore, phages might be used to treat infections!  In fact, the idea of phage 
therapy dates back nearly as long as the discovery of phages themselves.  Shortly 
after his (co)discovery of these viruses, d‘Herelle began employing them to treat 
human infections, often with a great deal of reported success.  These include his 
oft-cited application of phages to treat cases of Shigella dysentery in Paris in 1919, 
as well as later work with cholera and plague patients in India (Summers 1999).  
In 1923 he founded along with Georgian microbiologist Giorgi Eliava (who 
shortly after was executed by Stalin-era Soviet agents) the International 
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Bacteriophage Institute in Tbilisi, a center dedicated to phage-based treatment of 
infectious disease.  
In the years that followed, the future for phage-as-pharmaceuticals 
seemed incredibly bright.  (For more detailed historic and scientific information 
on phage therapy—from its beginnings to the present day—the reader is referred 
to numerous recent review articles and book chapters: Abedon et al. 2010 and 
accompanying articles; Górski et al. 2009; Housby and Mann 2009; Górski 2007; 
Merril et al. 2006; Sulakvelidze and Kutter 2005; McKinstry and Edgar 2005; 
Sulakvelidze et al. 2001; Chanishvili et al. 2001; Summers 2001; Carlton 1999).  By 
the early 1940‘s, more than 100 publications had been devoted to phage therapy 
(Krueger and Scribner 1941; Eaton and Bayne-Jones 1934), and pharmaceutical 
companies had begun marketing phage-based products in several countries 
(L‘Oréal in France, Behringwerke in Germany, and Eli Lilly in the United States) 
(Häusler 2006).   
Unfortunately, the results and reception of this initial work was mixed at 
best, with variable treatment success-rates and much skepticism among the 
scientific community.  In retrospect, many of the initial problems can be 
attributed to poor purification quality, a lack of proper control groups in clinical 
trials, and insufficient understanding of phage biology (e.g. using lysogenic 
phage instead of strictly lytic phage) (Housby and Mann 2009; Sulakvelidze et al. 
2001).  Nevertheless, these results soon lead to the abandonment of phage-
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therapy research in Western countries, especially in light of the development of 
small-molecule antibiotics that occurred around the same time. 
By contrast, phage therapy continued unabated in Eastern Europe during 
the decades that followed.  This work was especially prominent at the 
aforementioned International Bacteriophage Institute in Georgia (now known as 
the Eliava Institute, www.eliava-institute.org) as well as at the Hirszfeld Institute 
of Immunology and Experimental Therapy in Wroclaw, Poland 
(www.aite.wroclaw.pl/phages/phages.html).  Over the years, these centers 
reported numerous successful trials for various combinations of Gram-positive 
and Gram-negative pathogens and anatomic sites of infection (Sulakvelidze et al. 
2001).  Due to language barriers and cold-war era geopolitical realities, however, 
few of the results reached (or were evaluated by) Western scientists at the time 
the research was conducted.  It is only recently, in fact, that many written 
accounts of Eastern European phage therapy are starting to become available to 
the English-speaking world (Chanishvili 2009). 
This broadened access to data has corresponded to a rekindled global 
interest in phage therapy.  Changing attitudes have been motivated largely by 
the emergence of antibiotic-resistant bacterial pathogens (Wax et al. 2008), along 
with the decreasing efficiency and profitability associated with the development 
of new small-molecule antibiotics (Donadio et al. 2010).  In this light, Western 
scientists began reconsidering phage therapy in earnest during the 1980‘s and 
90‘s.  The initial focus was on animal models of human disease, including rodent 
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and ruminant models of E. coli and Pseudomonas aeruginosa infections (Smith et al. 
1982; Smith et al. 1983; Soothill 1994).  Subsequent model studies dealt with other 
pathogen-animal combinations; a summary of this work was recently provided 
by O‘Flaherty et al (2009).   
Moving ahead rapidly, phage-therapy research in Western nations has 
now progressed to actual human trials.  The first double-blinded clinical study 
involving phage therapy was recently completed in the United Kingdom (Wright 
et al. 2009).  This phase II trial, which involved 24 patients with chronic P. 
aeruginosa otitis media, demonstrated both efficacy and safety in treated patients 
versus controls.  Although efficacy data is still pending, a phase I safety trial was 
likewise recently completed in the United States involving phage treatment of 
venous leg ulcers (Rhoads et al. 2009).  In addition to these studies, done in 
association with (respectively) BioControl Limited and Intralytix Incorporated, a 
number of other biotechnology companies have recently been established that 
are developing phage-therapy products in pre-clinical phases (reviewed in 
Housby and Mann 2009). 
  One should note that this research is taking place alongside—and, often, 
in collaboration with—the continued use of phage therapy in its traditional 
Eastern European bastions.  For instance, a clinical trial is currently underway 
involving the Eliava Institute and Belgian physicians to treat burn infections with 
a cocktail of Staphylococcus and Pseudomonas phages, and initial quality-control 
data has already been reported (Merabishvili et al. 2009).  Various other 
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examples of current phage therapy can be found in the above-mentioned review 
articles.   A corollary message to all this work is that, if an individual patient is 
interested in phage therapy—and is willing to travel and pay—various avenues 
presently exist for obtaining it (www.phagetherapycenter.com). 
It is important to emphasize that the potential utility of phage therapy 
extends beyond the treatment of human disease.  Naturally, the same basic 
principles that apply to infections in man also apply to veterinary infections, and 
phage therapy has been explored as a novel means of treating disease in 
livestock and poultry (Johnson et al. 2008).  The use of phage to treat plant 
pathogens is likewise an intriguing possibility (Balogh et al. 2010), and EPA-
approved phage cocktails are already commercially available for controlling 
Xanthomonas and Pseudomonas infections (i.e. bacterial speck) in tomato and 
pepper plants (omnilytics.com/products/agriphage/agriphage4.html).  In 
general, phage therapy shows great promise in the field of food science, as the 
viruses could be used to prevent spoilage or to curtail the transmission of food-
borne illness.  Just recently, in fact, the Food and Drug Administration approved 
a cocktail of Listeria phage for use as an additive to commercial meat and cheese 
products (FDA Code of Federal Regulations 21CFR172.785). 
At this point, it is worthwhile to consider briefly the relative pros and cons 
of using purified phages as antibacterial agents.  These points are summarized in 
Table 1.1.   
Table 1.1 Advantages and Disadvantages of Phage Therapy 
This table was adapted from O’Flaherty et al. (2009) with permission (John Wiley 
and Sons, Licensing Number 2486030498200). 
Phage advantages Phage disadvantages 
Easy to isolate and propagate 
More complex pharmacology than 
 traditional small-molecule antibiotics 
Can overcome resistance Potentially immunogenic 
Self-replicating 
Subject to degradation as 
  proteinacious compounds 
Act synergistically in a cocktail  
or in combination with other  
antibiotics 
Need to select for virulent phage to 
 prevent genetic transfer 
Inhibits Gram-positive and 
 Gram-negative organisms 
Bacterial strains can develop 
resistance 
Some phage products already 
 have regulatory approval 
Many phages can have a limited 
 host range 
Potential for use in numerous 
 environments (human, animal,  
food, biofilm, etc.) 
Broader regulatory and consumer 
acceptance still required 
Historically have been in use for 
 nearly a century 
Possibility to genetically 
 engineer phage 




The biggest advantage to phage therapy is largely self-evident: namely, that 
phages provide an alternate mechanism for killing bacterial pathogens, 
particularly those that already demonstrate antibiotic resistance.  Phages also 
represent a unique sort of smart antibacterial agent whose concentration naturally 
amplifies itself at the relevant site of infection.  Moreover, given their host 
specificity, phages should not affect commensal and probiotic human flora in the 
same manner as traditional antibiotics, a relevant issue given the increasing 
prevalence of antibiotic-associated illnesses such as Clostridium difficile-associated 
enteritis (Kuijper et al. 2006).  
 An inherent corollary to the latter point is that phage therapy is inherently 
not broad-spectrum, and could not be employed for empiric therapy before the 
causative species of an infection is defined.  Likewise, even for a particular 
bacterial species, not all strains are equally susceptible to different phages.  This 
would necessitate the use of phage cocktails to ensure coverage, a practice that is 
already common in ongoing trials.  If phage therapy were to become widespread, 
an additional concern would involve the potential development of resistance 
among bacteria.  As with small-molecule antibiotics, bacteria are known to 
possess several mechanisms for acquiring resistance to phage infection.  These 
include the variation of surface epitopes (for initial phage binding), the 
horizontal acquisition of restriction enzymes, and the use of CRISPR genomic 
sequences (Hyman and Abedon 2010). 
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Outside these hurdles, the fact the phages are proteinacious particles 
naturally confers more complicated pharmacological parameters (involving 
application, biodistribution, biodegradation, and possible immunogenicity).  
Overall, while such drawbacks would likely preclude it from supplanting the 
role of antibiotics entirely, phage therapy could still serve as an important 
supplementary treatment strategy, particularly in the case of chronic infections 
or when initial options fail. 
 
THE LYTIC ENZYMES OF BACTERIOPHAGES 
 Although it could be considered in a state of product development for nearly 
a century, phage therapy (at least the idea behind it) is a long-established 
antimicrobial strategy.  At the same time, it is not the only phage-based approach 
for fighting bacterial pathogens.  More recently, another strategy has arisen that 
does not utilize phages in their entirety, but rather a particular class of phage-
encoded proteins: the phage lytic enzymes (also known as phage lysins, endolysins, 
or just lysins).  As described previously, the final stage of infection for tailed 
phages involves the lysis of the host cell with release of viral progeny—the phage 
lytic enzymes are molecular facilitators of this event.   
 These enzymes are expressed late in the cycle of phage infection, and they 
are responsible for digesting the peptidoglycan of the host bacterium.  This 
compromises the strength of the cell wall and subjects the bacterium (which 
experiences positive turgor pressure up to 25 atmospheres) to immediate osmotic 
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lysis (i.e. bacteriolysis-from-inside).  Biotechnological interest in phage lysins has 
peaked in recent years after it was shown that exogenously-applied lysin can 
effectively kill Gram-positive bacteria (i.e. bacteriolysis-from-outside).  This 
phenomenon has forced phage lysins into the spotlight as potential anti-infective 
agents in their own right, and has sparked a general interest in enzyme-based 
antibiotics, or enzybiotics.  (As with phage therapy, a number of recent reviews 
have examined the biology and applications of phage lysins, including: Fischetti 
2010; Villa and Veiga-Crespo 2010; Courchesne et al. 2009; O‘Flaherty et al. 2009; 
Fischetti 2008; Hermoso et al. 2007; Fischetti et al. 2006; Borysowski et al. 2006; 
Fischetti 2005a; Fischetti 2005b; Young 2005; and Loessner 2005). 
 
The concept of lysin therapy.  The ability of phage lysins to act as antibacterial 
agents is fundamentally linked to the structure of the bacterial cell envelope.  As 
noted above, the potential targets for lysin therapy would be limited to Gram-
positive species.  Without an outer membrane, their peptidoglycan layer is 
directly accessible to lysin treatment from the extracellular space.  Gram-negative 
bacteria, by contrast, are generally insensitive to lysin treatment due to the 
protective effect of their outer membrane1.  Despite a narrower target range, lytic 
enzymes do offer an important advantage over intact phage: while bacteria have 
co-evolved with predatory phage for millions of years (hence their resistance 
mechanisms), exogenous lysin treatment is an unnatural phenomenon.  
Consequently, the development of resistance should not occur readily— to date, 
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acquired lysin resistant has not been observed in experimental trials (Loeffler et 
al. 2001; Schuch et al. 2002).  Other relative advantages and disadvantages of 
phage lysin therapy are listed in Table 1.2.     
Like intact phage, purified lytic enzymes would provide an alternative 
bactericidal mechanism for antibiotic-resistant pathogens.  Much of the 
excitement surrounding these enzymes stems from the potency and specificity 
they demonstrate toward their particular Gram-positive targets.  In buffered 
solutions (referred to as in vitro conditions), lysins exert a rapid lethal affect at 
low g/ml-concentrations (Schuch et al. 2002; Porter et al. 2007), sometimes even 
less (Nelson et al. 2001).  Within minutes or seconds of lysin addition, a 
concentrated solution of live Gram-positive bacteria will undergo a several log 
decrease in viability with complete loss of turbidity (see Figure 1.4).  Typically, a 
given lysin demonstrates activity against the bacterial species that the encoding 
phage infects (Loeffler et al. 2001), although some cross-reactivity can exist 
toward other species within the same genus or related genera (Nelson et al. 2001; 
Yoong et al. 2004).  In the following paragraphs, I will provide a broad overview 
of the lysin field, including their biochemistry, genetics, and development as 
applied biomedical tools. 
 
Lysin enzymology.  A particular phage lysin can target one of several bonds 
within the peptidoglycan (or murein) macromolecule (Figure 1.5).   
Table 1.2 Advantages and Disadvantages of Lysin Therapy 
This table was adapted from O’Flaherty et al. (2009) with permission (John 
Wiley and Sons, Licensing Number 2486030498200). 
Lysin advantages Lysin disadvantages 
Not self-replicating, more 
 targeted defined control 
Not self-replicating 
Protein therapeutic 
Protein; therefore, susceptible to 
 inactivation 
Resistance not yet reported 
To date not yet successfully applied 
 against Gram-negative bacteria 
Possibility to genetically 
 engineer lysins 
Potentially immunogenic 
Specific bacterial targets 
Could be used as a prophylactic 
 and for treatment 
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Figure 1.4 Bacteriolytic Acitivy of Phage Lysins 
Depicted here is the effect of the PlyG lysin (encoded by the -phage) on B. anthracis. 
[A] Untreated cells, phase contrast microscopy (PCM); [B] 1 min post-treatment, 
PCM; [C] 15 min post-treatment, PCM; [D] 1 min post-treatment, transmission 
electron microscopy (TEM); [E] 10 min post-treatment, TEM.  Overall, by 1 min post-
treatment, the cells’ gross morphology is compromised and cytoplasmic contents are 
budding through the cell wall (arrows).  By 10 min, the cell wall is largely digested 
and only cellular ghosts remain.  NOTE: The above image originally appeared in 
Schuch et al (2002).  It has been reproduced here with permission (Nature Publishing 
Group, Licensing Number 2482150387937). 
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Figure 1.5 Bond Specificity of Phage Lysins 
A summary of the chemical structure of peptidoglycan is depicted above (MurNAc = 
N-acetyl-muramic acid; GlcNAc = N-acetyl-glucosamine).  Bonds targeted by known 
phage lysins are designated with an arrow.  To date, lysins have been identified that 
target nearly every backbone, stem, and cross-bridge position within the 
macromolecule.  The reader should note, however, that the above image is 
oversimplified: the identity of the cross-bridge (denoted here as X-X) can vary 
considerably among bacterial species.  In Gram-negative organisms (and some Gram-
positive ones), there is a direct cross-bridge between the position #3 and position #4 
stem peptides.  The identity of the stem peptides themselves can likewise differ after 






























The nomenclature of these enzymes is admittedly rather complex and (at times) 
inconsistent, but can generally be categorized as follows (Fischetti 2008).  [1] 
Muramidases (also referred to as muraminidases or lysozymes) cleave the 1-4 bond 
between N-acetylmuramic acid (MurNAc) and N-acetyl-glucosamine (GlcNAc).  
[2] Glucosaminidases cleave the 1-4 GlcNAc-MurNAc bond.  [3] Lytic 
transglycosylases (LTs) cleave the 1-4 MurNAc-GlcNAc bond and reform a 1,6-
anhydrobond within MurNAc (i.e. they do not generate a reducing end).  [4] 
Alanine-amidases cleave the amide bond between the C3-lactate of MurNAc and 
the -position L-alanine of the pentapeptide stem.  [5] Endopeptidases cleave 
subsequent peptide bonds within the pentapeptide stem (- or -positions) or the 
interstem cross bridge.  The specific designation of an endopeptidase (e.g. 
glycine-glycine endopeptidase or alanoyl-glutamate endopeptidase) depends on 
its site of cleavage and the identity of the particular peptides, which vary from 
bacteria to bacteria (Vollmer et al. 2008a). 
  Muramidases, glucosaminidases, and LTs are collectively referred to as 
endoglycosylases, as they target the carbohydrate backbone of peptidoglycan at 
internal positions of the chain.  Moreover, with the exception of the LTs, all 
phage lysins are also considered hydrolases based on their mechanism of bond 
cleavage.  Collectively, people often refer to lysins as peptidoglycan hydrolases or 
murein hydrolases—rigorously speaking, this is incorrect due to the existence of 
LTs.  Practically, though, this is of minor consequence concerning the role of 
lysins as enzybiotic agents. 
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Another noteworthy distinction involves the difference between enzymatic 
activity and protein domain.  The enzymatic region of most phage lysins can be 
categorized into one of various conserved domains.  The bond specificity of the 
lysin, however, does not always correspond one-to-one with the identity of this 
domain.  For instance, among the muramidase lysins that target the MurNAc-
GlcNAc bond, some possess enzymatic domains that belong to the ―phage 
lysozyme‖ family (Weaver and Matthews 1987), while others possess domains of 
the ―glycosyl-hydrolase type 25‖ family (Porter et al. 2007).  These two domains 
diverge sequentially and structurally, but still catalyze the same reaction.  
Conversely, CHAP domains have been described among different lysins that 
function alternatively as alanine-amidases (Nelson et al. 2006) or endopeptidases 
(Becker et al. 2009).   
A complete list of enzymatic domains found in phage lysins is provided in 
Table 1.3, along with their corresponding bond specificities and representative 
examples.  The domains are listed according to their Pfam nomenclature (Pfam is 
a central database of conserved protein domains—Finn et al. 2010, 
pfam.sanger.ac.uk).  One should note that, even for a particular enzymatic 
domain, primary sequence diversity does exist from lysin to lysin, reflecting the 
evolutionary accumulation of mutations.  Generally speaking, the degree of 
sequence homology between two domains of the same family reflects the 
phylogenetic closeness between the encoding phages. 
 













E. coli T4 lysin 
[NP_049736] 
 












P. aeruginosa KZ144 lysin 
[AAL83045] 
Briers et al. 2007 
Glucosaminidase PF01832 Glucosaminidase 
S. agalactiae LambdaSA2 lysin 
[NP_688827] 





S. pneumoniae Cp-1 lysin 
(CPL-1) [NP_044837] 
García et al. 
1988 
Amidase, Type 2 PF01510 Alanine-amidase 
B. anthracis  lysin (PlyG) 
[YP_338200] 
Schuch et al. 
2002 
Amidase, Type 3 PF01520 Alanine-amidase 
C. perfringens phi3626 lysin 
(Ply3626) [NP_612849] 
Zimmer et al. 
2002b 






S. pneumoniae Dp-1 lysin 
(PAL) [O03979] 
 
S. agalactiae LambdaSA1 lysin 
[NP_687631] 
 
Sheehan et al. 
1997 
 







S. dysgalactiae C1 lysin (PlyC) 
[AAP42310] 
 
S. aureus K lysin (LysK) 
[YP_024461] 
Nelson et al. 
2006 
 





L. monocytogenes A500 lysin 
(Ply500) [YP_001468411] 
Korndörfer et al. 
2008 
M23 Peptidase PF01551 
Endopeptidase 
 (cross-bridge) 
See Caption See Caption 













P. aeruginosa 8 lysin 
[NP_524573] 





Table 1.3, continued 
This table lists the enzymatic domains commonly encountered in phage lysins.  
For each domain, the pfam accession number is provided, along with a 
representative example among lysins whose properties have been studied 
recombinantly (the GenBank accession number of these is given in brackets).  
The table also lists the enzymatic specificity for each domain.  As is evident, 
certain reactions can be catalyzed by more than one domain.  In some instances, 
a conserved given domain is known to catalyze two different reactions, 
depending on the particular enzyme in which it is found.  In these instances, an 
example is given for each reaction type.  For the cross-bridge endopeptidases, a 
particular bond is not specified, as the nature of this bond varies considerably 
among different species.   
 
For one domain (M23 endopeptidase), no representative example is given.  No 
definitive phage lysins have  (as of yet) been characterized that possess this 
domain.  Nonetheless, M23 demonstrates peptidoglycan hydrolase activity in 
well-characterized non-phage enzymes (for instance, lysostaphin—see Kumar 
2008), and the domain can be identified in the sequences of putative phage 
lysins.  To date, the U40 endopeptidase has only been identified in the genome 
of a single dsRNA cystovirus.  The DUF847 domain has been identified in a 
cystovirus and several caudoviruses (all Gram-negative), and muramidase 





Lysin architecture.  For Gram-positive lysins, the enzymatic domain is one 
component of a larger overall architecture.  As shown in Figure 1.6, these 
proteins possess modular structures that typically combine an N-terminal 
enzymatic domain with a C-terminal binding domain (Fischetti 2008).  The latter 
recognizes (at nanomolar affinities) one of various epitopes within the target-cell 
envelope.  These include surface carbohydrates (Loessner et al. 2002), choline 
moieties (García et al. 1990), or peptidoglycan itself (Buist et al. 2008).  Like the 
enzymatic domains, the binding domains are also categorized into conserved 
protein families, a list of which is provided in Table 1.4.  For certain domains 
shown in the table, the specific molecular target has not yet been defined 
experimentally.  For some phage lysins, moreover, an extended C-terminal 
region is present, but cannot be identified computationally as a conserved 
domain.  Most likely, these regions do serve binding functions, albeit ones that 
have not yet been identified/classified in an organized manner. 
For a given bacterial species, it is not uncommon for its phage lysins to 
include various combinations of enzymatic and binding domains.  For instance, 
one lysin might combine an N-terminal muramidase domain with a C-terminal 
SH3 domain, while another will combine an alanine-amidase with the SH3 
domain (see Chapter 2).  In general, phage genomes are modular and are known 
to evolve through extensive inter-phage recombination (Hendrix 2005).   
Figure 1.6 Modular Architecture of Phage Lysins 
Typically, lysins for Gram-positive bacteria are characterized by an N-terminal 
enzymatic region and a C-terminal binding region.  There are a variety of 
possibilities as to the particular identity of these domains (see Tables 1.1a and 
1.1b for examples).  Gram-negative bacteria are generally comprised of an 
enzymatic domain alone.  It should be noted, however, that examples of lysins 
do exist (both Gram-positive and Gram-negative) that do not conform to these 
standard architectures.  These atypical enzymes are discussed at various points 
throughout the text (in particular, see Chapters 4 and 5). 
Typical Gram-Positive Lysin 
Typical Gram-Negative Lysin 
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Binding Target Example Reference 
Cell Wall Binding 
Repeat 
PF01473 Choline 
S. pneumoniae Cp-1 lysin 
(CPL-1) [NP_044837]] 
García et al. 
1988 
CPL-7 PF08230 Unknown 
S. pneumoniae Cp-7 lysin 
(CPL-7) [P19385] 
García et al. 
1990 
LysM PF01476 Peptidoglycan 
L.fermentum PYB5 lysin 
(Lyb5) [ABP88927] 
Hu et al. 2010 ; 







B. anthracis  lysin (PlyG) 
[YP_338200] 




SH3, Type 3 PF08239 
Unknown, perhaps 
surface protein 
C. perfringens 13124 prophage 
lysin (PlyCM) [YP_685420] 
Chapter 2 
SH3, Type 5 PF08460 
Unknown, perhaps 
surface protein 
B. anthracis BG-1 lysin 
(PlyBeta) 
[EU258891] 
Schmitz et al. 
2008 
PG-1 PF01471 Peptidoglycan  
P. aeruginosa KZ144 lysin 
[AAL83045] 




P. aeruginosa 8 lysin 
[NP_524573] 
Pei and Grishin 
2005 
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Table 1.4, continued 
Listed here are binding domains (both experimentally-confirmed and 
presumptive ones) utilized by phage lysins.  Domain accession numbers, 
representative examples, and corresponding references are provided.  For 
cases in which a specific molecular target has been identified, this moiety is 
also given.  Overall, several caveats must made about this list.  First, it is 
important to emphasize that it is far from complete.  Numerous Gram-positive 
lysins—both confirmed enzymes and putative ones for which only a genetic 
sequence is known—possess extended C-termini for which no pre-classified 
domain is (yet) identifiable bioinformatically.  
 
Second, for a given domain, the precise molecular target is not necessarily 
identical in every instance.  For example, the amidase 2-associated domain 
targeted GlcNAc-ManNAc residues in the B. anthracis strain in which it was 
characterized.  Although it is likely a carbohydrate-binding domain 
universally, the precise glycosidic signature recognized could vary from 
species to species (reflecting the primary sequence diversity within the domain 
itself).  Finally, for the last two domains listed, the specific examples represent 
atypical examples of Gram-negative lysins with binding domains.  For PG-1, 
Gram-positive lysins have also been identified with the domain (for instance, 
see Chapter 4).  For PG-3, however, the only lysins known to possess it are 
Gram-negative (in fact, the example given is encoded by a dsRNA phage, 




Presumably, these cut-and-paste lysin structures resulted from successful 
recombination events that occurred within the coding region of the lysin gene 
itself. 
A general paradigm in lysin research is that the binding domain is largely 
responsible for the specificity an enzyme demonstrates toward its particular 
Gram-positive target.  This concept derives from two different lines of 
experimentation.  First, it has been demonstrated with various lysins that 
truncating the protein after its enzymatic domain greatly diminishes its 
bacteriolytic activity (Schuch et al. 2002; Porter et al. 2007).  Second, in 
experiments with Lactococcus lactis and Streptococcus pneumoniae lysins, the 
enzymatic domain of one protein was recombinantly fused with the binding 
domain of the other (Sheehan et al. 1996).  The authors observed that the latter 
domain was sufficient to maintain bacteriolytic activity, even when paired with 
an unnatural partner.   
It should be emphasized, however, that these statements regarding the 
molecular basis of lysin specificity should be taken as common principles and not 
universal facts.  Given the tremendous diversity of phage, one generally finds that 
every so-called rule in phage research has its noteworthy exceptions.  
Accordingly, some lysins maintain high activity even with a deleted binding 
domain (Horgan et al. 2009).  And chimeric lysins have been observed that fail to 
effectuate the lysis of either original bacterial species (unpublished observations 
and personal communications). 
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Although Gram-negative lysins have not (as of yet) demonstrated great 
potential as enzybiotic agents, it is worth considering their structural 
architecture.  Unlike Gram-positive lysins (250 - 400 amino acids), Gram-negative 
lysins are typically smaller (150 – 200 amino acids) and consist of an enzymatic 
domain alone (see Figure 1.6, Young et al. 2005).  In this regard, they more 
closely resemble the nonspecific peptidoglycan hydrolases encoded by 
eukaryotic organisms, such as animal and plant lysozyme.  Overall, there are 
several possible explanations for the lack of Gram-negative binding domains.  
Given the relative thinness of Gram-negative peptidoglycan (as little as a single 
layer) and its lack of decoration with associated molecules, a non-specific lysin 
might be all that is required to compromise envelop integrity (Schmitz et al. 
2010b).  By contrast, Gram-positive peptidoglycan is sufficiently thick (~40 
layers) that the extra lytic potency/specificity afforded by the binding domain 
might be necessary for lysis.   
An alternative (or complementary) explanation could involve the 
potential effect of free lysin in a phage-infected Gram-positive population 
(Loessner et al. 2002).  After bacterial lysis, it is to the advantage of the progeny 
phage to locate other viable bacteria so that the infective cycle can expand.  
Soluble lytic enzyme, however, would compromise the viability of nearby cells 
and prevent them from becoming new hosts.  In this regard, the enzyme‘s 
binding domain could keep it tethered to the remnants of lysed bacteria, 
functionally inactivating it.   For Gram-negative bacteria, the outer membrane 
40 
 
desensitizes the cells to the effect of exogenous lysin in the first place.  So even if 
molecules of lytic enzyme are diffusing in their vicinity, the cells would remain 
viable. 
One should note that the above scenarios remain only theories and have 
yet to be confirmed with experimental evidence.  On the whole, the in vivo 
function of the binding domain remains somewhat obscured by the fact that 
Gram-positive lysins have only been studied in the context of recombinant 
expression and exogenous treatment.  To date, the effect of binding-domain 
deletions and chimeras has never been investigated in actively-propagating 
Gram-positive phages (Young 2005).  The situation is further complicated 
because—as more and more enzymes are characterized—Gram-negative lysins 
have been identified that do, in fact, encode short N-terminal (Briers et al. 2007) 
or C-terminal (Pei and Grishin 2005) binding domains.  Just as before, the 
traditional rules on lysin architecture (as depicted in Figure 1.6) seem full of 
apparent exceptions.  The same is true for Gram-positive lysins, some of which 
contain multiple enzymatic domain (Baker et al. 2006; Pritchard et al. 2007; 
Cheng and Fischetti 2007; Becker et al. 2009) or even multimeric subunits (Nelson 
et al. 2006).  
It is important to emphasize that the component domains listed in Tables 
1.3 and 1.4 (both enzymatic and binding) are not exclusive to phage lytic 
enzymes.  Bacteria themselves encode chromosomal peptidoglycan hydrolases 
that are involved in processes such as bacterial growth, division, sporulation, 
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and signaling (Vollmer et al. 2008b).  Collectively, these enzymes are known as 
autolysins, and they can share many of the same domains as phage lysins proper.  
In fact, it is thought that phage lysins co-evolved with (or perhaps co-opted) the 
autolysins of their bacterial hosts (López et al. 1997).  In terms of their modular 
architectures, some Gram-positive autolysins share an N-terminal-enzymatic-C-
terminal-binding arrangement (García et al. 1985); for many others, however, the 
combination of domains is more diverse.  Finally, even within phage genomes 
themselves, other structural proteins can include peptidoglycan-hydrolase 
domains.  In particular, tail fibers often contain lytic components that participate 
in the process of initial DNA injection (Kanamaru et al. 2004; Kenny et al. 2004; 
Piuri and Hatfull 2006).  Enzymatic head proteins have likewise been identified 
(Moak and Molineux 2004). 
 
Lysin-associated proteins.  Although lytic enzymes are ultimately responsible 
the affecting bacterial lysis during phage infection, they are not capable of this 
phenomenon by themselves.  As with all bacterial proteins whose site of activity 
is external to the cytoplasmic membrane, the lysins need a mechanism for 
traversing this hydrophobic barrier.  Unlike bacterial autolysins, which are 
typically secreted by the type II sec-mediated pathway, the phage lysins depend 
on accessory proteins known as holins (for reviews, see Gasset 2010; Young and 
Wang 2006; Young 2005; Wang et al. 2000).   
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These transmembrane proteins (typically 50 – 150 amino acids in length) 
insert into the cytoplasmic membrane and create lesions (i.e. death rafts) through 
which the lysin can diffuse to access the peptidoglycan.  The holins, in fact, are 
ultimately responsible for the timing of lysis during phage infection.  During the 
late stage of phage-gene transcription, lytic enzyme accumulates for a period of 
time within the bacterial cytoplasm.  The actual moment of lysis does not 
correspond to a particular lysin concentration, but rather the rapid formation of 
holin-induced pores. 
While the holins have a conserved (and relatively simple) biological 
function, their biochemical specifics are notably complex.  Structurally, holins are 
organized into three classes based on whether they are comprised of one, two, or 
three transmembrane α–helices (four-TM holins have also been observed).  On 
the level of primary sequence, however, these proteins are remarkable for the 
dissimilarity that individual holins can demonstrate toward one another, so 
much so that holins have been called ―arguably the most diverse functional class 
of proteins known in biology‖ (Young 2005).   
The regulation of holin activity is an intricate process involving the 
physical interaction of the holin with an additional protein, the antiholin, within 
the cytoplasmic membrane.  In many cases, the antiholin is encoded by the same 
gene as the holin itself, and simply represents transcription from an alternate 
start codon (Bläsi and Young 1996); in other cases, it is encoded by an 
independent gene (Ramanculov and Young 2001).  Overall, the formation of 
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functional membrane lesions is thought to depend on the holin-antiholin ratio, 
although the mechanistic specifics are variable from phage to phage, often poorly 
defined, and beyond the scope of the present text (see the review articles cited 
above for additional information). 
  Once again, it is worth noting that certain phage have been identified 
where the typical relationship between lysin and holin does not necessarily 
apply.  A phage infecting the Gram-positive bacterium Oenococcus oeni encodes a 
lysin with a canonical signal peptide for the sec-mediated secretion pathway 
(Parreira et al. 1999).  Likewise, a secreted autolysin of Enterococcus faecalis was 
recently shown to correspond to the lytic enzyme of an integrated prophage; it, 
too, includes an N-terminal signal peptide (Mesnage et al. 2008).  Interestingly, 
both the Oenococcus phage and the Enterococcus prophage also encode putative 
holins, and it remains unclear the role of this apparent secretory redundancy.   
Another variant situation exists for a group of Gram-negative phages (first 
defined for the E. coli P1 phage) whose lysins encode an N-terminal signal-arrest-
and-release (SAR) sequence (Xu et al. 2004).  Although the host‘s sec system 
initially engages and exports these lysins, signal peptide cleavage does not occur.  
Instead, the lysins remain tethered to the membrane as inactive, periplasmic 
proteins.  For these phages, the holins (known as pinholins) function by 
depolarizing the membrane without the formation of macromolecular lesions 
(Park et al. 2007).  This effect, however, is sufficient to release the lysins from 
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their membrane-bound state, thereby activating the enzymes and inducing 
bacterial lysis.   
In addition to the holin and lysin, Gram-negative phages can encode two 
additional lysis-related proteins that are responsible for destabilizing the outer 
membrane (Young 2005).  Generically, these proteins are referred to as Rz/Rz1-
like proteins, after the first such examples to be identified in the E. coli  phage 
(Young et al. 1979; Zhang and Young 1999).  Rz is anchored to the cytoplasmic 
membrane, while Rz1 is an outer membrane-associated protein.  The two are 
believed to physically interact in the periplasmic space, leading to the 
juxtaposition and fusion of the two membranes (Berry et al. 2008).  Phages with a 
defective Rz/Rz1 cassette are capable of lysis and propagation, but are inhibited 
by the extracellular presence of divalent cations (Young et al. 1979).  
 In terms of their primary sequence, these proteins (much like the holins) 
are quite divergent from one another.  After the initial identification of Rz/Rz1, a 
paucity of homologues was identified in other Gram-negative phages.  However, 
more recent bioinformatic predictions (combining topology and genomic-
architecture analysis) have revealed that orthologous proteins are nearly 
ubiquitous in sequenced Gram-negative phage (Summer et al. 2007).  For some 
phages, the Rz/Rz1-like proteins seem to be combined as a single polypeptide (a 




Genomic arrangement of phage lysins.  As the preceding sections indicate, at 
least two (and sometimes more) proteins are involved in host-cell lysis during 
phage infection.  It is worth considering the genes that encode these proteins 
and, specifically, their proximity within the viral genome.  This issue is 
particularly relevant to Chapter 4 of the present thesis.  If one had to designate a 
standard genomic arrangement for lysin-associated genes, it would be as follows 
(Wang et al. 2000).  The holin/antiholin-encoding ORF is located immediately 
upstream and in the same orientation as the lysin-encoding ORF (sometimes the 
two reading frames overlap by several nucleotides).  These two genes are thus 
under control of the same late-stage promoter.  In Gram-negative phage, the Rz 
and Rz1 genes would also be located nearby (either upstream or downstream), 
and often the Rz1 gene is embedded within the Rz gene in a different reading 
frame (Summer et al. 2007).  These standard genomic architectures are depicted in 
Figure 1.7.  
Yet again, though, various other arrangements have been reported for 
both Gram-positive and Gram-negative phages.  These include examples where 
the lysin is encoded immediately upstream of the holin, where the lysin and 
holin are separated from one another (Dunn and Studier 1983; Schuch et al. 
2004), where the holin gene is imbedded within that of the lysin (Loessner et al. 
1999), and where the phage encodes two putative holins (Delisle et al. 2006) or 
two lysins (van der Ploeg 2007).   
Figure 1.7 Genomic Architecture of Lysin-Associated Genes 
The standard genomic relationship among lysin-associated genes is depicted 
here.  The holin-encoding gene is encoded immediately upstream from the 
lysin-encoding gene, and both are under control of the same late-stage 
promoter.  Often, the holin-encoding gene also encodes the regulatory antiholin: 
transcription of the entire ORF yields the antiholin, while transcription from an 
alternate stat codon (anywhere from 2 – 10+ amino-acid residues downstream) 
yields the holin.  In Gram-negative phage, the OM-disrupting genes (Rz/Rz1) 
are also frequently encoded nearby.  Here, they are depicted immediately 
downstream from the lysin, the arrangment found in the E. coli  phage (Young 
2005).  Overall, it is important to emphasize that the above arrangements for 
these genes do not hold true universally.  Various other potential architectures 




In addition, several phage genomes have been sequenced that (based on 
homology analysis) do not seem to encode a lytic enzyme at all (Scholl et al. 
2004).  Several possibilities could explain this apparent omission.  These phages 
could encode completely novel lysins that do not correspond to any known 
enzymes.  Alternatively, they might utilize a structural peptidoglycan hydrolase 
(i.e. a tail-lysin) as the lytic agent, or rely upon an endogenous bacterial enzyme 
to digest the cell wall.  Finally, lysin-encoding genes have been identified among 
certain streptococcal and staphylococcal phage that include a self-splicing, group 
I intron (Foley at al. 2000; O‘Flaherty et al. 2005).  Truly, it appears that the 
potential variations that have evolved in phages are only limited by one‘s own 
imagination! 
 
Non-caudoviral lytic proteins.  The discussion to this point has focused 
exclusively on the lytic mechanisms of the caudoviruses.  This is understandable 
given their overwhelming predominance among known phage.  Nonetheless, a 
dedicated body of research has also studied lysis for non-tailed phage; this work 
will be summarized briefly here. As mentioned previously, all phage families 
except the filamentous inoviruses release progeny viruses through host-cell lysis.  
For several of these families, the mechanism is reminiscent of the caudoviruses 
and involves phage-encoded peptidoglycan hydrolases.  This is known to be the 
case for the dsRNA cystoviruses (Caldentey and Bamford 1992; Pei and Grishin 
2005) and the lipid-associated dsDNA tectiviruses (Verheust et al. 2004).  For 
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another lipid-associated dsDNA family, the corticoviruses, the mechanism 
remains ambiguous.  The genome of a single corticovirus (the only known 
isolate) has been sequenced and it fails to include any proteins with predicted 
murlaytic activity (Krupocič et al. 2007a).  Nevertheless, genomic analyses of 
various marine bacteria have revealed corticovirus-like prophage elements with 
putative lytic enzymes (Krupocič et al. 2007b). 
A divergent, and rather intriguing, strategy of host lysis is employed by 
the ssRNA leviviruses and the ssDNA microviruses.  These phages encode 
proteins that are collectively referred to as amurins.  Rather than hydrolyze 
peptidoglycan, the amurins inhibit the biosynthetic machinery that is responsible 
for its synthesis (Bernhardt et al. 2001; Bernhardt et al. 2000).  In a mechanism 
similar to small-molecule antibiotics, they comprise the cell-wall strength of the 
nascent bacteria and induce osmotic lysis.  For the dsDNA plasmaviruses, the 
mechanism of lysis is not well-established.  Given that these phages are only 
known to infect mycoplasma (which lack a cell wall), the mechanism almost 
certainly does not involve a peptidoglycan hydrolase.  Overall, when all the non-
tailed phages are considered, only the tectiviruses have been observed to infect 
Gram-positive species (including the pathogen B. anthracis).  So—at least at 
current state of the technology—they are the only ones whose lysins seem 




Phage lysins into the spotlight.  As the discussion to this point illustrates, 
phage-lysin research is clearly an expansive field.  At the same time, one 
important question has not yet been addressed: when exactly were these proteins 
first viewed as potential anti-infective agents?  The truth is that researchers were 
aware of lysins for decades before they were first considered pharmacologically.  
(A detailed history of the ―nuts and bolts‖ of lysin identification will be provided 
a little later, as the last main section of this introduction.)  It was not until the late 
1980‘s, in fact, that lysins were first viewed through the prism of applied 
microbiology.  Interestingly, some of this initial work did not have biomedical 
motivations.  Several lysins were studied that targeted species of lactic acid 
bacteria (LAB) commonly employed by the dairy industry (reviewed in Sable 
and Lortal 2005).  It was proposed that lysins could facilitate the release of 
intracellular enzymes from LAB, enhancing the ripening of fermented food 
products.   
Throughout the 1990‘s, two other groups—García, López and colleagues 
in Madrid and Loessner, Scherer, and colleagues in Munich—began investigating 
phage lysins in vitro against various human pathogens, including pneumococci 
(García et al. 1988 and 1990), staphylococci (Loessner et al. 1998), and Listeria 
(Loessner et al. 1995).  While their work demonstrated bacterial killing, the lysin 
field did not truly expand until after the turn of the millennium.  It was at this 
point that Fischetti and colleagues at Rockefeller began utilizing phage lysins in 
vivo with animal models of bacterial pathogenesis.  Published in 2001, two of the 
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first such studies involved pharyngeal colonization of mice with S. pneumoniae 
(Loeffler et al.) and S. pyogenes (Nelson et al.).  In both cases, a single treatment 
with the respective lysins PAL and PlyC abolished bacterial titers hours after 
dosing.  Similar results were later reported for the PlyGBS lysin following the 
pharyngeal and vaginal colonization of mice with S. agalactiae (Cheng et al. 2005).   
A common feature of these trials is that they involved selective 
decolonization of mucous membrane sites.  This is highly relevant given the 
pathogenesis of many common Gram-positive bacteria.  For virtually all 
streptococcal and staphylococcal pathogens, the presence of disease is not simply 
a binary issue of ―having the bacteria‖ or ―not having the bacteria‖.  Countless 
individuals are colonized with these organisms, generally at mucous 
membranes, without any clinical signs of infection.  The progression to actual 
pathology (either at the initial mucous membrane or at distal sites) depends on 
this initial colonization, but it is not synonymous with it.  In this light, phage 
lysins—or, for that matter, intact phages— could be used as targeted 
prophylactic agents that prevent the colonization/infection transition.  This 
application is be relevant even outside the discussion of burgeoning antibiotic 
resistance, although the latter issue imparts an even greater sense of priority. 
Subsequent in vivo trials have investigated the effect of lysin treatment 
against fulminant Gram-positive infections.  For example, Schuch et al. 
demonstrated the ability of the PlyG lysin to prevent lethality in mice with B. 
cereus peritonitis (2002).  This work generated significant attention at the time, 
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especially in light of heightened bioterrorism concerns over the closely-related 
species B. anthracis.  In other work, the pneumococcal lysin CPL-1 (different that 
the PAL lysin mentioned above) has been used successfully in rodent models of 
bacteremia (Loeffler et al. 2003), endocarditis (Entenza et al. 2005), otitis media 
(McCullers et al. 2007), and meningitis (Grandgirard et al. 2008).   
Just recently, an anti-staphylococcal lysin (ClyS) was utilized 
synergistically with traditional antibiotics to treat cutaneous S. aureus infections 
in mice.  This enzyme is currently employed in an ex vivo trial involving skin 
scraping from psoriasis patients (Daniel et al. 2010; Pastagia and Fischetti, 
personal communications).  Admittedly, the ability to treat particular anatomic 
sites with lysin could be limited by the fact that it is a protein.  Nevertheless, a 
growing body of research (reviewed in Fischetti 2008) has addressed the issues of 
biodistribution and immunogenicity of lytic enzymes.  The results provide 
cautious optimism that these agents might be useful even beyond their most 
straightforward application as topical agents.  Moreover, just as with bulk phage 
therapy, lysins also have potential applications as food additives (see Chapter 2) 
and veterinary pharmaceuticals (see Chapter 5).  They could likewise be used as 
industrial decontaminating agents for surfaces that have been colonized with 






PHAGE-LYSIN IDENTIFICATION THROUGHOUT THE YEARS 
 Despite the work dedicated to phage lytic enzymes of late, the number of 
lysins that have been studied functionally is still only a small fraction of the total 
lysin pool encoded by global phage.  With the numbers alluded to above (1031 
worldwide phage particles), bacteriophage are thought to be the single greatest 
source of genetic information on the planet.  Even among the known 
phage/prophage of Gram-positive pathogens, only a small minority have seen 
their lytic enzymes cloned, expressed, and examined as anti-infective agents.  In 
itself, the sheer number of lysins with the potential for development as 
enzybiotics makes this class of proteins extremely attractive pharmacologically.   
Considering this magnitude, future research will undoubtedly continue to 
isolate new lysins to complement those already in development.  And while it is 
the activity of these enzymes that will ultimately garner attention, the success of 
such work is fundamentally dependent on the techniques employed to identify 
the proteins in the first place.  The purpose of the current section, therefore, is to 
address the issue of lysin identification.  Following a summary of lysin isolation 
prior to modern molecular cloning, I will outline the various techniques 
currently available for cloning lysin-encoding genes within phage genomes.  The 
relative advantages and disadvantages of these approaches will be discussed, 
especially in the context of ongoing technological advances.  Overall, through the 
efficient identification of novel phage lysins, researchers can only broaden the 
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potential impact of these proteins and hasten their development into true clinical 
and industrial tools. 
 
Historical perspectives on lysin identification. While medical interest in phage 
lysins is a more recent phenomenon, initial observations of these enzymes and 
attempts to purify them date back much longer.  In 1921, Felix d‘Hérelle first 
proposed the existence of a phage-associated enzyme that was capable of lysing 
bacteria independently from total phage action.  His idea was based on 
experiments with alcohol-denatured phage; d‘Hérelle was able to extract an 
active agent that could lyse bacilli but not propagate between cultures.  Soon 
after, Vladimir Sertic reported the isolation of a lysine d’une race du bactériophagie 
that was responsible for creating altered morphological zones that surrounded 
Escherichia coli plaques proper (1929).  The lysin hypothesis was contested at the 
time, and it is difficult to judge whether these initial observations were truly due 
to the activity of what we now know as phage lytic enzymes.  Nevertheless, 
other contemporary studies did report the tendency of nonviable Gram-positive 
bacteria to lyse when in the presence of live bacteria and their corresponding 
phage (Gratia and Rhodes, 1923; Twort 1925; Bronfenbrenner and Muckenfuss, 
1927).  In retrospect, this activity could be attributed to the diffusion of lysin from 
dead cells.   
It was not until several decades later that the existence and activity of 
lysins were broadly accepted by the scientific community.  In 1955, Ralston et al. 
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described a lytic agent that appeared in the supernatant of a Staphylococcus aureus 
culture following infection by bacteriophage P14.  This protein, which they 
termed virolysin, could be separated from intact phage through ultra-
centrifugation and concentrated by ammonium sulfate precipitation (Ralston et 
al., 1957).  Their work was notable in that the phage enzyme was isolated and 
characterized alongside an endogenous lytic enzyme produced by the host 
staphylococci—the distinction between these molecules allowed the phage origin 
of virolysin to be established.  It was subsequently demonstrated that 
antigenically-distinct lytic enzymes could be isolated when the S. aureus host was 
infected with diverse phage (Ralston and McIvor 1964).  In later works, two 
staphylococcal lysins (from phages 80 and 53) were purified beyond ammonium 
sulfate precipitation by ion exchange chromatography (Doughty and Mann 1967; 
Sonstein et al. 1971).   
One should note that, in these initial attempts to isolate S. aureus lysins, 
the final products did not demonstrate the degree of activity currently associated 
with lytic enzymes.  Of the above (semi-pure) enzymes, only the phage-53 lysin 
could successfully lyse viable staphylococci; the phage-80 lysin was only active 
against isolated cell walls and the P14-virolysin required the bacteria to be 
―sensitized‖ by one of several additional agents.  It is unclear whether this 
diminished activity was due to less-than-ideal purification conditions at the time, 
or simply reflect the efficacy of these particular enzymes. 
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 During the same period as this work on staphylococcal enzymes, similar 
research was progressing on other bacteria-bacteriophage combinations.  Again 
with the strategy of isolating the proteins from culture supernatant, lysins were 
investigated from phage whose hosts included enterobacteria (Inouye and 
Tsugita 1966; Maass and Weidel 1963; Rao and Burma 1971), bacilli (Murphy 
1957; Welker 1967), lactococci (Tourville and Johnstone 1966), and streptococci 
(Reiter and Oram 1963; Oram and Reiter 1965).  Overall, one of the most 
extensively studied lysins of this time was that of the C1 phage infecting 
Lancefield group C Streptococci.  Two 1957 publications documented its ability 
to lyse not only live Streptococci of the same type, but also live Group A and E 
Streptococci (Maxted; Krause).   
Over the following years, several increasingly sophisticated attempts were 
made to purify the C1 lysin using a combination of ammonium sulfate 
precipitation, gel filtration, and calcium phosphate adsorption (Krause 1958; 
Doughty and Hayashi 1961).  In the process, it became a valuable tool for 
selectively removing and characterizing antigenic components of the 
streptococcal cell envelope.  The final obstacle to achieving a highly pure protein 
preparation (the presence of reactive sulfhydyl groups) was overcome by 
Fischetti et al., who utilized reversible sodium tetrathionate protecting groups to 
stabilize the lysin during chromatography (1971).  Interestingly, these non-
recombinant purification schemes for the C1-phage lysin, currently referred to as 
PlyC, endured into the modern era of lysins as enzybiotics.  In 2001, PlyC was 
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one of the first lysins to effectively decolonize a bacterial pathogen in vivo 
(Nelson et al.), even though the encoding genomic region was not cloned and 
characterized until several years later (Nelson et al. 2006). 
 
Into the age of molecular cloning.  Following the elucidation of the central 
dogma of molecular biology, attempts to characterize (and ultimately identify) 
phage lytic enzymes through genetic techniques began in earnest by the late 
1960‘s.  The first lysin amino acid sequence was reported in 1966 by Inouye and 
Tsugita for the E. coli T4 phage muramidase.  It was determined through Edman 
analysis of culture-purified enzyme, and it suggested an approximate nucleotide 
sequence by reverse translation.  This work on the T4 lysin, in fact, provided 
important evidence confirming the very nature of the triplet genetic code.  By 
inducing mutations in the T4 genome and observing the corresponding frame-
shifts in the purified lysin, the authors were able to verify Crick‘s hypothesis 
regarding the language of DNA codons (Terzaghi et al. 1966; Okada et al. 1968).   
The definitive nucleotide sequence for the T4 lysin was not published 
until 1983, when Owen et al. successfully cloned the gene by its ability to rescue 
a lysis-defective phage strain.  This sequence, in turn, allowed several additional 
lysin genes to be recognized through nucleotide homology.  In 1985, the 
Salmonella P22-lysin was identified in this manner from a sequenced fragment of 
the viral genome (Rennell and Poteete).  The first nucleotide sequence of a Gram-
positive lysin, from Bacillus subtilis phage 29, was likewise reported one year 
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later (Garvey et al. 1986).  It is important to note that the above work was 
conducted at the same time as the advent of modern protein expression 
technology; shortly after their cloning, the T4 and 29 lysins were the first such 
enzymes to be expressed and purified recombinantly from E. coli (Perry et al. 
1985; Saedi et al. 1987). 
 With molecular techniques at their disposal, researchers could now 
identify lysins directly from phage DNA, and this ability was soon utilized to 
search for enzymes against Gram-positive pathogens.  One of the first bacterial 
species targeted in this regard was S. pneumoniae, as the 1980‘s and 90‘s saw the 
cloning, expression, and functional analysis of a number of pneumococcal phage 
lysins.  The same general strategy was employed in identifying each of these 
proteins: following the cloning of an initial prototype enzyme, the gene was 
utilized to identify related lysins through Southern blot analysis.  Ironically, the 
prototype enzyme for these pneumococcal lysins was not actually viral in origin, 
but rather a genomic peptidoglycan hydrolase encoded by S. pneumoniae, LytA.  
Like the endogenous S. aureus lysin from Ralston et al. (1957), LytA is not a 
phage enzyme but rather a chromosomal autolysin.  Specifically, LytA is an 
alanine-amidase with various roles in pneumococcal physiology, including the 
release of cytoplasmic virulence factors during pathogenesis (Jedrzejas 2001) and 
the predation of non-competent cells by competent ones within pneumococcal 
communities (Guiral et al. 2005).  
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García et al. cloned LytA in 1985 through a complementation strategy in 
which an S. pneumoniae genomic fragment was identified by its ability to rescue 
autolytic activity in a mutant lytA- strain.  The resultant sequence was 
subsequently used to probe genomic DNA from several S. pneumoniae phages in 
order to isolate their lysin genes.  Successful hybridizations were noted in many 
instances, and the corresponding bands were cloned and sequenced to reveal 
viral LytA-homologues.  Specifically, the lysins from the following phage were 
identified [with corresponding enzyme names]: Cp-1 [CPL-1] (García et al. 1988); 
Cp-7 and Cp-9 [CPL-7 and CPL-9] (García et al. 1990); HB-3 [HBL] (Romero et al. 
1990); EJ-1 [EJL] (Díaz et al. 1992); and Dp-1 [Pal] (Sheehan et al. 1997).   
These enzymes demonstrated varied overall sequence homology to LytA 
itself.  HBL and EJL are highly homologous to the autolysin throughout their 
entire sequence, as they share both LytA‘s N-terminal amidase domain and its C-
terminal choline-binding domain.  By contrast, CPL- 1, CPL-7 and CPL-9 possess 
muramidase activity and are homologous to LytA only at the C-terminal binding 
end.  Pal likewise demonstrates only C-terminal homology.  Although both 
lysins possess alanine-amidase activity, Pal encodes a type 5 amidase domain 
while LytA encodes a type 2 amidase domain.  Of all these pneumococcal 
enzymes, CPL-1 has received by the far most attention in subsequent enzybiotic 
trials (as described in the preceding section).   
As for the hybridization strategy itself, the technique is no longer 
commonly used for identifying lytic enzymes.  A potential reason for this is 
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logistical: with more recent cloning strategies (described in the following 
sections), Southern blotting can be relatively cumbersome by comparison.  There 
also exists the possibility of limiting the results due to the sequence of the 
original DNA probe.  With this approach, it is only possible to identify genes 
with some homology to a prototype sequence.  But if a phage is relatively 
novel—for instance, in terms of its host bacterium or viral morphotype—suitable 
homologues might not exist for its lysin.  This is especially problematic 
considering that enzymes with highly novel sequences represent some of the 
most attractive targets for future discovery.   
Nevertheless, if one has good reason to suspect that a desired lysin is 
similar in sequence to one already characterized, techniques based on nucleotide 
homology can still be quite effective.  In this regard, several studies have utilized 
PCR-based approaches as more rapid alternatives to Southern blotting.  For 
example, Morita et al. designed primers from the genomic regions surrounding 
the lysin of a B. subtilis phage, which they used to amplify a related enzyme for 
B. amyloliquefaciens (2001b).  Romero et al. likewise synthesized various primers 
based on known LytA-like sequences when attempting to clone the lysins from 
two S. mitis phage (2004).  These authors successfully identified a primer-pair 
that amplified a portion of both enzymes; these partial sequences were 
subsequently used to characterize the remainder of the genes by genomic primer 
walking (i.e. chain termination sequencing with the genome as the direct 
template).  It should be mentioned that, although they have not been applied 
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specifically to lytic enzymes, several other techniques are available that could 
identify a complete lysin gene from only a partial sequence.  These include 
inverse PCR (Ochman et al. 1988) and semi-random PCR (Hermann et al. 2000). 
 
Phage lysins and functional screening.  To avoid the possibility of sequence-
based bias, it is ultimately necessary to identify lysin-encoding genes by the 
enzymatic activity of their translated proteins.  This approach is the foundation 
of functional genomic screening, and it has become a common tool for lysin 
identification over the past decade.  The experimental specifics of lysin-screening 
can differ slightly, and these variables are reviewed in the proceeding 
paragraphs.  Overall, however, such methods represent variations on the same 
general theme: [I] phage genomic DNA is isolated and digested into fragments; 
[II] the fragments are ligated into an expression vector and transformed into a 
host organism; [III] the transformants are clonally propagated and exposed to an 
inducing agent to force transcription of the genomic inserts; and [IV] the clones 
are analyzed for the acquisition of a phenotype that indicates the presence of a 
lysin-encoding gene.   
For the first three steps, the experimental considerations are fairly general 
in nature and unrelated to the activity of the targeted enzymes.  The original 
source DNA can be derived from either lytic phage, isolated from the 
environment or purchased from commercial sources, or lysogenic prophage, 
induced from host bacteria with an appropriate stressing agent (e.g. mitomycin, 
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phosphomycin, or UV-treatment).  For the fragmentation step, most lysin screens 
have utilized a standard shotgun approach to create a random array of genomic 
fragments.  Here, the phage DNA is partially digested with restriction enzyme, 
usually one with a 4-bp consensus sequence.  A final length distribution of 1.5 - 3 
kb is ideal, as it represents 2 - 3 times the length of typical Gram-positive lysins.   
While alternate methods have been used on occasion2, the second step 
typically involves ligation of these fragments into an expression plasmid with 
transformation of an E. coli host.  One should note that other vectors, in theory, 
could support longer DNA inserts (i.e. cosmids or bacterial artificial 
chromosomes).  However, these systems suffer from the fact that they would rely 
upon native promoters for recombinant expression.  Given the small size of 
Caudoviral genomes (several dozen to several hundred kilobases), plasmid-
based screens are still capable of identifying lytic clones with high efficiency.  In 
past studies, for example, hits have typically been observed at a frequency of 0.1-
2% of total colonies (Schuch et al., 2008).   
When choosing a particular plasmid for lysin screening, the same 
variables must be taken into consideration as during the recombinant expression 
of any protein.  These include the type of promoter, induction conditions, codon 
usage, and the host E. coli strain.  For a given lysin, the expression level and 
solubility can vary significantly from one system to the next, often in 
unpredictable ways.  Nevertheless, for a detailed protocol that we have found 
generally reliable, the reader is referred to Schuch et al. (2009).  The screen 
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outlined here utilizes an arabinose-inducible pBAD plasmid, which is attractive 
for its tight transcriptional control and the cost-effective nature of the inducing 
agent. 
 For the final steps of a lysin screen, induction and selection of positive 
clones, the following experimental manipulations are typically involved.  
Transformed E. coli are spread onto agar plates that lack inducing agent, 
allowing clones to proliferate without transcription of genomic inserts.  These 
master plates are replicated onto screening plates whose agar has been 
supplemented with inducing agent.  After propagating with forced transcription, 
the clones are exposed to chloroform vapor to permeabilize the E. coli and allow 
free diffusion of the expressed proteins.  The clones are overlaid with a soft agar 
media containing Gram-positive cells.  The plates are observed over time for 
clones over which there develops a zone of diminished bacterial density, 
indicating the presence of a lysin-encoding gene (see Figure 1.8).  The 
corresponding clone on the master plate is subsequently identified and expanded 
for sequencing and large-scale expression.  In early functional screens, the 
process occasionally differed in minor aspects (for instance, in the logistics of 
replica-plating or cell permeabilization).  In current studies, however, this 
procedure has become the norm. 
 The main enduring variable in the process of lysin identification lies at the 
end of the procedure, as several options are available regarding the type and 
quantity of Gram-positive bacteria in the soft-agar overlay step.   
Figure 1.8 Lysin-Induced Clearing Zone 
To identify a phage lystic enzyme in a functional screen, Gram-positive 
bacteria are overlayed on permeabilized E. coli clones expressing phage 
genomic inserts.  The desired clone (indicated above with an arrow) is 
identified by the development of a surrounding halo of Gram-positive lysis.  
The particular example shown here involves B. anthracis (strain 222) cells 
and the PlyB lysin from the BcpI phage (Porter et al. 2006).  One should note 
that the realtive size and intensity of the of the halo can vary depending on 




Table 1.5 summarizes these techniques and the individual studies in which they 
have been employed over the years.  In a few studies, permeabilized clones were 
overlaid with concentrated Micrococcus cells (Jayaswal et al. 1990; Bon et al. 1997).  
Decreased micrococcal turbidity is a classic method of quantifying the activity of 
eukaryotic peptidoglycan hydrolases (Shugar 1952).  The majority of screens, 
however, have utilized the host bacteria of the phage whose genome was being 
screened.  This makes intuitive sense considering the specificity that lytic 
enzymes demonstrate toward host organisms.   
At the same time, several variations do exist as to how these cells are 
applied.  The permeabilized clones can be overlaid with either [I] concentrated-
viable bacteria, [II] concentrated-nonviable bacteria (typically autoclaved), or [II] 
dilute-viable bacteria.  In the first two cases, plates are observed for clones 
around which bacterial density decreases, while, in the third, they are observed 
for clones around which bacteria fail to proliferate.  Previous examples of each 
approach include, respectively: several L. monocytogenes lysins (Loessner et al. 
1995); an enzyme targeting a novel Staphylococcus strain (Yokoi et al. 2005b); and 
the amidase of the  diagnostic phage of B. anthracis (Schuch et al. 2002).  
 While there has never been a dedicated study comparing the relative 
efficacy of these three variations, each type of overlay has been utilized within 
the Rockefeller University Laboratory of Pathogenesis with general effectiveness.  
One notable benefit, however, of employing dilute-viable cells is its particularly 
high level of sensitivity.   
Table 1.5 Lysins Cloned Through Functional Genomic Screening 
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Table 1.5, continued  
Provided here is a complete list (as of 2009) of recombinantly-expressed 
phage lytic enzymes against Gram-positive bacteria for which the original 
means of identification was a functional genomic screen.  They are 
organized by screening methodology, and include the corresponding target 
bacteria and year of identification.  The methodologies include: overlay by 
micrococcal cells; overlay by concentrated, viable Gram-positive bacteria 
(GPB) of the target species; overlay by concentrated, nonviable GPB; and 
overlay by dilute, viable GPB.  For two entries (Shearman et al. 1989; 
Henrich et al. 1995), a -phage screening strategy was used in place of a 




Since only enough lysin is required to prevent the growth of a small initial 
population, clearing zones are often evident even when an enzyme is not well 
expressed under the screening conditions.  Using this method, clearing zones 
have been observed even in instances when a particular clone does not produce 
sufficient lysin for recombinant purification or detection by Coomassie-staining 
(unpublished observations).  
Several other factors must likewise be considered when selecting a 
particular overly technique.  For instance, certain bacteria can react poorly to 
heat-killing (e.g. with aggregation or lysis), rendering the concentrated-nonviable 
approach ineffective.  Other bacterial organisms can interact non-specifically 
with the E. coli library clones when proliferating in soft agar, leading to 
widespread pseudo-clearing clones for the dilute-viable method.  While it is 
difficult to predict what approach is ideal for a given species/strain, this should 
not prevent one from successfully cloning a lytic enzyme.  All three techniques 
are ultimately straightforward, and (as replica plating is not a time-consuming 
step) one can readily conduct multiple types of overlays from each master plate. 
 
Recent additions to functional screening.  Despite the general success of the 
proceeding techniques, they are not the only functional methods available for 
cloning phage lysins.  Indeed, several additional strategies have been devised 
recently that complement or expedite these approaches.  One such example is 
holin-based screening for lytic enzymes.  As described above, it is the combined 
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action of lysin and holin that leads to host-cell lysis and the release of progeny 
viral particles.  The necessity of both proteins during phage infection explains 
why lytic enzymes can be overexpressed recombinantly in E. coli: even if a given 
lysin possesses activity against the E. coli peptidoglycan, it cannot exert a toxic 
effect as long as it is sequestered in the cytoplasm.  By contrast, co-expression of 
both lysin and holin can lead to marked toxicity, as holins can integrate non-
specifically into cytoplasmic membranes (including those of an E. coli host).    
 Due to the genomic adjacency of holins and lysins, lysin-containing 
fragments in shotgun libraries commonly encode holins as well.  This creates the 
potential for selective toxicity of exactly the clones one hopes to identify.  When a 
lysin-encoding clone is identified in an enzyme-based screen, it is generally one 
in which either [I] the holin and lysin happen not to be encoded adjacently in the 
particular genome, [II] the holin (fortuitously) is not sufficiently expressed, or 
[III] only a limited amount of genomic DNA surrounds the lysin, excluding the 
complete holin.  Due to the small size of phage genomes and the resultant high 
proportion of lysin-encoding clones, the issue of holin toxicity has not proven a 
tremendous obstacle in past screens.  Nevertheless, several studies have looked 
to avoid the situation altogether by selecting for holin-encoding clones.  By 
targeting the holin genes, it is possible to identify adjacent lysins without 
actually observing lysin activity. 
 In this regard, Delisle et al. utilized a plasmid release protocol to identify a 
phage lytic enzyme for the dental pathogen Actinomyces naeslundii (2006).  For 
69 
 
this study, mixed E. coli transformants were grown in a single liquid culture.  
Following induced expression, holin-encoding cells would undergo lysis, 
releasing their plasmid into the culture media.  The plasmids were then purified 
and used to retransform a new set of competent E. coli.  Through several rounds 
of this procedure, the authors were able to enrich for a set of clones encoding the 
holin-lysin region, ultimately allowing them to sub-clone and express the lytic 
enzyme.   
 One additional technology with potential relevance to lysin identification 
is that of whole-genome amplification.  PCR-based methods have recently come into 
prominence that allow for general amplification of viral (along with bacterial or 
eukaryotic) DNA.  These include the use of linker-based amplification (see 
Chapter 3), as well as high-diversity primers in combination with the ultra-
processive 29 polymerase.  For a review that discusses genome amplification 
specifically in the context of viruses, the reader is referred to Delwart et al. (2007).   
 The significance of these techniques lies in the access they provide to 
exceedingly small biological samples, as once-undetectable genetic material is 
now available for analysis.  From the perspective of lysin screening, whole-
genome amplification can significantly expedite the preparation time for library 
construction.  Purification of phage DNA is a relatively time-intensive process 
compared to that of cellular organisms.  Depending on the phage and the growth 
properties of the host, obtaining a high-enough viral titer for microgram 
quantities of DNA (typically required for shotgun cloning) can represent several 
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days to several weeks of work.  By amplifying a small initial quantity of phage 
DNA, one can side-step this issue and obtain essentially a limitless supply of 
genomic material. 
  
Lytic enzymes and whole-genome sequencing.  Despite this growing array of 
techniques, functional screening still represents only one side of the ongoing 
effort to clone lytic enzymes.  In fact, only ~50% of phage lysins that have been 
recombinantly expressed to date were first identified in this manner.  Many 
others, at the same time, have been the result of genomic sequencing and 
nucleotide homology analysis.  The field of whole-genome sequencing has 
expanded rapidly in recent years (for viruses, bacteria, and eukaryotes), driven 
in large part by the development of high-throughput technologies like 454 
pyrosequencing and Illumina/Solexa sequencing-by-synthesis (Strausberg et al. 
2008).   Publications documenting complete phage genomes have become 
commonplace, and a growing number of studies now focus on the genomes of 
numerous, interrelated phage.  To date, 500+ complete phage genomes are 
present within the NCBI database (not counting prophage), and this number is 
expected to increase substantially in the near future (Hatfull 2008).   
The impact of genomic sequencing on lysin research is simple: whenever 
the genome of a new phage is reported, another lysin gene is uncovered.  Their 
enzymatic motifs and overall structure are sufficiently conserved that standard 
algorithms (e.g. Blast, Pfam) generally make it possible for one to recognize a 
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lytic enzyme from a sequence alone.  Overall, identifying these enzymes through 
nucleotide homology is not a new concept; it was mentioned before that two of 
the earliest-known lysin genes (from the Salmonella P22 and B. subtilis 29 phage) 
were discovered based on their similarity to the E. coli T4 lysin.  What 
distinguishes today‘s bioinformatic analyses is the large (and ever growing) size 
of public databases, which allow one not only to locate a lysin gene itself, but 
often predict its enzymatic mechanism, domain phylogeny, or even catalytic 
residues3.  These genes can then be PCR-cloned and tested for and activity.   
 Table 1.6 provides a chronological list of recombinantly-expressed lysins 
whose genes were initially identified though DNA sequence analysis.  With a 
single exception (O‘Flaherty 2005), the genes were PCR-cloned directly from 
genomic DNA.  In the one instance, a staphylococcal lysin was interrupted by an 
intronic sequence, requiring the investigators to extract mRNA from infected 
bacteria and prepare cDNA as an amplification template.  Aside from the 
increasing number of lysins in recent years, Table 1.6 reveals several important 
trends.  For instance, whereas earlier lysins were often discovered within partial 
genomic sequences (i.e. a fortuitous sampling of restriction fragments), recently-
cloned enzymes have generally been identified from complete phage genomes.  
Presumably, this reflects both gains in sequencing technology, as well as 
improvements in functional techniques that make it possible to clone a lysin 
without resorting to partial sequencing.   
Table 1.6 Lysins Cloned Through Genomic Sequencing 
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Table 1.6, continued  
Organized by date, this table lists recombinantly-expressed lysins against 
Gram-positive bacteria which were originally identified through DNA 
sequencing and bioinformatic comparison to known proteins.  Three 
categories are present within the table: enzymes identified through partial 
sequencing of a phage genome, those identified through complete 
sequencing of a phage genome, and prophage lysins identified through 




One should likewise note that four lytic enzymes were amplified not from 
the genomes of individual phage, but rather from the genomes of their bacterial 
hosts.  These include PlyL (Low et al. 2005) and PlyPH (Yoong et al. 2006) from 
the Ames strain of B. anthracis, along with the LambdaSa1 and LambdaSa2 lysins 
from S. agalactiae 2603 V/R (Pritchard et al. 2007).   
Bacterial genomes in themselves represent attractive sources of lytic 
enzymes in the form of integrated viral DNA (this, in fact, is the focus of the next 
chapter of this thesis).  As the genomes of additional bacterial species/strains are 
sequenced, the number of prophage lysins that could serve as potential 
enzybiotics will only grow further. 
 
Sequence-based versus functional: pros and cons.  At this point, it is 
worthwhile to consider the relative advantages and disadvantages of identifying 
lysins through functional screening versus genomic sequencing and PCR-
cloning.  One of the most attractive features of the latter approach is its 
straightforward nature.  If one has isolated a phage and wishes to identify its 
lysin, genomic sequencing is a method for which success is highly likely.  The 
primary obstacle here is not cloning the gene itself, but rather identifying a 
suitable vector for active expression.  This challenge is true for all recombinant 
proteins, however, and is equally applicable to functional lysin screens.   
A sequence-based approach likewise allows one to mine genomic 
databases for lysins that have not yet been studied in detail.  In the process, one 
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can compare their putative biochemical properties and overall uniqueness 
through bioinformatic analysis (again, see Chapter 2).  For example, a lysin with 
a catalytic domain that is unique for a particular host bacteria is far more 
attractive than a lysin that is highly similar to a previously-expressed enzyme.  
Overall, while it is not always the case that a desired sequence is present within 
public databases, it is always advantageous to check, as this represents easily the 
most rapid singular approach to expressing a novel lysin. 
 Of course, identifying lysins through nucleotide homology does not 
always present the best optionquite frequently, the reason is purely logistical.  
Despite ongoing technological improvements, genomic sequencing does not yet 
represent an insignificant investment of time and resources, and high-
throughput access is far from universal.  For a majority of laboratories, functional 
screening is still the most cost-effective and rapid method for identifying lytic 
enzymes from individual phage genomes.  With sequence analysis alone, 
moreover, there exists a small chance of overlooking a lytic enzyme due to an 
atypical sequence.  While they are uncommon, lysins are occasionally identified 
whose genes deviate significantly from the norm.   
The most prominent example is the streptococcal C1 lysin (PlyC), 
described previously in this section for its early role in lysin purification.  The C1 
genomic sequence, reported in 2003, revealed an abnormal lytic region in which 
a putative holin (ORF8) lied adjacent to several ambiguous open reading frames 
(Nelson et al.).  While the theoretical translation of ORF9 corresponded to a 
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partial Edman sequence of the purified enzyme, none of ORFs demonstrated 
typical lysin features or possessed a molecular mass corresponding to PlyC.  
Only when the authors functionally screened the C1 genome and dissected the 
ORFs of the lytic clone were they able to determine that PlyC represents a unique 
multimeric phage lysin (resulting from ORFs 9 and 11) (Nelson et al. 2006).  In 
fact, PlyC remains without any homologues among sequenced phage, and it is a 
remarkable coincidence that one of the first lysins ever purified is so atypical.   
 Just recently, another highly novel lysin was reported for the IN93 phage 
of the extremophilic bacterium Thermus aquaticus (Matsushita and Yanase, 2008).  
Employing a more classical approach, the authors first purified the enzyme from 
infected culture supernatant and subjected it to Edman sequencing.  The N-
terminal amino acids were then cross-referenced to the sequenced genome to 
locate the lysin-encoding ORF, which until that point had remained unidentified 
due its lack of recognized domains or homology to other proteins.  While the 
authors did not utilize a functional screen to identify the enzyme, per se, this case 
again demonstrates how genomic sequences alone can occasionally be 
insufficient for lysin identification.  Overall, the value of this particular enzyme 
lies not in its anti-infective potentialT. aquaticus is neither Gram-positive nor 







OBJECTIVES AND OVERVIEW OF THE THESIS PROJECT 
The present body of research.  Between sequence-based and functional cloning 
approaches, the number of phage lysins that have been subject to recombinant 
analysis has steadily increased in recent years.  This trend should only continue, 
especially if pre-clinical work these enzymes successfully progresses to human 
trials.  At the same time—and despite their widespread use—the techniques 
described above are no longer the only (or even, necessarily, the most efficient) 
avenues for identifying new enzybiotic candidates.  My doctoral research at 
Rockefeller has addressed this very issue.  Broadly stated, the work presented in 
this thesis explores new approaches for cloning novel phage lytic enzymes.  The 
underlying motivation for this research is straightforward: by increasing the 
number characterized lysins, one will only hasten the development of these 
molecules into effective biomedical tools. 
 The work presented here does not focus on any particular bacterial 
pathogen or phage lysin.  Rather, the focus is on the process, and how researchers 
can move beyond traditional approaches in the lysin field—this includes a 
combination of [1] strategy and [2] methodology.  Strategy refers to potential 
genetic sources of lysins and whether it is possible to look for these enzymes 
elsewhere than individual phage genomes.  Methodology refers to experimental 
techniques and the creation of new protocols that will make cloning lytic 
enzymes more efficient and expansive.  This thesis is divided into four 
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individual sections (Chapters 2 - 5), each of which represents an independent 
(yet interrelated) investigation into strategy and/or methodology. 
 Chapter 2 focuses on bacterial genomic sequencing and its impact on the 
lysin field.  The recent explosion of sequenced bacterial genomes—which 
naturally include integrated prophages—has revealed numerous ORFs that can 
be assigned putative lysin functionality based on homology analysis.  In the past 
several years, in fact, the number of theoretical prophage lysins in computational 
databases has come to dwarf the number of lysins whose activity has been 
studied experimentally.   Identifying prophage lysins via bacterial genomic 
sequencing is no different than the phage-sequencing strategy discussed above.  
The difference now, however, is that high-throughput sequencing technology 
has made entire bacterial genomes (several Mb) as accessible as their smaller 
phage counterparts (tens of kb).  As a result, numerous prophage enzymes can 
be rationally compared and rapidly cloned without ever having to work with 
phage itself.   
Chapter 2 takes advantage of this information for the pathogenic anaerobe 
Clostridium perfringens.  The recently-sequenced genomes of 9 strains of C. 
perfringens were computationally mined for proviral lytic enzymes, and a 
comprehensive list of lysins was constructed and compared.  From this list, a 
particular enzyme was chosen for cloning, expression, and in vitro analysis based 
on its dissimilarity with the only other previously-studied C. perfringens lysin.  
Various biochemical properties of this lysin were determined, as well as its 
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activity profile against a panel of C. perfringens, non-perfringens clostridia, and 
other Gram-positive bacterial species. 
 By contrast, Chapter 3 of this thesis changes course; it is the first of two 
chapters to explore the rapidly expanding field of metagenomics as it relates to 
lytic enzymes.  Metagenomics refers to the direct expansion of DNA/RNA from 
environmental samples without first isolating and cultivating any of the 
individual component microbes (the reader is referred to the individual chapter 
for a more detailed review).  While the initial focus of metagenomics research 
was on environmental bacteria, the field has since expanded to include 
investigations of uncultured viruses.  In these studies, viral particles (consisting 
primarily of phage) are separated in bulk from environmental bacteria and other 
debris prior to DNA extraction and analysis. 
 To date, viral metagenomics has been primarily sequence-based in nature; 
here, uncultured phage sequences are compared to known genetic databases to 
address broad questions of phage biology and ecology.  On the other hand, 
functional screening of viral metagenomes could provide direct access to 
targeted classes of recombinant molecules.  Phage lysins, of course, represent an 
intriguing example.  Nevertheless, functional metagenomic screens for lytic 
enzymes would present several distinct challenges.  The goal of Chapters 3 and 4 
is to address these challenges and make metagenomic lysin screens a reality. 
Chapter 3 focuses on the issue of DNA quantity, as environmental phage 
samples do not typically provide a sufficient quantity of genetic material for 
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functional screening.  A technique known as E-LASL (for expressed linker 
amplified shotgun library) was developed that combines linker amplification of 
fragmented DNA with commercial topoisomerase cloning.  This creates a rapid 
protocol for constructing (in an E. coli host) expressible plasmid-based libraries 
from nanogram quantities of DNA (a typical yield for viral metagenomic 
extractions).  To validate the technique, various genomic libraries were 
constructed from Bacillus phage, and six lytic enzymes for B. anthracis were 
successfully cloned.  Additionally, a bacterial metagenomic E-LASL was 
constructed from the gut contents of an earthworm, and an active virulence 
factor was cloned in a subsequent hemolysis screen. 
With this method for library construction in place, Chapter 4 develops a 
procedure for selecting E. coli transformants that encode and actively express 
metagenomic lysins.  The method circumvents additional challenges that face 
metagenomic lysin screening, ones involving holin-induced toxicity of lysin-
encoding clones and the choice of an appropriate selection agent (see Chapter 4 
for additional information).  The technique utilizes two sequential steps:  a 
toxicity screen is first employed in which colonies are selected for holin-induced 
lysis following induced expression.  In a secondary step, then, the initial hits are 
overlaid with autoclaved Gram-negative bacteria (specifically Pseudomonas 
aeruginosa) to assay directly for the production of lytic enzyme.  As proof-of-
principle, a viral metagenomic library was constructed from mixed animal feces 
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and subjected to the screen.  It was validated by the successful cloning of 26 
lysins of various enzymatic activities and diverse modular architectures.   
 Finally, Chapter 5 takes the techniques developed in the preceding 
chapter and reapplies them back to a genomic DNA library.  While the two-step 
screen was designed with metagenomes in mind, it is still applicable to more 
traditional sources of lysins.  In this respect, the genome of a clinical strain of 
Streptococcus suis (a veterinary and opportunistic human pathogen) was subject 
to the screen, and a single prophage lysin was successfully cloned (PlySs1).  An 
additional prophage lysin (PlySs2) was likewise identified and cloned via 
inspection of various published S. suis genomes (i.e. in the same manner as 
PlyCM).  The PlySs1 lysin was subsequently purified and characterized so that it 
could be included in an ongoing veterinary trial involving experimentally-
infected pigs. 
 
Dissertation format.  At this point, before going on to present the research itself, 
it is necessary to provide some brief logistical information on the format of this 
thesis.  Although the work presented here is designed to be read as a single 
coherent document from beginning to end, Chapters 2 - 5 each represent a 
distinct sub-study in its own right.  For every individual chapter, the work 
described has been drafted into a separate manuscript for publication in a peer-
reviewed journal.  One of the studies (corresponding to Chapters 3) has already 
been accepted (Schmitz et al. 2008); the work in Chapter 4 has been submitted 
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and is currently under review (Schmitz et al. 2010b); and the work in Chapters 2 
and 5 will be submitted shortly.  Moreover, it should be noted that portions of 
this Introduction and have appeared in similar form in a recently published text 
(Schmitz et al. 2010a).  As a result of this breakdown, Chapters 2 -5 have been 
formatted so that (if desired) each can be read individually without loss of 
comprehension. 
The layout of Chapter 2 - 5 is each essentially the same.  They begin with 
an Introduction that provides additional background information on the 
particular research-related aspects of the chapter (for instance, this is where the 
reader would find an overview of C. perfringens, S. suis, or the field of 
metagenomics).  The Materials and Methods section details the experimental 
protocols employed in the chapter.  The data itself is reported in Results, and the 
Discussion analyzes the significance of that data in light of the current state of the 
field.  Several chapters include endnotes that provide additional commentary on 
particular points in the text.  Chapter 6 reflects upon the entire body of work and 
comments on future avenues for lysin discovery (as well as the discovery of 
enzybiotics other than phage lysins).  A single References section is included at 
the end of the document, along with an appendix that provides sequence 
information (DNA and amino acid) for all genes cloned here.   
From reading this thesis, one should gain an appreciation of just how 
rapidly the study of phage lysins and other enzybiotics has accelerated in recent 
years.  Considering the unrelenting emergence of antibiotic resistance, this work 
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should continue unabated into the foreseeable future.  Its eventual goal, of 
course, is to develop these agents to the point where they can have a positive 
impact on human health.  The process will take time, effort, good science, and a 
little luck.  But, fundamentally, it is still dependent on the efficient and intelligent 
identification of candidate enzymes.  It is my hope that the work presented here 
will contribute to that process, and (at least in a small way) will help bring the 
term enzybiotic from a promising idea to a proven reality. 
 
ENDNOTES 
1.  While it is true that several reports have documented the use of lytic enzymes 
against viable Gram-negative organisms (Alakomi et al. 2000; Morita et al. 2001a; 
Kim 2004; Briers et al. 2008), this activity was either quantitatively weak or 
required the addition of a general membrane-disrupting agent.  One should note, 
however, that co-treatment of Gram-negative bacteria with a membrane-
permeabilizing agent and a peptidoglycan hydrolase is already a common 
practice: it is the basis of commercial genomic extraction techniques and has 
various shortcomings from a drug-development perspective. 
 
2.  In the body of the text, we discuss the prevalent strategy for fragmenting and 
transforming phage genomic DNA for lysin screening (i.e. shotgun cloning into 
plasmid vectors).  Although no longer generally employed, alternative screening 
techniques were occasionally used in early studies.  For example, when cloning 
the lysin of a lactococcal phage, Shearman et al. utilized a -phage system that 
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relied upon infected E. coli for recombinant lysin expression (1989).  Henrich et 
al. also employed -phage when cloning a Lactobacillus lysin.  This study 
involved a defective -strain that required ligation of a complementary lysis 
cassette to form plaques on E. coli (1995).   
Furthermore, one should note that E. coli is not the only host that, in 
theory, could be used for lysin screening.  While it has been utilized exclusively 
to date, there is nothing about this species that makes it particularly well-suited 
for identifying lytic clones (other than the commercial prevalence of E. coli 
expression systems).  Lysins have been expressed recombinantly from other 
bacterial species for purification purposesand, in certain cases, these alternate 
species offered superior expression to E. coli (Yoong et al. 2004). 
 
3.  It is not always possible, however, to determine such information from a 
nucleotide sequence alone.  While analysis of a lysin‘s sequence typically reveals 
a conserved domainwhich, in turn, implies an enzymatic mechanismlytic 
enzymes with ambiguous domains are still reported (see the section ―Sequence-
Based versus Functional: Pros and Cons‖).  Moreover, computational analysis 
alone can occasionally make mistakes regarding a lysin‘s biochemical properties.  
For example, one recent study describes two S. agalactiae lysins that were 
predicted to encode alanine-amidase enzymatic domains.  Following expression 
and functional testing, they were instead determined to possess endopeptidase 
and glucosaminidase activity (Pritchard et al. 2007).   
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It is important to note that, for most phage lysins that have been studied 
recombinantly, the reported enzymatic activity was based on computational 
predictions rather than experimental observations.  While these predictions 
should be correct in a majority of circumstances, it still leaves open the 
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 Over the past decade, phage lytic enzymes (a.k.a. lysins or endolysins) 
have been the focus of a great deal of applied microbiological research (Villa and 
Veiga-Crespo 2010; Fischetti 2008; Borysowski et al. 2005; Loessner 2005).  
Encoded by virtually all double-stranded DNA phage, lysins are expressed late 
in the cycle of phage infection.  They are responsible for hydrolyzing the 
peptidoglycan of the host bacterium and—along with membrane permeablizing 
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proteins known as holins—they allow progeny viral particles to escape the 
cytoplasm and reinfect new cells (Gasset 2010).   
Biotechnological interest in these proteins stems from their ability to lyse 
Gram-positive species when applied exogenously, as the peptidoglycan of these 
organisms is directly accessible from the extracellular space.  Phage lysins have 
been proposed as novel enzybiotic (enzyme-antibiotic) agents against human and 
veterinary pathogens, in addition to other potential uses in the areas of food 
(Deutsch et al. 2004), agricultural (Kim et al. 2004), and industrial (Ye and Zhang 
2008) science.  Numerous individual lysins have been recombinantly expressed 
and characterized to date, including successful in vivo trials involving various 
animal models of colonization and infection (Daniel et al. 2010; Grandgirard et al. 
2008; Nelson et al. 2001).  Their appeal lies in both their potency and their 
specificity toward individual bacterial species, typically the host organism of the 
encoding phage. 
 Both enzymatically and architecturally, the lysins are a highly diverse 
group of proteins.  Gram-positive lysins are classically modular, 250-400 amino 
acids in length, with an N-terminal enzymatic domain and a C-terminal binding 
domain (Fischetti 2008).  The enzymatic domain itself can target numerous bonds 
within the peptidoglycan macromolecule.  These include: muramidase (glycan 
backbone, Porter et al. 2007), glucosaminidase (glycan backbone, Pritchard et al. 
2007), alanine-amidase (stem position ; Schuch et al. 2002), alanoyl-glutamate 
endopeptidase (stem position ; Korndörfer et al. 2008), glutaminyl-lysine 
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endopeptidase (stem position ; Pritchard et al. 2007), and cross-bridge 
endopeptidase (Baker et al. 2006).  The C-terminal domain likewise binds one of 
various epitopes within the target cell envelope (e.g. surface carbohydrate, 
choline, or peptidoglycan itself), and it is largely responsible for the specificity of 
a lysin toward particular bacteria (Diaz et al. 1991).  Gram-negative lysins, by 
contrast, are typically smaller and are comprised of an enzymatic domain alone.  
Occasionally, lysins are identified that do not conform to standard architectures, 
including Gram-positive lysins with multiple enzymatic domains (Baker et al. 
2006), Gram-negative lysins with an N-terminal binding domain (Briers et al 
2007), and a multimeric Gram-positive lysin (Nelson et al. 2006).   
 Most lysins characterized to date have been cloned through traditional 
phage genomic techniques (Schmitz et al. 2010a).  Here, a phage is first isolated 
through environmental sampling or prophage induction, and its genomic DNA 
is extracted following laboratory culture.  At this point, either the phage genome 
may be sequenced and the lysin-encoding ORF identified through sequence 
homology with known enzymes, or the DNA can be fragmented and subjected to 
a recombinant functional screen.  In the latter case, the lysin-encoding fragment 
is identified by its ability to confer a bacteriolytic phenotype on a host clone.  
While generally successful, these methods are still rather time-consuming and 
wholly defendant on the successful isolation/propagation of the initial phage.  
Moreover, they cannot predict a priori how novel the identified lysin will be 
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relative to previously-characterized enzymes, nor can they assess total lysin 
diversity for a particular bacterial host.   
In this regard, the rapidly expanding number of published bacterial 
genome sequences (1000+ at the time of writing) could prove quite valuable.  
Representative genomes have now been sequenced for hundreds of bacterial 
species; for many medically/technologically-relevant bacteria, numerous 
individual strains have been sequenced 
(www.ncbi.nlm.nih.gov/genomes/lproks.cgi).  If a particular strain is 
lysogenized with prophage, its genome becomes an easy source of lytic enzymes, 
which can be rapidly cloned through PCR.  In the case of polylysogenized strains 
or species with multiple sequenced strains, one can systematically compare the 
different lysins and their predicted properties (particularly enzymatic and 
binding domains) before choosing which one(s) to express.  In the current study, 
we wished to do precisely this—computationally analyze all known prophage 
lysins for a particular Gram-positive pathogen, and use this information as a 
guide for subsequent recombinant analysis. 
For this work, we chose to focus on the spore-forming, anaerobic rod 
Clostridium perfringens, one of the most frequently encountered species of 
clostridia in clinical and environmental laboratories.  C. perfringens is a common 
component of healthy human feces, and it is found in the digestive tracts of 
many other vertebrate and non-vertebrate animals, as well as environmental soil 
samples (Matches et al. 1974).  Despite its ubiquity, C. perfringens can 
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nevertheless be the etiological agent of various pathologies.  The species is 
taxonomically subdivided into five toxinotypes (A-E) based on the combinatorial 
presence of at least 15 exotoxins gene, including alpha, beta, beta-2, epsilon, iota, 
and enterotoxin/CPE (Smedly et al. 2004).  These toxins may be encoded on 
mobile genetic elements and they help determine a strain‘s pathogenic potential.   
The most commonly encountered toxinotype of the healthy human bowel 
(enterotoxin-negative type A, Carman et al. 2008) can induce myonecrosis in the 
context of wound infection (Bryant and Stevens 1997).  Enterotoxin-positive type 
A strains are prevalent agents of food-borne illness, causing up to 600,000 cases 
of self-limited enteritis annually in the United States (McClane 1997).  And while 
cases are uncommon, type C strains are the agents of the potentially-fatal gut 
condition enteritis necroticans (Lawrence 1997).  In addition to these human 
illnesses, all 5 toxinotypes of C. perfringens have been implicated in various 
maladies of poultry and livestock (van Immerseel et al. 2009; Uzal and Songer 
2008). 
To date, a single phage lysin for C. perfringens has been subject to 
recombinant expression and analysis.  Zimmer et al. (2002a) induced a temperate 
siphovirus (3626) from toxinotype B strain ATCC 3626 and sequenced the 
phage‘s 33.5 kB genome.  The ORF encoding the lytic enzyme (Ply3626) was 
subsequently identified by sequence homology and cloned into an inducible E. 
coli expression plasmid (Zimmer et al. 2002b).  The authors demonstrated that 
crude extracts of the induced E. coli clone were capable of lysing buffered 
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suspensions of viable C. perfringens.  Although the degree of lysis varied from 
strain to strain, every isolate of C. perfringens tested (48/48) demonstrated 
susceptibility to Ply3626, even ones that were not susceptible to infection by the 
phage itself.  In comparison, non-perfringens clostridia and other Gram-positive 
genera demonstrated virtually no susceptibility to the lysin.  It has subsequently 
been suggested that Ply3626 could be used as a topical agent or food additive to 
prevent associated illnesses (Jay et al. 2005; Zimmer et al. 2008). 
Since the above work on Ply3626, the genomes of 9 different strains of C. 
perfringens have been sequenced, all of which contain identifiable prophage 
regions (Shimizu et al. 2002; Myers et al. 2006; 
gsc.jcvi.org/projects/msc/clostridium/).  In the present study, we systematically 
examined the prophage lysins in these sequences, comparing them based on 
sequence homology and domain composition.  In the process, we identified 14 
lysin genes and 31 lysin-like genes (the latter being defined as having high 
homology to the lysins throughout their entire sequence, lacking a signal 
peptide, but not being encoded in a recognizable prophage region).  These 
proteins could be categorized into three enzymatic classes: type 2 alanine-
amidase, type 3 alanine-amidase, and muramidase (glycosyl hydrolase, type 25).   
Of the identified genes, a muramidase lysin from strain ATCC 13124 was 
selected for cloning and expression based on its divergent catalytic mechanism 
from Ply3626.  Following purification, the enzyme (termed PlyCM, for clostridial 
muramidase) was subject to a variety of in vitro tests to determine its potency, 
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specificity, and biochemical properties.  Overall, this work adds another phage 
lysin to the growing list of candidate enzybiotics, demonstrating an important 
role for comparative genomics in the development of these proteins. 
 
MATERIALS AND METHODS 
Computational identification/analysis of lytic enzymes.  The genomes of the 
following sequenced strains of C. perfringens were included in this study: ATCC 
13124 (toxinotype A, NCBI genome project #304); SM101 (A, #2521); 13 (A, #79); 
F4969 (A, #20031); NCTC 8239 (A, #20033); ATCC 3626 (B, #20027); JGS1495 (C, 
#20025); JGS1721 (D, #28587); JGS1987 (E, #20029).  The first step in compiling a 
comprehensive list of prophage lysins was to identify obvious proviral regions 
within each genome.  This was accomplished through a combination of manual 
inspection of the annotated ORFs and use of the prophage prediction algorithm 
Prophinder (Lima-Mendez et al. 2008).   
The lysin-encoding ORFs within each prophage regions were next 
selected.  In many cases, these ORFs were already designated explicitly (e.g. 
―endolysin‖) by the database annotation.  For other prophage, the existing 
annotations were insufficient—in these cases, we performed Pfam domain 
analysis on the individual proteins in the region (Finn et al. 2009; 
pfam.sanger.ac.uk/).  A set of several criteria (described in detail in the Results 
section) were applied to the Pfam predictions in order to designate a lysin for 
each case, and a preliminary list of probable lysin-encoding ORFs was compiled.  
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To ensure that no enzymes were overlooked in the process (for instance, ones 
encoded within short prophage remnants) the list was subjected to iterative Blast 
analysis (Altschul et al. 1990; blast.ncbi.nlm.nih.gov/Blast.cgi).  The protein 
sequences on the initial list were BlastP-queried against the nine sequenced C. 
perfringens genomes.  Any newly-identified homologs were added to the original 
list, and the process was repeated until no new ORFs were revealed.  The 
aforementioned criteria were then applied to the expanded list to eliminate any 
ORFs that were included erroneously. 
The sequences comprising this final list were phylogenetically compared 
to one another through the Phylip v3.67 package (Felsenstein 1989; 
evolution.gs.washington.edu/phylip.html).  The translated protein sequences 
were subject to multiple sequence alignment through the ClustalX algorithm, 
followed by 1000 rounds of boot-strapping with seqboot.   These alignments were 
analyzed in turn by the protdist (distance matrix generating) and fitch (tree 
generating) algorithms with default settings, and an unrooted consensus tree 
was generated with consense.  The enzymes were compared with other known 
proteins with the BlastP algorithm (blast.ncbi.nlm.nih.gov/Blast.cgi), using 
default search settings and the non-redundant protein database (nr).  Signal 
peptide predictions were made via the SignalP v3.0 server (Bendston et al. 2004; 
www.cbs.dtu.dk/services/SignalP/), employing both hidden Markov and 




Expression and purification of PlyCM.  Extracted genomic DNA from C. 
perfringens ATCC 13124 was subjected to taq-based PCR amplification with the 
following PlyCM-targeted primers: 
ACCATGGAAAGTAGAAACAATAATAATTTAAAAGG (fwd) and 
GTCAGATATTACTCTAACTAACCTTAAAA (rev).  The underlined G in the 
forward primer was intentionally altered from the wild-type C at that position (a 
Q2E mutation) in order to introduce an NcoI restriction site that overlaps with 
the start codon.  The PCR amplicon was topoisomerase cloned into pBad-TOPO 
(Invitrogen), an arabinose-inducible E. coli expression plasmid.  This construct 
was subsequently purified, NcoI-digested, and re-circularized to eliminate a 
plasmid-encoded N-terminal leader sequence and ensure translation from the 
native start codon.  This final construct was maintained and expressed in TOP10 
E. coli. 
 To express PlyCM, the clone was grown in LB broth to OD600 ≈ 0.5 and 
induced with 0.2% L-(+)-arabinose.  Following induction, the culture was shaken 
rigorously overnight at 30C; this specific temperature was important, as 
inclusion bodies preferentially formed at 37C.  The expressing cells were 
pelleted, resuspended in 15 mM phosphate buffer pH 7.4, and lysed by three 
passages through an EmulsiFlex C-5 homogenizer.  Cellular debris was removed 
by ultracentrifugation (1 hr, 35,000 X g), and the supernatant was (NH4)2SO4-
precipitated to 40% saturation (226 g/L).  The precipitated protein (which 
included the predominant amount of PlyCM) was pelleted, resolubilized in 15 
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mM phosphate buffer pH 7.4 (buffer A), and dialyzed against this buffer 
overnight. 
 The protein solution was next passed through a DEAE anion-exchange 
column equilibrated against buffer A (fast flow resin, General Electric).  Based on 
PlyCM‘s theoretical isoelectric point of 5.1, one would predict it to bind to DEAE 
at a pH of 7.4.  Nevertheless, the protein demonstrated an unusual 
chromatographic response: it neither bound the column in earnest nor flowed 
directly through it.  Rather, there was a transient interaction in which PlyCM 
would initially bind the resin, but then slowly elute over 5+ column volumes as 
the column was washed with buffer A (see Figure 2.1).  Although atypical, this 
property provided a fortuitous purification step, as PlyCM could be separated 
from the proteins in both the flow-through and tightly-bound fractions.  The 
PlyCM-containing ―slow wash fraction‖ was immediately passed through a 
ceramic hyroxyapatite column (Macro-Prep type II, 40 m, Bio-Rad) equilibrated 
against the same buffer A.  The lysin demonstrated non-transient binding to this 
resin, and it was subsequently concentrated/purified through a 20 column-
volume elution with buffer B (500 mM phosphate buffer pH 7.4), eluting at ~80 
mM.   
In the hours following purification, we observed that PlyCM would 
undergo irreversible precipitation in simple phosphate buffer.  Addition of L-
arginine to the lysin solution mitigated the precipitation, as has been reported for 
other recombinant proteins (Hamada et al. 2009).   
Figure 2.1 PlyCM Purification 
PlyCM was purified through a combination of DEAE and CHT 
chromatography, as described in the Materials and Methods section.  
Chromatograms for each successive step are presented here.  In both cases, the 
peak corresponding to PlyCM is denoted with an arrow. 
   DEAE 




As a result, 100 mM L-arginine (pH = 7.4) was included in the PlyCM stock-
preparation prior to freezing, lyophilization, and storage at -20C.  Overall, the 
above protocol generated ~10 mg of purified PlyCM per liter of original E. coli 
culture. 
 
In vitro analysis of PlyCM.  The activity of PlyCM was examined predominately 
through optical density analysis.  The various strains/species of bacteria were 
grown on agar plates at 37C.  Schaedler agar with vitamin K1 and 5% sheep‘s 
blood (Becton Dickinson) was employed for clostridial strains (perfringens and 
non-perfringens), and the bacteria were grown under anaerobic conditions.  For 
all non-clostridial strains, brain-heart infusion agar was employed with aerobic 
culture.  Following overnight growth, bacteria were scraped from the plates and 
suspended directly in buffer (which varied depending on the particular 
experiment) to the desired optical density.  PlyCM or lysin vehicle was added 
immediately prior to the start of each experiment, and OD600-measurments were 
conducted in 96-well plate format at 22C.  For experiments that involved CFU-
counts, each C. perfringens sample was diluted over five orders of magnitude, 
with triplicate plating at each dilution onto Schaedler agar.   
 
RESULTS 
We sought to compile a comprehensive list of phage lysins within all 
sequenced genomes of C. perfringens.  In doing so, the following criteria were 
used for designating a given ORF as a probable lysin: [1] The presence of an N-
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terminal enzymatic domain; [2] the presence of a C-terminal binding region1; [3] 
the absence of an N-terminal signal peptide; and [4] the absence of any 
additional domains with non-lysin function.  The third criterion is important 
because bacteria encode chromosomal peptidoglycan hydrolases (autolysins) 
that are involved in processes such as cell wall turnover, sporulation, and 
programmed death (Vollmer et al. 2008b).  Some autolysins possess the same 
domain architecture as phage lysins, except that they also typically include a 
signal peptide and transverse the plasma membrane via the type-II pathway 
(rather than with the aid of holins).  The fourth criterion is significant because 
phage themselves can encode other proteins (i.e. not lysins proper) that include 
peptidoglycan hydrolase domains, particularly structural proteins involved with 
DNA-injection (Rashel et al. 2008).  Usually, however, these structural lysins are 
readily discernable by their much greater size (upwards of 1000 amino acids) and 
the presence of additional domains. 
 In total, 45 ORFs were identified with the above criteria.  The GenBank 
accession numbers for their protein translations are provided in Figure 2.2, 
which depicts the predicted evolutionary relationships among the enzymes as a 
consensus phylogram.  Of the 45 proteins, 23 were predicted to possess N-
acetylmuramidase activity with an N-terminal GH-25 domain (glycosyl 
hydrolase type 25, Pfam accession number PF01183).  The 22 others were 
predicted to possess N-acetylmuramoyl-L-alanine-amidase activity.   
Figure 2.2 Lysin-Like ORFs in C. perfringens Genomes 
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Figure 2.2, continued 
The phylogenetic relationship among C. perfringens enzymes with phage-
lysin-like architectures is depicted here as a distance-based phylogenetic 
tree; the numbers at select nodes represent the consensus values following 
1000 rounds of bootstrap analysis.  The catalytic domain of each protein is 
indicated with the corresponding color scheme (see inset).  The proteins for 
which pfam analysis predicted a C-terminal SH3 type 3 domain (either a 
single or a dual) are marked with an asterisk*.  Of these 45 proteins, 14 
appear to be phage lysins proper, in that they are encoded within proviral 
regions within the C. perfringens genomes.  These are denoted with an 
underline.  The other lysin-like proteins are highly homologous to the phage 





Three encoded a type 2 alanine-amidase domain (PF01510), while 19 encoded a 
type 3 alanine-amidase domain (PF01520).  Although these two alanine-amidase 
families diverge sequentially, they target the same bond at the beginning of 
peptidoglycan‘s pentapeptide stem.  The only other characterized C. perfringens 
phage lysin, Ply3626, is a type 3 alanine-amidase and is specified in the figure. 
At their C-termini, 38/45 enzymes (also denoted in Figure 2.2) contained 
either a single or a double SH3-3 binding domain (PF08239).  For some of the 
proteins, the degree of alignment with the SH3-3 consensus sequence was rather 
low (E-value range: 10-17 – 0.03).  Although the molecular epitope is not well 
characterized, bacterial SH3 domains are commonly found in autolysins and 
phage lysins, and they presumed to function in binding the bacterial cell wall 
(Xu et al. 2009).  The other 7 enzymes possessed extended C-terminal regions (see 
Footnote 1), although Pfam failed to recognize any conserved domains.  One of 
these proteins, ZP_02636955, demonstrated Blast homology with the C-terminal 
regions of several of the other 45 enzymes.  Most likely, ZP_02636955 possesses 
the same binding functionality as the others, although its C-terminal domain 
differs too greatly from the SH3-3 consensus for Pfam recognition. Another 
enzyme, NP_562054, demonstrated closest C-terminal alignment (E-value ≈ 10-35) 
to a segment found within the C. perfringens bacteriocin BCN5 (Garnier and Cole 
1986).  Finally, a group of 5 muramidases (all clustered together in Figure 2.2), 
contained C-terminal regions that—while nearly identical to one another—
showed no homology to any other C. perfringens proteins. 
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Based on the selection criteria, we initially assumed all 45 of these proteins 
to represent legitimate phage lysins of proviral origin.  After inspecting the 
position of the ORFs within their respective genomes, however, it soon became 
apparent that this was not the case.  Many of the proteins (31/45) were encoded 
in genomic regions that did not correspond to prophage or prophage remnants.  
In fact, several patterns existed as to where these genes were encoded within the 
9 sequenced strains, including in the vicinity of UV-inducible bacteriocins.  The 
common occurrence of these lysin-like proteins within C. perfringens raises several 
interesting questions, and the issue will be discussed further in the Discussion 
section.  Fourteen of the enzymes did reside in clear prophage regions (i.e. 
adjacent to other viral proteins).  Underlined in Figure 2.2, these enzymes include 
a combination of muramidases, type 2 alanine-amidases, and type 3 alanine-
amidases.  The first two categories are of particular interest, as lysins of these 
classes have never been purified and characterized for C. perfringens. 
We decided to focus our subsequent efforts on a prophage muramidase 
encoded by the CPE-negative toxinotype A strain ATCC 13124 (which is also the 
original type-strain for the species).  We hereafter refer to this protein, 
YP_695420, as PlyCM (for C. perfringens muramidase).  It is one of 2 prophage 
lysins encoded by ATCC 13124, the other being muramidase YP_696011.  Several 
other non-perfringens phage lysins with GH-25 lytic domains have been 
characterized to date.  These enzymes are summarized in Figure 2.3a, along with 
the binding domains with which they are paired.   
Figure 2.3a Architectural Diversity among GH25 Phage Lysins 
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Figure 2.3a, continued  
Several phage lytic enzymes containing a GH-25 muramidase domain (all 
from non-clostridial phage) have been recombinantly expressed and studied 
to date.  These are depicted here along with the variety of C-terminal 
binding domains with which they are paired.  Lysins for which a crystal 
structure has been solved are indicated with an asterisk*.  Included are: 
CPL-1 from Streptococcus pneumoniae, choline bindings repeats (pfam 
PF01473; GenBank ABC88204; Hermoso et al 2003); CPL-7 from S. 
pneumoniae, eponymous binding repeats (PF08230; AAA72844; García et al. 
1990); PlyB from Bacillus anthracis, SH3-5 binding domain (PF08460; 
2NW0_A; Porter et al. 2007); PlyPH from B. anthracis, conserved hypothetical 
binding domain (PF12123; NP_845154; Yoong et al. 2006); Lyb5 from 
Lactobacillus fermentum, LysM binding domains (PF01476; ABP88927; Wang 
et al. 2008); and PlyGBS from Streptococcus agalactiae, single SH3-3 binding 
domain (PF08239; AAR99416; Cheng et al. 2005).  Also listed (in the inset) 




In Figure 2.3b, the GH-25 domain of PlyCM is aligned with that of 2 non-
clostridial lysins, ones for which crystal structures have been solved (Hermoso et 
al. 2003; Porter et al. 2007).  As shown, the catalytic residues are conserved in all 
3 cases. 
PlyCM was recombinantly expressed in E. coli and purified by column 
chromatography (Figure 2.4).  The lysin showed clear bacteriolytic activity in 
vitro against the encoding strain ATCC 13124.  When added to a buffered 
suspension (20/10 mM phosphate/citrate pH 6.4) of live cells for 1 hr, PlyCM 
generated a ~70% reduction in bacterial turbidity at low nM (low-to-sub g/ml) 
concentrations (Figure 2.5).  The time-versus-OD response for PlyCM is very 
similar to that which was observed for Ply3626 against its host strain (Zimmer et 
al. 2002b).  The required concentration of PlyCM is also commensurate with 
values observed for other Gram-positive bacteria and their respective lysins 
(Fischetti 2008).  The residual turbidity after 1 hr of treatment can be considered a 
baseline value for these buffering conditions—neither increasing the lysin 
concentration nor the incubation time lead to further OD-declines.  The reader 
should note that this baseline OD does not correspond to quantitative viability 
levels (see CFU analysis below). 
 Acidity represents one of the most important variables affecting lysin 
activity, so we sought to determine the effect of pH on PlyCM.  Two sets of OD-
drop experiments were conducted in which pH was varied at a constant lysin 
concentration.   
Figure 2.3b GH25 Domain Alignment 
The GH-25 catalytic domain of PlyCM is aligned with those of CPL-1 and PlyB.  
Three-way and pair-wise identities are indicated with a blue/pink/ 
yellow/gray color-scheme.  Putative catalytic residues (see Porter et al. 2007) are 
denoted with arrows.  
106 
Figure 2.4 Purified PlyCM 
PlyCM was purified following recombinant expression in E. coli.  Lane 1: 
molecular weight ladder.  Lane 2: crude extract of encoding strain prior to 
induction.  Lane 3: crude extract of encoding strain ~16 hours after induction.  
Lane 4: final product following isolation protocol.  By visual approximation, 
PlyCM is > 90% pure; its band appears at the level of the 37 kDa marker 
(predicted MW = 38.7 kDa).  
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Figure 2.5a PlyCM-Induced Lysis (Time Course) 
Depicted here is a representative example of an OD-drop experiment in 
which lysin was added to a buffered suspension (20/10 mM phosphate/ 
citrate pH 6.4) of live host strain ATCC 13124.  A 1.15 M (45 g/ml) 
















1.15 uM (45 ug/ml)
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Figure 2.5b PlyCM-Induced Lysis (Variable Concentration) 
The PlyCM concentration was decreased 10-1000 fold from the level shown 
in (A), and cell lysis was monitored over an hour.  The figure reports 
treated/untreated OD-ratios (to account for slight possible fluctuation in the 
untreated) at 10-min intervals; the average of three independent experiments 
is depicted.  As the graph indicates, concentrations as low as 11.5 nM (450 
ng/ml) were able to bring the OD to a baseline level within 1 hr. In 
comparison, hen egg white lysozyme (HEWL, a non-specific eukaryotic 
muramidase, NP_990612, PF00062) failed to affect the cells’ turbidity or 
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First, a broad-range buffer (25 mM boric/phosphoric acid) was utilized with a 
variable pH of 3.0 - 10.5 and a PlyCM concentration of 115 nM (4.5 g/ml).  
Enzymatic activity was observed between pH = 4.0 - 9.5, with a maximum from 
6.5 – 8.0 (Figure 2.6a).  To confirm these observations (and fine-tune an optimal 
pH), a narrow-range buffer (20/10 mM phosphate/citrate) was utilized with 
smaller pH-degradations and a lower PlyCM concentration (11.5 nM, 450 
ng/ml).  A similar profile was observed here (Figure 2.6b), with pH = 6.4 as the 
center of activity.   
Considering the acidic environment of the stomach (as well as many food 
items), we wished to determine whether the loss-of-activity at low pH 
represented a mechanistic inhibition or an irreversible denaturation.  The latter 
scenario turned out to be the case.  PlyCM was buffered at a range of acidic pHs, 
followed by titration back to pH = 6.5.  Activity was subsequently lost for 
samples at pH = 3.3 and below.  The pH = 4.3 sample, however, exhibited an 
identical lytic profile to the positive control maintained at pH = 6.5 (Figure 2.6c). 
Several other biochemical characteristics of PlyCM were likewise 
evaluated, in particular the temperature stability of the enzyme (this is important 
given the potential use of a C. perfringens lysin in food science).  Following 
incubation at various temperatures for 30 min, PlyCM demonstrated a sharp loss 































































































































Figure  2.6a/b, continued
[A] 115 nM PlyCM was incubated for 2 hr with suspensions of ATCC 
13124 in a variable-pH boric/phosphoric acid buffer (pH: 3.0 – 10.5, 0.5 
intervals, n = 3).  By the end of the experiment, some degree of activity 
was observed between pH = 4 - 9.5, although lysis was maximal from 
6.5 – 8. [B] The experiments in [A] were repeated under more sensitive 
digestion conditions.  This include a 10-fold reduction in PlyCM 
concentration and the use of a phosphate/citrate buffer (pH = 5.0 – 9.0, 
0.2 intervals, n = 3).  After 1 hr, maximal activity was centered around 






















Figure 2.6c Irreversible Acid Denaturation
Aliquots of PlyCM were diluted in 20/10 mM phosphate/citrate buffers of 
various pH-values, yielding solutions whose final pHs are indicated in the 
graph.  Each aliquot was titrated back to pH = 6.5 with dibasic phosphate; a 
positive control was maintained at pH = 6.5 for the entire experiment.  
Following volume normalization (with phosphate/citrate pH = 6.5), lytic
enzyme was added to the cells (final PlyCM concentration = 58 nM, final pH 
= 6.5) and lysis was observed for 2 hr.  The sample brought to a pH = 4.3 
showed identical activity to the positive control, while the others failed to 
induce lysis. 
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Figure 2.7 Temperature Stability of PlyCM 
Stock concentrations of PlyCM were incubated for 30 min at the indicated 
temperatures, after which they were added to buffered suspensions (pH 6.4) of 
C. perfringens ATCC 13124 at 11.5 nM (450 ng/ml) for 1 hr.  The figure reports 







































In separate experiments, molar excesses of either EDTA or DTT failed to inhibit 
lysin activity (data not shown), indicating that PlyCM is not dependent upon 
chelatable cations or intramolecular disulfide binds for activity.  
The above experiments were all conducted in low-osmolarity suspensions 
in which the only salt was the buffering agent.  Seeing as any real-world 
application would likely occur in a less hypotonic environment, we evaluated the 
effect of salt on PlyCM-induced lysis.   The experiments in Figure 2.5 were 
repeated with 150 mM NaCl in the lysis buffer.  Although the concentration-
dependence of PlyCM was virtually identical, the baseline OD of the treated cells 
jumped to ~60% of the untreated value (Figures 2.8a and 2.8b).  Microscopic 
inspection of the cells indicated the reason: in the presence of 150 mM NaCl, 
many of the cells collapsed to spheroplast forms without extrusion of their 
cytoplasmic contents (see Figures 2.8c and 2.8d, respectively, for phage contrast 
and scanning electron micrographs).   
In rod-shaped bacteria, the peptidoglycan layer serves two gross 
morphological functions.  It prevents osmotic lysis of hypertonic intracellular 
contents and it maintains the bacilloid morphology, the natural lowest energy 
form being coccoid (Pichoff and Lutkenhaus 2007).  Presumably, the addition of 
NaCl reduced the pressure on the cells to lyse, without affecting the pressure-
independent collapse to spheroplasts.  Indeed, when these lysin-treated cells 
were pelleted and resuspended in salt-free solution, immediate lysis was 
observed. 
Figure 2.8a NaCl Effect on Lysis in ATCC 13124 (Time Course) 
A single lytic time-course is shown with 1.15 mM PlyCM (45g/ml) and 















1.15 uM (45 ug/ml)
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Figure 2.8b NaCl Effect on Lysis in ATCC 13124 (Variable Concentration) 
The experiment in Figure 4b was repeated with the addition of 150 mM NaCl in 
the final lysis buffer (for B, n = 3).  The clostridia responded to PlyCM at nearly 
identical concentrations as in Figure 4b, except that the OD would fall to a 



























1.15 nM (45 ng/ml)
2.88 nM  (112 ng/ml)
5.76 nM  (225 ng/ml)
11.5 nM  (450 ng/ml)
28.8 nM  (1.12 ug/ml)
57.6 nM  (2.25 ug/ml)
115 nM (4.5 ug/ml)
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Figure 2.8c Light Microscopy of Lysin-Treated Cells in 150 mM NaCl 
The image compares (1000X magnification) the gross morphology of 
untreated ATCC 13124 with that of cells treated with 115 nM PlyCM for 1 hr 
in the presence of 150 mM NaCl.  Within the treated samples, there exists a 
combination of collapsed spheroplasts (black arrow) that have maintained 
their cytoplasmic contents and contribute to optical density, as well as 
clostridial ghosts and ghost-fragments (red arrow) that have undergone 





Figure 2.8d SEM of Lysin-Treated Cells in 150 mM NaCl 
Scanning electron microscopy was also conducted on untreated and PlyCM-
treated ATCC 13124 cells in the presence of 150 mM NaCl.  The treated image 
is dominated by clostridial spheroplasts; a presumptive ghost is denoted with 








The preceding observations raise the question of whether the spheroplast-
like clostridia are viable.  Ultimately, bacterial death following lysin treatment is 
a more significant metric than simple optical density.  Accordingly, CFU-analysis 
was conducted on cells treated in the presence of 150 mM NaCl.  Despite the 
residual turbidity, the cells were overwhelmingly non-viable.  The following 
percentages-killed were observed after 1 hr (relative to untreated, n = 5 
independent experiments): 11.5 nM (86 – 99.2%); 115 nM (> 99.7%); 1.15 M (> 
99.99%).  These data indicate that, even in environments that are incompatible 
with osmotic lysis, PlyCM exerts a potent lethal effect on ATCC 13124. 
We next attempted to gauge the effect of PlyCM on actively-dividing cells.  
Unfortunately, minimum-inhibitory-concentration (MIC) analysis in liquid 
culture proved unsuccessful.  At the concentrations employed in Figures 2.5 and 
2.8, PlyCM failed to prevent proliferation of ATCC 13124.  (An inoculum of ~5 X 
105 cells/ml was used, the minimal value for standard CFU analysis, Wiegand et 
al. 2008).  Although we would have liked to repeat these experiments at higher 
lysin concentrations, a technical barrier prevented it.  As mentioned in Materials 
and Methods, 100 mM L-arginine was added to the PlyCM stock solution to 
prevent enzyme precipitation.  Higher lysin concentrations would have likewise 
necessitated elevated amounts of L-arginine in the media.  In preliminary 
experiments, however, we observed that mM-concentrations of this amino acid 
could itself impact actively-dividing C. perfringens (the cells would proliferate 
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with defective division, yielding elongated rod forms2).  With this confounding 
variable, we did not feel MIC analysis would be rigorously meaningful. 
Finally, the activity of PlyCM was tested in vitro against a panel of other 
bacterial species and strains.  These include: 24 additional isolates of C. 
perfringens (with representative examples of each toxinotype); 10 non-perfringens 
clostridia; and 16 non-clostridial species of Gram-positive bacteria.  We found it 
necessary to conduct these experiments in a buffer (phosphate/citrate pH 6.4) 
that included 150 mM NaCl; without this, many strains of C. perfringens would 
self-adhere into macroscopic aggregates.  Given the above observations 
involving spheroplast-formation at 150 mM NaCl, we did not want to rely 
exclusively on OD-measurements in evaluating the panel (as is typically done for 
assessing a lysin‘s target range).   Consequently, a semi-quantitative scoring 
system was devised that relied upon microscopic inspection of the samples.  
Strains were ranked on scale from 1 (equally sensitive or more sensitive than host 
train ATCC 13124) to 4 (insensitive).  The results of this panel are summarized in 
Table 2.1 (see the table caption for the specific details of the scoring system).   
Overall, 23/24 strains of C. perfringens demonstrated susceptibility to the 
lysin, although the level varied quantitatively from strain to strain.  Outside of C. 
perfringens, only 3/10 other clostridia demonstrated susceptibility, and these 
were ranked at the lowest level.  Both of these findings are highly reminiscent of 
patterns observed for Ply3626 (although its panel of strains was evaluated on OD 
alone, Zimmer et al. 2002b).   
Table 2.1 PlyCM Species/Strain Specificity 
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Species/Strain Sensitivity 
C. perfringens ATCC 13124 (Type A, CPE -) I (reference)  
C. perfringens ATCC 3624 (Type A, CPE -) II 
C. perfringens ATCC 12915 (Type A, CPE +) II 
C. perfringens ATCC 12916 (Type A, CPE +.) III 
C. perfringens ATCC 12917 (Type A, CPE +) III 
C. perfringens ATCC 12919 (Type A, CPE +) II 
C. perfringens ATCC 3626 (Type B) I 
C. perfringens ATCC 3628 (Type C) I 
C. perfringens NCTC 8346 (Type D) II 
C. perfringens ATCC 27324 (Type E) III 
C. perfringens: 3 untyped human fecal isolates 
Two—I, 
One—II 





C. tetani ATCC 19406, C. septicum ATCC 12464,  
C. beijerinckii ATCC 8260 
III 
C. difficile ATCC 43593, C. difficile ATCC 700057,  
C. difficile ATCC 9689, C. histolyticum ATCC 19401,  
C. sordelli ATCC 9714, C. sporogenes ATCC 3584,  
C. bifermentans ATCC 638 
IV 
S. pyogenes D471, S. agalactiae 090R,  
S. pneumoniae R36, S. mutans in-house strain, 
E. faecalis V583, E. faecium EFSK-2,  
S. aureus RN4220, S. epidermidis ATCC 12228,  
M. lysodeikticus ATCC 4698, L. monocytogenes HER1083,  
B. anthracis 222, B. cereus ATCC 14579,  
B. subtilis SL4, B. thuringiensis HD-73,  
B. megaterium in-house strain, G. vaginalis ATCC 14018,  
P. aeruginosa PAO1,  E. coli TOP10 
IV 
Table 2.1, continued 
The above species/strains of bacteria were evaluated for their susceptibility 
to PlyCM.  If known, the toxinotype and CPE-status (for toxinotype A) are 
listed for C. perfringens strains.  Each bacteria was suspended in 
phosphate/citrate buffer (pH = 6.4) + 150 mM NaCl and exposed to three 
PlyCM-concentrations (11.5 nM, 115 nM, and 1.15 M).  11.5 nM represents 
the lowest concentration that brought the host strain ATCC 13124 to 
baseline OD (see Figures 4 and 7).  After 1 hr, the samples were visualized 
at 1000X-magnification and the OD was measured.  Each bacteria was 
assigned a rank based on the following semi-quantitative criteria: [I] 11.5 
nM PlyCM induced complete lysis, or > 9/10 cells had converted from rod-
forms to spheroplasts; [II] 115 nM PlyCM lead to either preceding 
observation; [III] 1.15 M PlyCM induced lysis/spheroplast conversion 
(complete or partial); [IV] No lysis or spheroplast conversion was observed 




The other non-clostridial bacteria were all insensitive to PlyCM treatment.  In 
total, this enzyme exhibits the kind of organism-specificity that has come to 
characterize phage lysins in general.   
 
DISCUSSION 
 The work presented here illustrates the general utility of bacterial genomic 
sequencing in the identification of candidate enzybiotics.  Moreover, the specific 
protein expressed and characterized (PlyCM) exhibits potent bacteriolytic ability 
in vitro, demonstrating potential as a novel antibacterial agent.  In theory, phage 
lysins seem well-suited as food additives to combat C. perfringens.  It is true that 
clostridia are spore-forming species, and that phage lysins are generally not 
effective against dormant spores (due to the external exosporium).  Nevertheless, 
C. perfringens enteritis is not caused by the ingestion of spores, but rather 
vegetative cells that have proliferated in food (most commonly meats and meat 
broths).  Rigorously-speaking, it does not represent food poisoning (i.e. involving 
preformed toxin), but rather foodborne infection.   It is estimated that ingestion 
of > 108 vegetative bacteria are required for clinical symptoms (USFDA 2009).  As 
a result, an agent that could selectively reduce the overall bacterial load or 
prevent its initial proliferation could prove quite useful. 
 Despite different enzymatic mechanisms, Ply3626 and PlyCM 
demonstrated several noteworthy similarities to one another.  The time-
dependant response of the host strain to treatment was nearly identical in both 
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cases.  And the two enzymes possessed broad activity against a panel of C. 
perfringens strains, with little effect against other species and genera.  
Quantitatively speaking, however, this level of sensitivity varied somewhat from 
isolate to isolate.  For both Ply3626 and PlyCM, the treatment-response of the 
host strain was more pronounced than certain others.  This observation 
underscores the importance of developing complimentary lysins with varied 
sequences and component domains.  In fact, the ability to accomplish this 
rationally and rapidly for a given pathogen is an inherent strength of 
multigenomic sequence analysis.   
In this regard, it would be informative for future work to consider the 
combined effect of a muramidase like PlyCM and an alanine-amidase like 
Ply3626.  For instance, one could observe whether they normalize the strain-to-
strain response or act synergistically with one another (as was observed for 
pneumococci in Loeffler and Fischetti 2003).  Going further, one could even 
include non-viral enzymes in a combined treatment pool.  Just recently, Camiade 
et al. characterized an endogenous C. perfringens peptidoglycan hydrolase (an 
autolysin) involved in cell division and stress responses (2010).  This protein 
(Acp) encodes a glucosaminidase domain (Pfam family PF01832), which is 
distinct from all the sequences considered here.  While autolysins have not 
received as much attention from the applied research community, nothing in 




 In terms of future work on PlyCM, the immediate next steps must involve 
the fine-tuning of certain biochemical properties.  In particular, the issue of 
solubility must be addressed; this would allow for increased concentrations of 
lysin to be tested against actively-proliferating cells (either in culture media or in 
the presence of actual food products).  Possible strategies include the use of 
additives other than arginine or the re-engineering of its sequence to increase 
solubility.  Specifically, the latter option could involve mutagenesis of the 
encoding gene or the design of a chimeric lysin that combines PlyCM‘s 
enzymatic domain with a different binding domain (either an SH3 domain with a 
somewhat varied sequence or another domain type altogether).  These strategies 
have been employed successfully in the past to optimize the activity of other lytic 
enzymes (Cheng and Fischetti 2007; Daniel et al. 2010). 
 Aside from the goal of enzybiotic development, one other relevant issue in 
this chapter warrants further discussion.  The initial genomic analysis revealed 
numerous enzymes that possessed all the architectural properties of a lysin (N-
terminal lytic region, C-terminal binding region, no signal peptide), but that did 
not reside in a recognizable prophage region.  Conceivably, they could represent 
small prophage remnants from their hosts‘ evolutionary history.  Nevertheless, 
many of them demonstrated conserved genomic arrangements from strain to 
strain, suggesting a dedicated in vivo role.  In fact, these lysin-like proteins are 
probably better classified as host autolysins, and their existence raises several 
noteworthy questions.  For instance, what biological purpose do they serve for 
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the bacteria?  And how do they gain access to the peptidoglycan layer without a 
secretion signal?   
 Several of the enzymes (ZP_02863923, ZP_02639407, YP_696189, 
ZP_02633392, NP_562418, ZP_02642513, ZP_02952533, YP_698802) are each 
encoded in the vicinity of a putative histidine kinase and metallo-beta-lactamase.  
They are classified as type 3 alanine-amidases, and are clustered together at the 
bottom of the phylogram in Figure 1.  Also clustered together in the figure are 
several additional type 3 alanine-amidases (YP_699923, NP_040458, YP_209681, 
ZP_02954906, YP_699912); for these enzymes, the genomic positioning suggests 
an intriguing biological function.  They are all encoded near UV-inducible C. 
perfringens bacteriocins known as BCN5 proteins3.  Four of these lysins are 
located on plasmids, while one is chromosomal (ZP_02954906, strain JGS1721). 
 The BCN5 protein was first identified many years ago (Wolff and Ionesco 
1975), as was its encoding gene within pIP404 plasmid of C. perfringens strain 
CPN50 (Garnier and Cole 1986; Garnier and Cole 1988).  When CPN50 is 
irradiated, it undergoes partial autolysis with the induction and release of BCN5.  
The resulting culture supernatant (or purified BCN5) is subsequently inhibitory 
toward other C. perfringens.  The genetic architecture of the BCN5-encoding 
region is conserved within the several strains in which it has (now) been 
sequenced.  In each case, the ~2.7 kb bcn gene is immediately preceded by two 
ORFs in the same orientation: the ~500 bp uviA followed by the ~200 bp uviB.  
Dupuy et al. recently demonstrated that uviA encodes a DNA-damage inducible 
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-factor responsible for bcn transcription (2005), although other aspects of BCN5 
activity remain undefined.  These include its antibacterial mechanism, as well as 
the molecular events responsible for autolysis and concomitant BCN5 
externalization (the bacteriocin contains no signal peptide).  The role of uviB also 
remains unknown, although it has been noted that it demonstrates Blast-
homology to a Bacillus subtilis phage holin (Dupuy et al. 2005). 
 In this regard, the above group of 5 lysin-like proteins offers potentially-
valuable insights.  Each is encoded immediately upstream of uviA on the 
opposite strand.  When one considers the two ORFs between which uviA is 
sandwiched, a hypothetical mechanism for BCN5 release becomes evident: a 
phage-like process combining the murlaytic activity of the lysin with membrane 
permeabilization by the uviB ―holin‖.  The release of the lytic enzyme during 
BCN5 induction could also contribute to the anti-clostridial effect attributed to 
BCN5 itself.   
Although not identical, this mechanism would be reminiscent of several 
other ―non-traditional‖ methods by which bacteria externalize intercellular 
contents.  These include the damage-induced release of colicin from Escherichia 
coli (Cascales et al. 2007; Lin et al. 2009), the secretion of virulence factors by C. 
difficile (Tan et al. 2001); and the autolysis/allolysis of Streptococcus pneumoniae 
during competence-programmed predation (Guiral et al. 2005).  The latter 
example involves the phage-lysin-like autolysin LytA; this enzyme has been 
studied at length, although it too lacks a signal peptide and its export mechanism 
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remains undetermined (Novak et al. 2000).  Ongoing research will explore these 
possibilities, as well as analyze whether similar elements exist in the published 
genomes of other clostridia and Gram-positive bacteria.   
 In conclusion, the increasing ease of genomic sequencing is clearly 
transforming the fields of both basic and applied microbiology.  These genomes 
are sources of both mechanisms and molecules, and it is through their careful 
inspection that researchers might uncover new avenues for improving human 
health and increasing general knowledge. 
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1.  ORFs that encoded an extended C-terminal region without a Pfam-recognized 
binding domain were not excluded on this fact alone.  There exist a number of 
Gram-positive phage lysins for which this is indeed the case.  Most likely, these 
C-termini do possess a cell-wall binding functions, albeit ones that have not yet 
been characterized and organized into conserved protein families. 
2.  It should be emphasized that L-arginine, in itself, had no effect on bacterial 
turbidity or viability when cells were exposed to the amino acid for a short time 
in buffered solution (as in previous experiments). 
3.  This is the same BCN5 mentioned previously in the text.  It demonstrated 
sequence-homology to the C-terminus of another C. perfringens lysin considered 
here (NP_562054, a type 2 alanine-amidase of evident proviral origin). 
 
**NOTE: In the manuscript to be submitted based on this chapter, the following 
individuals will be listed as co-authors (in the stated order): Maria Cristina 







Functional Viral Metagenomics I:                                        











 The rapidly growing field of metagenomics provides powerful new 
methods for studying environmental microorganisms and the natural products 
they synthesize (for reviews, see Green and Keller 2006; Ward 2006; Tringe and 
Rubin 2005; Daniel 2005; Handelsman 2004).  Metagenomics involves the direct 
extraction of DNA or RNA from environmental samples (e.g. soil, sediment, 
water, feces), without prior laboratory cultivation of individual species.  The 
appeal of metagenomics lies in the access it provides to genes and gene products 
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that cannot be isolated through typical culture-based techniques.  This is 
significant considering that only a small percentage of environmental microbial 
species (~1% of soil species, for instance) are thought to be culturable under 
standard laboratory conditions (Torsvik and Ovreas 2002).  Metagenomics is 
particularly well suited for the analysis of extreme environments whose 
conditions are notably difficult to reproduce in vitro (Baker et al. 2010).   
Metagenomics research can be subdivided into two general categories: 
sequence-based and functional.  In sequence-based studies, the environmental 
DNA (eDNA) is sequenced and compared to genetic databases to gain insight 
into environmental diversity, phylogeny, and ecology.  Notable examples 
include a 76-megabase analysis of an acid mine biofilm (Tyson et al. 2004), a 1-
gigabase analysis of the Sargasso Sea (Venter et al. 2004), and an extensive 
analysis of several oceanic samples (Rusch et al. 2007; Yooseph et al. 2007).   
In functional metagenomics, by contrast, eDNA is transcribed and 
translated directly within a host organism, and clones are screened for the 
acquisition of a desired phenotype1.  Although functional metagenomics has 
constraints—such as the potential for low expression, misfolding, or clonal 
toxicity—it has already identified a number of molecules with biotechnological 
potential.  These include regio- and enantio-selective biocatalysts (Ferrer et al. 
2005), enzymes involved in vitamin biosynthesis (Eschenfeld et al. 2001), and 
antibiotic-resistance mediators (Donato et al. 2010).  These examples are far from 
exhaustive, however, and the sorts of agents that could be targeted are 
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essentially only limited by one‘s imagination and ability to devise a read-out for 
identifying transformants.  For several reviews that cover the broad goals of 
functional metagenomics, the reader is referred to Li et al. (2009), Uchiyama and 
Miyazaki (2009), Ferrer et al. (2005), and Voget et al. (2005). 
It is important to note that functional metagenomic targets can be either 
proteins transcribed from individual genes or small molecules synthesized by 
several enzymes encoded by a contiguous cluster.  Antibiotics are the most 
prominent example of the latter (Brady et al. 2009; King et al. 2009; Courtois et al. 
2003; Gillespie et al. 2002; Brady et al. 2001).  In this case, cosmids are typically 
utilized as the cloning vector (Brady 2007).  Although they suffer (relative to 
plasmids) in that induced transcription is not possible, cosmids are capable of 
maintaining the lengthier inserts.  One challenge regarding this sort of cloning is 
that gene clusters are often so large that traditional techniques fail to capture 
them in their entirety.  This issue was recently addressed, however, by the use of 
transformation-associated recombination (TAR), in which overlapping contigs 
are reassembled in vivo (Kim et al. 2010).  Typically, E. coli is used as the host 
organism in metagenomic screens (both for single genes and gene clusters), 
although other species have recently been employed with particular advantages 
(Craig et al. 2010 and 2008; Kim et al, 2010).  
 It should also been noted that hybrid sequence-based/functional 
approaches have also been used to identify novel agents (Bell et al. 2002, 
Marchesi and Weightman 2003).  Here, eDNA is amplified with degenerate 
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primers targeted against conserved regions of known genes; the resultant 
amplicons can then be sequenced and tested for activity.  Single-primer genome 
walking techniques are also possible, which allow for amplification of targeted 
genes without the burden of having to specify a reverse sequence downstream 
the gene of interest (Kotik 2009). 
In addition to targeted amplification, random amplification has also 
proved an important metagenomic tool, as it allows for analysis of small initial 
quantities of eDNA (Rohwer et al. 2001; Delwart 2007).  This is valuable in 
situations where only a small amount of sample is available, where the purity of 
the sample is low (Abutencia et al. 2006), or where the analysis involves only a 
subset of an environmental population.  An example of the latter is the growing 
field of viral metagenomics (reviewed in Casas and Rohwer 2007; Delwart 2007, 
Edwards and Rohwer 2005), in which bacteriophage particles or other viruses are 
isolated prior to DNA (Angly et al. 2007; Breitbart et al. 2002 and 2003) or RNA 
(Culley et al. 2006, Zhang et al. 2006) extraction.  (The flowchart in Figure 3.1 
depicts how the field of metagenomics can be broken-down into its individual 
subfields: sequence-based versus functional, bacterial versus viral). 
One previously-described method of amplification in viral metagenomics 
is the linker-amplified shotgun library (LASL) approach (Breitbart et al. 2002).  Here, 
viral eDNA is mechanically fragmented, end-modified, and ligated to short 
double-stranded linkers; PCR is then performed with primers directed against 
the linkers.   
Figure 3.1 Metagenomics Flowchart  
In metagenomic analyses, DNA is extracted directly from bulk environmental 
samples without the initial isolation and laboratory culture of any individual 
organisms.  Metagenomics itself can be subdivided into several individual 
categories.  A primary distinction is between bacterial metagenomics and viral 
metagenomics.  In the former, total DNA (overwhelmingly bacterial in origin) is 
purified from a sample, whereas in the latter, the viral (predominantly 
bacteriophage) fraction is separated from the bacterial fraction prior to nucleic 
acid extraction.  Bacterial and viral metagenomics, in turn, can each be 





Although typically applied to metagenomic samples, the technique is equally 
applicable to genomic samples and could be particularly useful for genomes 
where the collection of large quantities of DNA is difficult or time-intensive 
(such as with certain environmental bacteriophages or slow-growing microbes). 
 In this study, we have combined the LASL approach with topoisomerase 
cloning to develop a rapid method of constructing expressible libraries with 
gene-sized inserts.  Topoisomerase cloning utilizes the ability of vaccinia-virus 
topoisomerase to associate with terminal CCCTT motifs and ligate single-
stranded threonine overhangs to complimentary adenines (Shuman 1994).  3‘-
adenine overhangs are generated automatically during Taq-based PCR by the 
template-independent terminal transferase activity of the polymerase.  
Amplification of genomic or metagenomic fragments with Taq polymerase, 
therefore, allows for ligation in this manner.  Our method is particularly well 
suited for functional screens, as commercially-available topoisomerase cloning 
kits allow for rapid ligation of PCR amplicons with subsequent inducible 
transcription in E. coli.  Consequently, we refer to these libraries as ―E-LASLs‖ 
(expressed linker-amplified shotgun libraries). 
The utility of the technique was first demonstrated genomically with 
libraries constructed from the DNA of several recently-isolated B. anthracis 
bacteriophages.  Antibacterial screening led to the identification of six new phage 
lytic enzymes with activity against this species.  One of these lysins is the closest 
known homologue of a heretofore novel Bacillus muramidase, PlyB.  Second, a 
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metagenomic DNA library was constructed from the gut contents of the 
European night crawler Eisenia hortensis.  Functional screening of this library 
identified a positive clone in a hemolysis screen.  The resultant protein—a new 
member of the aerolysin family—was purified and its activity confirmed against 
erythrocytes from several species, as well as human epithelial cells.  It is the first 
example (to our knowledge) of a hemolysin isolated through functional 
metagenomic screening.   
In total, the E-LASL approach may be used to mine for numerous classes 
of proteins from environmental bacteria and viruses.  It is especially useful in 
any scenario (genomic or metagenomic) in which larger quantities of DNA are 
difficult or impossible to obtain, or where speed of library construction is of 
particular importance. 
 
MATERIALS AND METHODS 
Isolation of Bacillus phage DNA.  The following commercially-available brands 
of bat and bird guano were screened for the presence of anti-Bacillus lytic phages: 
[I] High Phosphorous Bat Guano 0-4-0, Fox Farm Soil and Fertilizer Company; 
[II] Superswell 0-7-0, Guano Company International, Inc. (GCI); [III] Bat Guano 
4-6-2, e-Bio Organic; [IV] Jamaican Bat Guano 1-10-0.2, Sunleaves.com; [V] Dry-
Bar Cave Bat 3-10-1, GCI; [VI] Desert Bat 8-4-1, GCI; [VII] Indonesian Bat Guano 
0.5-12-0.2, Sunleaves.com; [VIII] Budswell 0-7-0, The Guano Company; [IX] 
Peruvian Seabird Guano 10-10-2, Sunleaves.com; [X] Mexican Bat Guano 10-2-1, 
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Sunleaves.com; [XI] Original Sea Bird 13-12-2, GCI; [XII] Fossilized Sea Bird 1-10-
1, GCI; [XIII] Peruvian Seabird 10-10-2.5, GCI.   
For each sample, ~5 g of guano were added to an equal volume of PBS 
(pH = 7.4) and shaken overnight at room temperature.  The emulsions were 
centrifuged (20 min, 4,000 X g), and the supernatant passed twice through 0.22-
micron PES filters (Millipore).  Samples were loaded into 15-ml spin 
concentrators (15 kDa MWCO, Amicon) and reduced to ~100 l.  Each 
concentrate was spread on freshly solidified fields of BHI soft-agar impregnated 
with B. anthracis strain Sterne (3 ml molten soft-agar, 200 l stationary-phase 
culture, 10-cm plates).   
Plates were incubated overnight at 30C and inspected for plaques, which 
were noted for samples I - VII.  Of these, isolates I - IV were chosen for further 
use in this study (designated BG-1, BG-2, BG-3, and BG-4).  Phages were 
propagated for three generations on soft-agar, followed by two days of liquid 
culture (20 ml BHI, mid-log phase B. anthracis, 30C).  Following bacterial 
pelleting and sterile filtration, the culture solutions were subject to 
ultracentrifugation in a cesium chloride step gradient (150 min, 22,000 X g) and 
the phage-containing (1.45)/(1.5) interface was collected (Sambrook et al. 
1989).  DNA was extracted directly by phenol-chloroform treatment, with 
chloroform wash and ethanol precipitation. 
In addition to these phages, several additional Bacillus cereus sensu latu 
phages (A10, A14, A17, and TSH) were provided by Mr. Tommie Hata of the 
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Pingry School (Martinsville, New Jersey).  They were isolated from 
environmental sources by local high-school students as part of a science-
education curriculum (Hata 2010).  As they were already purified as high-titer 
stocks; these phages were subjected directly to genomic extraction without 
further purification. 
 
Isolation of worm-gut DNA.  The method was adapted from Steffan and Atlas 
(1988).  Live earthworms (species Eisenia hortensis) were isolated from forest litter 
from Stroudsburg, Pennsylvania.  A single large adult was washed twice in 
phosphate buffered saline (pH = 7.4) and twice in dH2O.  The worm was 
transected into four equal sections to ease isolation of gut contents, which were 
manually extracted and resuspended in 1X PBS.  The contents were pooled, 
sterile dH2O was added, and the suspension was vortexed vigorously.  The 
sample was centrifuged for 10 min at 1000 x g to remove large debris and soil 
particles.  This step was repeated twice and the supernatants were pooled and 
centrifuged at 10,000 x G for 30 min.   
The resulting bacterial pellet was resuspended in buffer (350 mM Tris-Cl, 
pH 8.0 + 10 mM EDTA) and centrifuged at 10,000 x g for 30 min.  The pellet was 
resuspended in 1 ml of the same buffer, lysozyme was added (5 mg/ml final 
concentration), and the suspension was incubated at 37ºC for 1 hr.  Following a 
5-min incubation at 60ºC, SDS was added (1% final concentration) and the 
suspension was incubated at 60ºC for 10 additional min.  The suspension was 
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cooled on ice for 1 hr and centrifuged at 12,000 x g for 20 min at 4ºC.  Solid 
ammonium acetate was added to the lysate to a final concentration of 2.5 M and 
centrifuged at 12,000 x g for 30 min at 4ºC.  DNA in the supernatant was 
precipitated by adding 2.5 volumes of ice-cold ethanol and incubated at -70ºC for 
1 hr followed by centrifugation at 12,000 x g for 30 min at 4ºC.  The pellet was 
washed with 70% ethanol, air-dried, and resuspended in appropriate amount of 
TE buffer (10 mM Tris-Cl, pH 8.0, 1 mM EDTA).  
 
Construction of E-LASLs.  0.01 or 0.1 units Tsp509I (diluted in 1X NEB Buffer II) 
were added to 100 ng genomic or metagenomic DNA in 50 l total volume 1X 
NEB Buffer II.  Samples were incubated at 65C for 1 min and an equal volume of 
25:24:1 phenol:chloroform:isoamyl alcohol (Roche) was added to terminate the 
digestion.  The aqueous layer was isolated and washed with 50 l chloroform.  50 
l 5 M ammonium acetate and 200 l 100% ethanol were added to precipitate 
DNA, which was washed twice in 200 l 70% ethanol.  The DNA was desiccated 
and the following reagents were added: 6.5 l dH2O, 2 l 20 ng/l linker DNA 
(AATTCGGCTCGAG), 1 l 10X ligase buffer, and 0.5 l T4 DNA ligase 
(Fermentas).  The underlined portion of the linker consists of single-stranded 
overhang, complimentary to the overhang generated by Tsp509I.   
Based on the average size of the fragmented DNA (~1.5 kb) and assuming 
a DNA recovery of 100% following phenol/chloroform extraction (greater than 
the actual value), this mixture contains a ~55-fold molar excess of linker-to-insert 
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DNA.  Following overnight ligation at 16C, 4 l of the reaction mixture were 
added to 44 l dH2O, 2 l 10 M linker-targeted primer 
(CCATGACTCGAGCCGAATT), and 50 l Taq PCR Master Mix (Invitrogen).  
DNA was amplified with the following thermocycling conditions: 95C-1 min.; 
(95C-30 s.; 55C-30 s.; 72C-5 min.) X 40; 72C-10 min. 
 
Topoisomerase cloning of genomic/metagenomic inserts.  1 l of the above PCR 
reaction mixture was added directly to 3 l dH2O, 1 l 1X salt solution, and 1 l 
linearized, topoisomerase-conjugated pBAD expression vector (pBAD-TOPO TA 
Expression Kit, Invitrogen).  The mixture was incubated at room temperature for 
1 min and divided (2 l each) between three 50-l vials of TOP10 chemically 
competent E. coli (Invitrogen).  Cells were placed on ice for 20 min, heat-shocked 
at 42C for 30 s, and placed back on ice for 5 min.  250 l SOC media was added 
and the cells were incubated at 37C for 30 min (as opposed to the manufacturer-
suggested 60 min, to minimize the possibility of clonal expansion).  Cells were 
spread onto LB agar with ampicillin (500 g/ml), and these master plates were 
incubated overnight at 37C. 
 
Colony PCR.  Individual colonies were picked and suspended in 25 l 0.5 M 
NaOH, to which 25 l 1 M Tris (pH = 8.0) and 450 l dH2O were added.  1 l of 
this mixture was added to 1 l 10 M BadF primer 
(ATGCCATAGCATTTTTATCC), 1 l 10 M Bad3 primer 
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(GCAGTTCCCTACTCTGCC), 12 l dH2O, and 50 l Taq PCR Master Mix 
(Invitrogen).  The BadF and Bad3 target sites are located, respectively, 160 bp 
upstream and 284 bp downstream from the point of topoisomerase-mediated 
cloning.  Thermocycling was conducted under the same conditions as during 
library construction.  Certain amplified inserts were sent for sequencing with 
BadF and/or Bad3 primers to Genewiz, Inc. (South Plainfield, NJ).   
 
Functional screening of clones.  To identify clones with antibacterial activity, 
two different screening methodologies were used.  [1] For the BG-1, BG-2, BG-3, 
and BG-4 libraries, master plates were replicated with sterile velvet onto LB-agar 
with 0.2% arabinose (the pBAD-TOPO plasmid is arabinose inducible) and 
incubated overnight at 30C.  E. coli cell membranes were permeabilized by a 15-
min exposure to chloroform vapor.  The cells were overlaid with 7 ml molten 
BHI soft-agar containing 5 l overnight culture of B. anthracis (Sterne), 
Pseudomonas aeruginosa (PAO1), or Staphylococcus aureus (RN4220).  Plates were 
left at room temperature for 5 hr, transferred to 4C for overnight storage, 
returned to room temperature the following day, and placed back at 4C for one 
more night.  Plates were inspected for clearing zones devoid of bacteria.  [2] For 
phages BG-3, BG-4, A10, A14, and A17, the E-LASL were also screened using a 
novel hemolysis-based method that relies upon the toxic effect of the adjacent 
holin.  This technique is the focus of Chapter 4, and the reader is referred there 
for experimental details. 
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For hemolysis screens, master plates were constructed and replicated as in 
method [1] above.  Permeabilized clones were overlaid with 6 ml molten BHI 
soft-agar containing 1 ml defibrinated sheep blood (Cleveland Scientific).  Plates 
were placed directly at 37C and monitored for hemolytic zones.  For any 
observed hit in the above screens, the corresponding colony on the master plate 
was identified, expanded, and retested in a second experiment.  Confirmed hits 
were subject to PCR and sequence analysis. 
Qualitative analysis of lysin activity.  An E. coli clone expressing PlyBeta was 
streaked onto LB-agar with 0.2% arabinose and incubated overnight at 30C.  
Cells were chloroform permeabilized and soft agar overlays were conducted as 
described above with a variety of bacterial species/strains.  These were: B. 
anthracis Sterne, B. anthracis RS222, B. cereus ATCC 10987, B. cereus ATCC 14579, 
B. cereus 13100; B. cereus 4429/73 FRI-16, B. cereus 03BB87, B. cereus E33L ZK, B. 
thuringiensis HD73, B. thuringiensis HD866, B. thuringiensis Al Hakam, B. subtilis 
SL4, B. mycoides 6462, B. megaterium in-house strain, Staphylococcus aureus RN4220, 
L. monocytogenes HER 1083, Streptococcus pyogenes D471, and S. agalactiae O90R.  
All species were grown in BHI soft agar at 37C in ambient atmosphere.  Plates 
were inspected for clearing zones around the PlyBeta expressing patches; 




Purification of environmental aerolysin.  The aerolysin-containing E. coli clone 
was expanded in 2 liters of LB at 37C.  At OD600 = 0.5, arabinose was added to a 
final concentration of 0.2%, and the cells were incubated for 4 more hr.  Cells 
were pelleted and the culture supernatant was subject to ammonium sulfate 
precipitation.  (NH4)2SO4 was slowly added to 40% saturation, and the solution 
gently rotated for 12 hr at 4C.  The precipitate was spun down (20 min, 7,000 X 
g), dissolved in 10 ml 10 mM phosphate buffer (pH = 7.4), and dialyzed for 24 hr 
against 100-fold excess of this buffer with three buffer changes.   
The dialysate was loaded onto a MonoQ anion exchange column 
(Amersham), and eluted with a gradient of 10 mM phosphate buffer (pH = 7.4), 
1M NaCl.  Hemolytic activity was observed in the fractions corresponding to ~33 
mM NaCl.  These fractions were pooled together and subject to SDS-PAGE, 
which revealed a single ~48-kDa band upon Coomassie staining.  Protein 
concentration was determined using BCA analysis with albumin standards.  50 
l of protein at 117 ng/l was submitted to the Rockefeller University 
Proteomics Facility for 10 cycles of N-terminal sequence analysis.  
 
Quantitative hemolysis assay.  Hemolysis was quantified using a variation of 
the protocol of Eschbach et al. (2001).  Defibrinated sheep and rabbit blood and 
alsevers-treated chicken blood were purchased from Cleveland Scientific 
(Cleveland, OH).  Human blood was drawn from a healthy donor (with 
informed consent) into a heparinized vacuum tube (BD) immediately prior to 
146 
 
use.  All samples were centrifuged (10 min; 2,500 X g), and the plasma and 
leukocyte layers removed.  Erythrocytes were washed 4 times and resuspended 
in PBS to 109 cells/ml.  10-l aliquots of this suspension were diluted to 100 l 
with PBS containing various concentrations of aerolysin.  Samples were 
incubated for 1 hr at 37C.  A 0% hemolysis standard was created by adding 10 l 
of the 109 cells/ml suspension to 90 l PBS, which was incubated for 1 hr at 37C.  
A 100% hemolysis standard was created by adding 10 l of the suspension to 80 
l dH2O, followed by 37C incubation and brief vortexing; 10 l 10X PBS were 
then added.   
Following incubation, 900 l PBS were added to all experimental samples 
and standards, and 250 l of the supernatant were loaded into the wells of a 96-
well plate.  The supernatants of the 0% and 100% hemolysis standards were 
mixed to create intermediate standards.  Absorbance was measured at  = 410 
and hemolysis of the experimental samples was calculated through linear 
reduction versus standards.  The aerolysin itself exhibited negligible absorbance 
at this wavelength. 
 
Computational analysis.  Metagenomic sequences were analyzed with the 
TBlastX algorithm (translated query versus translated database; 
www.ncbi.nlm.nih.gov/Blast/).  Searches were conducted against the non-
redundant database (nr) with a maximum reported E-value of 0.001 and all other 
parameters at default value (Altschul et al. 1997).  For the genes cloned in this 
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study, homologues were identified through the BlastX algorithm (translated 
query versus protein database) with default parameters.  Predicted enzymatic 
and binding domains were assigned through Pfam analysis (Finn et al. 2009; 
pfam.sanger.ac.uk/) 
 Multiple sequence alignment of known aerolysins was conducted with 
ClustalX, v1.81 (ftp-igbmc.u-strasbg.fr/pub/ClustalX/; Thompson et al. 1997).  
From this alignment, phylogenetic analysis was performed with PHYLIP v3.67 
(evolution.genetics.washington.edu/phylip.html; Felsenstein 1989); DNA 
distance and parsimony methods were employed with 1,000 rounds of 
bootstrapping and all other parameters at default value.  The sequences cloned in 
this study were submitted to GenBank with the following accession numbers: 
BG-1 lysin (PlyBeta), EU258891; BG-2 lysin, EU258892; BG-3 lysin, EU258893; 
environmental aerolysin (AerM), EU258894.  The sequences for lysins BG-4, A14, 
and TSH lysins have not yet been submitted to GenBank, although they are 
reported in the appendix of this thesis. 
 
RESULTS 
Construction of E-LASLs.  To conduct functional genomic and metagenomic 
screens, a rapid technique was devised that combines linker amplification with 
topoisomerase cloning.  The overall E-LASL procedure is outlined in Figure 3.2.   
Figure 3.2 Constructing an E-LASL  
Genomic or metagenomic DNA (represented by the circle at the upper-left) is 
enzymatically fragmented by brief exposure to Tsp509I.  A short segment of 
linker DNA with a complementary overhang is ligated to both ends of the 
fragments.  PCR is conducted with Taq polymerase and a primer targeted against 
the linker sequence.  The resultant amplicons have a range of molecular weights, 
but all posses 3’-adenine overhangs.  The agarose gel at bottom-right depicts 
bacteriophage genomic DNA (left lane) alongside its E-LASL amplification 
products (middle lane).  The amplicons are cloned directly into linearized pBAD 
plasmids using commercial topoisomerase cloning.  E. coli are transformed with 
the plasmids and screened for the acquisition of a desired phenotype (in our 




Rather than fragmenting DNA with a mechanical shearing apparatus (as in 
previous studies, Breitbart et al. 2002 and 2003), we instead relied upon brief 
enzymatic digestion with Tsp509I.  The four-nucleotide consensus sequence 
(AATT) would be expected to appear once every 256 bases of random DNA.  As 
shown in Figure 3.3a, the following conditions for partial digestion lead to the 
desired gene-sized lengths after amplification: 100 ng genomic or metagenomic 
DNA; 0.01 or 0.1 units Tsp509I; 50 l reaction volume; and a 1 min digestion at 
65C.   
The length distributions of the amplicons ranged from 500 bp to 4 kb, 
with the maximum intensity centered around ~2 kb (for 0.1 units of enzyme) or 
~3 kb (for 0.01 units of enzyme).  The length distribution of pooled, unamplified 
genomic DNA digested under the same conditions differed in that it extended to 
a slightly lower mass (~300 bp) and contained prominent amounts of undigested 
DNA (Figure 3.3b).  The undigested DNA, however, is not amplified during 
linker-based PCR and is non-contributory to the final libraries.   
We should note that it is possible that the amplified libraries contained 
ligated chimeras of two or more digested fragments (possibly the origin of the 
longest E-LASL fragments).  Such chimeras are of little concern, however, given 
the functional nature of the screens and the fact that the majority of digested, 
unamplified DNA was gene-sized or greater in length.  In preliminary 
experiments, E-LASLs were also constructed with 10 ng and 1 ng of starting 
DNA.   
Figure 3.3a E-LASL Amplification Products 
Lanes 2-5 depict E-LASLs constructed from four Bacillus phage genomic 
samples (100 ng DNA/sample; 1 min digestion; 0.01 unitsTsp509I; 2 l 
reaction product/well).  The lane 6 E-LASL was constructed from 
metagenomic DNA extracted from earthworm gut contents (100 ng DNA; 1 
min digestion; 0.1 units Tsp509I; 2 l reaction product/well).  
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Figure 3.3b Digested DNA Prior to Linker Amplification   
Lane 2 contains undigested phage genomic DNA.  1 ug was digested under the 
same conditions as during E-LASL construction: 0.1 units Tsp509I/100 ng 
DNA/50 l reaction volume (lane 3) and 0.01 units Tsp509I/100 ng DNA/50 l 
reaction volume (lane 4).  The undigested DNA, however, is not amplified 
during PCR and is non-contributory to the final libraries.  We should note that 
the amplified libraries could contain ligated chimeras of two or more digested 
fragments (the likely origin of the longest E-LASL components of 1a).  These are 
of little concern, however, given that these are functional screens and that the 









With these quantities, however, the success and efficiency of library construction 
were variable (most likely due to the physical loss of DNA during laboratory 
manipulations involved in E-LASL construction).  Consequently, all libraries 
used in this study were constructed from 100 ng starting DNA.  
Following E. coli transformation, the mean insert size of the library was 
determined through colony PCR and gel electrophoresis of randomly selected 
clones.  The average insert size for the worm-gut metagenomic library digested 
with 0.1 units of Tsp509I was 1.99  0.61 kb (n = 65), while for the phage genomic 
libraries digested with 0.01 units it was 2.27  0.74 kb (n = 97, across all libraries).  
During this gel electrophoresis, a number of bands (~34%) ran at ~450 bp, 
corresponding to a circularized vector without any insert (verified through 
sequencing).  These bands were not included as part of the above mean length 
calculations.  Such clones also appeared in control experiments in which E. coli 
were transformed with a topoisomerase reaction mixture from which the insert 
DNA was omitted.   
While the presence of these self-ligated clones in the final libraries was an 
unavoidable byproduct of the cloning kit, they did not affect the subsequent 
functional screens.  Fortuitously, any clones containing this plasmid failed to 
proliferate in the presence of arabinose.  The translated 36 amino-acid 
polypeptide encoded by these plasmids (consisting of an N-terminal 
enterokinase domain, a V5 epitiope, and a C-terminal His-tag) apparently 
hindered E. coli growth when overexpressed by itself.  Conversely, all clones that 
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did successfully transfer from the master plates to the arabinose plates were 
observed to contain a plasmid with a genomic/metagenomic insert. 
In terms of colony yield, the number of individual clones that could be 
generated per topoisomerase cloning reaction (1 l enzyme-conjugated plasmid, 
1 l E-LASL, 4 l buffer) varied depending on the given cloning reaction and 
decreased with the age of the cloning kit (we recommend using freshly-
purchased kits).  For all libraries considered2, the average number of clones per 6 
l reaction was 1187 (range: 596 – 2713).  This number reflects the colonies that 
successfully transferred onto arabinose plates, thus specifically excluding 
colonies whose plasmids lacked an insert.  We should note that increasing the E-
LASL volume in a given reaction mixture or gel-purifying and concentrating the 
E-LASL prior to ligation did not improve (and, in fact, diminished) the colony 
yield. 
Screening of bacteriophage genomic libraries.  Various lytic bacteriophage 
capable of infecting B. anthracis (strain Sterne) were isolated from commercially 
available brands of bat guano.  E-LASLs derived from four of these phages (BG-
1, BG-2, and BG-3, and BG-4) were subjected to soft agar overlay screens in 
search of colonies with acquired antibacterial activity against B. anthracis.  In 
general, such screens of bacteriophage genomes are ideal for testing the utility of 
the E-LASLs.  All double-stranded DNA phage encode a cell wall hydrolase 
(known as a bacteriophage lytic enzyme, or lysin) with activity against the host 
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species.  These enzymes are expressed at the end of a phage infective cycle, and, 
along with a pore-forming protein known as a holin, are responsible for lysing 
the host and freeing newly assembled viral particles.  Lysins have generated 
considerable pharmacological interest due to their ability to lyse Gram-positive 
pathogens when added exogenously (Fischetti 2008 and 2005). 
In bacterial-overlay screens, we were able to clone the lysin genes from 
three of the four libraries tested: BG-1, BG-2, and BG-3.  In screens conducted 
during the development of the E-LASL protocol, we likewise cloned the well-
characterized PlyG lysin from genomic DNA of the Bacillus  phage (Brown and 
Cherry 1955, Schuch et al. 2002).  The proportion of positive lysin hits among all 
clones varied for each library: BG-1: 8 confirmed hits, 640 clones screened;  
phage: 2 confirmed hits, 1600 clones screened; BG-2: 1 confirmed hit, 540 clones 
screened; BG-3: 1 confirmed hit, 2710 clones screened.  For the BG-4 phage, 1220 
clones were screened, but no hits were generated.   
Each of the 8 confirmed hits for BG-1 encoded the full-length lysin, 
although no two contained flanking DNA of identical lengths.  Six of these 8 
clones, moreover, encoded the lysin on the strand whose transcription was not 
under control of the arabinose-inducible promoter (indicating the presence of an 
endogenous promoter with strong activity in E. coli).  When considering only the 
two clones with the lysin in the forward orientation, the proportion of hits for 
BG-1 (2/640) is closer to that of BG-2 and  phage.  For BG-3, the one confirmed 
lysin hit encoded only the N-terminal fragment of the complete protein.  This 
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fragment was still sufficient to create a zone of mildly decreased Bacillus density 
and altered coloration, allowing for identification.  The remainder of the gene 
was sequenced through genomic primer walking. 
Additionally, E-LASLs from BG-3, BG-4, and four other Bacillus phages 
(A10, A14, A17, and TSH) were screened for lytic enzymes using a novel 
technique described in Chapter 4.  With this approach, the BG-3 lysin was 
successfully re-cloned (in its entirety, without the need for primer walking) and 
the BG-4 lysin was identified for the first time.  Of the three new phages, the 
lysin for the A14 phage was successfully cloned.  The A10 and A17 E-LASLs 
were not subsequently rescreened using the standard cellular-overlay technique, 
and their lysins remain undetermined. 
Based on Pfam domain prediction, the majority of the cloned lysins (BG-2, 
BG-3, BG-4, A14, and TSH) are N-acetylmuramoyl-L-alanine-amidases.  The first 
five of these enzymes possess an N-terminal type 2 alanine-amidase motif, while 
the TSH lysin possesses a type 3 alanine-amidase motif.  Blast analysis suggests 
that this enzymatic specificity is very common among Bacillus phage and 
prophage lysins, with PlyG lysin as a notable example (Schuch et al. 2002).  By 
contrast, the BG-1 lysin is predicted to have N-acetylmuramidase activity with a 
glycosyl hydrolase, type 25 domain; this motif appears less common among 
known Bacillus phages.  At their C-termini, all the above lysins possess either a 
single or dual SH3 binding domain; BG-1 and the TSH lysin encode type 5 SH3 
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domains, while the others encode type 3 SH3 domains (see the Appendix for 
exact positional details). 
The BG-1 lysin (henceforth referred to as PlyBeta) demonstrates homology 
throughout its entire sequence to only one other known lysin3—PlyB lysin from 
the Bacillus BcpI phage, which was also recently characterized by the Fischetti 
laboratory (Porter et al. 2008).  PlyB and PlyBeta are each other‘s closest known 
homologues (E-value = 10-143).  They share 78% nucleotide identity and 81% 
amino acid identity (Figure 3.4).  The crystal structure of PlyB‘s catalytic domain 
(residues 1-190) was recently solved (Porter et al. 2008).  Based on this structure, 
all active site residues are conserved between PlyB and PlyBeta, with a single 
exception.  The tyrosine residue at position 160 of PlyB (part of the proposed 
substrate-binding interface) corresponds to a threonine residue at position 161 of 
PlyBeta.  The most noted region of divergence between the two lysins is a 9 
residue Asn-rich stretch beginning at position D189 of PlyBeta, immediately 
following the end of the catalytic domain.  This region of PlyBeta also encodes an 
additional cysteine residue, increasing the total number of cysteines in PlyBeta to 
3 (PlyB encodes 2 cysteines).  
The activity of PlyBeta was examined qualitatively against a variety of 
Bacillus species.  Soft agar overlay experiments were conducted with a PlyBeta-
expressing E. coli clone and 14 strains composed of B. anthracis, B. cereus, B. 
thuringiensis, B. subtilis, B. mycoides, and B. megaterium.   
Figure 3.4  Sequence Comparison of PlyB and PlyBeta   
The lysins share 81% amino acid identity, including all putative catalytic 
residues (noted with arrowheads). The most prominent area of divergence is a 
9-residue, Asn-rich stretch immediately following the catalytic domain at 




PlyBeta (like PlyB) is active against B. anthracis and other bacilli, although the 
activity varies considerably between species/strains.  Clearing zones were noted 
for 7/14 strains: 2/2 B. anthracis, 3/6 B. cereus; 1/3 B. thuringiensis, 1/1 B. subtilis, 
0/1 B. mycoides, and 0/1 B. megaterium.  Representative examples of susceptible 
and non-susceptible strains are shown in Figure 3.5.  Clearing zones were not 
observed for soft-agar overlays conducted with PlyBeta and strains of 
Streptococcus, Staphylococcus, and Listeria.     
 
Screening of worm gut metagenomic library.  An E-LASL was next constructed 
with DNA extracted from the gut contents of a single European night crawler 
(Eisenia hortensis).  Prior to functional screening, a brief sequence-based analysis 
was performed to verify the bacterial origin of the extracted DNA.  The inserts of 
50 clones were subjected to a single sequencing read (37.8 kb total).  When 
analyzed with the TBlastX algorithm, 46 of the 50 reads returned known 
homologues.  For each read, we calculated the relative contribution of different 
taxa to the total number of hits.  The average of these values across the 46 reads 
is shown in Table 3.1a.   
The most highly represented group is the proteobacteria (66%), with -
proteobacteria making the largest contribution (38%).  Firmicutes contributed 
~13% of hits, with all other bacterial phyla each contributing less than 5%.  
Viruses, archaea, and the eukaryotic kingdoms likewise contributed less than 5% 
each.   
TOP10 
PlyBeta 
Figure 3.5  PlyBeta Clearing Zones 
In soft agar overlay experiments, PlyBeta-expressing E. coli clones created 
clearing zones for some, but not all, species/strains of Bacillus.  Depicted 
here are representative examples of strain that [A] did and [B] did not 
demonstrate susceptibility.   
(A) 




Figure 3.5, continued 
(B) 
B. cereus 13100  
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Table 3.1a Taxonomic Distribution of Metagenomic BLAST Hits 
Forty-six of 50 metagenomic sequences generated BLASTX homologies, for 
which the encoding organisms were noted.  The proportion of individual taxa 
among all hits was calculated for each sequence.  Listed above are the average 









 Firmicutes 0.134 
 Actinobacteria 0.038 
 Bacteroides/Chlorobi 0.025 
 Cyanobacteria 0.021 
 Spirochaetes 0.019 
 Other Bacteria 0.020 
 Animal 0.032 
 Plant 0.011 
 Fungi 0.006 
 Protozoa 0.005 
 Archaea 0.015 





The top hit for each of the 46 reads was bacterial in origin (Table 3.1b), and 11 of 
the 46 top hits were from various species of the genus Aeromonas, suggesting a 
gut environment dominated by aeromonads. 
The metagenomic library was subject to soft agar overlay screens in which 
5005 permeabilized clones were each overlaid with B. anthracis (Sterne), P. 
aeruginosa (PAO1), S. aureus (RN4220), and sheep‘s blood.  The blood-agar screen 
was included here due to the bacterial origin of the extracted DNA, with its 
potential for identifying encoded hemolytic virulence factors.  Indeed, while no 
clearing zones were observed in the bacterial screens, a zone of -hemolysis was 
noted around a single clone in the blood-agar screen (see Figure 3.6a).  The 
clone‘s metagenomic insert was sequenced and BlastX analysis showed it to 
encode a new member of the aerolysin gene family.   
Aerolysin is a pore-forming exotoxin encoded by various Aeromonas 
species.  The protein is secreted through the type II pathway, and—following a 
C-terminal cleavage event in solution or at the target cell surface—it 
multimerizes and inserts into eukaryotic plasma membranes (Fivas et al. 2001).  
When the hemolytic clone was further tested, it was found that chloroform 
permeabilization was not required for hemolysis.  The clone had acquired a -
hemolytic phenotype when grown on blood agar (Figure 3.6a, inset), indicating 
the aerolysin is recognized by the E. coli type II secretion system (both inner and 
outer membrane components).   







No Match 3 
 











TAXA Top Hits 
Aeromonas 11 
Salmonell  5 
Escheri ia 4 
Clostridium 3 
Shewanella 3 
Psuedom nas 3 
No Match 3 
 











Table 3.1b Top BLAST Hits by Genus 
For each of metagenomic sequences, the encoding organism of the hit with the 
lowest e-value was noted.  The table compiles these hits organized by genus, 
with Aeromonas being the most highly represented. 
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Figure 3.6a Positive Hemolysin Clone  
During the metagenomic screen of worm-gut contents, a single positive 
clone was observed in blood agar overlay screens (indicated by arrow).  
The corresponding colony on the master plate was identified, 
amplified, and shown to contain a metagenomic DNA insert encoding 
a novel aerolysin (AerM).  When propagated on LB-blood agar, this E. 
coli clone demonstrated -hemolysis without chloroform 




Overall, aerolysin sequences have been reported for a number of 
Aeromonas species/strains (Epple et al. 2004; Wang et al. 2003 and 1996; Fujii et 
al. 1998; Khan et al. 1998; Husslein et al. 1998; Hirono and Aoki 1993; Chopra et 
al. 1993; Hirono et al. 1992; Howard et al. 1987; Chakraborty et al. 1986; Howard 
and Buckley 1986).  When compared to these proteins, the new aerolysin 
(subsequently referred to as AerM) demonstrated an average Clustal nucleotide 
alignment score of 71.1 (range: 68-78) and an average amino acid alignment score 
of 73.2 (range: 68-79) (all pairwise E-values < 10-120).  Phylogenetic analysis, 
moreover, showed it to occupy a relatively unique evolutionary position relative 
to other aerolysins (Figure 3.6b).   Considering that the other aerolysins did not 
always group according to their species, however, one cannot surmise whether 
AerM is encoded by a different strain of one of the species listed in Figure 5b or a 
different aeromonad species entirely. 
AerM was purified so that its activity could be confirmed quantitatively.  
In SDS-PAGE, the protein ran at a molecular weight of ~48 kDa (Figure 3.6c and 
d).  This is the predicted mass of AerM following C-terminal cleavage.  To verify 
this assumption—and not the alternate possibility of a nonspecific degradation 
product of coincidental molecular weight—Edman sequencing was conducted.  
The N-terminus was shown to begin at residue A24 (immediately following the 
predicted position of signal peptide cleavage), implying the presence of the final 
processed protein (Figure 3.6e). 
   Distance Method 
Figure 3.6b Aerolysin Phylogeny   
Multiple sequence alignment was conducted with AerM and all other non-
redundant aerolysin sequences in the NCBI database: A. hydrophila I 
(GeneBank accession number M16495); A. hydrophila II (X65044); A. hydrophila 
III (X65045); A. hydrophila IV (AY611033); A. hydrophila V (AF41110466); A. 
hydrophila VI (M84709); A. hydrophila VII (DQ40826); A. hydrophila VIII 
(AY378303); A. sobria I (X65046); A. sobria II (AY157998); A. sobria III (Y00559); 
A. salmonicida I (X65048); A. trota I (AF064068); A. caviae (AAC44637).  
Phylograms constructed from these alignments (using DNA parsimony and 
distance methods, distance shown here) indicate that AerM occupies a relatively 
unique evolutionary position relative to the other aerolysins.  Bootstrap 
consensus values (out of 1000) are indicated at their respective nodes. 
166 
Figure 3.6c  Purification of AerM 
AerM was secreted by the encoding E. coli into the culture supernatant.  As 
a result, the cell-cleared media was ammonium sulfate-precipitated and 
the total extracellular protein fraction was collected, resuspended, and 
subject to Mono-Q anion exchange chromatography. The peak 
corresponding to AerM (as determined by drop tests onto blood agar) is 
indicated with an arrow. 
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Figure 3.6d  Purified AerM 
In SDS-PAGE, AerM ran at a molecular mass slightly below 50 kDa.  
The predicted molecular mass of the initial translated protein 
(preproaerolysin) is 54.5 kDa.  Following inner membrane 
translocation and N-terminal cleavage, the protein (proaerolysin) has 
a predicted mass of 52.0 kDa.  The final, processed protein (following 
C-terminal cleavage) has a predicted mass of 47.5 kDa.  The mass of 
the purified protein above suggests that it was isolated in this form.  
50 kDa 
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Figure 3.6e  Edman Sequencing of AerM 
To confirm the that AerM was recognized and secreted by the E. coli sec-
mediated pathway— and to verify the predicted position of signal peptide 
cleavage—the purified protein was subject to N-terminal sequencing by the 
Rockefeller Proteomics Facility.  Indeed, both were confirmed, as the 




The activity of AerM against various erythrocytes was tested with an in 
vitro hemolysis assay.  While the toxin showed activity against all cells tested 
(sheep, rabbit, chicken, human), the specific sensitivity varied among the species 
(Figure 3.6f).  Under the assay conditions (108 RBC/ml in PBS, 1 hr incubation, 
37C), the erythrocytes could be ranked by increasing sensitivity as follows: 
sheep (complete hemolysis at 200 nM) < human < chicken < rabbit (complete 
hemolysis at 5 nM).  The activity of AerM was also confirmed against an actively 
dividing mammalian cell line, Detroit 562 (human pharyngeal carcinoma).  When 
added to a 75% confluent culture, 2 nM AerM induced near total cellular 
dissociation with loss of viability by 48 hr (images not shown).  Boiling AerM 
prior to its addition to culture media abolished the cytotoxic affect, indicating 
that the cellular response was attributable to the protein itself and not residual 
endotoxin contamination from the purification protocol. 
 
DISCUSSION 
 We describe here a novel technique for screening genomic or 
metagenomic DNA that utilizes a combination of PCR amplification and 
topoisomerase cloning.  This expression-based approach has several strengths 
that make it a useful tool in the search for metagenomic proteins of interest.  
Library construction is rapid and straightforward, and only nanogram quantities 
of DNA are required.   
Figure 3.6f AerM-Induced Hemolysis of RBCs.   
Erythrocytes from several species all showed susceptibility to AerM in a 
quantitative in vitro hemolysis assay.  Rabbit erythrocytes demonstrated the 
highest sensitivity, sheep erythrocytes demonstrated the lowest sensitivity, 
while human and chicken erythrocytes demonstrated intermediate sensitivity.  
For each measurement, n = 6, except human (n = 3).  Several hemolysis 
measurements extend slightly above the 100% value.  This is merely an artifact 
of the experimental standards; in these cases, AerM-induced hemolysis 




Moreover, the use of commercially-available cloning products makes the 
technique desirable for laboratories that are entering the field of metagenomics 
and might lack dedicated expression systems.  Overall, the great potential of 
metagenomics is attracting much attention, so the development of simple, 
functional screens could broaden accessibility to an already rapidly growing 
science.   
 A particularly well-suited application for the technique is the functional 
screening of viral metagenomes.  Viral metagenomics is an emerging area in 
which bacteriophage particles (or other viruses) are purified from environmental 
samples prior to library construction.  Given that bacteriophages are likely the 
most abundant genetic entities on Earth (Hatfull 2008), metagenomics provides a 
powerful tool for investigating their ecology and diversity.  Previous viral 
metagenomic studies have utilized linker amplification, as phage DNA is 
relatively scarce relative to the total metagenomic pool.  Nevertheless, this work 
has been entirely sequence-based in nature (Angly et al. 2007; Culley et al. 2006; 
Zhang et al. 2006; Breitbart et al. 2002 and 2003).  Functional viral metagenomics 
could provide an important compliment, especially in the search for antibacterial 
proteins (e.g. phage lysins) or ones involved in bacterial pathogenesis (e.g. 
phage-encoded virulence factors). 
 The E-LASL approach is likewise applicable to functional screening of 
bacterial metagenomes (such as the worm-gut contents screened here).  Although 
used here to identify a new hemolysin, the method is equally applicable in 
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mining for other classes of active proteins.  By simply changing the readout of 
the soft agar overlay step, for instance, one could search for various bacteria-
encoded antibiotics or biocatalysts.  In the case of antibacterial proteins, the 
screens could target cell wall remodeling enzymes (autolysins), peptide 
antibacterial compounds (bacteriocins), or lysins from integrated prophage.  
Given the size of bacterial genomes, such genes would comprise a smaller 
proportion of the total DNA and would likely necessitate that a greater number 
of clones be screened to generate hits.  It is therefore not surprising that the 
relatively small metagenomic screen conducted here against B. anthracis, S. 
aureus, and P. aeruginosa did not identify any antibacterial proteins.   
 One should note that the E-LASL method admittedly has several 
limitations that must be taken into consideration.  Like all functional 
metagenomic screens, there is always the possibility that foreign proteins may 
misfold, not express, or prove toxic to the host species.  Moreover, the technique 
would not be expected to identify secondary metabolites from environmental 
organisms, as the DNA inserts are too short.  Ultimately, the insert-length cannot 
exceed the substrate length limit of the polymerase itself.  Considering current 
polymerase technology, it is theoretically possible to construct an E-LASL with 
inserts in the range of tens of kilobases (i.e. for use in cosmids).  At the same 
time, commercially-available systems do not yet exist that would make such 
libraries compatible with topoisomerase cloning. 
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It is important to mention that there are several other ways in which the 
method presented here could be adapted to fit specific situations.  Although 
Tsp509I was employed here to fragment DNA, other restriction enzymes exist 
with suitable 4-bp consensus sequences.  For instance, one might employ BfuCI 
(/GATC) or MspI (C/CGG), especially if dealing with a more GC-rich organism 
or environmental sample.  Enzymatic digestion of DNA could even be omitted 
entirely in favor of mechanical fragmentation, although this would create a need 
for overhang digestion and blunt-ended ligation (as in previous studies, Breitbart 
et al. 2002 and 2003).   We also envision a protocol in which RNA is extracted in 
bulk from an uncultured sample.  An E-LASL could then be constructed from 
reverse-transcribed metagenomic cDNA.   
In the current study, several functional proteins were identified through 
the E-LASL technique.  Although they are presented more as proof-of-principal, 
these proteins raise several issues that, in themselves, merit further discussion.  
For instance, the B. anthracis lysins cloned here further expand the list of 
potential enzybiotics that have been identified for this important bioterrorism-
related pathogen (Porter et al. 2008; Yoong et al. 2006; Low et al. 2005; Schuch et 
al. 2002).  Moreover, the AerM protein represents the first example of a hemolytic 
virulence factor characterized through metagenomics.  Although hemolysis of 
blood agar is a classic method of identifying bacterial species, surprisingly few 
metagenomic screens have focused on an acquired hemolytic phenotype.   
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To our knowledge, the only previous examples are the studies of Rondon 
et al. (2000) and Gillespie et al. (2002).  In the former, the authors identified a 
number a hemolytic BAC clones from a soil-derived metagenomic sample.  This 
screen was performed as proof-of-principal of their screening technique, 
however, and the responsible molecules were not identified.  In Gillespie et al. (a 
follow-up of the previous paper), one of these clones was investigated further 
and was demonstrated to encode a biosynthetic enzyme leading to the 
production of the small molecule turbomycin.   
Admittedly, AerM is not a protein whose cloning would have absolutely 
required a metagenomic approach.  Aeromonads are generally culturable, so the 
AerM-encoding species presumably could have been isolated from the worm gut 
first, and the aerolysin cloned through genomic techniques.   Nevertheless, this 
approach would have required considerably more effort (as well as the specific 
original intent of looking at this genus).  In general, environmental virulence-
factor screening represents an interesting avenue for future metagenomic 
screening.  Given the role they play in pathogenesis and inter-species 
competition, the identification of such proteins could prove valuable from an 
ecological or infectious disease perspective. 
In summary, we have presented here a novel method for constructing 
genomic and metagenomic expression libraries from small initial quantities of 
extracted DNA.  This plasmid-based approach utilizes linker-amplification and 
topoisomerase cloning, and provides a rapid, technically straightforward, and 
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adaptable means of functional screening in an E. coli host.  Overall, the E-LASL 
approach may be utilized to mine uncultured bacterial or viral populations for 
novel antibiotics, as well as other protein compounds with pharmacological, 
industrial, or pathogenic potential.  
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ENDNOTES 
1. The distinction between sequenced-based and functional metagenomics is 
blurred somewhat by certain publications that refer to the homology-based 
prospecting for desired enzymes as functional (Schoenfeld et al. 2010).  In the 
current text, however, the term functional is reserved recombinant screens, and 
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not sequence-based searches that subsequently lead to PCR-cloning and 
functional analysis (as in Chapter 2). 
 
2.  The numbers regarding transformation efficiency are those that were 
originally reported in Schmitz et al. (2008).  They were derived from the E-LASLs 
for phages BG-1, BG-2, BG-3, BG-4, and the worm-gut metagenome.  Colonies 
were not counted when the phage-genomic E-LASLs were used in combination 
with the holin-based hemolysis screen.  The latter screens, in fact, transpired after 
this data was originally published.  They represent the preliminary work that led 
to the development of screening technique itself (see Chapter 4).  The 
information is included in this chapter so that Chapter 4 can best reflect the 
format that appeared in Schmitz et al. (2010b).   
 
3.  This was true at the time of original publication in 2008.  Since that time, 
genomic sequencing of numerous Bacillus strains has revealed various other 
lysin-genes with an N-terminal GH-25 domain and a C-terminal SH3-5 domain.  
PlyB and PlyBeta remain each other‘s closest known homologue, but their overall 
architecture can no longer be considered unique among Bacillus.  To date, none of 




**NOTE: In the published manuscript based on this chapter (Schmitz et al. 2008), 
the following individuals were included as co-authors (in the stated order): Anu 
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The field of metagenomics has expanded rapidly in recent years, providing 
access to environmental microorganisms that would remain unapproachable by 
standard, culture-based methods.  The foundation of metagenomics lies in the 
direct extraction of DNA/RNA from environmental samples (e.g. soil, water, or 
feces), without prior isolation of individual microbial species (reviewed in Green 
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and Keller 2006, Tringe and Rubin 2005).  It has been estimated that only a small 
proportion of naturally occurring microbesapproximately 1% of soil bacteria, 
for instanceare culturable under standard laboratory conditions (Torsvik and 
Ovreas 2002).  In this light, metagenomics has become an increasingly common 
tool for studying diverse ecosystems, from around the globe to within the human 
body. 
 Overall, metagenomics research can be divided into two general 
categories: sequence-based and functional.  In the former, environmental DNA is 
sequenced in mass and compared with genetic databases to address broad 
questions of ecology, taxonomy, and diversity.  Some of the most extensive 
metagenomic studies to date have been sequence-based in nature, benefiting 
greatly from the development of high-throughput sequencing technologies.  
Notable examples include a 76-megabase study of an acid-mine biofilm (Tyson et 
al. 2004), a 1-gigabase analysis of the Sargasso Sea (Venter et al. 2004), and a 6.3-
gigabase sampling of global oceanic samples (Rusch et al. 2007).   
In functional metagenomics, by contrast, environmental genes are 
recombinantly expressed within a host organism, which is monitored for the 
acquisition of a desired phenotype.  Rather than provide insight into entire 
ecosystems, functional studies aim to identify individual molecules with 
biomedical or industrial value.  Such compounds may either be proteins 
(encoded directly by environmental genes) or small molecules (synthesized by 
several enzymes of a gene cluster).  Numerous classes of molecules have been 
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identified to date, with particular interest in the areas of biosynthesis, biomass 
degradation, and antibiotic discovery (reviewed in Brady et al. 2009, Uchiyama 
and Miyazaki 2009, Voget et al. 2005).   
While bacteria provide the majority of DNA to most metagenomic pools, 
recent studies have begun focusing on subsets of total environmental 
populations.  A prominent example is viral metagenomics, in which viral particles 
(predominately bacteriophage) are purified from cellular material prior to DNA 
extraction (reviewed in Delwart 2007, Edwards and Rohwer 2005).  Although the 
yield of DNA from environmental phage isolates is generally low, PCR-
amplification techniques have been developed to overcome this issue (Breitbart 
et al. 2002, Schmitz et al. 2008).  Viral metagenomic analyses have been 
conducted on a growing number of samples, including ones purified from soil 
(Fierer et al. 2007), sea-water (Breitbart et al. 2002, Williamson et al. 2008), and 
human feces (Breitbart et al. 2003).   
These studies have revealed a remarkable abundance of novel sequences, 
supporting the notion that phage represent the largest source of untapped 
genetic diversity on the planet (Hatfull 2008).  Despite this wealth of information, 
however, viral metagenomic studies to date have remained predominantly 
sequence-based in nature.  In this regard, functional screens of viral 
metagenomes could provide a large source of recombinant molecules.   
Recently, one class of phage-encoded protein has received particular 
attention from the biotechnology field: phage lytic enzymes (also referred to as 
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endolysins or lysins) (reviewed in Fischetti 2005, Fischetti et al. 2006).  These 
peptidoglycan hydrolases are expressed late in the infective cycle of double-
stranded DNA phage, andalong with a membrane permeablizing protein 
known as a holinthey are responsible for disrupting the bacterial cell envelope 
and freeing progeny viral particles.   
Despite this conserved biological function, phage lysins (especially Gram-
positive ones) are a tremendously diverse group of proteins whose enzymatic 
specificity includes various bonds within the peptidoglycan macromolecule.  
They include glycosyl hydrolases that target the polysaccharide backbone 
(muramidases/lysozymes and glucosaminidases), alanine-amidases that target 
the initial L-alanine of the pentapeptide stem, and endopeptidases that target 
subsequent peptide bonds in the stem or cross-bridge.  While lysins of Gram-
negative phage generally consist of an enzymatic domain alone, Gram-positive 
lysins are modular and combine an N-terminal lytic domain with a C-terminal 
binding domain that can recognize various epitopes within the target cell 
envelope. 
Although researchers have known of lysins for decades, interest has 
increased markedly in recent years after it was proposed that they could act as 
novel anti-infective agents against Gram-positive pathogens, whose 
peptidoglycan is directly accessible from the extracellular space (for instance in 
Nelson et al. 2001, Schuch et al. 2002, Cheng et al. 2005).  A growing number of in 
vitro and in vivo studies have confirmed the ability of recombinantly expressed 
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lysins to kill such organisms, and their appeal lies in both the potency and the 
specificity they demonstrate toward individual Gram-positive species.  This 
enzybiotic value of phage lysins goes alongside additional proposed applications 
in the areas of food (Deutsch et al. 2004), agricultural (Kim et al. 2004), veterinary 
(Celia et al. 2008), and industrial science (Matsushita and Yanase 2008, Ye and 
Zhang 2008). 
Considering this potential, lytic enzymes represent an intriguing 
functional target for viral metagenomic screens.  At the same time, identifying 
lysins in this manner would present several distinct challenges.  Aside from 
general concerns common to all functional screens (e.g. protein expression and 
solubility), metagenomic lysin identification would face the following particular 
issues.   
(I) Clonal toxicity: Recombinant lysin expression is typically well-tolerated 
by host bacteria, as the enzymes are sequestered in the cytoplasm away from the 
peptidoglycan layer.  Holins, on the other hand, interact nonspecifically with 
plasma membranes and are generally toxic to an E. coli host, inducing 
bacteriolysis from within (9).  Since holins are short (~100 residues) and often 
encoded adjacent to lysins, they can lead to selective toxicity of many of the 
clones one hopes to identify.  In a metagenomic screen, where numerous lysins 
are present within a single library, this effect could lead to a significant loss of 
positive hits.  (II) Target bacterial species: In standard phage genomic screens, 
lysin-encoding clones are selected by their ability to kill the host bacterium of the 
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encoding phage, which generally demonstrates the highest sensitivity.  In a 
metagenomic screen, however, numerous host species of unknown origin could 
be present, confounding this choice of screening agent. 
 To address these issues, we have devised a novel functional strategy for 
the general cloning of lytic enzymes from uncultured phage DNA.  It utilizes a 
plasmid-based E. coli expression system and consists of a two-step process.  
Following induction by nebulized arabinose, clones are first screened for holin-
mediated lysis by a hemolytic effect they create in the surrounding blood agar.  
These initial hits are then restreaked as patches and overlaid with Gram-negative 
cells whose outer membranes have been permeabilized by autoclaving, serving 
as a general source of peptidoglycan.  The clones are observed for surrounding 
Gram-negative clearing zones to assay directly for the recombinant production of 
lytic enzymes encoded adjacent to the holins.   
As proof-of-principle, we applied our methodology to a viral 
metagenomic library constructed from mixed animal feces, identifying 26 
actively-expressed lysins of diverse molecular architectures.  The first of its kind, 
this study presents a general model for lysin identification through viral 
metagenomics, highlighting the potential of this field for cloning proteins of 






MATERIALS AND METHODS 
DNA library construction.  Fecal specimens were collected at the Long Island 
Game Farm Wildlife Park and Children‘s Zoo (Manorville, New York) from the 
following species: giraffe, zebra, donkey, domestic goat, llama, lion, and bison.  
Additionally, two dried fecal specimens were obtained from commercial sources: 
bat guano (Fox Farm Soil and Fertilizer Company) and cricket droppings 
(www.cricketpoo.com).   
Viral fractions were purified by an adaptation of the procedure of Casas 
and Rohwer (2007).  In summary, fecal samples (~100 g each) were suspended in 
an equal volume of PBS (pH 7.4) and agitated overnight at 4C.  
Particulate/cellular material was removed by centrifugation, followed by two 
passages through a 0.22-micron filter.  Phages were precipitated by addition of 
polyethylene glycol 10,000 MW (10% w/v).  Centrifuged precipitates were 
pooled to form a collective phage library, which was subject to 
phenol/chloroform extraction and ethanol precipitation.  Phage DNA was 
separated from co-precipitated compounds by agarose gel electrophoresis and 
extraction of high molecular weight DNA.  From this material, an expressible 
linker amplified shotgun library (E-LASL) was constructed, as previously 
described (see Chapter 3).   
 
Lysin screening methodology.  Amplified metagenomic inserts were ligated into 
the arabinose-inducible pBAD plasmid using the TOPO-TA Expression Kit 
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(Invitrogen).  Transformed clones were initially plated onto LB-agar 
supplemented with 100 g/ml ampicillin and 5% defibrinated sheep‘s blood.  
Following overnight growth at 37C, clones were subject to an initial toxicity 
screen to isolate potential holin-encoding clones.  Plates were sealed in a 
container into which a nebulized solution of aqueous arabinose (20% w/v) was 
pumped for 1 hr.  Following induction, the plates were returned to 37C and 
observed for colony lysis, as indicated by the development of a zone of 
hemolysis in the surrounding blood agar.  Hits were identified over the 
subsequent 6-8 hr period, as nonspecific blood-agar oxidation (i.e. alpha-
hemolysis) would often appear around colonies at longer times (~16 hrs).  
Chosen clones were streaked onto separate LB-ampicillin plates (lacking 
arabinose) and allowed to repropagate without induced expression. 
 For the secondary (i.e. lysin-targeting) screen, the above hits were 
streaked as patches onto LB-ampicillin plates supplemented with 0.2% arabinose.  
Following overnight expression at 37C, cells were exposed to chloroform vapor 
(15 min) to kill and permeabilize any still-viable E. coli (by this point, many cells 
had already undergone lysis due to holin expression).  The patches were then 
overlaid with molten soft agar containing autoclaved P. aeruginosa (see below), 
and observed for clearing zones for up to 24 hr.  For all lytic clones, the encoded 
metagenomic insert was sequenced with plasmid-targeted primers (Genewiz; 
South Plainfield, NJ).  When primer-walking was required to sequence an insert 




Preparation of Gram-negative overlay.  Gram-negative soft agar was prepared 
as follows: P. aeruginosa strain PAO1 was grown to stationary density in Brain-
Heart Infusion media.  Cells were pelleted and resuspended in PBS pH 7.4 to half 
the volume of the original liquid culture.  Agar was added directly to this 
suspension (7.5 g/L), which was autoclaved for 15 min at 122C, 15 psi.  
Solidified aliquots were stored at 4C until the time of use, at which point they 
were melted and equilibrated at 55C.  For a single 150-mm Petri dish, 15 ml of 
soft agar was overlaid.   
 
Computational analysis.  Protein sequences of the cloned lysins were subject to 
BlastP analysis to identify known homologues among defined organisms 
(blast.ncbi.nlm.nih.gov/Blast.cgi).  As a reference database, the NCBI non-
redundant sequence collection (nr) was utilized.  Putative catalytic and binding 
domains were assigned via Pfam v24.0 (Finn et al. 2010; pfam.sanger.ac.uk).  
Multiple sequence alignment of cloned lysins (amino acid sequence) was 
conducted with the ClustalX algorithm (Thompson et al. 1997).  From this, a 
phylogenetic tree was constructed with the PHYLIP v3.67 software package 
(Felsenstein 1989) using the Protdist and Kitch programs (default settings).   
 
RESULTS 
A plasmid-based shotgun library was constructed with pooled DNA 
extracted from the phage fraction of multiple animal fecal samples.  In order to 
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clone lytic enzymes from this metagenomic pool, we first sought to address the 
issue of holin-based clonal toxicity.  Rather than attempt to mitigate the effect, we 
instead chose to exploit it by selecting for toxic clones.  In the literature, there 
exists one example in which a lysin-encoding clone was identified through the 
lytic activity of its adjacent holin.  When screening a genomic library from 
Actinomyces naeslundii phage AV-1, Delisle et al. utilized a ―plasmid release‖ 
protocol in which mixed E. coli transformants were grown in a single liquid 
culture (2006).  Holin-encoding cells would undergo lysis following induced 
expression, releasing their plasmids into the culture media, from which they 
could be purified and characterized.  Their approach was adapted here for 
metagenomic libraries, in which numerous targeted clones are present within a 
single library. 
Following transformation, E. coli clones were plated onto agar media 
supplemented with 5% sheep‘s blood, but lacking arabinose inducing agent.  The 
latter was supplied via a nebulized mist only once the clones had proliferated to 
visible colonies.  In the hours following arabinose induction, colonies undergoing 
lysis could be visualized by the appearance of subtle, yet definitive, hemolytic 
zones in the surrounding blood agar (Figure 4.1).  This effect was often 
accompanied by the development of a viscous colony-phenotype: when a pipette 
tip was touched to a hemolytic colony and lifted up, the bacterial mass would 
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Figure 4.1 Preliminary Hemolysis Screen 
189 
Figure 4.1, continued 
Depicted here are seven E. coli Top-10 clones on LB-ampicillin 
supplemented with 5% sheep’s blood.  Each clone is transformed with a 
pBAD plasmid containing a different protein-encoding insert. A-Top left: 
empty plasmid; B-Top right: aerolysin, a hemolytic bacterial exotoxin 
encoded by the genus Aeromonas; C-Center left: Bacillus anthracis phage 
alanine-amidase with adjacent holin; D-Center middle: lysin PlyM14 from 
this study with adjacent holin; E-Center right: arbitrary metagenomic 
insert from this study; F-Bottom left: Bacillus anthracis phage alanine-
amidase without adjacent holin; G-Bottom right: Bacillus anthracis phage 
muramidase without adjacent holin.  Prior to induction with nebulized 
arabinose, the clones are indistinguishable against the blood agar 
background.  Following induction (apparent at 6 hrs and more prominent 
at 24 hrs), a zone of hemolysis is present around the clones encoding 
holin/lysin combinations (C and D).  No such zones are present 
surrounding the clones encoding empty plasmid (A), random sequence 
(E), or lysin only (F and G).  The aerolysin-encoding clone (B) is included 




Presumably, both the hemolysis and the viscosity were due to the release of 
intracellular contents from the lysing colonies.  The hemolytic effect could 
likewise be attributable to interactions between the expressed holins and the 
blood-agar erythrocytes, as holins have been shown capable of permeablizing 
eukaryotic membranes in vitro (Agu et al. 2007). 
Approximately 200,000 clones were screened in this manner, and 502 
preliminary hits were identified and repropagated on media lacking inducing 
agent.  To confirm the identity of the cloned inserts, 52 of these hits were subject 
to DNA sequencing.  Forty-one unique clones were observed in this analysisof 
these, 17 contained ORFs that encoded both a complete holin and a complete 
lysin gene (as determined through Blast-homology analysis); 4 encoded a 
complete holin with only a partial (i.e. truncated) lysin; 2 encoded complete 
holins without any recognizable lysin; and 18 did not demonstrate homology to 
either holins or lysins.  The latter 18 inserts encoded ORFs with a variety of 
predicted functions, including a number phage structural proteins and DNA-
interacting proteins.  For 5 inserts, Blast analysis did not reveal any putative 
genes of known function.   
As these sequencing results indicate, the hemolysis screen was not 
absolutely specific for holin/lysin cassettes, although this finding is not 
unexpected.  In theory, the technique could select for any toxic proteins that 
compromise the viability (and, resultantly, the envelope integrity) of the host E. 
coli.  Moreover, even among those clones encoding putative lysins, this initial 
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screen does not reveal which ones express soluble, active enzymes in the 
recombinant system.  A secondary screen was thus necessary to specifically 
identify these clones.   
For this step, we exploited the cell-envelope properties of Gram-negative 
bacteria.  To explain, viable Gram-negative cells are generally resistant to 
exogenous lysin treatment, as their peptidoglycan layer is surrounded by the 
lipophilic outer membrane.  Once this membrane is compromised, however, they 
become highly sensitized to enzyme action.  This includes lysis by both non-
specific eukaryotic lysozymes (forming the basis of many commercially-available 
extraction kits), as well as by phage lytic enzymes from viruses that infect other 
bacterial species (Briers et al. 2007).  This sensitivity is attributable to the thinness 
of the Gram-negative peptidoglycan layer, and it is reflected in the very structure 
of Gram-negative phage lysins.  As mentioned above, Gram-positive lysins 
possess both an N-terminal enzymatic domain and a C-terminal binding domain 
(which leads to target specificity), while Gram-negative lysins are classically 
comprised of an enzymatic domain alone (Fischetti 2005).   
Consistent with these properties, we have previously observed 
(unpublished findings) that clearing zones appear in soft-agar experiments in 
which autoclaved Gram-negative cells are exposed to any number of diverse 





Figure 4.2a Lysin-Encoding Clones with  




Figure 4.2b Lysin-Encoding Clones with  
Pseudomonas Overlay (Metagenomic)  
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Figure 4.2, continued 
Various lysin-encoding clones are overlaid here with autoclaved P. 
aeruginosa PAO1. [A] Previously characterized phage lysins. As opposed to 
the negative control (top), Gram-negative clearing zones are apparent 
around E. coli clones encoding CPL-1 (Streptococcus pneumoniae 
muramidase), PlyG (Bacillus anthracis alanine-amidase), PlyB (Bacillus 
anthracis muramidase), and PlyCM (Clostridium perfringens 
muramidase).  In each case, the cells were streaked onto LB-agar 
containing arabinose inducing agent, allowed to proliferate overnight, and 
chloroform permeabilized prior to Gram-negative overlay.  [B] 
Metagenomic lysin hits.  Four representative examples of the 26 enzymes 
cloned during this study are depicted here (PlyM4, PlyM6, PlyM19, and 
PlyM22).  As mentioned in the text, these clones (which encode 
holin/lysin combinations) often demonstrated toxicity when streaked onto 
arabinose-containing agar.  This is particularly evident for the clones 
encoding PlyM4, PlyM6, and PlyM19, in which punctate colonies 





While this phenomenon was of little practical significance when cloning lytic 
enzymes by standard genomic techniqueshere, the encoding phage and target 
species are known a priori it could be useful for identifying unknown lysins 
from a metagenomic pool.  (We should note that permeabilized Gram-negative 
cells are not broadly susceptible to endopeptidase lysins, as the peptidoglycan 
cross-bridge varies considerably among bacterial species; a more detailed 
discussion of this point is provided in the Discussions section of this chapter). 
To these ends, the 502 hits identified in the initial hemolysis screen were 
generously restreaked as patches onto arabinose-containing agar and tested for 
their ability to lyse a soft-agar overlay of autoclaved P. aeruginosa, strain PAO1.  
This particular Gram-negative species/strain was chosen as the screening agent 
based on the visual clarity of the clearing zones it produced in preliminary 
experiments.  Seeing that the 502 strains were selected for the toxicity of their 
encoded insert, the streaked patches obviously did not proliferate well on the 
arabinose plates; following overnight incubation, they were often comprised of 
lysed cells with occasional punctate colonies (presumably recombinant mutants 
with down-regulated insert expression, see Figure 4.2b).  Nevertheless, even with 
little growth, enough recombinant protein was synthesized to produce distinct 
clearing zones in the overlay.   
In total, 65 positive clones were identified in the secondary screen (Figure 
4.2b), which were shown by sequencing to encode 26 unique lysins (denoted as 
PlyM1-PlyM26, GenBank accession numbers HM011589-HM011614).  Of these 
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enzymes, 15 were observed for the first time during the secondary screen, while 
11 had had been identified previously during the aforementioned sequencing of 
52 hemolytic clones.  Conversely, 6 of the putative lysins identified during the 
initial sequencing (PlyM27-PlyM32, GenBank accession numbers HM011615-
HM011620) were not detected by the secondary screen, attributable to insoluble 
or insufficient recombinant expression. 
Based on Pfam analysis, the 26 actively-expressed enzymes comprise a 
variety of molecular architectures and enzymatic motifs.  They are summarized 
in Table 4.1 along with their putative domain assignments and known 
homologues among defined organisms.  (For a complete list of Blast homologues, 
refer to the on-line supplementary information of the associated article.)  The 
majority of the genes (PlyM1-PlyM20) encode typical Gram-positive lysins, with 
an N-terminal catalytic region and a C-terminal binding region.  Of these 20 
genes, 15 encode full-length lysins and 5 encode slightly truncated proteins (as 
an artifact of library construction) that lack the final portion of the C-terminal 
region but retain detectable catalytic activity.  Of the 6 remaining lysins, 3 
represent typical Gram-negative lysins (comprising only a catalytic domain, 
PlyM22-PlyM24) while 3 posses attypical architectures uncommon among 
bacteriophage (PlyM21, PlyM25-PlyM26).  As expected, a large majority of the 
lysin-expressing clones (24/26, exceptions being PlyM18 and PlyM19) also 
encode a short, adjacent ORF that can be assigned putative holin functionality 
based on its database homologues and/or predicted transmembrane topology. 
Table 4.1 Cloned Metagenomic Lysins 
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Table 4.1, continued 
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Table 4.1, continued 
The 26 actively-expressed lysins cloned in this study are summarized 
here.  [A] Lysin name.  [B] GenBank accession number.  [C] Protein length in 
amino acid residues.  Five lysins (indicated with trunc.) were cloned as 
enzymatically active C-terminal truncations; for these proteins, the indicated 
length is that which was included on the plasmid insert.  [D] Predicted 
enzymatic domains.  The reader is referred to the text or Supplementary 
Document 1 for corresponding Pfam accession numbers.  [E] Predicted cell-
wall binding domains.  For PlyM1, the protein was truncated within the C-
terminal region, preventing an accurate prediction of a binding domain.  Pfam 
analysis did not recognize conserved binding domain for the Gram-positive 
lysins PlyM17 and PlyM21, although a distinct C-terminal region exists that 
presumably serves this purpose.  Binding domains were not predicted for 4/5 
Gram-negative lysins (PlyM22-PlyM24, PlyM26).  [F] Database homologues.  
Cloned lysins were subject to BLASTP analysis to identify homologues among 
sequenced bacteria/phage.  In many instances, a lysin demonstrated highest 
homology to proteins encoded by a particular bacterial genus/species (or its 
phage).  The identities of these taxa are identified here, and the degree of 
homology is indicated numerically with E-values (or a minimum E-value if 
numerous proteins demonstrated a continuous range of homology).  In other 
cases, as noted, no genus/species was preferentially represented among the 





Among the Gram-positive lysins, Pfam domain analysis suggests that all 
20 possess N-acetylmuramoyl-L-alanine-amidase activity: 8 are predicted to be 
type 2 amidases (Pfam family PF01510), and 12 are predicted to be type 3 
amidases (PF01520).   Although these two protein families diverge sequentially, 
they target the same bond at the beginning of peptidoglycan‘s pentapeptide 
stem.  At the C-terminal ends of the Gram-positive lysins, a variety of cell-
envelope binding domains are likewise predicted.  These include: 10 PG-1 motifs 
(PF01471); 1 PG-3 motif (PF09374); 5 SPOR motifs (PF05036); 1 SH3 type 5 motif 
(PF08460), 1 LysM motif (PF01476), and 1 amidase II-associated domain 
(PF12123).  For two of the Gram-positive enzymes (PlyM17 and PlyM21), a clear 
C-terminal region is present, even though Pfam analysis fails to predict a binding 
motif.  Most likely, these regions do possess binding functions, albeit ones that 
have not yet been categorized as conserved protein families.   
Multiple sequence alignment of PlyM1-PlyM20 reveals strong similarities 
among some of the cloned proteins, summarized phylogenetically in Figures 4.3a 
and b.  In particular, PlyM5 – PlyM11 demonstrate high sequence homology with 
one another, with pairwise sequence identities of 91-95% on the nucleotide level 
and 95-98% on the amino acid level (all E-values < 10-159).  PlyM3 and PlyM4 
share this homology with PlyM5-PlyM11 at the C-terminus, but diverge in their 
enzymatic regions.  These lysins were presumably derived from a group of 
highly similar phage infecting one of the component bacterial species of the fecal 
sample.   
1.18 
Figure 4.3a Similarity among Gram-Positive Hits (Non-Bootstrapped) 
The sequence homology among the typical Gram-positive lysins (PlyM1-PlyM20) 
is organized here as a contemporaneous-tip phylogenetic tree (one branch length 
is included as reference).  Several clusterings are apparent, especially PlyM5-
PlyM11; these enzymes are depicted as a single node in the image, as their degree 
of homology (90+ pairwise nucleotide/amino acid identity) prevents individual 
visual differentiation.  The reader should note that this tree was generated from a 
single multiple sequence alignment (MSA) so that the distance-values between 
proteins would be most visually apparent as the branch lengths. 
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Figure 4.3b Similarity among Gram-Positive Hits (Bootstrapped) 
Bootstrap analysis (100 rounds) was also conducted on the original MSA of 
PlyM1-PlyM20 and a consensus cladogram was generated.  As in [A], 
PlyM5-PlyM11 have been collapsed here to a single node.  The bootstrap 




When the sequences of PlyM5-PlyM11 are compared to known proteins via Blast 
analysis, they demonstrate closest homology (E-values ≈ 10−16) to two putative 
prophage lysins from the sequenced genomes of Delsulfotomaculum reducens MI-1 
and Alkaliphilus metalliredigins QYMF, both spore-forming organisms of the class 
Clostridia.   
The remainder of the Gram-positive lysins were likewise subject to Blast 
analysis; for many of the proteins (PlyM1-PlyM4, PlyM13-PlyM17, PlyM19), the 
closest homologues are encoded by phage/prophage infecting Bacillus and 
related genera.  In general, these homology findings are consistent with the fecal 
origin of the library, although one should not draw conclusions on the ecology of 
the sample based on this information alone.  Aside from potential biases inherent 
in functional screening, it is important to emphasize that the sample was not a 
natural ecosystem in the first place, but rather a combination of several fecal 
samples pooled to increase diversity.  Overall, if one is interested in viral 
metagenomics as a tool for studying microbial ecology, sequenced-based 
approaches are superior to functional screens. 
Among the lysins that do not demonstrate typical Gram-positive 
structures, PlyM21 possesses two distinct catalytic regions—an N-terminal M23 
endopeptidase domain (PF01551) and a central lambda phage-like muramidase 
domain (PF00959).  While it is uncommon, several lytic enzymes from Gram-
positive phage have been characterized that possess multiple catalytic domains 
(Cheng et al. 2005, Wang et al. 2009).  It is currently unclear what, if any, 
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advantage is offered by this extended architecture.  By contrast, lysins PlyM22-
PlyM24 are relatively short in length and consist of single catalytic domain 
without any C-terminal binding region, an arrangement typical for Gram-
negative phage.  These three enzymes are each predicted to have the same 
muramidase domain (PF00959), although they share only moderate primary 
sequence homology with one another. 
Finally, PlyM25 and PlyM26 differ significantly from the other enzymes 
cloned in this study and, in general, represent poorly characterized varieties of 
lytic enzymes.  Domain analysis of PlyM25 predicts an N-terminal PG-1 binding 
motif (residues 3-38), but fails to recognize any catalytic domain.  Rather, 
residues 76-249 correspond to a domain of unknown function (PF11860), from 
which the enzymatic activity presumably originates.  Blast analysis of PlyM25 
reveals several dozen ORFs of moderate homology (E-values: 10-20 – 10-40) within 
the genomes of sequenced Gram-negative phage/prophage.  Virtually none of 
these homologues, however, are currently annotated as lysins, exceptions being 
ORF12 of P. aeruginosa phage phiCTX (Nakayama et al. 1999) and ORF27 of 
Burkholderia cepacia phage Bcep781 (Summer et al. 2006).  The latter two enzymes 
share the PG-1/DUF architecture of PlyM25, although only the Burkholderia 
protein has been assigned lytic function experimentally (its enzymatic class 
remains undetermined).   
For PlyM26, Pfam analysis predicts neither a cell-wall binding nor a 
peptidoglycan hydrolase motif, but rather a chitinase enzymatic domain 
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(PF00182).  While it is conceivable that PlyM26 represents a dedicated phage-
encoded chitinase with cross-reactivity to Pseudomonas peptidoglycan (and not a 
lysin proper), this is an unlikely scenario.  The first four nucleotides of PlyM26 
overlap with an upstream 101-amino acid ORF containing three predicted 
transmembrane domains, making it a strong candidate for an adjacent holin.  
Moreover, given the structural similarity of chitin to peptidoglycan—and the fact 
that chitinases belong to the same protein clan (Pfam CL0037) as muramidases, 
glucosaminidases, and transglycosylases—it is more probable that PlyM26 
represents a lysin of one of the later functionalities whose sequence merely 
deviates from the norm.   
As with PlyM25, Blast analysis of PlyM26 reveals a number of 
homologues among sequenced Gram-negative phage/prophage.  Again, 
however, few are annotated as phage lytic enzymes and (to our knowledge) none 
have been recombinantly expressed and characterized biochemically.  Taken 
together, lysins PlyM25/PlyM26 and their database homologues argue that the 
complexity of many Gram-negative lysins is more complex than the classical 
picture suggests, reinforcing the need for further research in the field. 
 
DISCUSSION 
Overall, the above study represents one of the first functional screens of a 
viral metagenomic sample, and the technique serves as a general method for 
cloning lytic enzymes from uncultured phage.  This naturally raises the 
207 
 
question—what applied or basic purposes could such screens serve?  One 
possibility involves the identification of new enzymes with antibiotic activity 
against medically-relevant bacteria.  To these ends, the 26 lysin-expressing clones 
were overlaid with various species of autoclaved Gram-positive pathogens.  One 
of the enzymes (PlyM12) did produce clearing zones against Bacillus anthracis 
and Enterococcus faecium.  It was subsequently sub-cloned to exclude the adjacent 
holin and subjected to preliminary chromatographic purification (data not 
shown).  Nevertheless, when tested against live organisms in OD-drop 
experiments, PlyM12 failed to show activity comparable to previously-
characterized lysins, and it was deemed a poor candidate for further study.  
Given the specificity that lysins show toward individual Gram-positive bacteria, 
finding a medically-relevant lysin would likely depend on whether a phage 
infecting that pathogen was represented in the original metagenomic pool.   
When one considers the origin and relative simplicity of the current library, it is 
not overly surprising that no such enzymes were identified here. 
Metagenomic lysin screens could also be useful for identifying enzymes 
that are active under a desired set of biochemical conditions (temperature, pH, 
salts, etc…).   For instance, several proviral lytic enzymes have been 
characterized from thermophilic species with the motivation that temperature 
resistance is an industrially attractive feature for peptidoglycan hydrolases (Ye 
and Zhang 2008, Matsushita and Yanase 2008).  In this regard, a strength of 
metagenomics is its ability to study extreme environments whose bacteria/phage 
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are difficult to culture under laboratory conditions (Ferrer et al. 2007).  One could 
easily envision isolating the phage fraction from an extreme environment (such 
as in Santos et al. 2010) and screening it for lytic enzymes with the above 
technique, circumventing the need for laboratory culture or prophage induction.  
For such cases, the buffered agar in which the secondary Gram-negative 
detection agent is suspended (here, PBS pH 7.4) could be varied to reflect the 
biochemical conditions under consideration. 
That said, one must note that a sequence-based study of an environment 
(extreme or otherwise) could also identify lytic enzymes, as the assembled 
contigs of sequenced viral metagenomes have revealed numerous putative 
examples (Breitbart et al. 2002, Breitbart et al. 2003, Fierer et al. 2007, Williamson 
et al. 2008).  Nevertheless, if the stated goal is to identify proteins of a particular 
functionality, clonal screening represents a far more rapid and cost-effective 
approach.  Sequencing data alone does not predict what proteins are actively 
expressed in a recombinant host, and any candidate genes identified with high-
throughput sequencing would have to be re-cloned via PCR into an appropriate 
expression vector.   
All of this, moreover, presupposes that a DNA-sequence shows sufficient 
homology to other lysins already annotated in the database.  In fact, 
metagenomic lysin screening is perhaps most useful in a very academic sense—
the identification and characterization of new classes of catalytic and binding 
domains.  Although lysins are already known to be remarkably diverse, enzymes 
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are still identified with completely novel sequences (Matsushita and Yanase 
2008, Nelson et al. 2006).  Even the simple library employed here yielded several 
clones whose identity as phage lysins would not have been obvious from their 
sequences alone.  Accordingly, the characterization of PlyM25 and PlyM26 
remains a subject of ongoing study, as does the screening of new libraries for 
additional novel enzymes. 
Finally, it is important to note one limitation of this screening protocol and 
mention several ways it could be adapted to fit particular needs.  Clearly, the 
method is capable of identifying lysins with glycosyl-hydrolase or alanine-
amidase activity.  At the same time, only one endopeptidase was cloned here 
(PlyM21), and this lysin possessed a secondary muramidase domain.  In fact, 
endopeptidases present a particular obstacle for the technique, as it would be 
impossible to identify all endopeptidases using a single bacterial species in the 
soft agar overlay step.   
While the polysaccharide backbone of peptidoglycan and the initial L-
alanine of the pentapeptide stem are highly conserved among bacteria, 
considerable variability exists at the other stem positions and within the peptide 
cross-bridge (Vollmer et al. 2008a).  Without the targeted bond, Gram-negative 
peptidoglycan would not be susceptible to a Gram-positive endopeptidase.  For 
instance, as opposed to the clearing zones in Figure 4.2a (involving previously-
characterized amidases and muramidases), no clearing zones were observed 
when several defined endopeptidases were applied to autoclaved P. aeruginosa.  
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To ensure endopeptidase coverage against a particular Gram-positive species, 
therefore, one could conduct the secondary screen in duplicate, including that 
species along with the general Gram-negative screening agent.   
Another potential variation in the protocol could involve omitting the 
preliminary hemolysis screen entirely and progressing directly to the Gram-
negative overlay step.  In this case, one would replica-plate the original 
transformants onto additional LB-ampicillin plates (without arabinose, to avoid 
clonal toxicity), which could then be nebulized with inducing agent, chloroform 
treated, and overlaid with heat-killed P. aeruginosa,  Clearing zones could then be 
traced to the respective colonies on the master plates.  One potential advantage 
of this approach is that it could identify lysins from phage where the lysin and 
holin are not adjacent, which is the case in a minority of circumstances.  Our 
rationale for not utilizing this approach here is that, on a single-colony scale, the 
hemolytic phenotype is more visually detectable than a clearing zone in a soft-
agar overlay, which is better suited for the larger E. coli patches employed in the 
secondary screen.  Nevertheless, the two approaches are hardly mutually 
exclusive and one could easily include both while screening a viral library to 
maximize lysin discovery.   
Overall, the functional screening process described here is both 
straightforward and generalizable, allowing one to mine for biotechnologically- 
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 Streptococcus suis is a Gram-positive, α- or -hemolytic bacteria that is 
known for the variety of infections that it causes in pigs, including meningitis, 
septic arthritis, pneumonia, and bacteremia (Segura and Gottschalk 2004).  It 
frequently leads to fatalities among commercial swine, and is especially 
problematic among newborn animals (Staats et al. 1997).  S. suis is likewise an 
emerging zoonotic agent and can induce similar pathologies in humans as seen 
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in pigs (almost exclusively in those with occupational exposure to the animals) 
(Feng et al. 2010).   
 Reported veterinary and human cases of S. suis infection date back to the 
1950‘s and 1960‘s (Field et al. 1954; Arends and Zanen 1988), although the species 
was not formally defined until 1987 (Kilpper-Bälz and Schleifer).  Taxonomically, 
S. suis does not belong to the seven standard clusters of streptococci, nor does it 
group conveniently among Lancefield antigenic classifications (Facklam 2002).  
Instead, it is subdivided into 35 serotypes that depend on the nature of its 
polysaccharide capsule (Higgins et al. 1995).  Various biochemical parameters 
have been defined for clinical identification of S. suis (Higgins and Gottschalk 
1990).  In practice, however, presumptive isolates are typically confirmed by 
antigenic or genetic methods (Lun et al. 2007).     
The pathogenesis of S. suis infections in swine involves the initial 
colonization of the nasopharynx and palatine tonsils.  The bacteria are thought to 
invade the tonsils, followed by dissemination via the lymphatics and/or efferent 
blood vessels; intracellular dissemination within host phagocytes has also been 
proposed (Segura and Gottschalk 2004).  A number of potential S. suis virulence 
factors have been identified (reviewed in Staats et al. 1997), although the precise 
molecular mediators of pathogenesis are not well-defined.  The extracellular 
capsule is necessary for infection, and serotype 2 strains are most commonly 
observed worldwide.  It is important to note, however, that not all serotype 2 
strains are virulent and other serotypes are frequently seen to cause disease.  In 
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particular, serotype 9 infections are becoming more prominent in certain 
geographic regions (Blume et al. 2009).  Complicating the situation further, 
colonized animals are often observed without signs of infection, and they are 
believed to play an important role in the epidemiology of S. suis (Luque et al. 
2009).  Dedicated environmental reservoirs have not been identified, although 
the isolation of the bacteria from other animal species suggests a more 
widespread distribution (Devriese et al. 1991). 
The etiology of disease in humans likewise remains poorly understood.  In 
all, there have been ~550 clinical cases of S. suis infection reported worldwide, 
with ~75 associated deaths (Feng et al. 2010; Lun et al. 2007).  Many of these 
deaths stemmed from 1998 and 2005 outbreaks in China, which were particularly 
troubling given their association with a novel streptococcal toxic shock syndrome 
(Tang et al. 2006).  It has been calculated that the annual risk of infection for 
employees of pig farms and slaughterhouses is roughly 3/100,000 (Arends and 
Zanen 1988).  These estimates, however, are confounded by more recent 
immunological analyses of asymptomatic swine workers in the USA, ~10% of 
whom demonstrated high-titer seroconversion for S. suis antibodies (Smith et al. 
2008).  Moreover, it has been suggested that most hospital laboratories would 
misidentify S. suis isolates without a particular reason for suspecting the 




 Considering the broad relevance of S. suis, there is great deal of interest in 
strategies for preventing its transmission within animal populations.  While most 
S. suis isolates are sensitive to traditional antibiotics, there are significant 
downsides to large-scale antibiotic prophylaxis of swine (Staats et al. 1997).  
Vaccine development is naturally an area of focus, and positive results have been 
obtained during previous in vivo trials (Swildens et al. 2007).  Commercially, it is 
not uncommon for animals to be vaccinated empirically with inactivated bacteria 
(Baums and Valentin-Weigand 2009; Haesebrouck et al. 2004).  Nevertheless, the 
safety and overall efficacy of this practice are uncertain, and concerns remain 
regarding immunity across S. suis serotypes.  As a result, innovative approaches 
for curtailing infections would be highly welcome. 
 In this light, phage lytic enzymes (also known as endolysins or lysins) 
have garnered much attention recently as novel antibacterial agents (reviewed in 
Villa and Veiga-Crespo 2010; O‘Flaherty et al. 2009; Fischetti 2008).  These 
peptidoglycan hydrolases (targeting a variety of specific bonds) are encoded by 
virtually all dsDNA phages and are responsible for digesting the host cell well 
during phage infection.  This leads to osmotic lysis of the bacteria and release of 
viral progeny.  Biotechnological interest in these proteins stems from their ability 
to lyse Gram-positive bacteria when applied exogenously, as the peptidoglycan 
of these species is continuous with the extracellular space.  Lysins have been 
proposed as potential enzybiotic agents, and are notable for the potency and 
specificity they demonstrate toward particular bacteria (generally, species that 
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the encoding phage infects or closely-related organisms).  In a number of in vivo 
trials, lysins have successfully eliminated targeted pathogens from colonized 
and/or infected mucous membranes (Daniel et al. 2010; Cheng et al. 2005; 
Loeffler et al. 2001; Nelson et al. 2001). 
 To date, two phages infecting S. suis have been isolated and studied.  
Harel et al. (2003) induced a siphoviral prophage from the genome of a serotype 
2 strain, although the identity of its lysin remains undetermined.  More recently, 
Ma and Lu (2008) isolated a lytic phage from nasal swabs of healthy pigs, 
sequencing its 36 kb genome. This phage, termed SMP, demonstrated a limited 
host range, infecting only 2/24 S. suis strains within serotype 2.  The same group 
later PCR-cloned and recombinantly expressed the SMP lysin (LySMP); the 
enzyme demonstrated broad bacteriolytic activity in vitro against several 
serotypes (albeit with the addition of protease inhibitors and at somewhat higher 
concentrations, 50+ μg/ml, than typically associated with phage lysins).  The 
main drawback of LySMP was technical: the recombinant protein did not fold 
properly by itself and was only active in the presence of reducing agents, which 
could complicate potential in vivo trials (Wang et al. 2009). 
 In the current study, we sought to expand and evaluate the collection of 
known S. suis lysins.  Through a combination of functional screening and 
sequence analysis of recently-published genomes, we identified two new 
prophage lytic enzymes (termed PlySs1 and PlySs2).  PlySs1 is a homologue of 
the above-mentioned LySMP (but demonstrating superior expression 
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properties), while PlySs2 represents a divergent class of enzyme altogether.  Both 
lysins were purified and characterized biochemically, and they are currently 
being employed in an ongoing in vivo trial involving experimentally-infected 
pigs.  In the present thesis, I describe the cloning of PlySs1 and PlySs2, as well as 
the in vitro characterization of the former.  Overall, through agents like these, it is 
possible to expand the potential of enzybiotics into the often overlooked—but, 
nevertheless, crucial—world of veterinary microbiology. 
 
MATERIALS AND METHODS 
Prophage functional screening.  The genomes of several clinical strains of S. suis 
were subjected to functional shotgun screens is search of lytic enzymes from 
incorporated prophage.  Microgram quantities of gDNA were briefly subjected to 
restriction digestion with Tsp509I (NEB).  Fragments 1.5 – 4 kb in length were 
isolated via agarose-gel electrophoresis and ligated into EcoRI-linearized 
pBAD24 plasmid (Guzman et al. 1995).  This plasmid confers ampicillin 
resistance and allows for arabinose induction of the recombinant insert.   
To identify lysin-encoding clones, libraries were subject to a novel 
screening technique that relies upon the toxicity of adjacently-encoded holin 
proteins (see Schmitz et al. 2010b or Chapter 4 for details).  Briefly, E. coli TOP10 
transformants were plated onto LB-agar supplemented with ampicillin and 
sheep‘s blood.  Following proliferation to macroscopic colonies, the plates were 
exposed to a mist of arabinose to induce recombinant transcription.  Toxic clones 
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were revealed by the development of surrounding zone of hemolysis.  These 
colonies were identified, re-propagated and subject to a secondary screen in 
which they were overlaid with heat-killed bacteria (to assay directly for the 
production of lytic enzyme).  For the S. suis strain (7711) that yielded the PlySs1 
lysin, ~3,500 clones were subjected to the original hemolysis screen; 100 of these 
were selected for the secondary screen, 2 of which encoded the lytic enzyme. 
 
Sub-cloning of truncated PlySs1.  For the positive hits identified above, 
recombinant inserts were amplified and sequenced with pBAD-targeted primers 
(Genewiz, Inc., South Plainfield, NJ).  The specific position of the lysin gene was 
located by analysis with ORF Finder (www.ncbi.nlm.nih.gov/projects/gorf/) 
and BlastX (Altschul et al. 1990; blast.ncbi.nlm.nih.gov/Blast.cgi).  For the 
translated protein, putative enzymatic and binding domains assignments were 
made via Pfam (Finn et al. 2009; pfam.sanger.ac.uk). 
 Based on this information, primers were designed for synthesizing a 
truncated constructed (PlySs1) with an inserted stop codon preceding the C-
terminal glucosaminidase domain (specifically, after D254).  The primer 
sequences were: 
TTTGAATTCTTTATGACAATCAATCTTGAAACATCCATTCGT—fwd and 
TTTGCATGCTTAGTCCCCGTCCTCCTTGAATTGC—rev.  The engineered stop 
codon is double-underlined, while the single-underlined nucleotides correspond 
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to EcoRI and SphI restriction sites for ligation into pBAD24.  The resultant 
plasmid was cloned and maintained in TOP10 E. coli. 
 
Genomic sequence analysis and cloning of PlySs2.  The genomes of 8 
sequenced isolates of S. suis were inspected for the presence of lysin-encoding 
genes within integrated prophage (Holden et al. 2009; Chen et al. 2007).  These 
strains were: 05ZYH33 (NCBI Genome Project #17153); 98HAH33 (#17155); 
BM407 (#32237); GZ1 (#18737); P1/7 (#352); SC84 (#32239); 05HAS68 05HAH33 
(#17157); and 89/1591 (#12417).  For each genome, the topologically-arranged list 
of annotated ORFs was manually inspected for potential prophage regions.  If a 
prophage was suspected, the theoretical translations of each ORF in that region 
were subject to BlastP and Pfam analysis.   Putative lysin-status was assigned 
based on the combination of predicted enzymatic and binding domains. 
 The only lysin gene identified in this manner (PlySs2 from strain 89/1591) 
was PCR-cloned from genomic DNA with the following primers: 
AATGCTAGCCTGATACACAGTTAGAGACC—fwd and 
CCTAAGCTTCTTTTCACAAATCATAATCCCCAG—rev.  The underlined 
nucleotides again represent restriction sites (NheI and HindIII) for cloning into 
pBAD24.  It should be noted that the forward primer corresponds to a position 
~60 bp upstream the start of the gene.  For plySs2, several in-frame ATG triplets 
are situated near one another at the 5‘-end.  To avoid choosing the incorrect start 
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codon, the upstream region was included so that transcription could be guided 
by the native ribosome binding site (instead of the engineered RBS of pBAD24).  
 
Recombinant expression and purification of PlySs1.  To express PlySs1, the 
clone was grown in Power Broth + LB-Booster (Athena Enzyme System) to OD600 
≈ 1.0 and induced with 0.2% arabinose.  The culture was shaken for 4 hr at 37C 
(inclusion bodies would form at longer times).  The expressing cells were 
pelleted, resuspended in 15 mM phosphate buffer pH 6.2, and lysed by three 
passages through an EmulsiFlex C-5 homogenizer.  Residual debris was removed 
by centrifugation (1 hr, 35,000 X G), and ammonium sulfate was added at 225 
g/L (40% saturation).  The precipitated protein was pelleted and resolubilized in 
15 mM phosphate pH 7.4, and dialyzed against this buffer overnight. 
 The dialysate was next passed through a DEAE anion-exchange column 
equilibrated against the same buffer (fast flow resin, General Electric).  Quite 
surprisingly, PlySs1 demonstrated the same sort atypical binding response 
observed for PlyCM in Chapter 2.  With a predicted pI of 7.7, one would expect 
PlySs1 to bind weakly to DEAE at pH = 7.4, or perhaps flow directly through it.  
Again, however, there was a transient interaction in which PlyCM would 
initially bind the resin, but then slowly elute as excess Buffer A was passed over 
the column (see Figure 5.1).  The effect here was even more pronounced than 
with PlyCM, as the initial flow-through trace would return almost completely to 
baseline before PlySs1 began eluting.   



























Figure 5.1, continued 
The dialyzed 40% ammonium sulfate cut of PlySs1-lysate was loaded onto 
DEAE resin at pH = 7.4.  Non-binding proteins flowed through the column 
as the sample was loaded.  After continued wash in the same buffer, an 
extended secondary peak eluted.  Non-transiently binding proteins eluted 
with the addition of 1M NaCl.  The extended-wash fraction, when analyzed 




This phenomenon led to a highly pure lysin preparation in only a single 
chromatographic step.  For every liter of original E. coli culture, 50-100 mg of 
final PlySs1 could be obtained. 
   
PlySs1 enzymatic specificity. To determine the bond specificity of the N-
terminal enzymatic domain of PlySs1, cell-wall preparations were made from S. 
suis type-strain S735.  The Gram-positive protocol of Rosenthal and Dziarski (1994) 
was utilized with only slight modifications.  Purified cell walls were suspended 
in phosphate buffered saline (pH 7.4); PlySs1 and hen egg-white lysozyme 
(Sigma) were both added to 500 μg/ml, and the solution was shaken gently 
overnight at room temperature.  The digest was centrifuged (20 min, 16,000 X g), 
and the supernatant passed through a 10,000 MWCO micro-filter (Ultracel YM-
10, Millipore) to remove the lytic enzymes and remaining macromolecular cell-
wall components.  This sample and an undigested negative control were subject 
to MALDI-TOF mass spectrometry (positive ion mode, Applied Biosystems DE-
STR spectrometer) by the Rockefeller University Proteomics Core Facility. 
 
In vitro characterization of PlySs1.  The biochemical properties and strain-
specificity of PlySs1 were examined mainly through optical density-drop 
experiments.  All bacteria were maintained on Brain Heart Infusion (BHI) agar 
plates.  For each experiment, individual colonies were inoculated into 50 ml 
liquid BHI, which were gently shaken (125 rpm) for several hours at 37C.  When 
the cells had reached mid-log phase (OD ≈ 0.5), they were pelleted, washed and 
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resuspended in the appropriate buffer (which varied from experiment to 
experiment) to an OD600 ≈ 0.8.  Optical density measurements were performed in 
96-well plates at 37C.  PlySs1 or lysin vehicle was added immediately prior to 
the start of each experiment, and measurements were taken every minute.   
For CFU analysis, cells were treated with PlySs1 in a similar manner as 
above.  After 1 hr at 37C, samples were each diluted over five orders of 
magnitude, with triplicate plating at each dilution onto BHI agar.  For 
(attempted) MIC-analysis, cells were suspended in 2X BHI to ~106 cells/ml 
(determined by comparison with a McFarland standard).  Sterile-filtered lysin 
and/or vehicle was added at the appropriate concentrations, yielding a final 
suspension of ~5 X 105 cells/ml in 1X broth (Wiegand et al. 2008).  Cells were 
distributed within a 96-well plate, and OD600-measurments were taken overnight 
(every 2 minutes) with the plate maintained at 37C. 
 
RESULTS AND DISCUSSION 
Identification of PlySs1 and sub-cloning of truncated construct.  A prophage 
lytic enzyme, PlySs1, was cloned from a functional genomic screen of S. suis 
strain 7711, a serotype 7 isolate originating from the Netherlands1.  PlySs1 is a 
452-residue protein: Pfam analysis predicts a type 5 alanine-amidase domain 
(PF05832) at the N-terminus, followed by a double CPL-7 cell-wall binding 
domain (PF08230) in the central region, and a secondary glucosaminidase 
domain (PF01832) at the C-terminus (Figure 5.2a).   
Figure 5.2 PlySs1 Prophage Lysin 
PlySs1  MTINLETSIRWMSDRVGKVSYSMDYRNGPNSYDCSSAVYYALMAGGAISAGWAVNTEYMH 60 
LySMP   MTINIETAIRWMTDRVGLVKYSMDYRNGPNSFDCSSSVYYALMAGGAISAGWAVNTEYEH 60 
        ****:**:****:**** *.***********:****:********************* * 
 
PlySs1  DWLIRNGYVLVAENKPFNAQRHDVCILGKRGYSSGAGGHVVIFVDNVNVIHCNYARNGIS 120 
LySMP   DWLIKNGYKLIAENQDWDAKRGDIFIWGRRGQSSGAGGHTGIFVDPDNIIHCNYANNSIT 120 
        ****:*** *:***: ::*:* *: * *:** *******. ****  *:******.*.*: 
 
 
PlySs1  IDNYNQVHRG---MYYYLYRPANQPSIS--NKSLDQLVKETLAGVHGNGDTRKASLGSQY 175 
LySMP   INNYNQTAAASGWMYCYVYRLGNQPTTSPAGKTLDTLVKETLAGKYGNGDQRKAALGNQY 180 
        *:****.  .   ** *:** .***: *  .*:** ******** :**** ***:**.** 
 
PlySs1  EAVMAVINGKASASEKSDEELAREVLAGKHGAGEDRKRSLGPRYEPVQAKVNELLK---- 231 
LySMP   EAVMAVINGKATAPKKTVDQLAQEVIQGKHGNGEDRKKSLGPDYDAVQKRVTEILQGSTS 240 
        ***********:*.:*: ::**:**: **** *****:**** *:.** :*.*:*:     
 
PlySs1  --AKEKPSETAKN-------EPQTVQ------------FKEDGDLSFNGAILKKSVLEII 270 
LySMP   GNAPKLASDAPKNEVVNSSTEPKTEETWATGKATDTKITKEDGDLSFNGAILKKSVLDVI 300 
          * : .*::.**       **:* :             ******************::* 
                                                   ↑     
 
PlySs1  LKKCKEHDILPSYALTILHYEGLWGTSAVGKADNNWGGMTWTGQGNRPSGVIVTQGLARP 330 
LySMP   LANCKKHDILPSYALTILHYEGLWGTSAVGKADNNWGGMTWTGKGERPSGVTVTQGTARP 360 
        * :**:*************************************:*:***** **** *** 
 
PlySs1  SNEGGHYMHYATVDDFLTDWFYLLRKDGSYKVSGALTFSESIKGMFQVGGAKYDYAAAGY 390 
LySMP   ACEGGHYMHYASVDDFLTDWFYLLRSGGSYKVSGAKTFSDAVKGMFKIGGAVYDYAASGF 420 
        : *********:*************..******** ***:::****::*** *****:*: 
 
PlySs1  DSYLVGATSRLKAIESENGSLTRFDATSNNVHSVD-PDKISVDIDGIEVTINGVVYKLEK 449 
LySMP   DSYIIGASSRLKAIEAENGSLDKFDKQT--VTDVGQSDKIEVTIEGIEISINGVTYTLSK 478 
        ***::**:*******:***** :**  :  * .*. .***.* *:***::****.*.*.* 
 
PlySs1  KPV 452 
LySMP   KPV 481 




Figure 5.2, continued 
[A] The molecular architecture of PlySs1.  The N- and C-terminal 
enzymatic domains are shown, along with the central cell wall-binding 
region.  The N-terminal enzymatic domain is annotated according to its 
observed activity (-endopeptidase), rather than its predicted activity 
(alanine-amidase).  Prior to purification and functional analysis, PlySs1 
was recombinantly truncated to exclude its C-terminal glucosaminidase 
domain (PlySs1).  The position of that truncation, D254, is likewise 
denoted (red lightning-bolt).  [B] S. suis lysin alignment.  The protein 
sequences of PlySs1 and LySMP (YP_950557) are compared here.  Residue 
identities are denoted with underlying asterisks and (in most cases) 
highlighting.  The color of the highlighting indicates the particular domain 
to which the sequence corresponds (endopeptidase-yellow, CPL-7-blue, 
glucosaminidase-pink).  Residue identities that do not fall within a 
predicted domain are not highlighted (only denoted with an asterisk).  The 
position of the engineered C-terminal truncation of PlySs1 is designated 




PlySs1 demonstrates high homology to the previously-characterized LySMP 
lysin throughout its entire sequence (Figure 5.2b).  The proteins share ~70% 
nucleotide and amino-acid identity with one another (all E-values < 10-60).   
Architecturally, the domain arrangement of PlySs1 (and LySMP) is highly 
atypical.  Gram-positive lysins typically consist of an N-terminal enzymatic 
domain and a C-terminal binding domain (Fischetti 2008).  While occasionally 
lysins are seen with two N-terminal lytic domains (for instance, Baker et al. 2006; 
Cheng and Fischetti 2005), it is rare for a second enzymatic functionally to be 
encoded after the binding domain.  Besides PlySs1 and LySMP, the only other 
example characterized to date is the LambdaSa2 lysin of S. agalactiae (a few more 
putative examples exist within nucleotide databases) (Pritchard et al. 2007).  
Interestingly, the C-terminal enzymatic domains of these lysins demonstrate 
homology to several annotated bacteriophage tail proteins; the latter are known 
to possess muralytic activity for purpose of viral DNA injection (Kenny et al. 
2004; Piuri and Hatfull 2006).  Conceivably, the PlySs1/LySMP/LambdaSa2 
group of enzymes could have evolved from a recombination event that 
juxtaposed a tail enzyme with a phage lysin proper. 
Working with LambdaSa2, Donovan and Foster-Frey surprisingly 
observed increased enzymatic activity following removal of the C-terminal 
glucosaminidase domain (2008).  With this motivation, we engineered a 
truncated PlySs1 construct with only the N-terminal enzymatic and central 
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binding domains.  This construct was expressed and purified for subsequent 
functional analysis (Figure 5.3); it will henceforth be referred to as PlySs1. 
 
Identification of PlySs2.  A second lysin, PlySs2, was identified (and, 
subsequently, PCR-cloned) through sequence analysis of 8 published S. suis 
genomes.  PlySs2 is encoded in a prophage region of serotype 2 strain 89/1591 
(the lysin-encoding ORF was originally annotated as SH3-type 5 domain protein, 
ZP_03625529; Lucas et al. 2004); it was the only lysin identified through our 
database search.  The structure of PlySs2 is quite unlike that PlySs1 and LySMP.  
It encodes a predicted N-terminal CHAP domain (cysteine-histidine 
amidohydrolase/ peptidase, PF05257) and a C-terminal SH3-type 5 domain 
(PF08460) (Figure 5.4a).   
CHAP domains are included in several previously-characterized 
streptococcal (Nelson et al. 2006; Baker et al. 2006) and staphylococcal (Daniel et 
al. 2010; Becker et al. 2009) lysins.  On a primary sequence level, however, the 
CHAP domain of PlySs2 is rather divergent from other database CHAP domains 
(all pairwise E-values > 10-15).  In Figure 5.4b, CHAP domain of PlySs2 is aligned 
with that of the well-characterized streptococcal PlyC lysin, demonstrating 
conserved catalytic residues but only a modest level of identity overall (28% 
sequence identity, E-value = 10-8) (Nelson et al. 2006).  SH3 domains are 
commonly seen in viral and bacterial cell wall-binding proteins, although the 
exact molecular target remains unknown (Xu et al. 2009). 
Figure 5.3 Purified PlySs1 
PlySs1 was chromatographically purified after recombinant 
expression.  Lane 1: molecular weight ladder.  Lane 2: crude extract of 
encoding strain prior to induction.  Lane 3: crude extract of encoding 
strain 4-hr after induction.  Lane 4: final product following isolation 
protocol.  By visual approximation, PlySs1 is > 90% pure; its band 
appears just above 25-kDa marker (predicted MW = 28.1 kDa). 
(1) (2) (3) (4) 
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Figure 5.4 PlySs2 Prophage Lysin 
[A] The molecular architecture of PlySs2.  [B] Enzymatic domain 
alignment.  The CHAP domains of the streptococcal lysins PlySs2 and 
PlyC (subunit A, GenBank no. AAP42310) are aligned here.  Amino-acid 
identities are indicated with underlying asterisks and highlighting.  The 
positions of the presumptive  catalytic residues (cysteine and histidine, 








Enzymatic characterization of PlySs1.  The first issue to be addressed for 
PlySs1 was its enzymatic specificity.  Although Pfam predicts a type 5 alanine-
amidase domain, this motif is historically associated with false computational 
assignments.  The same domain was predicted at the N-terminus of LambdaSa2, 
but was instead shown to be a -glutaminyl-L-lysine-endopeptidase 
experimentally (Pritchard et al. 2007).  To clarify the situation here, purified S. 
suis cell walls (from type strain S735) were subject to double digestion with 
HEWL (a muramidase) and PlySs1.  Mass spectrometric analysis of the filtered 
digest revealed the expected peaks for combined muramidase/-endopeptidase 
activity, demonstrating that PlySs1 hydrolyzes the same bond as LambdaSa2 
(Figure 5.5).   
The enzymatic specificity of PlySs2 currently remains in doubt.  CHAP 
domains are catalytically diverse and can possess either alanine-amidase (Nelson 
et al. 2001) or cross-bridge endopeptidase activity (Daniel et al. 2010), depending 
on the particular lysin.  Further complicating the situation here is the fact that the 
molecular nature of the peptidoglycan cross-bridge in S. suis can vary between 
strains (Kilpper-Bälz and Schleifer 1987).  Accordingly, mass-spectrometric 
experiments with PlySs2 are ongoing. 
 
Optimization of PlySs1 activity.  The optimal biochemical conditions for 
PlySs1 were determined against live cells of the encoding S. suis strain (7711).   
Figure 5.5 PlySs1 Enzymatic Specificity 
Depicted here is the mass spectrum of digested (and filtered) S. suis S735 cell 
wall.  Hen egg-white lysozyme (a eukaryotic muramidase) was used in 
combination with PlySs1.  The two predominant peaks (with respective 
isotopic tails) are m/z = 718 and m/z = 734.  This corresponds exactly to the 
predicted masses of the [Na-M]+ and [K-M]+ adducts of GlcNAc-MurNAc-L-
Ala-D-Gln.  This suggests that PlySs1 possesses gamma-endopeptidase 
activity, cleaving the peptidoglycan stem between D-Gln and L-Lys.  When a 
mass spectrum was taken of undigested cell wall (not shown), the above two 




For these experiments, activity was gauged through the degree of turbidity 
reduction (OD600) of an aqueous bacterial suspension following the addition of 
lysin.   The pH-dependence of the enzyme was first addressed using two buffer 
sets with adjacent pH ranges, citrate/phosphate: 4.6 – 8.0; and bis-tris-propane 
(BTP): 7.0 – 9.7.  An extended spectrum of lysis was observed, from 5.4 – 9.4 
(Figure 5.6).  In BTP, lysis was maximal from 8.2 – 9.0; at commensurate pH-
values, however, the magnitude of the OD-drop was slightly more pronounced 
in citrate/phosphate.  The role of salt concentration was likewise considered, 
although it did not greatly affect PlySs1-induced lysis.  At constant enzyme 
concentrations, bacteriolysis varied little from 0 – 1000 mM NaCl, with only 
small numeric increases under the most hypotonic conditions (Figure 5.7). 
Exposure of PlySs1 to an excess of DTT had no impact (either positive or 
negative) on activity (Figure 5.8a).  This indicates both that [1] the lysin does not 
rely on intramolecular disulfide bridges, as well as [2] that it was properly folded 
following recombinant expression and purification.  The latter point is significant 
given that LySMP had to be treated with reducing agents prior to use (Wang et 
al. 2009).  The reason for this discrepancy between two homologous lysins is 
unclear, although (most likely) it involves the numerous variable cysteine 
residues between the proteins (see Figure 5.2b).   
Interestingly, treatment with EDTA enhanced PlySs1-induced lysis of S. 
suis (Figure 5.8b).  





Figure 5.6, continued 
[A] Cells of host strain 7711 were suspended in  phosphate-citrate buffer 
(40/20 mM) at a range of pH-values from 4.6 to 8.0.  PlySs1 was added 
(110 g/ml) and OD600 was measured over 60 min (horizontal axis) at 37C.  
The vertical axis represents the treated/untreated OD600-ratio at each time-
point.  For each pH-value, the curve depicts the running average of 3 
independent experiments.   Overall, activity was maximal at the upper end 
of the buffering range.  [B]  Here, bis-tris-propane (40 mM) was employed 
as the buffering agent with a pH-range from 7.0 to 9.7; PlySs1 was again 
added to 110 g/ml.  Each curve depicts the running average of 3 
experiments.  Maximal activity was observed at pH = 9.0, although the 





Figure 5.7 PlySs1 NaCl Dependence 
S. suis 7711 cells were suspended in phosphate-citrate buffer pH = 7.8 
(40/20 mM).  NaCl was added to the above concentrations, followed by 
PlySs1 at 110 g/ml.  Optical density at 600 nm was observed over 60 
min at 37C.  In this figure, the vertical axis represents the treated-
untreated OD600-ratio for each NaCl concentration, averaged over 3 
independent experiments.    
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Figure 5.8 PlySs1 DTT and EDTA Susceptibility  
[A] PlySs1 was pre-incubated for 1 hr with 5 mM DTT (a large molar excess) 
prior to addition to 7711 cells; activity was unchanged.  [B] Here, various 
concentrations of EDTA were included in the buffered suspension of cells prior 
to addition of PlySs1 (110 μg/ml lysin).  For both images, the vertical axis 
represents the treated/untreated OD600-ratio for each condition, averaged over 3 








The lack of inhibition naturally suggests that PlySs1 does not rely upon divalent 
cations as cofactors, and several potential mechanisms could underlie the 
increased activity.  A particularly attractive scenario is that the lysin is 
susceptible to metal-dependent proteases on the S. suis surface.  Wang et al. 
previously demonstrated that bacterial proteases desensitize S. suis to lysin 
activity (2009).  Unser this hypothesis, EDTA would mediate bacteriolysis by 
inhibiting lysin-degradation and increasing the effective PlySs1 concentration. 
 The thermal stability of PlySs1 was examined by incubating the enzyme 
at various elevated temperatures prior to use (the OD-drop experiment itself was 
always conducted at 37C).  When held at 35C – 60C for 30 min, lysin activity 
was virtually unaffected until 50C, at which point it was completely abolished 
(Figure 5.9a).  For a 6-hr incubation, a partial decrease in activity was observed at 
45C, while the 40C sample was unaffected (Figure 5.9b).  The latter corresponds 
to typical porcine body temperature.   
 
PlySs1 activity against S. suis and other bacteria.  Given the above 
experiments, the following optimal buffering conditions were employed for all 
further in vitro experiments with PlySs1: 20 mM phosphate buffer, pH = 7.8, 2 
mM EDTA.  A range of lysin concentrations, from 6.5 – 130 μg/ml, were 
introduced to live S. suis cells in this buffer.  Three strains were considered 
particularly relevant: 7711, the serotype 7 strain that encodes PlySs1; S735, the 
serotype 2 reference strain; and 7997, a highly virulent serotype 9 strain.   







Figure 5.9, continued 
[A] A PlySs1 stock solution was held at each of the above temperature 
for 30 minutes, followed by addition to 7711 cells (270 μg/ml final 
enzyme concentration, final temperature = 37C, ideal buffering 
conditions).  The curves in this image represent running averages of 3 
individual  experiments.  In each case, complete loss of activity was 
observed between the 45C and 50C samples.  The 3 hottest samples 
show a slightly higher OD600 reading than the untreated control due to 
flocculation of PlySs1 upon denaturation.  [B] The above experiment 
was repeated, but with 6 hours of heat-treatment prior to the assay.  At 
this longer incubation time, the 45C sample showed some loss of 






For each of these strains, the time-dependent OD600 response at various PlySs1 
dosages is given in Figure 5.10. 
 Overall, these data are notable for the relatively high concentration of 
PlySs1 needed to induce efficient bacteriolysis (> 65 μg/ml).   For many phage 
lysins, only low μg/ml-concentrations are required to lyse their respective 
bacteria in vitro (see Nelson et al, 2001; Schuch et al. 2002; or Chapter 2 of this 
thesis).  At the same time, the higher concentrations needed here are highly 
commensurate with the amount of LySMP that was needed in that study (in fact, 
the magnitude of the turbidity-decreases is slightly more favorable here).  In 
terms of bacterial viability, only the highest PlySs1-concentration (130 μg/ml) 
led to a >90% decrease in CFUs for 7711, S735, and 7997 after 1 hr treatment 
(Table 5.1).  The lysin was also tested against actively-dividing cells in broth 
culture (strain 7711).  Although it delayed bacterial proliferation in a dose-
dependent manner (Figure 5.11), these effects were generally mild and PlySs1 
could not inhibit S. suis growth outright. 
 PlySs1 was further tested against a panel of 19 other S. suis strains of 
diverse serotypes, as well as other species of Gram-positive bacteria.  The same 
lysin concentrations were used as above.  For each dosage, the observed lysis-
values after 1 hr are listed in Table 5.2, and the information is summarized 
graphically in Figure 5.12.  All S. suis strains demonstrated some degree of 
susceptibility—for certain isolates, lysis was more pronounced than that 









Figure 5.10 PlySs1 Bacteriolytic Activity 
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Figure 5.10, continued 
Depicted here are OD-drop curves for three strains of S. suis: 7711, the 
serotype 7 strain from which PlySs1 was originally cloned (i.e. the host 
strain); S735, a serotype 2 isolate that is the type-strain for the species; and 
7997, a virulent serotype 9 strain.  Bacteria were suspended in 20 mM 
phosphate buffer pH 7.8, 2 mM EDTA (defined as optimal conditions).  
PlySs1 was added to the cells at a range of concentrations (indicated by 
the inset).  For each sample, optical density at 600 nm (vertical axis) was 
measured over the course of an hour (horizontal axis) at 37C.  In this 
image, all curves represent running averages of 3 or 4 independent 
experiments.   
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Table 5.1 CFU Analysis of Strains 7711, S735, 7997 
For two PlySs1 concentrations (130 and 13 g/ml), CFU analysis was 
conducted on S. suis strains S735, 7997, and 7711 after 1 hr treatment (optimal 
buffering conditions).  In each experiment, the percentage-decrease in CFUs 
was determined for the treated sample versus the untreated.  The range of the 
values observed (across 3 independent experiments) is reported here for each 
strain.  The serotype of each strain is indicated in parentheses. 
Strain 13 μg/ml 130 μg/ml 
S735 (ST2) 80.4% – 92.6% 95.4% – 99.5% 
7997 (ST9) 16.8% – 30.3% 89.9% – 93.9% 
7711 (ST7) 0% – 35.6% 95.3% – 99.2% 
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Figure 5.11 PlySs1 Growth Inhibition of S. suis 7711  
PlySs1 was added at the above final concentrations to a dilute suspension of S. 
suis strain 7711 in BHI broth (see Materials and Methods for experimental 
details).  The optical density of each sample was measured continuously 
overnight in 96-well plate format.  Overall, bacterial growth was delayed in a 
dose-dependent manner.  However, for enzyme-concentrations that were 
sufficient to induce lysis in buffered solutions (130 and 50 g/ml), the effect 
was quite minimal here.  Moreover, none of the above PlySs1 concentrations 
inhibited growth outright—hence, a MIC could not be assigned.  For all of the 
treated samples, one will note that the final optical densities are actually higher 
than that of the untreated sample.  This is an artifact of the accumulation of 
aggregated bacterial debris that occurred in the presence of lytic enzyme. 
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Table 5.2a Analysis of Other S. Suis Strains 
Strain 6.5 μg/ml 13 μg/ml 30 μg/ml 65 μg/ml 130 μg/ml 
ST13 0.32 0.17 0.04 0.02 0.02 
6112 (ST1) 0.14 0.11 0.06 0.02 0.01 
ST8 0.25 0.12 0.06 0.03 0.03 
6388 (ST1) 0.15 0.13 0.06 0.03 0.02 
10 (ST2) 0.29 0.18 0.10 0.05 0.02 
8076 (ST9) 0.52 0.40 0.21 0.14 0.04 
ST9 0.50 0.30 0.23 0.13 0.05 
ST4 0.63 0.47 0.32 0.22 0.12 
ST11 0.64 0.47 0.32 0.19 0.07 
ST14 0.79 0.57 0.33 0.15 0.06 
ST7 0.65 0.47 0.34 0.22 0.11 
ST1 0.80 0.34 0.36 0.19 0.06 
ST5 0.78 0.59 0.39 0.22 0.10 
7197 (ST7) 0.64 0.49 0.39 0.16 0.07 
ST6 0.76 0.56 0.40 0.21 0.06 
ST3 0.81 0.71 0.48 0.32 0.16 
ST2 0.79 0.70 0.49 0.34 0.17 
ST10 0.85 0.72 0.55 0.44 0.28 
ST12     See Caption     
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Table 5.2a, continued 
Various isolates of S. suis were  exposed (at optimal buffering conditions) 
to PlySs1 at the above concentrations.  The majority of these bacteria are 
unnamed clinical isolates of the indicated serotype (e.g. ST1, ST2, etc…).  
For the named strains, the serotype is given in parentheses.  The 1-hour 
treated/untreated OD600-ratio is given for each PlySs1 concentration 
(representing a single experiment), and the strains are listed in the order of 
decreasing sensitivity.  For strain ST12, it was not possible to conduct OD 
analysis.  Upon the addition of PlySs1 (all above concentrations), the cells 
would rapidly self-adhere and fall out of suspension.  This phenomenon 
was not observed for untreated ST12-cells. 
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Table 5.2b Analysis of Other Gram-Positive Bacteria 
The experiments summarized in 5.2a were repeated here for various Gram-positive 
bacterial species other than S. suis.  As before, 1-hr OD600-ratios are given (again, 
each representing a single experiment). 
Strain 6.5 μg/ml 13 μg/ml 30 μg/ml 65 μg/ml 130 μg/ml 
S. oralis 35037 0.30 0.13 0.08 0.07 0.04 
S. agalactiae type II 0.61 0.21 0.11 0.08 0.04 
S. dysgalactiae 21597 0.26 0.18 0.12 0.10 0.09 
S. pyogenes A486 0.12 0.13 0.13 0.11 0.10 
S. pneumoniae R36 0.25 0.22 0.14 0.16 0.12 
S. dysgalactiae GGS 0.30 0.27 0.15 0.11 0.14 
S. equi 700400 0.48 0.25 0.15 0.07 0.09 
S. uberis 27598 0.42 0.23 0.16 0.14 0.12 
S. pyogenes D471 0.39 0.27 0.17 0.13 0.09 
S. gordonii 10558 0.76 0.32 0.19 0.09 0.06 
S. equi 9528 0.66 0.45 0.25 0.19 0.16 
L. monocytogenes HER1084 0.63 0.52 0.26 0.14 0.04 
S. sanguinis 10556 0.48 0.44 0.28 0.21 0.11 
Group E streptococci K131 0.69 0.50 0.33 0.22 0.15 
S. sobrinus 6715 0.64 0.48 0.39 0.32 0.23 
E. faecium EFSK2 0.85 0.67 0.52 0.32 0.13 
S. aureus RN4220 0.89 0.78 0.55 0.31 0.10 
S. salivarius 9222 0.80 0.76 0.56 0.53 0.37 
S. rattus BHT 0.82 0.84 0.82 0.83 0.79 
M. luteus 4698 0.84 0.90 0.83 0.87 0.82 
E. faecalis V583 0.98 0.93 0.84 0.71 0.52 
B. cereus 14579 0.93 0.92 0.86 0.90 0.86 
B. thuringiensis HD73 0.99 0.98 0.93 0.86 0.60 
S. mutans U159 0.95 0.99 0.94 0.76 0.85 
S. epidermidis HN1292 1.04 1.00 0.96 0.94 0.87 
S. agalactiae 090R 0.97 0.99 0.97 0.98 0.93 
S. simulans TNK3 0.96 1.00 1.00 1.00 0.96 
B. anthracis Sterne 1.02 1.03 1.02 0.98 0.90 
B. subtilis SL4 1.07 1.05 1.04 1.03 0.96 
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Figure 5.12 PlySs1 Bacterial Strain Panel 
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Figure 5.12, continued 
The information provided in Figure 5.10 and Tables 5.2a and 5.2b is 
summarized graphically for two PlySs1 concentrations, 130 g/ml and 
32.5 g/ml.  In the image, strains of S. suis are denoted with double red 
asterisks and non-suis streptococci are denoted with single black asterisks.  
The optical density response (treated-versus-untreated OD600 ratio) after 1 
hr is shown.  The reader is referred to Table 5.2a for the serotype 




Interestingly, many of the non-suis streptococci (and even some non-
streptococci) also lysed at commensurate enzyme concentrations.  Classically, a 
phage lysin demonstrates a marked decrease in activity when going from within 
its host species to outside of it.  Here, however, a broad range of susceptibility 
was seen among non-suis bacteria, with some demonstrating identical lysis to S. 
suis itself.  This phenomenon raises interesting questions regarding the specificity 
of the dual CPL-7 binding domain of PlySs1. 
 
Comments on ongoing work.  Admittedly, the characterization of PlySs1 does 
not represent a tremendous theoretical step forward (given its similarity to the 
previously-characterized LySMP).  And we would prefer to have seen 
bacteriolytic activity at lower overall concentrations.  From a technical 
perspective, however, PlySs1 can be purified rapidly (in a single 
chromatographic step), solubly (without additional reducing agent), and in large 
quantities (100‘s of mg in a single protocol), all of which offer practical 
advantages over LySMP.   
Although it was not discussed in this thesis—see Chapter 6 for further 
explanation—PlySs2 has also been purified and tested in vitro against the same 
panel of S. suis isolates.  Fortunately, the potency of this enzyme seems far 
greater that of PlySs1 (i.e. similar bacteriolytic responses at 10-fold lower 
concentration).  Among the two lysins, PlySs2 is clearly the superior enzybiotic 
candidate.  In this regard, combination therapy with both lysins (by intranasal 
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lavage) is currently being tested as a means of preventing colonization/infection 
of newborn piglets by serotype 2 and 9 strains of S. suis.  This work is being 
undertaken by collaborators at the University of Utrecht in the Netherlands (see 
Acknowledgements).   
Overall, an inherent advantage of applying phage lysins to veterinary 
pathogens is that, ethically, one can rapidly progress to applying the agents in 
their intended clinical setting.  It is true that several previous reports have 
investigated lysins from, broadly speaking, a veterinary perspective (Hoopes et 
al. 2009; Celia et al. 2008; Nelson and Fischetti 2004).  Nevertheless, the ongoing 
trials with PlySs1 and PlySs2 represent the first instance of enzybiotic agents 
being used to treat a bacterial disease in its natural context (as opposed to animal 
models of human infections).  The fact that the progression of this research—
from initial identification to in vivo experiments—took only slightly more than 
half a year makes the work particularly exciting.   From this perspective, we feel 
that PlySs1 and PlySs2 are indeed expanding the horizons of the enzybiotics 
field in a significant way. 
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1.  There was no pre-designed rationale for choosing this particular strain or 
serotype for functional genomic screening.  A variety of clinical isolates were 
available for this purpose, and 7711 just happened to be the first (out of 4 tested) 
to successfully yield a lysin.  After the identification of PlySs1 (and, 


















REFLECTIONS ON THE CURRENT PROJECT 
 Looking back at the work presented in this thesis, it is tempting to 
consider how I would expand on the various topics given the opportunity to 
pursue them further.  In the following paragraphs, I will examine briefly for each 
chapter what I consider the most promising next steps for ongoing research.  
Some of these possibilities were already mentioned in the Discussion sections of 
the individual chapters.  Here, however, I will focus exclusively on the most 
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practical priorities in the context of an academic research lab (and, specifically, 
the Laboratory of Bacterial Pathogenesis at Rockefeller). 
 For Chapter 2, one of the most straightforward extensions would be to 
apply a similar in silico lysin screen to the published genomes of other Gram-
positive bacterial species.  As the results of the chapter demonstrated, this 
information can be valuable both in the identification of novel enzybiotic 
candidates, as well in the generation of new hypotheses regarding the biology of 
the host bacteria (with C. perfringens, for example, involving BCN5 
externalization).  In the present work, however, the search strategy was 
essentially manual.  In theory, however, the same set of steps (i.e. the algorithm) 
could be conducted computationally, expediting the process tremendously.  A 
program such as this could readily be applied to all known genomes—as well as 
new sequencing data, assembled or unassembled—with the goal of generating a 
single, organized database of lysins. 
 Experimentally speaking, one of the most intriguing next steps does not 
actually involve work with PlyCM itself, but rather the non-viral ―lysins‖ in the 
C. perfringens genomes.  In particular, the BCN5-assoicated lysins are a tempting 
area for investigation.  Although this possibility was mentioned in the chapter as 
more of an afterthought, its potential implications (i.e. secretion-by-suicide) and 
the relative ease with which the hypothesis could be tested make it an extremely 
attractive project.  Since these genes are already plasmid-encoded, it should be 
straightforward to introduce them into a C. perfringens/E. coli shuttle plasmid 
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while maintaining natural function.  Knockouts or mutations of the lysin-like 
ORF could then be constructed; the plasmid would be reintroduced to C. 
perfringens, which would be observed phenotypic differences in response to UV-
radiation. 
In contrast, the work in Chapter 3 could probably be considered a closed 
topic from a theoretical perspective.  This not to say that E-LASLs are no longer 
relevant… to the contrary, the technique is still widely used within the 
Laboratory of Bacterial Pathogenesis for screening genomes and metagenomes.  
It is just that—from a methodological standpoint—any developments of the E-
LASL protocol would likely just represent incremental adjustments rather than 
major advances.   
In this regard, a more relevant issue involves the actual screens that are 
conducted once the libraries are synthesized.  Phages encode numerous 
biotechnologically-relevant proteins other than lysins (Schoenfeld et al. 2010). 
From a screening perspective, the biggest issue is how to readily identify their 
associated properties within transformed clones.  While a bacteriolytic or 
hemolytic phenotype is visually straightforward, the same might not be true for 
a colony that expresses, say, an interesting phage polymerase.  Overall, as more 
and more screening techniques are devised, the utility of the E-LASL can only 
expand. 
For Chapter 4, the most pressing avenue for ongoing research is 
abundantly clear: applying the protocol to larger and more diverse viral 
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metagenomes so that the holin-based method can be exploited for its full worth.  
The 26 enzymes identified here demonstrate the validity of the technique, and 
several possess interesting sequences that could merit future purification and 
biochemical analysis.  At the same, the true value of the method can only be 
realized in the identification of novel enzymes that would not have been 
approachable by genomic techniques alone.   
Based on the extreme abundance of phage in the biosphere and the results 
of previous viral metagenomic sequencing studies, there is good reason to 
believe that we have only seen the tip of the iceberg when it comes to the diversity 
of proteins that phages encode.  These studies have been remarkable for the lack 
of similarity between the new metagenomic sequences and genetic information 
already in the databases (Edwards and Rohwer 2005).  Personally, I am 
optimistic that the same holds true specifically for lytic enzymes.  In this regard, 
our laboratory has been in contact with other research groups about potential 
collaborations, so that we can apply our functional techniques to existing phage 
libraries that have only been examined via sequencing to date. 
Finally—regarding the S. suis lysins of Chapter 5—it is admittedly 
difficult to surmise where the work presented here will lead in the future.  Much 
of this is dependent on the success of ongoing in vivo trials.  At this point, we are 
cautiously hopeful that combination treatment with PlySs1 and PlySs2 will have 
a positive impact on experimentally-infected pigs.  In a small cohort of animals, 
lysin treatment prevented clinical progression of disease in 4/5 subjects, while 
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4/5 untreated subjects experienced fulminant lethal infection (Dekker and 
Wagennar, personal communications).  At the same time, more data analysis and 
further experimental trials are pending, and these will assuredly affect future 
decision making on how intensely PlySs1 and PlySs2 will be pursued. 
It is also important to emphasize that, of the two S. suis lysins, PlySs1 
actually represents the less promising enzybiotic candidate.  Although only the 
characterization PlySs1 is presented in this thesis, it is the weaker enzyme 
quantitatively.  PlySs2 demonstrates similar anti-streptococcal activity, but at 
~10-fold lower concentrations than PlySs1 (values that are more representative of 
the typical potency of phage lysins).  The reason that PlySs2 data is not presented 
in this thesis is purely logistical.  The PlySs1 and PlySs2 enzymes were initially 
identified and cloned around the same time (autumn/winter 2009).  Without 
prior knowledge of their behavior, I chose to focus on the characterization of 
PlySs1, while similar work on PlySs2 was undertaken by Mr. Daniel Gilmer (a 
rotation student in the Laboratory of Bacterial Pathogenesis, who has since joined 
as a permanent member).  Mr. Gilmer has assumed PlySs2 as part of his own 
doctoral research, and is actively pursuing its characterization.  We plan to co-
author a manuscript that combines the in vitro characterization of both enzymes.   
 
THE FUTURE OF GENOMICS AND METAGENOMICS 
 Looking beyond the specific work conducted here, it also valuable to 
consider other potential developments that might impact lysin identification in 
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the future.  Overall, the ideal lysin screen (from an enzybiotic perspective) would 
be one that combines the large number of enzymes encoded by metagenomic 
samples with the specificity that individual lysins demonstrate toward their host 
bacteria.  One possible solution could involve screens in which genomic DNA 
from numerous strains of a single pathogen is pooled to form a multi-genomic 
library.  Each strain would likely contain integrated prophage, such that a 
combination of diverse strains should encode a large collection of lysins.  A 
functional screen of this library would generate many hits, like a metagenomic 
screen, with the exception that all enzymes would target the same bacteria de 
facto.   
An alternative multi-genomic approach could involve large-scale proviral 
induction.  A collection of strains could be grown in liquid culture and treated 
with an agent such as mitomycin or phosphomycin (Ryan and Hébert 2009).  
This would induce lysogen activation, and the resultant viral particles would be 
released into the culture supernatant.  These could readily be purified by a 
combination of filtration, nuclease treatment (to remove free bacterial 
DNA/RNA), and polyethylene glycol precipitation.  The DNA from a pooled 
lysogen library could then be subject to a single functional screen.  This method, 
in fact, is currently being employed with success by other members of the 
Fischetti Laboratory (Schuch and Pelzak, personal communications).   
Comparing these two functional multi-genomic approaches, the main 
advantage of the former is its ability to identify all proviral lysins, including ones 
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from cryptic prophages and those that do not induce well in vitro.  At the same 
time, considering the much larger size of bacterial genomes, the lysin-encoding 
clones would represent a much smaller proportion of the overall library 
population.  With induced phages, by contrast, the total diversity of lysins might 
be diminished somewhat, but the desired transformants would be relatively 
abundant within the library. 
Of course, both of these methodologies assume that whole-genome 
sequencing is beyond the reach (and cost) of a typical academic laboratory.  
While this technology is vastly more accessible than a decade ago (500+ phage 
and 1,000+ bacteria been sequenced to date), the preceding statement still largely 
rings true.  For instance, at the time of writing, the in-house cost of a single run of 
Solexa high-throughput sequencing at the Rockefeller University core facility is 
upwards of $1,000 per sample.  Although affordable for a limited number of 
isolates, this figure is still likely excessive when numerous bacterial or phage 
isolates are considered.  And this does not even include the genomic-assembly 
process from the short sequencing reads, or the time needed to mine the 
assembled genomes for lysin-encoding ORFs (in this regard, the sort of 
computational algorithm mentioned above would be valuable).  At the present 
time, while published genomes are valuable sources of enzymes, a search-for-




 Fortunately, high-throughput sequencing technology is still considered to 
be in its infancy, and the associated efficiency and cost are only expected to 
become more favorable in the future.  Commentators have suggested the 
eventual possibility of the $1 bacterial genome (Ussery et al. 2009).  In this 
circumstance, the sequencing of numerous genomes would definitely seem 
warranted, even if it is only to identify a single class of proteins (lysins or 
otherwise).  The same holds true, of course, for metagenomic sequencing.  For 
metagenomics, in fact, sequencing advances could prove even more valuable due 
to the extra complexity associated with assembling metagenomes beyond the 
short initial sequencing reads, which—from a perspective of cloning recombinant 
proteins—are not useful (Schoenfeld 2010). 
 All of this is not to say that DNA sequencing can completely replace 
functional screening as a method for identifying new enzybiotics.  No matter 
how powerful the technology becomes, a sequence is only able to identify a 
protein that demonstrates homology to something that has already been 
characterized.  To find something completely novel, functional screening is still a 
necessity.  Ultimately, in this regard, the two approaches are vital complements 
to one another.  Whenever a novel protein is uncovered, the vast database of 
existing sequences makes it all the more likely that homologues can be 
recognized immediately, facilitating rapid progression beyond the initial 





ENZYBIOTICS BEYOND PHAGE LYSINS 
 For this discussion to be complete, it is important to emphasize that phage 
lytic enzymes are not the only molecules that can be included under the umbrella 
of enzybiotics.  The two terms are often used interchangeable, and understandably 
so.  Phage lysins have generated considerably more attention than any other 
class of enzyme as far as antibiotic potential is concerned.  Rigorously speaking, 
however, any enzyme with antimicrobial properties could be considered an 
enzybiotic.  These other proteins will be considered briefly here, so that the 
field—and ongoing developments within it—can be appreciated in their entirety. 
First, bacteriophages encode enzymes other than lysins proper that have 
been examined as potential antibacterial agents.  Like the lysins, some of these 
other proteins function as peptidoglycan hydrolases.  It was mentioned briefly in 
Chapter 1, for instance, that hydrolase motifs are often present within proteins of 
the phage tail assembly (Kanamaru et al. 2004; Kenny et al. 2004; Piuri and 
Hatfull 2006) or even the head (Moak and Molineux 2004).   Presumably, these 
structural enzymes facilitate the initial injection of viral DNA.  Although it is not 
their natural purpose, recent evidence has shown that these enzymes can lead to 
Gram-positive lysis when added exogenously.  Rashel et al. identified a tail-
associated protein from the genome of an S. aureus phage that contains two 
putative lytic motifs; when individually expressed and purified, both domains 
induced staphylococcal death (2008).   
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Despite these findings, no tail enzymes have ever been identified during a 
functional screen of a phage genome.  Several reasons could underline this 
discrepancy.  For instance, some enzymes might require the presence of the 
entire macromolecular tail assembly for proper activity.  Moreover, structural 
lysins often represent component domains within much larger polypeptides; in 
the context of a functional screen, these domains would not be expressed 
individually and the bulk proteins could prove difficult to obtain due to their 
size.  Nevertheless, if future research could reliably harness the enzymatic 
activity of tail lysins, it would represent another promising avenue within the 
enzybiotics field. 
Outside of their enzymatic activity, phage tail structures are additionally 
remarkable for their ability to traverse the other components of the bacterial cell 
envelope, including the outer membrane of Gram-negative bacteria.  In this 
regard, various Gram-negative species encode protein complexes (―monocins‖) 
that kill closely-related organisms through a cell-envelope depolarization effect 
(Zink et al. 1995; Strauch et al. 2001; Jabrane et al. 2002).  These multimeric 
structures resemble isolated phage-tail assemblies, and are believed to represent 
proviral remnants that have been co-opted by the host.  In a recent study, 
Williams et al. demonstrated that, by exchanging a component gene of one such 
complex with the tail fiber genes of another phage, they could engineer 
complexes with species-targeted activity (2008).  While not examined specifically, 
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the study raises interesting questions about potential synergies between these 
complexes and recombinant lysins. 
Other than peptidoglycan hydrolases, several other classes of phage-
encoded enzymes have been examined for their overall antibacterial activity.  For 
instance, some phages are known to produce depolymerases that digest the 
exopolysaccharide of bacterial capsules and biofilm matrices.  (Although not 
discussed at length in this thesis, the dynamics of biofilm communities are 
thought to play a key role in pathogenesis of certain infections, as well as in the 
bacterial contamination of medical and industrial devices.)  These enzymes may 
be associated with the actual viral particle or synthesized intracellularly during 
phage infection (Donlan 2009).  Although phage-associated depolymerases have 
been known for some time (Eklund and Wyss 1962; Sutherland 1967), it is more 
recently that these enzymes have been proposed as recombinant agents for 
alterting the course of bacterial growth and infection (Glonti et al. 2009; Lu and 
Collins 2007).   
Another extracellular molecular complex with an important role in 
bacterial pathogenesis is the arabanogalactan layer of mycobacteria.  Although 
this genus is considered a Gram-positive actinobacterium evolutionarily, it 
possesses a unique cell-envelope structure in which covalently-linked 
arabanogalactan and mycolic acid layers overlay the peptidoglycan.  While 
mycobacteriophage have been studied extensively (Pedulla et al. 2003), it is never 
before been addressed whether specific phage-encoded proteins are responsible 
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for attacking these layers during lysis.  Recently, however, Payne et al. identified 
a conserved arabanogalactan esterase that fulfills this role and is encoded 
adjacently to the lysin within the phages‘ genomes (2009).  Although the authors 
did not demonstrate that exogenous enzyme was bacteriolytic (either by itself or 
in combination with lysin), their work raises the possibility that enzybiotics 
might still be possible against a group of pathogens for whom they were 
previously assumed to be irrelevant.  
Although unrelated to host lysis, a variety of other phage proteins (many 
poorly described) exert an intracellular antibacterial effect (Liu et al. 2004; Sau et 
al. 2008).  They are believed to be anti-host factors that allow the viruses to 
disrupt bacterial physiology following infection.  From a perspective of drug-
development, these proteins (not necessarily enzymes) do face the additional 
challenge of cytoplasmic delivery.  Limited experimental evidence, however, also 
suggests that phages encode other poorly-defined proteins that are bactericidal 
from the outside.  For instance, functional screening of the B. cereus Bcp-1 phage 
genome revealed two distinct clones that prevented the growth of Bacillus cells in 
soft-agar overlays.  One clone encoded a typical modular lysin (PlyB), while the 
other encoded a short, difficult-to-purify protein termed KOA (for Killer of 
Anthrax).  The latter is similar to only a limited number of hypothetical proteins 
from several other Bacillus phage genomes (Schuch, unpublished observations).   
While it is half the size of standard Gram-positive lysins and does not 
contain any traditional sequences common to major lysin families, KOA 
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nevertheless possesses lytic activity against a range of Bacillus cereus organisms, 
including B. anthracis.  It remains unclear what roles PlyB and KOA play 
(independently or in conjunction) during Bcp-1 infection, as the identification of 
this protein represents a fortuitous side-effect of the screening process.  Overall, 
it is difficult to predict what sort of antibacterial compounds (enzymatic or 
otherwise) might be encoded by global phage, mainly because such a relative 
few have undergone functional analysis.    
At the same time, phages are not the only genetic entities that can encode 
potential enzybiotic agents.  As mentioned several times throughout this thesis, 
bacteria likewise encode autolytic proteins that mediate activities such as 
growth, division, and sporulation (Vollmer et al. 2008b).  Some autolysins—like 
pneumococcal LytA and the C. perfringens enzymes discussed here—demonstrate 
high architectural homology to phage lysins, while others are more divergent.  
Although phage lysins have received more attention, various reports have 
documented the ability of recombinant autolysins to act as lytic agents against 
Gram-positive organisms (for instance, Dhalluin et al., 2005; Fukushima et al., 
2008; Yokoi et al, 2008).  And while their roles differ from those of phage lysins, 
the process of identifying and developing autolysins as antibacterial agents 
would follow essentially the same principals.   
In fact, the categories of peptidoglycan hydrolases with enzybiotic 
potential extends even beyond these proteins.  Many bacteria also encode 
proteins and peptides (broadly known as bacteriocins) that exert an antibiotic 
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effect on other species, often closely related ones.  Of these molecules, several 
notable examples function through a cell wall-lytic mechanism1.  The most 
prominent example is lysostaphin, a poly-functional hydrolase originally 
identified in Staphylococcus simulans that targets rival staphylococci (Kumar 
2008).  In light of growing resistance to traditional antibiotics, lysostaphin has 
received considerable attention as a possible weapon against MRSA and non-
MRSA isolates of S. aureus.  Comparable enzymes, namely millericin B and 
zoocin A, have been isolated from streptococcal strains (Beukes et al. 2000; 
Akesson et al. 2007).   
Going even further, other bacterial enzymes (glucanases and chitinases) 
have evolved that digest the cell wall of competing fungal species (Salazar and 
Asenjo 2007).  Overall, biotechnological interest in these proteins stems more for 
their ability to manipulate yeast in laboratory settings.  Nevertheless, given the 
existence of various fungal pathogens, these enzymes are still worth noting from 
an enzybiotics perspective.  They are also worth considering evolutionarily, as 
mycolytic enzymes share certain structural and biochemical properties with their 
glycosyl hydrolase cousins among the peptidoglycan hydrolases (Veiga-Crespo 
and Villa 2010).  All considered, the above proteins serve as important reminders 
that the enzybiotics field covers more than phage lysins, and necessitates that 







 In the field of phage-lysin research (and enzybiotics, in general), one 
observation is unmistakably clear: between established strategies of enzyme 
identification and novel techniques, there will be no shortage of candidate 
molecules in the foreseeable future.  As methods and technology continue to 
advance, what is already a dense field is only likely to become more crowded.  
Perhaps a greater challenge than merely identifying phage lysins, in fact, will be 
the ability to compare them systematically on a protein level.  Enzyme kinetics, 
thermal and pH tolerance, immunogenicity, in vivo half-life, and biodistribution 
are only a few of quantities that could vary from one lysin to the next and, 
ultimately, they are the factors that will determine an enzyme‘s therapeutic 
promise.   
Unfortunately, none of these properties can be measured (as of yet) with a 
mere shotgun screen or nucleotide sequence, as protein purification and old-
fashioned pharmacological analyses are still required.  In this regard, the 
enzybiotics field is in a unique position, as cloning technologies have created a 
pronounced gap between our ability to identify an enzyme-of-interest and the 
effort it takes to study it in detail and move it through the drug-development 
process.  Nevertheless, if and when the first phage lysin progresses to human 
useand an increasing body of experimental evidence suggests that day is 
comingthere will already be a large reserve of similar agents set to join it in the 





1.  As mentioned in the text, the term bacteriocin is commonly used to describe 
bacteria-encoded proteins and peptides with antibacterial activity.  The 
classification of peptidoglycan hydrolases as bacteriocins, however, is an issue on 
which a definitive consensus does not yet exist.  Under some schemata, virtually 
all antibacterial proteins encoded by bacteria themselves should be considered 
bacteriocins (Heng and Tagg 2006).  In this case, enzymes such as lysostaphin 
and zoosin A are categorized as class IIIa bacteriocins.  At the same time, other 
systems reserve the term bacteriocin for distinct classes of peptides that function 
through a non-hydrolytic mechanism (Cotter et al. 2005).  In either case, it should 
be emphasized that such schemata function only as organizational tools, and do 
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APPENDIX OF DNA AND AMINO ACID SEQUENCES 
A number of genes and their corresponding protein translations are 
referred to throughout the text of this thesis (primarily involving cloned phage 
lysins).  This appendix reports their nucleotide and amino acid sequences.  In a 
majority of cases, the sequences have already been submitted to the National 
Center for Biotechnology Information (NCBI) for inclusion in GenBank 
(www.ncbi.nlm.nih.gov/genbank/), in which case the corresponding accession 
numbers are provided.   
Several basic parameters are also reported for each protein, including gene 
and protein length, protein molecular mass, and theoretical isoelectric point.  For 
phage lysins, the predicted enzymatic and binding domains are also designated 
here.  The position of these domains within the amino acid sequences are 
denoted with the following color scheme: enzymatic domains are highlighted in 
blue and binding domains are highlighted in red.  The positions of all domains 
were predicted with the Pfam v24.0 algorithm (pfam.sanger.ac.uk). For several of 
the metagenomic lysins from Chapter 4, the genes were cloned with a truncated 
C-terminus (as described in the text); these cases are denoted as such in the 
appendix.  No predicted isoelectric point is provided for the truncated lysins. 
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Chapter 2: PlyCM 
GenBank Accession Number: YP_695420 (from C. perfringens ATCC 13124) 
Originally annotated in GenBank as ―Glycosyl hydrolase family protein‖ 
1029 base pairs; 342 amino acids; 38.73 kDa; Theoretical pI = 6.04 
Glycosyl Hydrolase Type 25 (i.e. muramidase) enzymatic domain (PF01183) 
Dual SH3-Type 3 binding domain (PF08239) 
ATGGAAAGTA GAAACAATAA TAATTTAAAA GGAATTGATG TATCAAACTG 
GAAAGGAAAT ATAAATTTTC AAAGTGTAAA AAATGATGGT GTAGAAGTAG 
TTTATATTAA AGCTACAGAA GGTAATTACT TTAAGGATAA ATATGCTAAA 
CAAAATTATG AGAGAGCGAA AGAACAAGGA TTAAGAGTAG GATTTTATCA 
TTTCTTTAGA GCTAATAAAG GAGCCAAGGA TCAAGCAAAT TTTTTCGTAA 
ATTATTTGAA TGAAATAGGA GCAGTTAATT ATGATTGTAA ATTAGCTTTA 
GATATAGAAA CTACTGAAGG GGTAGGAGCA AGAGATTTAA CTTCTATGTG 
TATAGAATTC TTAGAAGAGG TAATAAGAAT TACTGGAAAA GAAGTTGTTG 
TATATACATA TACAAGCTTT GCAAATAATA ATTTAGATAG TAGATTATCC 
AGTTATCCAG TTTGGATAGC TCATTATGGT GTAAACACTC CTGGAGCTAA 
CAATATATGG AGTGAATGGG TTGGGTTCCA ATATTCAGAG AATGGAAGTG 
TAGCTGGTGT AAGTGGTGGA TGTGATATGA ATGAGTTCAC TAATGGAATA 
TTCATTGATT CAAATAATTT TACTTTAGAC AATGCTACTA CTAAAAATGT 
AAGTATTAAA TTAAATATAA GAGCTAAAGG AACTACTAAT TCTAAAGTAA 
TTGGTTCAAT ACCAGCCAAT GAGAAGTTTA AAATAAAATG GGTTGATGAA 
GATTATCTTG GTTGGTATTA CGTTGAGTAT AATGGAATAG TTGGCTATGT 
AAATGCAGAT TATGTAGAAA AGCTACAAAT GGCTACTACT CATAATGTAA 
GTACTTTTTT AAATGTAAGA GAAGAAGGAT CATTAAATTC TAGAATAGTA 
GATAAGATAA ATACAGGTGA TATTTTTAGA ATAGATTGGG TGGATTCCGA 
TTTTATAGGT TGGTATAGAG TAACAACTAA AAATGGAAAA GTTGGATTTG 
TTAATGCTGA ATTTGTTAAG AAATTATAA 
 
MQSRNNNNLK GIDVSNWKGN INFQSVKNDG VEVVYIKATE GNYFKDKYAK 
QNYERAKEQG LRVGFYHFFR ANKGAKDQAN FFVNYLNEIG AVNYDCKLAL 
DIETTEGVGA RDLTSMCIEF LEEVIRITGK EVVVYTYTSF ANNNLDSRLS 
SYPVWIAHYG VNTPGANNIW SEWVGFQYSE NGSVAGVSGG CDMNEFTNGI 
FIDSNNFTLD NATTKNVSIK LNIRAKGTTN SKVIGSIPAN EKFKIKWVDE 
DYLGWYYVEY NGIVGYVNAD YVEKLQMATT HNVSTFLNVR EEGSLNSRIV 
DKINTGDIFR IDWVDSDFIG WYRVTTKNGK VGFVNAEFVK KL 
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**NOTE: In the preceding sequences for PlyCM, the underlined residues 
represent positions at which the experimentally-observed sequence differed from 
that in GenBank.  4G / 2E was intentionally changed from the wild-type 4C / 2Q 
to introduce an NcoI restriction site.  374T / 125I differed from the reported 374A 
/ 125K, but the change was not intentional. 
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Chapter 3: BG-1 Phage Lysin (i.e. PlyBeta) 
GenBank Accession Number: EU258891 
867 base pairs; 288 amino acids; 32.27 kDa; Theoretical pI = 5.96 
Glycosyl Hydrolase Type 25 (i.e. muramidase) enzymatic domain (PF01183) 
SH3-Type 5 binding domain (PF08460) 
ATGGGTTATA TTGTTGATAT TTCTAAATGG AACGGTGACA TTAACTGGGA 
CGTTGCAGCA GGTCAATTGG ATTTAGCAAT TGCTCGTGTT CAAGACGGTT 
CGAACTATGT TGACCCTATG TATAAGTCTT ACGTAGCATC TATGAAAGCT 
CGTAACGTGC CATTTGGTAA CTACGCTTTC TGTCGTTTCG TATCTGTAGA 
AGATGCAAAA GTAGAAGCTA GAGACTTTTG GGCTCGTGGA GACAAAGACG 
CTTTATTTTG GGTAGCGGAC GTAGAAGTAA AAACTATGGG CGACATGCAA 
GCGGGAACAC AAGCATTCAT TGACGAGCTA TATCGTTTAG GAGCTAAAAA 
AGTAGGTCTA TATGTCGGGC ATCACACTTA TGTGGCTTTC GGTGCTAAAA 
ACATTAGATG TGACTTCACT TGGATTCCTC GTTATGGTGG ACTAAAGCCT 
GATTTCCCTT GTGATCTATG GCAGTACACT GAAACAGGTA ATGTTCCTGG 
AATCGGTAAA TGTGACATTA ACAGCTTAAA CAGCGACAAG ACACTAGAAT 
GGTTCACAGG TAAAGATTGC AACAACGGTA ACGTGACTCC GCCACCACAG 
GGAGCTTACG ATTCTAGTTG GTTCACTAAG CAAACTGGTG TCTTCACTTT 
AGATCGTACG ATTAACTTAC GTACTGCACC ATTCCCAAAT GCACCGTTAA 
TTGCCCAATT AAACGCAGGA GATAACGTTA ACTACGAAGC GTACGGATAT 
GAAAAAGACG GTTACGTTTG GTTACGTCAG CATCGTGGTA ATGGTAACTT 
CGGTTACATC GCATCAGGCG AAACTAAAAA CGGTCAACGT ATCTCTACTT 
GGGGAACTTT TAAATAA 
 
MGYIVDISKW NGDINWDVAA GQLDLAIARV QDGSNYVDPM YKSYVASMKA 
RNVPFGNYAF CRFVSVEDAK VEARDFWARG DKDALFWVAD VEVKTMGDMQ 
AGTQAFIDEL YRLGAKKVGL YVGHHTYVAF GAKNIRCDFT WIPRYGGLKP 
DFPCDLWQYT ETGNVPGIGK CDINSLNSDK TLEWFTGKDC NNGNVTPPPQ 
GAYDSSWFTK QTGVFTLDRT INLRTAPFPN APLIAQLNAG DNVNYEAYGY 





Chapter 3: BG-2 Phage Lysin 
GenBank Accession Number: EU258892 
936 base pairs; 311 amino acids; 34.31 kDa; Theoretical pI = 9.19  
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510) 
Dual SH3-Type 3 binding domain (PF08239) 
ATGGCTATTT CAGTAAGACA AAAAATGGTG GATTCAAGTA AGTATTCTTT 
AAAATGTCCT TATGCTATGA CAGCAGAGTA CATTACAATC CACAACACGT 
ACAATGATGC AAGTGCGAAC AATGAGGTTC AATACATGAT TACTAATAGT 
AATGCAACTT CATTTCACTA TGCAATTGAT GATTTCGAAG TTGTACAAGG 
TATTCCAACA AACCGTAATG CATGGCATTG TGGAGATGGA AACGGTAATG 
GTAACCGTAA ATCTATCGGT GTTGAAATCT GTTACTCTAT GAGTGGTGGC 
GATAGATATC GTAAAGCACA AGCTTTAGTT ATCAAATTCG TTGCACAACT 
TTTAAGAGAA CGTGGATGGG GAATTGATAG AGTTAAGAAA CACCAAGATT 
GGAGTGGAAA ATATTGTCCA CACCGTATCC TAGACGAAGG ACGTTGGCAA 
TCAGTTCTAA ATGCTATTAA AGCAGAATTA AATGGTGGAG GTTCTACAGG 
TGGAGGAACA ACTCAACCAC CAGTTGATAA CTCTACAGGT GTAGTTAGAG 
TAACAGCAGA TGTTCTAAAC TTGCGTAATC AACCATCTAC TAACGGTTCT 
ATCGTTGGTA AAATCTACAA AGGTCAAGAT TACAAGTTCT GGGCTATCTC 
TAACGGATGG TACAACTTAG GTGGTAACCA ATGGGCTTCT GGTACTTATT 
TACAAGTAAT TAGTGGAGGA ACGCCACAAC CACCAAAAGC AGTAACAGGT 
ATTGCATATA TCACTGGATA CAATGTTAAT ATGCGTACAG GTGCAGGAAC 
AGGTTACTCA GTAATCCGTC AATTAAATGC ACCAGAATCT TACAAAGTTT 
GGGGAATGAA GGACGGTTGG TTAAACCTTG GTGGCGACCA ATGGATTAAG 
AACGACTCTT CATTTGTTAG ATTTGTACAA GACTAA 
 
MAISVRQKMV DSSKYSLKCP YAMTAEYITI HNTYNDASAN NEVQYMITNS 
NATSFHYAID DFEVVQGIPT NRNAWHCGDG NGNGNRKSIG VEICYSMSGG 
DRYRKAQALV IKFVAQLLRE RGWGIDRVKK HQDWSGKYCP HRILDEGRWQ 
SVLNAIKAEL NGGGSTGGGT TQPPVDNSTG VVRVTADVLN LRNQPSTNGS 
IVGKIYKGQD YKFWAISNGW YNLGGNQWAS GTYLQVISGG TPQPPKAVTG 





Chapter 3: BG-3 Phage Lysin 
GenBank Accession Number: EU258893 
1056 base pairs; 351 amino acids; 39.35 kDa; Theoretical pI = 9.37 
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510) 
SH3-Type 3 binding domain (PF08239) 
ATGAAAAAAA CGTTAAAACA CATTTCTTCT GTAGTCTTTG CAACTATTTT 
AGCGTTATCC ATTACAACAA GTGCTGTTGC TGACAGAGTA TTGATCATTC 
CTGATTTGCC GAAGCAAGGA TATAGAAATG GGGTAGGAGC TTATGAAGGT 
GTAGTGGCGC ATAGTACAGC GACTCCAGAA GCTCCAGCAA TCAATATCCA 
ACGTTATGAA ACGCGTACTT GGAGAAGTGC ATTTGTACAT TATGCAGTTG 
ACTGGGATGA AGTTATTCAA ATTGCAGATA CACGTTATAT TGCGTATGGC 
GCTGGACCAG CTGCTAACGC ACGTTTTGTA CACGTTGAAC TTTGTGAGAC 
TTCAGATTAT AGCAAGTTTA AGCGAAGCTA TGACAAGTAT GTAAAATTAC 
TAGCAAAAAT TTTACGTGAT CGTGGACTTT CAGTAGAAAA AGGATTATGG 
ACACATGATG ACGTAAGGAA ATATCTTGGT GGAACAACTC ACACGGATCC 
ACTGGATTAT CTAAAAAAAC ATGGTATATC TGAAGCTCAA TTCCGAGCAG 
ATGTGAAACG TGCTTATAAT AACACGGGTA TTTCTATTCC TGAACAACCT 
TCTAAACCAG CGGAAAAACC AACAGCCAAT GTAGAAGGTG TAGCTTATAT 
TGAAGGATAT AATGTAAATC TACGCAAAGG CCCAGATGCA AGCTATTCTG 
TTATTCGTCA ATTAAATAAA CCAGAGGCTT ATAAGGTTTG GGGAGAAAAG 
GGCGGATGGC TAAATTTAGG TTGGAATCAG TGGGTAAAAT ATAATCAATC 
GTATATCCGA TTTGAAAAGA AAGAAGCTGT AAGTCCAGTT GCTGGAAAAC 
GTGTAGTGTC GAAAGTGAAT AATCTCAGAT TTTATAGCGC TCCATCGTGG 
GAAGATAAGT ATGTTGCAGG TACTGTAGAT GTAGGATTAG GTTTTACGAT 
TGACGCAACG GTAATGGTAA ATGGTTCCCC ACAATACAAA GTACACAATA 
GTAAAGGAAC CACATACTAT ATCCCAGCAA GTGAAGCCTA TGTGTATGTG 
AAGTAG 
 
MKKTLKHISS VVFATILALS ITTSAVADRV LIIPDLPKQG YRNGVGAYEG 
VVAHSTATPE APAINIQRYE TRTWRSAFVH YAVDWDEVIQ IADTRYIAYG 
AGPAANARFV HVELCETSDY SKFKRSYDKY VKLLAKILRD RGLSVEKGLW 
THDDVRKYLG GTTHTDPLDY LKKHGISEAQ FRADVKRAYN NTGISIPEQP 
SKPAEKPTAN VEGVAYIEGY NVNLRKGPDA SYSVIRQLNK PEAYKVWGEK 
GGWLNLGWNQ WVKYNQSYIR FEKKEAVSPV AGKRVVSKVN NLRFYSAPSW 




Chapter 3: BG-4 Phage Lysin 
GenBank Accession Number: Not yet submitted 
1068 base pairs; 355 amino acids; 39.94 kDa; Theoretical pI = 9.11 
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510) 
SH3-Type 3 binding domain (PF08239) 
ATGAAAAAGA CAGTGAAACA TATTACCTCG TTCCTTATGA TTCTAGTACT 
TGCCGTTTCG TTTGCTACAA GTGCTTTCGC GGATAGAACA CTTATTATTC 
CTGATTTACC GAAACAACCA TACCGTAACG GTGTAGGTGC TTATGAGGGT 
GTTGTAGCAC ATTCTACAGC AACACCAGAA GCGCCAGCTA TTAATATTCA 
AAAATATGAG TCTCGTACAT GGCGTTCAGC ATTCGTACAT TATGCAGTTG 
ATTGGAATGA AACAATCCAA ATTGCTGATA CGAAATACAT TGCTTATGGT 
GCTGGACCAG GAGCAAATAA ACGATTTGTT CATGTGGAAT TATGCGAAAC 
AAAGGATTAT GAGAAATTCA AACGCAGCTA TGATAAATAC GTTAAGCTAT 
TAGCTAAAAT TCTTCGTGAC CGTGGATTAT CTGTAGAAAA AGGATTATGG 
ACTCACTATG ATGTTACAAA GTATCTTTTC GGTACAGATC ATGAAGATCC 
ACTTGATTAC TTACGTAGTC ATGGAGTTTC AGAAGCGCAA TTTAGAACAG 
ATGTACAACG AGCATACAAT AATTCTAATG TTGATGTTTC TGTACCGGAG 
AAGCCATCTA AACCAGCGGA AGTTCCAATG GCTGTAACAG ACGGAATCGC 
GTATATTGAA GGTTACAATG TTAACTTACG TAAAGGACCT GGTTCAAGTT 
ATTCTAAGAT TCGTCAGTTA AACAAACCAG AAGCTTATGT TGTATGGGCT 
GAAAAGGATG GTTGGTTAAA TCTTGGTGGC GAACAATGGA TTAAGAACGA 
TCCATCTTAT GTAAAGTTTA GTAAGAAAAG CACTGTGGAT TCCTCTATTG 
TAGGTAAACG CGTTGTTTCT AAAGTTAATA ATCTACGATT CTATGATGTT 
CCATCTTGGC AGGATAAAGA TGTTGCTGGT TCTGTAGATG CAGGATTAGG 
ATTTACAATT GATGCAAAAA TAAACGTCAA TGGATCACCA CAATACAAAG 
TGCACAATAG TAAGGGTATA ACATATTATG TTACTGCAAA TGAAGCCTAT 
GTGTATGTAG TAAAGTAA 
 
MKKTVKHITS FLMILVLAVS FATSAFADRT LIIPDLPKQP YRNGVGAYEG 
VVAHSTATPE APAINIQKYE SRTWRSAFVH YAVDWNETIQ IADTKYIAYG 
AGPGANKRFV HVELCETKDY EKFKRSYDKY VKLLAKILRD RGLSVEKGLW 
THYDVTKYLF GTDHEDPLDY LRSHGVSEAQ FRTDVQRAYN NSNVDVSVPE 
KPSKPAEVPM AVTDGIAYIE GYNVNLRKGP GSSYSKIRQL NKPEAYVVWA 
EKDGWLNLGG EQWIKNDPSY VKFSKKSTVD SSIVGKRVVS KVNNLRFYDV 





Chapter 3: A14 Phage Lysin 
GenBank Accession Number: Not yet submitted  
954 base pairs; 317 amino acids; 34.84 kDa; Theoretical pI = 8.74 
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510) 
Dual SH3-Type 3 binding domain (PF08239) 
ATGACTATTT CAGTAAGACA AAAATTGGTG GATTCTAGTA AGTATGGTTT 
AAAGTGTCCA AACGCTATGA CAGCAGAATA CATTACTATC CACAATACTT 
ACAATGATGC AAGTGCAAAC AATGAGGTTC AGTACATGAT TACAAATGGT 
AATGCTACTT CATTCCACTT TGCAATTGAT GATTTCGAGG TTGTCCAAGG 
TATCCCTACA AACCGTAATG CTTGGCATTG TGGAGATGGA ACAGGTAGCG 
GTAACATGAA GTCTATCGGA ATCGAAATCT GCTACTCTCT TTCTGGTGGA 
GACAGATATC GTAAAGCAGA AGCTTTAGCT GTAAAATTTA CTGCTCAACT 
TTTAAGAGAG CGTGGATGGG GAATTAGCCG AGTTAAGAAG CATCAAGATT 
GGTCTGGTAA ATATTGTCCA CACCGTATCT TAGATGAAGG ACGTTGGCAG 
TCATTCCTTA ATGCTGTTCA AACAGAACTT AATGGTGGAG GTTCTACACA 
ACCACCAGTA AACAATACTA CAGGTGTTGT TCAAGTAATG GTTGCAGATT 
TAAATCTACG TACACAACCA AGTGCAAGCG CTCCAATCAT CCGTAAATTA 
GGTATCGGTG AAACTTACCA GTTCTGGGCA ATTTCTAATG GATGGTACAA 
CTTAGGTGGA GACCAATGGG CTTATGGAGA CAATGGCAAC TACTTAAAAG 
TTATTAGCGG TGGAAGTTCT GTAGCACCTG CTCCACAACC AAAACCAGAG 
CCAAAACCAA TTACAGGTGT TGCTTATATC ACTGGATATA ATGTTAACAT 
GCGTAAAGGT GCAGGAACAG GTTACGCTGT AATCCGTCAA TTGAATGCAC 
CAGAATCATA TCAAGTGTGG GCAGTTAAAG ACGGTTGGTT GAATCTTGGT 
GGAGACCAAT GGATTAAGAA TGACGCTTCA TTTGTCAGAT TCGTACAAGA 
CTAA 
 
MTISVRQKLV DSSKYGLKCP NAMTAEYITI HNTYNDASAN NEVQYMITNG 
NATSFHFAID DFEVVQGIPT NRNAWHCGDG TGSGNMKSIG IEICYSLSGG 
DRYRKAEALA VKFTAQLLRE RGWGISRVKK HQDWSGKYCP HRILDEGRWQ 
SFLNAVQTEL NGGGSTQPPV NNTTGVVQVM VADLNLRTQP SASAPIIRKL 
GIGETYQFWA ISNGWYNLGG DQWAYGDNGN YLKVISGGSS VAPAPQPKPE 




Chapter 3: TSH Phage Lysin 
GenBank Accession Number: Not yet submitted 
819 base pairs; 272 amino acids; 29.22 kDa; Theoretical pI = 6.65 
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520) 
SH3-Type 5 binding domain (PF08460) 
ATGGGAACAT ATAACGTACA CGGTGGTCAC AACTCGATCG TACAAGGTGC 
TAACTGGGGT AACCGAAAAG AACACGTTAT GGATCGCCAG GTTAAAGACG 
CTTTAATTAG CAAACTTCGT AGCCTTGGTC ACACAGTTTA TGACTGCACA 
GACGAAACAG GTTCTACGCA AAGCGCTAAC TTACGTAACA TCGTAGCGAA 
ATGTAATGCT CACCGAGTAG ACTTAGACAT TTCATTACAC TTAAATGCTT 
ACAATGGTTC TGCTAGTGGC GTAGAGGTTT GTTACTACGA CCAACAAGCA 
TTAGCTGCTA AAGTTTCTAA ACAGCTTTCA GACGACATCG GTTGGTCTAA 
CCGTGGAGCT AAACCTCGTA CAGACCTTTA CGTATTAAAT AGCACGTCTG 
CACCTGCTAT CCTAATCGAG CTTGGTTTCA TCGACAACGA GAGCGATATG 
GCTAAATGGA ATGTAGACAA AATTGCAGAC TCTATCTGCT ATGCTATCAC 
AGGGCAACGT ACAGGCTCTA CTGGTGGAAG CACAGGAGGT TCTACAGGCG 
GAAGCACTGG TGGAGGTGGA TACGACTCTA GTTGGTTCAC ACCACAAAAC 
GGTGTATTCA CAGCTAACAC TACAATCAAA GTAAGAAGCG AGCCAAGCGT 
AAATGCAACT CACCTTCGTA CTCTGTACAG TGGTGGAACG TTCACGTATA 
CTTCATTCGG AATGGAGAAA GACGGTTACG TTTGGATCAA AGGCGTAGAC 
GGTACATACG TTGCAACAGG TGAAACTAGT AACGGAAAAC GTACCTCTTA 
CTGGGGAACT TTCCAGTAA 
 
MGTYNVHGGH NSIVQGANWG NRKEHVMDRQ VKDALISKLR SLGHTVYDCT 
DETGSTQSAN LRNIVAKCNA HRVDLDISLH LNAYNGSASG VEVCYYDQQA 
LAAKVSKQLS DDIGWSNRGA KPRTDLYVLN STSAPAILIE LGFIDNESDM 
AKWNVDKIAD SICYAITGQR TGSTGGSTGG STGGSTGGGG YDSSWFTPQN 
GVFTANTTIK VRSEPSVNAT HLRTLYSGGT FTYTSFGMEK DGYVWIKGVD 




Chapter 3: AerM (Hemolysin, not a lysin) 
GenBank Accession Number: EU258894 
ATGGATAAAG TAAAAATAAC GGGTTTGGCG TTGAGCATTT CGACGCTGTT 
GATGAGCCAG GCTCATGGGG CAGAGCCCGT CTATCCTGAT CAGCTGAGAC 
ACTTCAGCCT CGGTAGCCAG CGCTGTGGCG ATGATTATCG TGCCCTGACG 
CGCAATGAGG CCATGAGTAT CCGCAGCGAT ATAGTCAGCA AGATGGGGCA 
GTGGCAGATC ACCGGTCTGG CTGACAACTG GGTCATCATG GGGTCAGGTT 
ATAATGGCGA AATAAAGCAA GGCAGCGCGA GCGATACCTG GTGTTATCCC 
ACGAAACCGG TAGCGGGGGA AATACCAGTT CTATCCGCAT GGAATATTCC 
AGCTGGTGAC GAGATCGATG TGCAATGGCG AATGGTCCAT GATAATGATT 
ATTTTATCAG ACCGATAAGT TATCTTGCGC ATAATTTGGG TTATGCCTGG 
GTCAGTGGAA ACCATAGCCA ATATGTGGGT GAGGATATGG ACGTCACTCG 
CGTCAGTGAT GGCTGGCTCA TTCAGGGAAA TAATGGGGGT GGCTGCAGTG 
GTTATCGCTG TAGCGAGAAG AGCTCCATCA AGGTGAGCAA CTTCTCCTAC 
ACCCTGGATC CCGGTTCGTT CAGCCATGGC CTGGTGACTG AAAGCGGCAA 
GCAGCTGGTC AAGACCATCA CAGCTACGGC GACCAACTAT ACCGATTTGC 
CCCAGCAGGT GGTGGTGACC CTCAAATATG ACAAGGCCAC CAACTGGTCC 
AAGACCGACA CTTATGGTCT GAGTGAGAAG GTGGGCATCA AGAAGACCTT 
CCAGATCCCA CAAGTATCCA GTACCGAATA CTCGGTGGAG ATATCGTCCA 
GCCAGAGCTG GGCTCGCCAA GAAGGGGGGT CGGCAACCGA GACGGTATCG 
ATAGAAGCCC GCCCGACGGT GCCGCCTCAC TCCAGCGTGC CGGTCCGGGT 
TGCGCTCTAC AAGGCCAATG TATCTTATCC GTATGAGTTC AAAGCAGATA 
TCAACTATGA CCTCACCTTG AATGGTTTCC TGCGCTGGGG CGGCAACGCC 
TGGCACACCC ATCCGGACAA CCGGCCGACC TGGAATCACA CCTTCGTCAT 
CGGTCCGTTT AAGGACAAGG CGAGCAGCAT CCGTTACCAG TGGGACAAGC 
GCTACATCCC GGGTGAGGTG AAGTGGTGGG ACTGGAACTG GACCATACAA 
CAGAACGGTG CCGACACCAT GAAGAATGCC CTGGCCAGGG TGCTGCGCCC 
GGTGCGCGCC AGCATCACGG GGGACTTCCA CGCCGAGAGC CAGTTCGCCG 
GCAATATCGA GATAGGTGCG GCCGTGCCCA TCGGGGGCGA CAGCAAGGTG 
CGTCGTGCCC GCAGCGTCGA CAGCCCGGCA ACTGGCCTGC GCCTGGAGAT 
CCCGCTCGAT GCCAGCGAGC TCTCGGCGCT GGGCTTTGAC AACGTCCAGC 
TCACGCTGGA ACCCGCTACC GACAAATAA 
 
MDKVKITGLA LSISTLLMSQ AHGAEPVYPD QLRHFSLGSQ RCGDDYRALT 
RNEAMSIRSD IVSKMGQWQI TGLADNWVIM GSGYNGEIKQ GSASDTWCYP 
TKPVAGEIPV LSAWNIPAGD EIDVQWRMVH DNDYFIRPIS YLAHNLGYAW 
VSGNHSQYVG EDMDVTRVSD GWLIQGNNGG GCSGYRCSEK SSIKVSNFSY 
TLDPGSFSHG LVTESGKQLV KTITATATNY TDLPQQVVVT LKYDKATNWS 
KTDTYGLSEK VGIKKTFQIP QVSSTEYSVE ISSSQSWARQ EGGSATETVS 
IEARPTVPPH SSVPVRVALY KANVSYPYEF KADINYDLTL NGFLRWGGNA 
WHTHPDNRPT WNHTFVIGPF KDKASSIRYQ WDKRYIPGEV KWWDWNWTIQ 
QNGADTMKNA LARVLRPVRA SITGDFHAES QFAGNIEIGA AVPIGGDSKV 
RRARSVDSPA TGLRLEIPLD ASELSALGFD NVQLTLEPAT DK 
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**NOTE: The above gene/protein is for a bacterial virulence factor of the 
aerolysin gene family.  Aerolysin exotoxins are initially translated in the bacterial 
cytoplasm as preproaerolysin; this corresponds to the sequences listed above in 
their entirety.  Preproaerolysin is recognized by the type II (i.e. Sec-dependent) 
secretion apparatus and translocated across the cytoplasmic membrane, with 
concomitant cleavage of the N-terminal signal peptide (designated with a single-
underline), yielding proaerolysin.  Following outer-membrane translocation, 
proaerolysin undergoes a C-terminal cleavage event (cleaved portion designated 
with a double-underline).  This yields the final aerolysin protein, which 
undergoes subsequent insertion and homopentamerization in the target 
eukaryotic membrane.  In the above amino-acid sequence, the position of the 
cleaved signal peptide was predicted with the SignalP v3.0 algorithm 
(www.cbs.dtu.dk/services/SignalP/) and verified experimentally by N-terminal 
sequencing.  The position of the C-terminal cleavage point was predicted (but 
not experimentally confirmed) by homology analysis with previously-
characterized aerolysin proteins. 
Gene length: 1479 bp 
Initial protein transcript (preproaerolysin): 492 amino acids; 54.45 kDa; pI = 6.14 
Translocated protein (proaerolysin): 469 amino acids; 52.05 kDa; pI = 5.97 




Chapter 4: PlyM1 (Truncated) 
GenBank Accession Number: HM011589 
591+ base pairs; 197+ amino acids; 22.12+ kDa 
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510) 
No C-terminal binding domain was recognized.  However, given the fact that 
this lysin was cloned as a truncated construct—along with the fact that its N-
terminal region demonstrated Blast homology to other Gram-positive enzymes—
it is likely that a binding domain does exist but could not be recognized by Pfam 
due to the truncation. 
ATGAGTATTA ATGTAGTTAA GAATTTGGTG TCTTCAAGTA AATATAGTGT 
TAAGTGTCCT TATCCTATGA ATCCAGAAAT AATTGTCGTA CACAATACGG 
CAAACGATGC ATCGGCTAAG TCAGAAATTT CTTATATGAT TAACAACAAT 
AATGAAGTTT CCTACCATTT CGCTGTTGAT GACAAAGAAG TTGTTCAAGG 
ATTGCCATTA AATCGAAATG GTTGGCATGC AGGTGACGGT GGTTCGGGAC 
GTGGTAACAG AAAAGGTATT GGAGTTGAAA TTTGTTATTC TAAGTCTGGT 
GGTATTAAAT ATAAAAAAGC AGAAGTTTTA GCTATCAAAT TTATTGCACA 
ATTATTACAT GAAAGAAATT GGTCAATTGA TAGAGTAAAA ACTCATAATC 
AGATGAATGG CAAGTATTGT CCCCATAGAA TCCTATCTGA AGGAAGATGG 
GATGATGTAC TACGAGCAAT CCAAAAAGAG TTAGATAGAT TAAATAATGT 
GGAAGTAAAA CCTGCTCCAG ATACTCAAGT GGATTCAGAA ATAACAACTA 
AACCAAATAA ACCAAAAGAA GAAAACAAAG TGGAATCAAT T… 
 
MSINVVKNLV SSSKYSVKCP YPMNPEIIVV HNTANDASAK SEISYMINNN 
NEVSYHFAVD DKEVVQGLPL NRNGWHAGDG GSGRGNRKGI GVEICYSKSG 
GIKYKKAEVL AIKFIAQLLH ERNWSIDRVK THNQMNGKYC PHRILSEGRW 
DDVLRAIQKE LDRLNNVEVK PAPDTQVDSE ITTKPNKPKE ENKVESI… 
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Chapter 4: PlyM2 
GenBank Accession Number: HM011590 
750 base pairs; 249 amino acids; 28.23 kDa; Theoretical pI = 9.11 
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510) 
Alanine-amidase-type-2-associated putative binding domain (PF12123) 
ATGAAAATCC CCGTAAGACA AATGCTCGTT AATTCAAAGA ATCATAACAT 
TAAATGTCCT TTCGACATGC AAGCAGAGTA TATTACCATC CACAATACCT 
ATAATGATGC AAGCGCCAAT AACGAAATAC AATATATGAT TAACAATGCA 
CACGAAGTAT CCTTTCACTT TGCTGTAGAT GACAATGAGG TTGTTCAAGG 
ATTGCCATTA AACCGTAACG GATGGCACTG CGGAGATGGC GGAAAAGGTT 
CTGGAAATCG AAAGTCTATT GGTGTTGAAA TCTGTTACTC CAAGTCAGGA 
GGTACCAAAT ACTACAAAGC AGAAGGATTA GCTATCCAAT TTGTTGCTCA 
ACTTTTGCAT GAAAGAGGAT GGGGGATTGA TCGAGTAAAA AAACATCAGG 
ATTGGTCAAA GAAACATTGC CCACATCGTA TTTTAGATGA AGGTCGCTGG 
CAGTCAGTGC TGGATGCAAT CTCAAAGGAA TTAGATGCAC TTAAAAAACC 
TGTTAAAACT TCCGTTGTTG CTGCCGTTGA AAATTCCCCT TCTGTTAAAA 
TCCAGACGGG TGGTTTAAAT CCTGAAATGG TAAAGGAAAT ATCTGATTTC 
TTCATACAAA ACAAATGGTA TGCTGAAATC ACGTTCAATT TCAAAAAAGG 
AAATCCAACA GCTGTGACAG GAGGTTTATC CGGGGCTACC AGGGATAAAT 
TTGAATCCTG GCTAAAAGAA CGCGGCTGGT GGTATAAAGT AATTAAGTAA 
 
MKIPVRQMLV NSKNHNIKCP FDMQAEYITI HNTYNDASAN NEIQYMINNA 
HEVSFHFAVD DNEVVQGLPL NRNGWHCGDG GKGSGNRKSI GVEICYSKSG 
GTKYYKAEGL AIQFVAQLLH ERGWGIDRVK KHQDWSKKHC PHRILDEGRW 
QSVLDAISKE LDALKKPVKT SVVAAVENSP SVKIQTGGLN PEMVKEISDF 
FIQNKWYAEI TFNFKKGNPT AVTGGLSGAT RDKFESWLKE RGWWYKVIK 
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Chapter 4: PlyM3 (Truncated) 
GenBank Accession Number: HM011591 
921+ base pairs; 307+ amino acids; 33.21+ kDa 
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510) 
PG-1 binding domain (PF01471) 
ATGGCATACA CAATTGTTAA CAAATATATC CCTACATCTA AATACGGTAG 
AAAAGCGCCA TACTCGATGA ATGCAGAAAC TATCACCTTC CACAATACAG 
CAAATGACGC AACTGCGTTA GGCGAGATTT CTTACATGAC GAATAACAAT 
AATCAAACTT CCTATCACGT CGCTATTGAT GATAAACACG CTGTGCAGGC 
GATTCCGTTC AACCGGTCAG CTTGGCACGC AGGCGATGGT CAGGGAGCAG 
GAAATCGCAA GTCTATTGGT ATCGAGGTGT GCTATAGCAA AAGCGGCGGC 
GTGAAATATG CGGCGGCAGA AGAAAACGCC ATTGAATATA TCGCACACAT 
TCTCAAAGAT AAAGGTTGGG GAATTGATCG CGTGAAATGG CATCGTGACT 
GGTCGGGTAA AAATTGCCCG CATCGCGTAT TAGATGAAGG AAGAGCAACG 
AGTGTGCGTA ACCGAATCAG CGCTAAATTA GCAGAGTTGA AAGGTGAGAA 
GGTCGTTGAA GTTGCATCGC CTTCCACAGT GAAGAGAGAC TACCTATTAG 
ATGGCGATAC AGGCGCAGCG GTTAAAACGC TACAAAGCGA ATTGAAGCAA 
GCAGGTTTCT TACTATCTGT GGATGGCATA TTCGGAAAAG GCACAGAGAC 
AGCGGTTAAG GCGTTCCAGC GTGCGAATGG ATTAGCCGTT GATGGCGTGT 
TCGGAACAGG CTCACAGGCT AAACTCAACG CAATACTGGC TAATTTGAAT 
AAGAAGCCGG TAGTTAAGCC TGCAGCGCCA ACAAAACCAA AGGAGGAATC 
CACAGTGGAG AAAACAAACG AACCCTCAAA ATGGGCAGAA GCGACGATTA 
AAGAAGCGGT GAAGATTGGC GTTACCGATG GCAGCAACTT GCACGATCCA 
GTCACAAGAC AGGAAGCAAT T… 
 
MAYTIVNKYI PTSKYGRKAP YSMNAETITF HNTANDATAL GEISYMTNNN 
NQTSYHVAID DKHAVQAIPF NRSAWHAGDG QGAGNRKSIG IEVCYSKSGG 
VKYAAAEENA IEYIAHILKD KGWGIDRVKW HRDWSGKNCP HRVLDEGRAT 
SVRNRISAKL AELKGEKVVE VASPSTVKRD YLLDGDTGAA VKTLQSELKQ 
AGFLLSVDGI FGKGTETAVK AFQRANGLAV DGVFGTGSQA KLNAILANLN 




Chapter 4: PlyM4 
GenBank Accession Number: HM011592 
990 base pairs; 329 amino acids; 35.61 kDa; Theoretical pI = 9.69 
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510) 
PG-1 binding domain (PF01471) 
ATGGTTACAA TCAAAAAACA GATAGTTCCG GAATCGAACG TTAGAACGCG 
CACGTTTGGC AGGTTGAACA AGAAGCGGTA CATCACAATC CACGAAACGG 
GTAACGCCAG TAGAGGTGCA GGCGCTCAAA GCCACGCCAA TCTACAAAGC 
AACACAAATC CACGCGCAGC TTCCTGGCAT TGGCAAGTGG ATGAAAAGGT 
AGCGATTCAA TCATACGATC ATTCGGTATC GTGTTGGGCC GGTGGCGATG 
GGCGAGGGAA TGGCAACATG AATTCGATTC ACATTGAAAT TTGTATCAAC 
AGTGATGGCG ACTATTTGAA AACGATAGAA AACGCAGCGC AATTGGTCAA 
GTATATAATG AAGGAAGAGA ATATTCCGTT GGCTAATGTG GTGCAGCATA 
ACAAGTGGTC TGGCAAGAAT TGCCCTACGT TGTTACGCGC AGGCAATCGC 
GGCATTAATT GGGGCGGCTT CCTTAGCAAA GTTAACGGTG CGGTTGTATC 
GGCTACGCCT AAGCCTTCCA CAGTGAAGAG AGACTACCTA TTAGATGGCG 
ATACAGGCGA TAACGTCAGA GCGCTACAGA CCGGATTAAA GCAAGCAGGT 
TTCTTACTAT CTGTGGATGG CATATTCGGT AAAGGCACAG AGACAGCGGT 
TAAGGCGTTC CAACGTGCGA ATGGATTAGC AGTTGATGGC GTGTTCGGAA 
CAGGCTCACA GGCTAAACTC AACGCAATAC TGGCGAATTT GAATAAGAAG 
CCGGTAGTTA AGCCTGCAGC GCCATCAAAA CCAAAGGAGG AATCCACAGT 
GGAGAAAACA AACCAACCCT CAAAATGGGC AGAAGCGACG ATTAAAGAAG 
CGGTGAAGAT TGGCGTTACG GATGGCAGCA ACTTGCACGA TCCAGTTACA 
AGACAGGAGG CAATTGTGCT GGCGATGCGT GCCGCAGGAC TTGCGCCAAG 
ACTTAAACAA CACACTTATA AATATTGTAA GAATTGTTAA 
 
MVTIKKQIVP ESNVRTRTFG RLNKKRYITI HETGNASRGA GAQSHANLQS 
NTNPRAASWH WQVDEKVAIQ SYDHSVSCWA GGDGRGNGNM NSIHIEICIN 
SDGDYLKTIE NAAQLVKYIM KEENIPLANV VQHNKWSGKN CPTLLRAGNR 
GINWGGFLSK VNGAVVSATP KPSTVKRDYL LDGDTGDNVR ALQTGLKQAG 
FLLSVDGIFG KGTETAVKAF QRANGLAVDG VFGTGSQAKL NAILANLNKK 
PVVKPAAPSK PKEESTVEKT NQPSKWAEAT IKEAVKIGVT DGSNLHDPVT 




Chapter 4: PlyM5 (Truncated) 
GenBank Accession Number: HM011593 
853+ base pairs; 284+ amino acids; 30.86+ kDa 
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520) 
PG-1 binding domain (PF01471) 
ATGGCAAAAT TATATAACGA ACCAGGACAC GGCGTAAATA CATGGCCGCC 
AAGCAAAGGG ACGCGCGCGA GTGGTGGCGT TCCTGAAATG GCAGAACATG 
ATTTTAATGC AGCTGTAGCA GATGAAGTGA ATCGCCTGTT AAGCGGCAAG 
CTAACGACTT ATAGCGCGCA GCCGAGTCGC GGCAAGGATG TTTCGCTAAC 
GACGCGCACG CGCCTATATA ATGAAGAGTT TCGCAAAGAT AAGAGCGCAA 
TTGGCTTCTC GCATCACGGA AACGCCAACG CTAACAAAGC GACAAAAGGA 
TTCGGTGTAT TCTACTGGGG TGGATCTGCA ACGGGTAAGA AGTTGGCGCA 
AATGCTACTC GCGGCGTATA AAAAAGAATT CCCTGGCTAT CCAATTTGGG 
GCAGCGGGAT ATTCGAAAGC AAGCGCGGAG ACTGGACTAA CTTCGCAATC 
CTGCGCGATA CATCAGCGCC TTTCGTGTTG ATCGAGTGGG ATTTCTTTAC 
GAATGATGAA GCGCGGAAAC GTATGCTATC CACAGATTAT AGAAAGCGCT 
GCGGTAAGGT GGCGGCAAGT GTCGCGTGTG ATTGGTACGG GATTCCGTTT 
ACTGATTTCA CAGCAGCGAA ACCTACGCCT TCCACAGTGA AGAGAGACTA 
CCTGTTAGAT GGCGATACAG GCGCAGCGGT TAAAACGCTA CAAAGCGAAT 
TGAAACAAGC AGGTTTCTTA CTATCTGTGG ATGGCATATT CGGAAAAGGC 
ACAGAGACAG CGGTGAAGGC GTTTCAGCGC GGCAACGGAC TAGTTGTTGA 
TGGCGTGTTC GGAACAGGCT CACAGGCTAA ACTCAACGCA ATACTGGCTA ATT… 
 
MAKLYNEPGH GVNTWPPSKG TRASGGVPEM AEHDFNAAVA DEVNRLLSGK 
LTTYSAQPSR GKDVSLTTRT RLYNEEFRKD KSAIGFSHHG NANANKATKG 
FGVFYWGGSA TGKKLAQMLL AAYKKEFPGY PIWGSGIFES KRGDWTNFAI 
LRDTSAPFVL IEWDFFTNDE ARKRMLSTDY RKRCGKVAAS VACDWYGIPF 
TDFTAAKPTP STVKRDYLLD GDTGAAVKTL QSELKQAGFL LSVDGIFGKG 




Chapter 4: PlyM6 
GenBank Accession Number: HM011594 
1074 base pairs; 357 amino acids; 38.63 kDa; Theoretical pI = 9.62 
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520) 
PG-1 binding domain (PF01471) 
GTGGCGAAGT TATATAACGA ACCAGGACAC GGCGTAAACA CATGGCCGCC 
AAGCAAAGGG ACTCGCGCAA GTGGCGGCGT TCCCGAAATG GCGGAACATG 
ATTTTAACGC AGCGGTAGCA GATGAAGTGA ATCGCCTATT AAGCGGCAAG 
CTAACGACTT ATAGCGCGCA GCCTAGTCGC GGCAAGGATG TTTCGCTAAC 
GACGCGCACA CGCCTATATA ATGAAGAGTT TAAGAAGGAC AGAAGCGCAA 
TCGGATTTTC ACACCACGGA AACGCCAATG CCAACAAAGC AACTAAAGGA 
TTCGGTGTAT TCTACTGGGG CGGATCTGCA ACAGGCAAAA AGTTGGCGCA 
AATGCTACTT GCTGCATACA AGAAAGAATT CCCTGGCTAT CCGATTTGGG 
GCAGCGGGAT ATTTGAAAGC AAGCGCAGCG ACTGGACCAA CTTTGCTATC 
TTGCGTGATA CGTCAGCGCC TTTCGTGTTG ATCGAGTGGG ATTTCTTTAC 
GAATGATGAA GCGCGCAAAC GTATGCTATC CACAGATTAT AGAAAGCGCT 
GCGGTAAGGT GGCGGCAAGT GTCGCGTGTG ATTGGTACGG CATTCCGTTT 
ACTGATTTTA CAGCAGCGAA GCCTACGCCT TCCACAGTGA AGAGAGACTA 
CCTATTAGAT GGCGTTACAG GCGCAGCGGT TAAAACGCTA CAAAGCGAAT 
TGAAGCAAGC AGGTTTCTTA CTATCTGTGG ATGGCGTATT CGGAAAAGGC 
ACAGAGACAG CGGTTAAGGC GTTCCAACGT GCGAATGGAT TAGCCGTTGA 
TGGCGTGTTC GGAACAGGCT CACAGGCTAA ACTCAACGCA ATACTGGCGA 
ATCTGAATAA GAAGCCGGCA GTTAAGCCTG CAGCGCCAAC AAAACCAAGG 
GAGGAATCCA CAGTGGAGAA AACAAACCAA CCCTCAAAAT GGGCAGAAGC 
GACGATTAAA GAAGCAGTGA AGATTGGCGT TACGGATGGC AGCAGCTTAC 
ACGATCCAGT CACAAGACAG GAAGCAATTG TGCTGGCGAT GCGTGCTGCA 
GGACTTGCGC CAAAACTTAA GTAG 
 
MAKLYNEPGH GVNTWPPSKG TRASGGVPEM AEHDFNAAVA DEVNRLLSGK 
LTTYSAQPSR GKDVSLTTRT RLYNEEFKKD RSAIGFSHHG NANANKATKG 
FGVFYWGGSA TGKKLAQMLL AAYKKEFPGY PIWGSGIFES KRSDWTNFAI 
LRDTSAPFVL IEWDFFTNDE ARKRMLSTDY RKRCGKVAAS VACDWYGIPF 
TDFTAAKPTP STVKRDYLLD GVTGAAVKTL QSELKQAGFL LSVDGVFGKG 
TETAVKAFQR ANGLAVDGVF GTGSQAKLNA ILANLNKKPA VKPAAPTKPR 




Chapter 4: PlyM7 
GenBank Accession Number: HM011595 
1071 base pairs; 356 amino acids; 38.53 kDa; Theoretical pI = 9.41 
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520) 
PG-1 binding domain (PF01471)  
ATGGCAAAAT TATATAACGA ACCAGGACAC GGCGTAAACA CATGGCCGCC 
AAGCAAAGGG ACGCGCGCAA GTGGTGGCGT TCCCGAAATG GCGGAACATG 
ATTTTAATTC AGCTGTAGCA GATGAAGTGA ATCGCCTGTT AAGTGGCAAG 
CTAACGACTT ATAGCGCGCA GCCTAGTCGC GGCAAGGATG TTTCGCTAAC 
GACGCGCACA CGCCTATATA ATGAAGAGTT TCGCAAAGAT AAGAGCGCAA 
TCGGCTTCTC GCATCACGGA AATGCCAACG CTAACAAAGC GACAAAAGGA 
TTCGGCGTAT TCTACTGGGG CGGATCGGCA ACGGGTAAGA AGTTAGCGCA 
AATGCTACTC GCGGCGTATA AAAAAGAACT CCCTGGCTAT CCGATTTGGG 
GCAGCGGGAT TTTTGAAAGC AAACGCGGCG ACTGGACCAA CTTCGCTATC 
TTGCGTGATA CGTCAGCGCC TTTTGTATTA ATCGAGTGGG ATTTCTTTAC 
GAACGATGAA GCGCGCAAAC GGATGCTATC CACAGATTAT AGAAAGCGTT 
GCGGTAAAGT GGCAGCGAGT GTTGCGTGTG ATTGGTACGG CATTCCGTTT 
ACTGATTTCA CTGCAGCTAA ACCTTCGCCG TCCACAGAGA GAGACTACCT 
ATTAGATGGC GATACAGGCG CAGCGGTTAA AACGCTACAA AGCGAATTGA 
AGCAAGCGGG TTTCTTACTA TCTGTGGATG GCATATTCGG AAAAGGCACA 
GAGACAGCGG TTAAGGCGTT CCAACGTGCG AATGGATTAG CAGTTGATGG 
TGTTTTCGGA ACAGGCTCAC AGGCTAAACT CGACGCAATA CTGGCTAATC 
TGAATAAGAA GCCGGTAGTT AAGCCTGCAG CGCCAACAAA ACCAAAGGAG 
GAATCCACAG TGGAGAAAAC AAACCAACCC TCAAAATGGG CAGAGGCGAC 
GATTAAAGAA GCGGTGAAGA TTGGCGTTAC GGATGGCAGC AACTTACACG 
ATCCAGTTAC ACGACAGGAG GCAATTGTGC TGGCGATGCG TGCTGCAGGA 
CTTGCGCCAA AACTTAAGTA A 
 
MAKLYNEPGH GVNTWPPSKG TRASGGVPEM AEHDFNSAVA DEVNRLLSGK 
LTTYSAQPSR GKDVSLTTRT RLYNEEFRKD KSAIGFSHHG NANANKATKG 
FGVFYWGGSA TGKKLAQMLL AAYKKELPGY PIWGSGIFES KRGDWTNFAI 
LRDTSAPFVL IEWDFFTNDE ARKRMLSTDY RKRCGKVAAS VACDWYGIPF 
TDFTAAKPSP STERDYLLDG DTGAAVKTLQ SELKQAGFLL SVDGIFGKGT 
ETAVKAFQRA NGLAVDGVFG TGSQAKLDAI LANLNKKPVV KPAAPTKPKE 




Chapter 4: PlyM8 
GenBank Accession Number: HM011596 
1074 base pairs; 357 amino acids; 38.72 kDa; Theoretical pI = 9.62 
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520) 
PG-1 binding domain (PF01471) 
ATGGCGAAAT TATATAACGA ACCAGGGCAC GGCGTAAACA CATGGCCGCC 
AAGCAAAGGG ACGCGCGCAA GTGGCGGCGT TCCCGAAATG GCGGAACATG 
ATTTTAACGC AGCGGTAACA GATGAAGTGA ATCGCCTGTT AAGCGGCAAG 
CTAACGACTT ATAGCGCGCA GCCGAGTCGC GGCAAGGATG TTTCGCTAAC 
GACGCGTACA CGCCTATATA ATGAAGAGTT TCGCAAAGAT AGAAGCGCAA 
TCGGTTTTTC TCACCACGGA AACGCCCATG CCAACAAAGC GACAAAAGGA 
TTCGGCGTAT TCTACTGGGG CGGATCTGCA ACGGGTAAGA AGTTGGCGCA 
AATGCTACTC GCGGCGTATA AAAAAGAATT CCCTGGTTAT CCAATTTGGG 
GCAGTGGGAT ATTCGAAAGC AAGCGCGGCG ACTGGACAAA CTTTGCAATT 
CTGCGCGACA CATCAGCGCC TTTCGTATTA ATCGAGTGGG ATTTCTTTAC 
GAATGATGAA GCGCGCAAAC GGATGCTATC CACAGATTAC AGAAAGCGTT 
GCGGTAAAGT GGCAGCGAGT GTCGCGTGCG ATTGGTACGG TATTCCGTTT 
ACTGATTTTA CAGCAGCGAA ACCTACGCCT TCCACAGTGA AGAGAGATTA 
CCTACTACTT GACGATACCG GCGCAGCGGT TAAAACGCTA CAAAGCGAAT 
TGAAACAAGC AGGTTTCTTA CTATCTGTGG GTGGCATATT TGGTAAAGGT 
ACAGAGACAG CGGTTAAGGC GTTCCAACGT GCGAATGGAT TAGCAGTTGA 
TGGCGTGTTC GGAACAGGCT CACAGGCTAA ACTCAACGCA ATACTGGCGA 
ATCTGAATAA GAAGCCGGTA GTTAAGCCTG CAGCGCCAAC AAAACCAAAG 
GAGGAATCCA CAGTGGAGAA AACAAACCTA CCCTCAAAAT GGGCAGAAGC 
TACGATTAAA GAAGCGGTGA AGATTGGCGT TACCGATGGC AGTAACTTAC 
ACGATCCGGT CACAAGACAG GAGGCAATTG TGCTGGCGAT GCGTGCTGCG 
GGACTCGCGC CAAAACTCAA GTAG 
 
MAKLYNEPGH GVNTWPPSKG TRASGGVPEM AEHDFNAAVT DEVNRLLSGK 
LTTYSAQPSR GKDVSLTTRT RLYNEEFRKD RSAIGFSHHG NAHANKATKG 
FGVFYWGGSA TGKKLAQMLL AAYKKEFPGY PIWGSGIFES KRGDWTNFAI 
LRDTSAPFVL IEWDFFTNDE ARKRMLSTDY RKRCGKVAAS VACDWYGIPF 
TDFTAAKPTP STVKRDYLLL DDTGAAVKTL QSELKQAGFL LSVGGIFGKG 
TETAVKAFQR ANGLAVDGVF GTGSQAKLNA ILANLNKKPV VKPAAPTKPK 




Chapter 4: PlyM9 (Truncated) 
GenBank Accession Number: HM011597 
1029+ base pairs; 343+ amino acids; 37.2+ kDa 
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520) 
PG-1 binding domain (PF01471) 
ATGGCAAAAT TATATAACGA ACCAGGACAC GGCGTAAATA CATGGCCGCC 
AAGCAAAGGG ACGCGCGCAA GTGGTGGCGT TCCTGAAATG GCGGAACATG 
ATTTTAACGC AGCGGTAGCA GATGAAGTGA ATCGCCTTTT AAGCGGCAAG 
CTAACGACTT ATAGCGCACA GCCGAGTCGC GGCAAGGATG TTTCGCTAAC 
GACGCGCACA CGCCTTTACA ACGCTGAATA CAGCAAAGAC AGAAGCGCAA 
TCGGTATGTC ACATCACGGA AACGCCCACG CCCACAAAGC AACAAAAGGT 
TTCGGCGTAT TCTATTGGGG CGGATCTACC ACAGGTAAGA AGTTGGCGCA 
AATGCTACTC GCGGCGTATA AGAAAGAATT CCCTGGCTAT CCGATTTGGG 
GCAGCGGGAT ATTCGAAAGT AAGCGCGGAG ACTGGACTAA CTTTGCAATC 
CTGCGCGATA CATCAGCGCC TTTTGTATTA ATTGAGTGGG ATTTCTTTAC 
GAATGATGAA GCGCGGAAAC GTATGCTGTC CACAGATTAT AGAAAGCGTT 
GCGGTAAAGT GGCAGCGAGT GTCGCGTGTG ATTGGTACGG TATTCCGTTT 
ACTGATTTTA CAGCAGCGAA ACCTACGCCT TCCACAGAGA AGAGAAACTA 
CCTATTAGAT GGCGATACAG GCGCAGCGGT TAAAACGCTA CAAAGCGAGT 
TGAAGCAAGC AGGTTTCTTA CTATCTGTGG ATGGCATATT CGGAAAAGGC 
ACAGAGACAG CGGTTAAGGC GTTCCAACGT GCGAATGGAT TAGCGGTTGA 
TGGCGTGTTC GGAACAGGCT CACAGGCTAA ACTCAACGCA ATACTGGCTA 
ATTTGAATAA GAAGCCGGTA GTTAATCCTG CAGCGCCAAC GAAACCAAAG 
GAGGAATCCA CAGTGGAGAA AACAAACCAA CCCTCAAAAT GGGCAGAAGC 
GACGATTAAA GAAGCAGTTA AGATTGGCGT TACCGATGGC AGCAGCTTAC 
ACGATCCAGT CACAAGACAG GAAGCAATT… 
 
MAKLYNEPGH GVNTWPPSKG TRASGGVPEM AEHDFNAAVA DEVNRLLSGK 
LTTYSAQPSR GKDVSLTTRT RLYNAEYSKD RSAIGMSHHG NAHAHKATKG 
FGVFYWGGST TGKKLAQMLL AAYKKEFPGY PIWGSGIFES KRGDWTNFAI 
LRDTSAPFVL IEWDFFTNDE ARKRMLSTDY RKRCGKVAAS VACDWYGIPF 
TDFTAAKPTP STEKRNYLLD GDTGAAVKTL QSELKQAGFL LSVDGIFGKG 
TETAVKAFQR ANGLAVDGVF GTGSQAKLNA ILANLNKKPV VNPAAPTKPK 




Chapter 4: PlyM10 (Truncated) 
GenBank Accession Number: HM011598 
848+ base pairs; 282+ amino acids; 30.7+ kDa 
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520) 
PG-1 binding domain (PF01471) 
ATGGCAAAAT TATATAACGA ACCAGGACAC GGCGTAAACA CATGGCCGCC 
AAGCAAAGGG ACGCGCGCAA GTGGTGGCGT TCCCGAAATG GCGGAACATG 
ATTTTAACGC AGCGGTAGCA GATGAAGTAA ATCGCCTGTT AAGCGGCAAG 
CTAACGACTT ATAGCGCACA GCCTAGTCGC GGCAAGGATG TTTCGCTAAC 
GACGCGCACA CGCCTATATA ATGAAGAGTT TCGCAAAGAT AAGAGCGCAA 
TTGGCTTCTC ACATCACGGA AACGCTAATT CCAACAAAGC GACAAAAGGT 
TTCGGCGTAT TCTATTGGGG TGGATCTGCA ACGGGTAAGA AGTTGGCGCA 
AATGCTACTC GCGGCGTATA AGAAAGAATT CCCTGGCTAT CCGATTTGGG 
GCAGCGGGAT ATTCGAAAGT AAGCGCGGCG ACTGGACCAA CTTCGCTATC 
TTGCGTGATA CGTCAGCGCC TTTCGTGTTA ATCGAGTGGG ATTTCTTTAC 
GAATGACGAA GCGCGCAAAC GGATGCTATC CACAGATTAT AGAAAGCGTT 
GCGGTAAAGT GGCAGCGAGT GTCGCGTGTG ATTGGTACGG GATTCCGTTT 
ACTGATTTCA CAGCAGCGAA ACCTTCGCCG TCCACAGAGA GAGACTACCT 
ATTAGATGGC GATACAGGCG CAGCGGTTAA AACGCTACAA AGCGAATTGA 
AACAAGCGGG TTTCTTACTA TCTGTGGATG GCATATTCGA TAAAGGTACA 
GAGACAGCGG TTAAGGCGTT CCAACGTGCG AATGGATTAG CCGTTGATGG 
CGTGTTCGGA ACAGGCTCAC AGGCTAAACT CAACGCAATA CTGGCTTA… 
 
MAKLYNEPGH GVNTWPPSKG TRASGGVPEM AEHDFNAAVA DEVNRLLSGK 
LTTYSAQPSR GKDVSLTTRT RLYNEEFRKD KSAIGFSHHG NANSNKATKG 
FGVFYWGGSA TGKKLAQMLL AAYKKEFPGY PIWGSGIFES KRGDWTNFAI 
LRDTSAPFVL IEWDFFTNDE ARKRMLSTDY RKRCGKVAAS VACDWYGIPF 
TDFTAAKPSP STERDYLLDG DTGAAVKTLQ SELKQAGFLL SVDGIFDKGT 




Chapter 4: PlyM11 
GenBank Accession Number: HM011599 
1071 base pairs; 356 amino acids; 38.52 kDa; Theoretical pI = 9.45 
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520) 
PG-1 binding domain (PF01471) 
ATGGCGAAGT TATATAACGA ACCAGGACAC GGCGCTAACA CATGGCCGCC 
AAGTAAAGGG ACGCGCGCAA GTGGTGGCGT TCCTGAAATG GCGGAGCATG 
ATTTTAACGC AGCGGTAGCA GATGAAGTTA ATCGCCTGTT AAGCGGAAAG 
CTAACGACTT ATAGCGCACA GCCTAGTCGC GGCAAGGATG TTTCGCTGAC 
GACGCGCACA CGCCTATATA ATGAAGAGTT TCGCAAAGAT AAGAGCGCAA 
TTGGCTTCTC ACATCACGGA AATGCTAATG CTAACAAAGC GACAAAAGGA 
TTCGGCGTAT TTTATTGGGG CGGATCGGCA ACGGGTAAGA AGTTAGCGCA 
AATGCTACTC GCGGCGTATA AAAAAGAATA CCCTGGCTAT CCGATTTGGG 
GCAGCGGAAT ATTCGAAAGT AAACGCGGCG ACTGGACAAA CTTTGCAATT 
CTGCGCGACA CATCAGCGCC ATTTGTATTA ATCGAGTGGG ATTTCTTTAC 
GAATGATGAA GCGCGTAAAC GGATGCTATC CACAGATTAT AGAAAGCGTT 
GCGGTAAAGT GGCAGCGAGT GTCGCGTGTG ATTGGTACGG AATTCCGTTT 
ACTGATTTTA CAGCAGCGAA ACCTACGCCT TCCACAGAGA GAGACTACCT 
ATTAGATGGC GATACCGGCG CAGCGGTTAA AACGCTACAA AGCGAATTGA 
AACAAGCGGG TTTCTTACTA TCTGTGGATG GCATATTCGG AAAAGGCACA 
GAGACAGCGG TTAAGGCGTT CCAACGTGCG AATGGATTAG CCGTTGATGG 
CGTGTTCGGA ACAGGCTCAC AGGCTAAACT CAACGCAATA CTGGCTAATT 
TGAATAAGAA GCCGGTAGTT AAGTCGGCAG CGCCAACAAA ACCAAAGGAG 
GAATCCACAG TGGAGAAAAC AAACCAACCA TCAAAATGGG CAGAAGCGAC 
GATTAAAGAA GCCGTTAAGA TTGGCGTTAC GGATGGCAGC AGCTTACACG 
ATCCAATTAC ACGACAGGAA GCAATTGTGC TGGCGATGCG TGCTGCAGGA 
CTTGCACCAA AACTTAAGTA A  
MAKLYNEPGH GANTWPPSKG TRASGGVPEM AEHDFNAAVA DEVNRLLSGK 
LTTYSAQPSR GKDVSLTTRT RLYNEEFRKD KSAIGFSHHG NANANKATKG 
FGVFYWGGSA TGKKLAQMLL AAYKKEYPGY PIWGSGIFES KRGDWTNFAI 
LRDTSAPFVL IEWDFFTNDE ARKRMLSTDY RKRCGKVAAS VACDWYGIPF 
TDFTAAKPTP STERDYLLDG DTGAAVKTLQ SELKQAGFLL SVDGIFGKGT 
ETAVKAFQRA NGLAVDGVFG TGSQAKLNAI LANLNKKPVV KSAAPTKPKE 





Chapter 4: PlyM12 
GenBank Accession Number: HM011600 
1017 base pairs; 338 amino acids; 37.39 kDa; Theoretical pI = 9.36 
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510) 
Additional conserved domain of unknown function DUF 3957 (PF12200) 
PG-1 binding domain (PF01471); PG-3 binding domain (PF09374) 
**NOTE: The above binding domains show only low homology to the consensus 
sequences for PG-1 and PG-3, with respective E-value scores of 0.0045 and 
0.0056. 
ATGGTAGCAT TAAATTATAA GAAAGATTAC GTAATTAAAA ATAAATACTC 
ACGCCCTGGG TTGAAGCTAC TTGGCGTAAG GGCTATCGTT CTACACTACA 
CGGCTAGTCC GGGAGGTTCC GCGCAAAACC ACCAAGACTT CTTCGATGGG 
GCTGACGGAG GCGCCTACCG TTACGCAGGG GCGCACATAT TCGTAGATAA 
AAAGGAAGCA ATCGAGATCA TCCCGTTAAA CGAGGTTGCA TATCACGCCA 
ACGAGAGGTC GCCTAAACTG TCGTACCTAC GGGCGTCAAC GTCTTCTTAC 
AACGGAAATG CGAACCTAAC AACGATCGGC ATCGAGATGT GTATCGAAAA 
AGACGGATCC TTCCACCCGG ACACTGTCGA GCGTACAGCG CTAGTAGTCG 
AGAAGCTACG TAAACAGTTC GGCAAAGTCC CTGTAATCCG TCACTACGAT 
GTAACAGGCA AGATCTGCCC GAAACCTTTC GTAGAGGACG TATCTGCGTG 
GAAGGCGTTC TTAAAGCGCT TAGACGGTGG CGTTACGGTC AAGCCTGCGC 
CTAAAACCGA AGTTAAGGCC GTGTCCACAG AAAAAGAATA CACGAGCATC 
GTCGAGTATC TGAAAGATCT CGGAAAACCT TACTCGTTCT CTTACCGTAA 
AGAACTAGCG AAGGATTACG GGATCACTAA TTACGAAGGT TCAGCAGCGC 
AAAACCTAGA GTTGCTCGAT CTTCTCCAAA ACGGAAGACC GAAAGCCAAC 
CTGACGGTAG ACGGTTACTT CGGACCGGCA ACGATAAAAG CATTACAGCG 
TTACTTCGGT ACCCCGGTTG ACGGCGTAAT CAGCGAACCT TCGTTGGTTG 
TAAAAGCCCT GCAGGGGTTA CTAGACGTGA GACAAGACGG TTACATGGGT 
CCAATCACGA TCAAGGCGTT ACAGAAACGT TTCGGCACTC CGGTTGACGG 






MVALNYKKDY VIKNKYSRPG LKLLGVRAIV LHYTASPGGS AQNHQDFFDG 
ADGGAYRYAG AHIFVDKKEA IEIIPLNEVA YHANERSPKL SYLRASTSSY 
NGNANLTTIG IEMCIEKDGS FHPDTVERTA LVVEKLRKQF GKVPVIRHYD 
VTGKICPKPF VEDVSAWKAF LKRLDGGVTV KPAPKTEVKA VSTEKEYTSI 
VEYLKDLGKP YSFSYRKELA KDYGITNYEG SAAQNLELLD LLQNGRPKAN 
LTVDGYFGPA TIKALQRYFG TPVDGVISEP SLVVKALQGL LDVRQDGYMG 




Chapter 4: PlyM13 
GenBank Accession Number: HM011601 
699 base pairs; 232 amino acids; 25.07 kDa; Theoretical pI = 9.52 
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520) 
SPOR binding domain (PF05036)  
ATGGCGAAAA GGAAAGTATA TATTGATTTA GGGCACGAAG GCGACGGAAA 
GGGAATGGAT CCTGGAGCAG TTGCCAATGG GTTGAAAGAA GCTAATGTTG 
TTTTAGAGAT TGGGAAGTAT ATGAAAGATA TGTTTGCCAA CTATGAGAAT 
GTAGAAGTGA AGTTTTCAAG ATTGGCAAAT AAAAATCTTT CTTTAAATCA 
GCGCACGAAT GAAGCTAATG CCTGGGGTGC TGATGTTCTC TGTTCAATCC 
ATATTAATGC AGGCGGCGGT AAAGGGTTTG AATCCTTCAT ATATCCAGGT 
GCAGGATCAG CAACGCAGGC TTTCCAAAAT GCTGTTCATG CCAAGATTAT 
GGGAACAGGG GTATTCACGA CAGACAGAGG GAAGAAAAAG GCGAATTTCC 
ATATGTTAAG AGAATCTAAA ATGACCGCAA TCTTAACCGA AAATGGGTTC 
ATTGATAACG GTACAGACGC AGCAACTTTG AAAAACAGAG CAAAGTTAAT 
CGCTATAGCT TCAGGTCATG TGGAGGGAGT AGCTTCTTTC CTTAACCTTA 
AAAAGAAACC TGTTTCTAAA CCAGAGCCGA AACCATCTGG TAAGTTATAC 
AAAGTTCAAG TAGGTGCTTT CTCTGACCGA AAGAACGCTG ACAACTTAGC 
TGCTGAACTA AAGAAAATAG GCTATTCAAC TTATATTGTT CACGAATAA 
MAKRKVYIDL GHEGDGKGMD PGAVANGLKE ANVVLEIGKY MKDMFANYEN 
VEVKFSRLAN KNLSLNQRTN EANAWGADVL CSIHINAGGG KGFESFIYPG 
AGSATQAFQN AVHAKIMGTG VFTTDRGKKK ANFHMLRESK MTAILTENGF 
IDNGTDAATL KNRAKLIAIA SGHVEGVASF LNLKKKPVSK PEPKPSGKLY 




Chapter 4: PlyM14 
GenBank Accession Number: HM011602 
792 base pairs; 263 amino acids; 28.8 kDa; Theoretical pI = 9.78 
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520) 
SPOR binding domain (PF05036) 
ATGACGAAGA TAATCGCTAT CGACGCTGGC CACGGACTTA ATACTCCGGG 
CAAACGTACG CCGGATAATG AGCGCGAATG GTCGTTTAAT AATAAGGTCA 
CACTAGCCGC GATTAAGTAT TTGAACGATT ATGAAGGCGT TAAAATCGTA 
AGACTCGACG ATCCGACCGG TAAATCGGAC GTACCTTTAA AAGCGCGCAC 
CGACAAGGCG AATAAGGCGA AGGCTGACGT ACTAGTGTCG ATTCATCATA 
ATGCGCTCAC GGGCAAGTGG GGAACGCACG GCGGTACGGA AGTATTTACG 
TATCTCGGAA ACTGGCCGGA CGCGGAAAGG CTGGCGAAGT TAGTACTCGA 
TCGTATCCTA AAAGCTTACG GATTAAAGAG TCGCGGACTA AAGAAGGCTA 
ACTTCCACAT GGTACGCGAG AGCGCTATGC CTGCGATATT AATCGAAGGA 
GGCTTCATGG ACTCGACCGT CGATATTAAG AAGATGCGCG ACGATAAAGT 
CCTCGATGAA GCCGGCAAAG CTATCGCGGA AGCACTGGCG GTCTACTTCG 
GATTAAAGAA GAAGAAACCC GCAGCACCTT CGAAACTGTA TCGCGTACAA 
ATCGGAGCTT ATTCGGTAAA AGCGAACGCT GACGCACAAG CTGCGAAAGC 
TAAACGCGCA GGCTATTCGC CATATATCGC ACGCGAAGGC GGACTTTACA 
AAGTTCAAAT CGGAGCTTAT TCCGTCAAAG CGAACGCCGA TAAAATGGCA 
TCGGAATTGA AGCGCAAAGG CTTCAACGTA TATATTGCGT AA 
 
MTKIIAIDAG HGLNTPGKRT PDNEREWSFN NKVTLAAIKY LNDYEGVKIV 
RLDDPTGKSD VPLKARTDKA NKAKADVLVS IHHNALTGKW GTHGGTEVFT 
YLGNWPDAER LAKLVLDRIL KAYGLKSRGL KKANFHMVRE SAMPAILIEG 
GFMDSTVDIK KMRDDKVLDE AGKAIAEALA VYFGLKKKKP AAPSKLYRVQ 





Chapter 4: PlyM15 
GenBank Accession Number: HM011603 
693 base pairs; 230 amino acids; 25.71 kDa; Theoretical pI = 9.17 
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520) 
SPOR binding domain (PF05036)  
ATGAGCAAAT GGATTCAAGA TGCAGGACAC GGAGGAAAAG ACCCTGGCGC 
AGTTACGAAA GGAAATACCG AAAAAGTTTA CACTCTTGAA GCTGCACTTT 
ATGTAGACAA GCGTCTGGAT GAATTAGGGA TTAAAAGTGA TGTGACTCGT 
TCAAGTGATG TTACGTTAGA TCAAGGCCCG CGTACTGGAA AAGTTAAAGC 
TTTCGACAAG TGTATTTCTC ACCACTTTAA CGCAGGGGGC GGTAGTGGTT 
TTGAAGCAAT TCATTCTATC TACTCAAACG GGAAGTTTGA ACACCTAATT 
GCAGAAGAAT TTAAAAAAGC GGGATATCCA GTGCGACCTC GTTCAGTGTA 
TTTTAAAAAA TACGGAAACA ACGATTATTA CTACATGCAC CGCCAAACAG 
GTAAATGTCG GACTACGATT GTAGAATATG ACTTTGTGGA CGGTCCGCAA 
TCTGAAAAGA TTAAGGATAA AGCCTATCGT GAAGGCATGT ATGAATGTGT 
AGTGCGAGCC ATTTGCCGTG ATGAAGGGGT AACATATAAA GCGCCTAATC 
AACCTAAACC ACAATCTAAA CCATCTAATA AAGGCGGATT ATACAAGGTG 
CAAGTAGGTG CATTTTCGGA TAAATCAAAC GCAGATAAAC TTGCAGCAGA 
TCTAAAGAAA AAAGGCTACA GCACCTATAT TGTACAGGAA TAA 
 
MSKWIQDAGH GGKDPGAVTK GNTEKVYTLE AALYVDKRLD ELGIKSDVTR 
SSDVTLDQGP RTGKVKAFDK CISHHFNAGG GSGFEAIHSI YSNGKFEHLI 
AEEFKKAGYP VRPRSVYFKK YGNNDYYYMH RQTGKCRTTI VEYDFVDGPQ 
SEKIKDKAYR EGMYECVVRA ICRDEGVTYK APNQPKPQSK PSNKGGLYKV 




Chapter 4: PlyM16 
GenBank Accession Number: HM011604 
702 base pairs; 233 amino acids; 26.15 kDa; Theoretical pI = 8.98 
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520) 
SPOR binding domain (PF05036) 
ATGAGTGAAA AGTGGAAAAA CGATGGTGGT CATGGCGGTA CAGATCCCGG 
AGCGGTTGCC AATGGTATCA AGGAAAAGGA ATACACGCTT GAAGCGGCTT 
TATATGTAGA CAAGCGTTTA AAGGAGCATG GTATTGACTC AGGACTCACA 
AGAGATAAAG ACATCACCCT TGAACCAAAC GCGCGTACTG CGGTTGTCAG 
AGCTTCTAAA GCACCATTCG GATTAAGTCA CCATTACAAT GCCGGCGGTG 
GTGCCGGTGC AGAGTTCATC CATTCCATTC ATTCTGATGG CAAGTTTGAA 
AACATGCTTG CTGATGAATT TAAAAGAGCC GGTTATCCTG TTCGTAGAGT 
ATTCTGCAAA GCTGGCAAAA ACCCGGCAAA GGACTATTAC TACATGCACA 
GGGAAACGGG CTTTTGCAGA ATGACGATTG TGGAATATGA TTTTGTTGAC 
GGCCCGAACG CTGAAAAGCT GAAAGACCGT AAATATCGCG AGTGTATGTA 
TGAGTGCGTA GTGAGGGCTG TATGTCGTCA GGAAGGGAAA GCCTATAAAC 
CTGTCGAGCA ACCGAAACTA AAGCCACAGG AAGCCCCTAA GAAGGGATTA 
TACAAGGTTC AAGTGGGCGC ATTCGGCGAT AAATCAAATG CTGACCGACT 
CGCCAAAGAA TTAGAGGGCA AAGGGTATAA AACGTATATT GTGCAGGAGT AA 
 
MSEKWKNDGG HGGTDPGAVA NGIKEKEYTL EAALYVDKRL KEHGIDSGLT 
RDKDITLEPN ARTAVVRASK APFGLSHHYN AGGGAGAEFI HSIHSDGKFE 
NMLADEFKRA GYPVRRVFCK AGKNPAKDYY YMHRETGFCR MTIVEYDFVD 
GPNAEKLKDR KYRECMYECV VRAVCRQEGK AYKPVEQPKL KPQEAPKKGL 





Chapter 4: PlyM17 
GenBank Accession Number: HM011605 
771 base pairs; 256 amino acids; 28.98 kDa; Theoretical pI = 8.86 
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510) 
No recognized binding domain 
ATGTACCAAA TCACAAGGGA TTACATTAAA TTCGGTAATT CTCGATGCGG 
GCAACAAATT AAGAAAGTGT TGTTTATCGT AAGCCATGAC ACAGGGAATC 
CTGGTAGTAC AGCATACGGG AATCGAAATT ACTTTAATAA TCAACAACCT 
AGTGCGTCAG CCCACACGTT CATTGATGAT AAATACATTT TGGAGATCAT 
CCCTATCTAT GAGAAAGCAT GGCACGTACA GTATCAAAAA CCAAAAGATA 
ATCAAATGTT TGGTGATGAT GCGAATGATG CAGCTATCGG GGTTGAACTT 
TGTTGGGGGA ATGGTATCAA CTTCAATGAA GCATACAAGC GTTTTGTGTG 
GTATCATGCT CATCTTTGTA AGACATTTAA ACTCAATCCT AGAAAGCACA 
TCGTATCTCA TAAGACATTG GATCCAGAAC GTAAAGTAGA CCCGATAGAC 
TGCTTTAAAC GTCATGGTAT TACATGGGAA CAATTCATAA ATGATGTAGA 
AAATGTGTTT GTAGGGAAAA AGGAGGAAAA TGATATGTTA GAAAAAGCGA 
TTCTAATAGG TGGATTCCCT GATTTTGCAG TAGCGGAGAT ATTAGCAGCA 
CGATTAAAAG CACCTATCTA CACTCGTGAT GCTTATCCGG GTGGAAAGGT 
TACAAAAGAA TTATTTGTAG TCGGTGGTTC TACCGCAGGC CTACAAGCAG 
ACAAAGTAAT CAATCTATCC GGAAAAGACC GATTTGCTGT TGCTGCAGCA 
GTTAAAAAGT TTATCGGATA A 
 
MYQITRDYIK FGNSRCGQQI KKVLFIVSHD TGNPGSTAYG NRNYFNNQQP 
SASAHTFIDD KYILEIIPIY EKAWHVQYQK PKDNQMFGDD ANDAAIGVEL 
CWGNGINFNE AYKRFVWYHA HLCKTFKLNP RKHIVSHKTL DPERKVDPID 
CFKRHGITWE QFINDVENVF VGKKEENDML EKAILIGGFP DFAVAEILAA 





Chapter 4: PlyM18 
GenBank Accession Number: HM011606 
762 base pairs; 253 amino acids; 28.71 kDa; Theoretical pI = 7.77 
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510) 
LysM binding domain (PF01476) 
ATGTTGACGG TCCAGCAGAT CATCCGGCAG GGTGGCAAGA GATTGATTAG 
CCACCCCAGC GACTATCAGG TCGCTTTTTT AATGGAGATT TTTATGGCAT 
ACGAATTGAG AGACAATAGA CGCTCTACCT ACCTGGCTAA AGGCAGAGCC 
AATACAGCGA TTGACGTCAT TGTTATCCAT CACTGGGGTG TTGACGGTCA 
AAATTGGGAG AACTTAACCA CCTACACGGC CAATAACCGC AATATGAGTA 
CCCATTACGT TGCCATGGCT GGCAAGGTCG AGCGACAGGT GGACGAGGAG 
GATACGGCTT ACCATGGTGG CAATCCACCG ATCAATCAAC GCTCTATCGG 
CATTGAGTGC CGTCCAGAAG CCACAGACGG CGATTACGAC ACAGTGGCTG 
AGCTGGTGGC TGATATCTGG AACAGGCACG GCAAGCTACC CTTGGTCGGC 
CATAAGCAAG TGCCATCCGT CAGGCCGGGT CAGCAATACG TGGCGACAAG 
CTGCCCGGGC AGATACGATG TGGAGCGGAT CCGTAAAGAA GCGGAGGGTT 
GGTACACGAA GAAGTACGCC AAGAAGGACA GCGACGCACG ACCTAAGACG 
CACACGGTCG TGAGTGGCGA ATCCTACTGG AGTATTGCAG CCAAGTACCT 
AGGCGATGGC ATGAGGTACA CAGAAATATT AGACCTGAAC AAGGTCAAAG 
ATCCGAGTGC CTTATTAGTC GGACAGGTCT TGGAACTGCC TGAAAAGTAC 
GCTAAGCACT GA 
 
MLTVQQIIRQ GGKRLISHPS DYQVAFLMEI FMAYELRDNR RSTYLAKGRA 
NTAIDVIVIH HWGVDGQNWE NLTTYTANNR NMSTHYVAMA GKVERQVDEE 
DTAYHGGNPP INQRSIGIEC RPEATDGDYD TVAELVADIW NRHGKLPLVG 
HKQVPSVRPG QQYVATSCPG RYDVERIRKE AEGWYTKKYA KKDSDARPKT 




Chapter 4: PlyM19 
GenBank Accession Number: HM011607 
819 base pairs; 272 amino acids; 29.1 kDa; Theoretical pI = 7.05 
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520) 
SH3-Type 5 binding domain (PF08460) 
ATGGGTACAT ATAACGTTCA TGGTGGTCAC AACTCTATCG TACAAGGTGC 
TAACTGGGGT GCTCGTAAAG AACACGTTAT GGATCGCCAA GTAAAAGATG 
CTTTAATTAG CAGGCTACGT AGCCTTGGTC ACACAGTTTA TGACTGCACA 
GACGAAACAG GTTCTACGCA ATCTGCTAAC TTACGTAACA TCGTAGCTAA 
ATGTAATGCT CACCGAGTAG ACTTAGGCAT TTCGTTACAC TTAAACGCAT 
ACAATGGTTC TGCTAACGGA GTAGAGGTTT GCTATTCCGA CCAACAAGCG 
TTAGCTGCTA AAGTTTCTAA GCAATTGTCT GACGACATCG GATGGTCTAA 
CCGAGGAGCT AAACCTCGTA CAGACCTTTA CGTACTAAAC AGCACATCTG 
CACCTGCTAT CCTAATCGAG TTAGGTTTCA TCGATAACGA GGGCGATATG 
GGTAAATGGA ACGTGGATAA AATCGCAGAC TCCATCTGCT ATGCTATCAC 
GGGTCAACGT GCAGGTTCTA CAGGTGGAAA CACAGGTGGA GGTTCTACAG 
GCGGAAGCAC TGGTGGTGGA TACGACTCTA GTTGGTTCAC TCCACAAAAT 
GGTGTATTCA CAGCTAACAC AGCAATCAAA GTTAGAAGCG AACCAAGTGT 
AAATGCAACT CATCTTCGTA CTCTGTACAG TGGCGGCACA TACAAGTACA 
CTTCATTCGG AATGGAGAAA GACGGTTACG TTTGGATCAA GGGAGCAGAC 
GGTACATACG TTGCAACAGG GGAAACTCGT GACGGTAAAC GTATCTCTTA 
CTGGGGTTCT TTCGAGTAA 
MGTYNVHGGH NSIVQGANWG ARKEHVMDRQ VKDALISRLR SLGHTVYDCT 
DETGSTQSAN LRNIVAKCNA HRVDLGISLH LNAYNGSANG VEVCYSDQQA 
LAAKVSKQLS DDIGWSNRGA KPRTDLYVLN STSAPAILIE LGFIDNEGDM 
GKWNVDKIAD SICYAITGQR AGSTGGNTGG GSTGGSTGGG YDSSWFTPQN 
GVFTANTAIK VRSEPSVNAT HLRTLYSGGT YKYTSFGMEK DGYVWIKGAD 





Chapter 4: PlyM20 
GenBank Accession Number: HM011608 
909 base pairs; 302 amino acids; 33.34 kDa; Theoretical pI = 8.81 
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510) 
SPOR binding domain (PF05036) 
ATGGCTTATA CGAACAGTCC TTTGGTGGAC TACACGAAAC TGAGTCCCAA 
TCATTCGGGA CAGAGAAACC ACGCTATTGA CACCATCACA ATCCATTGTG 
TAGTAGGTCA ATGCTCGGTA GAGACTCTTG GAGAGATTTT CGCACCTACT 
TCGAGACAGG CATCTTCCAA CTACGGCGTA GGCGTGGATG GTCGAATCGG 
AATGTATGTT GAAGAGAAGA ATCGTTCTTG GTGTACTTCT TCTGCATCCA 
ACGACCACAG AGCAATCACC ATTGAGGTTG CAAGTGATAC CACCGAACCT 
TATGCGGTAA ACGACAAAGC GTATGCCGCA ATGCTCGACC TTGTAACCGA 
TATTTGCAAG AGAAATGGTA TCAAGAAGTT GGTATGGTCT ACCAACAAAT 
CCGACAGAGT GAATCACAAA AACGGATGCA ATATGACCGT TCACAGAGAC 
TATGCGAATA AGTCCTGTCC CGGCAAGTAT CTGTATGACC GCCATCAGCA 
GATTGCAGAT GAGGTCAACA AGAGATTGAA TGGTGCAAAT GAGGAGGGAA 
GCAAGGTGCT ATACAAGGTA CAAATCGGTG CTTACTCTAA GGTAGAGAAC 
GCCGAAAAGC AGTTAGAGAA AGCAAAGGCA GCAGGTTTCA CCGATGCTTT 
TATCGTTAAG ACTGTCGTAG AAAATGAACC TGCGAAGCAA GAACCCCCGA 
AAGAACCCGA AGTGGTTTTA GCCGTTGGCG ATAAGGTCAA GATGGCTAAG 
GATGCTCCTG TTTATGGAAA GACCACTAAG TTTCAGTCTT GGGTTTATGA 
CTCTGTGCTT TATGTTCGTG AAATCAACGG CTCTCGTGTG GTTATTTCCA 
CCTTGAAGAC AGGTGCAGTA ACGGGTGCAG TTGACAAGAA ATATCTTACC 
AAAGTATAA 
 
MAYTNSPLVD YTKLSPNHSG QRNHAIDTIT IHCVVGQCSV ETLGEIFAPT 
SRQASSNYGV GVDGRIGMYV EEKNRSWCTS SASNDHRAIT IEVASDTTEP 
YAVNDKAYAA MLDLVTDICK RNGIKKLVWS TNKSDRVNHK NGCNMTVHRD 
YANKSCPGKY LYDRHQQIAD EVNKRLNGAN EEGSKVLYKV QIGAYSKVEN 
AEKQLEKAKA AGFTDAFIVK TVVENEPAKQ EPPKEPEVVL AVGDKVKMAK 




Chapter 4: PlyM21 
GenBank Accession Number: HM011609 
1092 base pairs; 363 amino acids; 41.07 kDa; Theoretical pI = 9.26 
N-terminal M23 peptidase enzymatic domain (PF01551) 
  Central phage lysozyme (i.e. muramidase) enzymatic domain (PF00959) 
No recognized binding domain 
ATGATTTTTA AACCGCCAGT ACAGAACATG AAGCTAACTA GCGAATACGA 
TCCTTTAAGG TTGCATCCAG TATTGAAGAT TGTACGCAAA CATGCAGGTG 
TTGATTTAAT TAACACCAAA TTAGGAAAAG CTCCGATATT TGCAACTGCT 
AATGGTAAAG TACGCTTAGT TAAAACAACA GTAGATGGTT ATGGTAAGCA 
CGTCATCATA ACACATAAAG TAGGTGGACA AGTGTACGAG AGTGTATACG 
CACATTTAGA TTCATACGAG GTAAAAGTTG GTCAAGAAGT TTTACAAGGC 
CAGAAAATAG GCGTAATGGG TAATACAGGT ATAGGAACGG GAATCCACTT 
GCATTTTGAG TTACATAGGA ATCAGTGGGA ATTCGATAAC TATAATTATC 
CTAATAGCTT CAATCCATGG CCTTGGATAA ACGAAGGGGA GTTTAAAATG 
AAAGTATCTA AAGAAGGATT GGATTTAATT AAGTTTTACG AAGGTTTTTA 
CGATAAAACT TACTTGGATC CTATTGGACT TCCTACTATT GGCTACGGTA 
CAACTAAGTG GCCTAATGGT AATTCTGTAA AAATGGGTGA AAAGATTAGT 
AAGGTTGAAG CTGATATTTT ACTAGAGCAA CAGGTTAATG AACACGCTAA 
GACAATATTC AATTACGTTA AGGTTGATTT AACTCAAAAT CAATTCGATT 
CTTTAGCTTC TTTCCAATAC AACTTAGGTA GTGGAATACT TAAAAAGGAC 
CCATCTATTG CTGCATATAT TAATAAAAAG GATTGGGCTA ACGCTACTCG 
CGTTATGAAG CTATACAATA AGGCTGGTGG TAAAGTATTA GCTGGATTGG 
ATAAACGTAG GATTGCTGAA GCTGAATTGT TTATGAAGCA ATCTGATAAG 
AATAAGGAGG ATGACGATAC ATTGAAATTC ACTAACGAAG CCACAAAGAG 
CATTGTTAAG CAATTCTTAG AACAATCAAT TAAAGCGGGT TACTTCGATA 
AGTCATGGTT AACTAAGTTT AATGAAGGAA CTATTACTAA TGGAGACATT 
ACAGGTTTAC AAATGATTGC TAACAACAAA AAGAATAAAT AA 
 
MIFKPPVQNM KLTSEYDPLR LHPVLKIVRK HAGVDLINTK LGKAPIFATA 
NGKVRLVKTT VDGYGKHVII THKVGGQVYE SVYAHLDSYE VKVGQEVLQG 
QKIGVMGNTG IGTGIHLHFE LHRNQWEFDN YNYPNSFNPW PWINEGEFKM 
KVSKEGLDLI KFYEGFYDKT YLDPIGLPTI GYGTTKWPNG NSVKMGEKIS 
KVEADILLEQ QVNEHAKTIF NYVKVDLTQN QFDSLASFQY NLGSGILKKD 
PSIAAYINKK DWANATRVMK LYNKAGGKVL AGLDKRRIAE AELFMKQSDK 




Chapter 4: PlyM22 
GenBank Accession Number: HM011610 
480 base pairs; 159 amino acids; 17.38 kDa; Theoretical pI = 8.49 
Phage lysozyme (i.e. muramidase) enzymatic domain (PF00959) 
No recognized binding domain 
ATGGCGCGCG CAAAAGGCTT GAGTCGCAAC ATGGCTGCAT TCTTGGATAT 
GATTGGTTGG TCTGAGATTG GCGATAAATT GTTGGCAGTG TCCGACGATG 
GGTATAACGT TATCGTTGGC TCCACCCCCA CCAAACCAAA GCTGTTTGAC 
GACTACGCCG CTCATCCGCA AATTTATGTG AAGTCGGTTA ACTCGACCGC 
TGCGGGCAGA TATCAGATTC TCGGTAAGTA CGCAACTCAT TACATGGCCC 
AACTCAAGTT GCCTGATTTT GCCCCTGCAT CACAAGACAA AATTGCAATT 
CAATTGATCC GCGAATGCAA GGCGGTCCAG TTGATTGAAG ATGGCCACAT 
TGGTCGAGCA ATCACTGCTT GCAAAAGCCG CTGGGCGAGT TTTGAGGGTG 
CCGGGTACGG CCAACGTGAG CACTCTATTG ATGATTTGAT TTCCCATTTC 
ATTGCGTATG GTGGAGTTCT TGCAAAATGA 
 
MARAKGLSRN MAAFLDMIGW SEIGDKLLAV SDDGYNVIVG STPTKPKLFD 
DYAAHPQIYV KSVNSTAAGR YQILGKYATH YMAQLKLPDF APASQDKIAI 





Chapter 4: PlyM23 
GenBank Accession Number: HM011611 
450 base pairs; 149 amino acids; 16.39 kDa; Theoretical pI = 9.38 
Phage lysozyme (i.e. muramidase) enzymatic domain (PF00959) 
No recognized binding domain 
ATGCAAGTTA GTGATGCAGG TATTGAGTTA ATCAAGTCAT TCGAGGGATT 
CCGCGCTAAC GCATATCCCG ACCCGAAATC AGGTGGCGAC CCGTGGACCG 
TTGGCTACGG CACCACCAAA TTCCCATCCG GCAGACCAGT CAAGCAAGGC 
GATAAGGTAA CGCCTGGCCA GGCTGAGCTA TATCTTCGCG AGGATGTGAA 
GAAGTTTGCA AACTCAGTTG ACGCTCTTGT CACCGCCCCT CTGAAGCAAT 
GCCAGTATGA TGCGCTGGTG TCATTCGTTT ACAACCTTGG CGCAACCAAT 
TTCCGCACGT CCACCCTACT GAAGAAATTG AACGCCAAAG ACTACAATGG 
TGCTGCTGAT GAATTTCTCC GCTGGGTATC TCCCGGCTCA TCCGTTGAGG 
CTGGATTACG CCGCCGTCGC ACGGCAGAGC GCGCTATGTT CCTTTCGTAA 
 
MQVSDAGIEL IKSFEGFRAN AYPDPKSGGD PWTVGYGTTK FPSGRPVKQG 
DKVTPGQAEL YLREDVKKFA NSVDALVTAP LKQCQYDALV SFVYNLGATN 




Chapter 4: PlyM24 
GenBank Accession Number: HM011612 
546 base pairs; 181 amino acids; 20.15 kDa; Theoretical pI = 9.59 
Phage lysozyme (i.e. muramidase) enzymatic domain (PF00959) 
No recognized binding domain 
ATGAAACTCA TATTCGACGA GTTCCGAAAA CTGGCAGGCG GTAAATTAAC 
GCAAGCGCAA GTGGATAAAA TCAATGCTCT GATTGATGAA ATCCAGGTTA 
AGTCTATGAA GGTCGATGCG GCAGGGATTG ACTTGATTGG TCAGTTTGAA 
GGGCTGCGCC TAAATTCCTA TGATGATGGC GTTGGTGTGT GGACTATCGG 
ATGGGGAACA ACGGTTTACC CAAACGGTCA AAAGGTCAAG AAAGGCGATA 
AAATCACACT AGAGCAGGCG AAGCAATACA AGGCGCATGA TTTAGCTAAG 
TTTGAAAAAG CTGTCAATGA TGCGGTTAAA GTGCCGCTGA ATCAAAACCA 
GTTTAACGCT TTGGTGTCAC TGGCCTATAA TATTGGGGTA TCTGCTTTCT 
CTAACAGCAC ATTAGTCAAG CGGTTAAACG AAGGCAACTA TAAGGCTGCT 
GCTGATCAGT TTTTAGTGTG GGTCAATGCA GGCGGTAAAC GTATGCAGGG 
CTTAGTCAAT CGACGTAATA AAGAACGGGA GTTATTTTTA AAATGA 
 
MKLIFDEFRK LAGGKLTQAQ VDKINALIDE IQVKSMKVDA AGIDLIGQFE 
GLRLNSYDDG VGVWTIGWGT TVYPNGQKVK KGDKITLEQA KQYKAHDLAK 
FEKAVNDAVK VPLNQNQFNA LVSLAYNIGV SAFSNSTLVK RLNEGNYKAA 




Chapter 4: PlyM25 
GenBank Accession Number: HM011613 
771 base pairs; 256 amino acids; 28.17 kDa; Theoretical pI = 8.76 
N-terminal PG-1 binding domain (PF01471) 
Domain of unknown function DUF3380 (PF11860), likely enzymatic domain 
**NOTE: The above binding domain shows only low homology to the consensus 
sequences for PG-1, with an E-value score of 0.0007. 
ATGGCGAAAA CACACATAGT ACAGGCACAA ACAGCACTGG CGGCGGCAGG 
TTATTATAAC GGTAAGATTG ACGGCGATTT TGGCGGCGGT TCATTGCGAG 
CAGTGCAAAA TTTAATCGAC AATACAGATA AGGCGGTTGA TATTTTGAGC 
AAGCCTGATA TTGCTGAGCC AGTAGATAAA AAACTATCTA AAGCTGATAT 
TATCGCAGTG GCTAATGATT TAAACATTGA GCCAGCAGCA CTTAAAGCAG 
TCATTGATGT TGAGGCAGCC GGCAATGGTT TTGATAATCA AGGTCGTCCG 
ACAATACTTT TTGAGCCTCA TGTGTTTTGG GATGAATTAG GTAAAATACA 
TTACTACACT AAACGCGCCG AACTAGCTAA AAAGCATAAC GGGTTGTTGT 
CACCAAAGTG GGATAGGTCG CTATATCGCA TTGGTGGTAG CTCGCATGAT 
AAGTTAAAGA TTGCTGCTGA TCTACACTGG GAGGCGGCGC ACAAATCTGC 
ATCATGGGGT TTGGGGCAAA TCATGGGGTT TAACGCACAA AAGATAGGCT 
ATGCAACGCT TAAAGAGTTT ATTGATGATA TGTATGAGAG CGAAGCTAAG 
CAACTTAAAG CGATGGGAAT GTTTTTAAAA GCTAACGGCT TAATCAGTAA 
GCTACAGCGC CATGATTGGG CGGGGTTTGC ACGAGGTTAT AACGGCTCGG 
CTTATGCCAA AAATCAGTAT GATGTAAAAC TCGCTGATGC CTACAATCTG 
GCTAAAAAAC AAGGTTGGTA G 
 
MAKTHIVQAQ TALAAAGYYN GKIDGDFGGG SLRAVQNLID NTDKAVDILS 
KPDIAEPVDK KLSKADIIAV ANDLNIEPAA LKAVIDVEAA GNGFDNQGRP 
TILFEPHVFW DELGKIHYYT KRAELAKKHN GLLSPKWDRS LYRIGGSSHD 
KLKIAADLHW EAAHKSASWG LGQIMGFNAQ KIGYATLKEF IDDMYESEAK 





Chapter 4: PlyM26 
GenBank Accession Number: HM011614 
567 base pairs; 188 amino acids; 21.16 kDa; Theoretical pI = 9.56 
Glycosyl Hydrolase Type 19 (i.e. chitinase class I) enzymatic domain (PF00182), 
not likely a dedicated chitinase 
No recognized binding domain 
 
ATGATCCTGA CTGCCGGTGG TTTTAATATT CTTCGCAATG GCTTGGGTCG 
ATTAAACCAG AGCCAGGTTA ATGAGATTAA TTTTCTAGTA TCCCAATTCG 
ACAAAGACAA ATCTATTTCC TACCCACAAG CTGCCTATAT GTTGGCGACA 
ACATGGCATG AAACTGCGGC AACCATGCTG CCAATTGAGG AATATGGAAA 
GGGCAAAGGT CGCACCTATG GCAAAAAAAT TGATAGTAAT GGCTCTGCCT 
ATACTGGCTT GGATCATATT TATTATGGTC GTGGTTATGT TCAGCTCACC 
TGGCTTAGCA ACTACGTTCT AGCCAAAAAG AAACTTGGCA TTGATTTTGT 
GAACAAGCCT GAATTGGCTC TGGTTCCTGA GCATGCAGTC AAGATTCTGA 
TTACCGGAAT GAAGGAAGGT TGGTTTACCG GCAAGAAACT TTCCGACTAT 
ATCCATCAAT CCAAAAAGGA CTACATTAAC GCTCGACGTA TTATCAATGG 
AACTGATAAA GCAAAACTTA TCGCCGGCTA TGCCGAAATA TTTGAACGTG 
CTTTGAGGTC CTTATAA 
MILTAGGFNI LRNGLGRLNQ SQVNEINFLV SQFDKDKSIS YPQAAYMLAT 
TWHETAATML PIEEYGKGKG RTYGKKIDSN GSAYTGLDHI YYGRGYVQLT 
WLSNYVLAKK KLGIDFVNKP ELALVPEHAV KILITGMKEG WFTGKKLSDY 




Chapter 4: PlyM27 (Not actively expressed) 
GenBank Accession Number: HM011615 
534 base pairs; 177 amino acids; 19.93 kDa; Theoretical pI = 9.7 
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510) 
SH3-Type 3 binding domain (PF08239) 
ATGCAGAGCA ACAATAAGCA GACATCATTC CATTACGCTG TTGATGACAA 
GGAAGTCATC CAAGGTATCC CCCTTGATAG GAATGCCTGG CATGCGGGGG 
ATGGCAGAAA CGGAAAAGGG AATAGAGAGG GAATAAGTAT CGAGATCTGT 
TACTCCAAGA GTGGCGGGTC TCGTTTTATT TTGGCTGAAA AGAGGGCTGC 
AAAGCTTATC GCTGATATTC TGGACGAGAA AGGATGGGAT ATCTCAAAAG 
TAACTAAGCA TAGGGATTAT TCAGGCAAGT ATTGCCCACA TCGTACACTG 
GATATGGGAT GGGACCGATT CCTTAAGCTG GTTGAATCAG AACGAAAGAC 
ATCTTTTAAG GTTAGAGTAA CTGCAGACTC CCTGAACTAC AGGGCAGGAG 
CTGGGATCAA ATACAAGATA AATGGAGCGA TTACGGATAA GGGAGTATAT 
ACAATCGTTG ATCAGACTAA TGGCTGGGGC AAACTTAAGA GCGGGGCAGG 
CTGGATAAAT TTGAAATATA CGAAAAGAGT ATAA 
 
MQSNNKQTSF HYAVDDKEVI QGIPLDRNAW HAGDGRNGKG NREGISIEIC 
YSKSGGSRFI LAEKRAAKLI ADILDEKGWD ISKVTKHRDY SGKYCPHRTL 
DMGWDRFLKL VESERKTSFK VRVTADSLNY RAGAGIKYKI NGAITDKGVY 




Chapter 4: PlyM28 (Not actively expressed) 
GenBank Accession Number: HM011616 
711 base pairs; 236 amino acids; 26.42 kDa; Theoretical pI = 9.62 
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520) 
SPOR binding domain (PF05036) 
ATGAAAATTA TATTAGACGC AGGTCACGGA CCAAACACGC CAGGCAAACG 
GAGTCCTGAC GGAATGCGCG AATTTCAGTT TAATAGTCGA GTTGCTGACG 
TCATGAAAGC GGAGCTTGAG AAATACGAAG GCGTGACGGT CTACTTTGCG 
CACGATCCCA AGCGCGACGT TCCGTTGAAG GAGCGGACTG ACAAGGCGAA 
TAAGCTTTGC GTCGACCTAT TCTTCAGTAT TCACGCGAAC GCTAACACCG 
GCAAGATGGG CGATTGGGGC GGAATCGATT CGTTCGTCTA CACGTCTAAT 
CCGAAGGAAG CGCGCAAGCT GGCCGACATT GTGCAACGCA ATCTGATTGC 
GGCCACTAAA CTGCGTAATC GCGGCGTCAA GACGGCCGAC TTCCTCGTAC 
TGCGCGAAAC ACATATGACA GCAATCCTCG TCGAGCACGG ATTTATGGAT 
TCGAAGACCG ACTTGCCGTA CTTGAAATCG GACGCCTATC GCAAGCTTTG 
CGCAGTAACT AACGTAAAGT CAATCGCGCA AATGTACGGA TTGAAGCCAA 
AGAAGGTTGC GCCAAAGCCT GCGGTCAAAC CTGCCGTCAG CTCTGACGTA 
TTTTATCGCG TTGTGACCGG CTCATTTGGC GACAGAGAAA ACGCCGAAAA 
GCGTATGGCT CAGTTGAAGA AAGCCGGATT CGAATCGTTC ATTGACGCTT 
ATAAAAAATA A 
 
MKIILDAGHG PNTPGKRSPD GMREFQFNSR VADVMKAELE KYEGVTVYFA 
HDPKRDVPLK ERTDKANKLC VDLFFSIHAN ANTGKMGDWG GIDSFVYTSN 
PKEARKLADI VQRNLIAATK LRNRGVKTAD FLVLRETHMT AILVEHGFMD 
SKTDLPYLKS DAYRKLCAVT NVKSIAQMYG LKPKKVAPKP AVKPAVSSDV 




Chapter 4: PlyM29 (Not actively expressed) 
GenBank Accession Number: HM011617 
708 base pairs; 235 amino acids; 26.33 kDa; Theoretical pI = 9.34 
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520) 
SPOR binding domain (PF05036) 
ATGAAAATAT TAATCGATGC CGGCCACGGA CCAAACACGC CAGGCAAACG 
GAGTCCTGAC GGAATGCGCG AATTCGAATT TAATAGCCGA GCTGCTGACG 
TCATGAAGGC GGAGCTTGAA GAATACGAGG GTGTGACGGT CTACTTTGCG 
CATGAGCCTA AGCGCGATGT GCCGTTGAAA GAGCGGACTG ACAACGCGAA 
CAAACTTTGC GTCGACCTAT TCTTCAGTAT TCACGCGAAC GCTAACACCG 
GCAAGATGGG CGACTGGGGC GGAATTGATT CGTTCGTCTA TACGTCCAAT 
CCGAAGGAAG CACGGAAGCT GGCCGACATT GTGCAGCGCA ATCTAATCGC 
GGCTACTAAA CTTCGTAATC GCGGCGTCAA GACGGCCGAC TTTCACGTAC 
TGCGCGAAAC GCACATGACG GCAATCCTCG TCGAGCACGG CTTTATGGAT 
TCGAAGACAG ACTTGCCGTA CTTGAAGTCG GATGCCTATC GCAAGCTTTG 
CGCTGAGTCT AACGTAAAGT CAATCGCGCA AATGTACGGA CTCAAGCGCA 
AGCCTGCGCC GAAGCCCGTG GTCAAGCCAG CCGTCAGCTC CGACGTATTC 
TATCGCGTTG TGACCGGTTC ATTTGGCGAC AGGGATAACG CCGGACGACG 
CCTGGCTGAG CTGAAAAAGG CCGGCTTTGA TTCGTTCATT GACGTTTATA 
AAAAGTAA 
 
MKILIDAGHG PNTPGKRSPD GMREFEFNSR AADVMKAELE EYEGVTVYFA 
HEPKRDVPLK ERTDNANKLC VDLFFSIHAN ANTGKMGDWG GIDSFVYTSN 
PKEARKLADI VQRNLIAATK LRNRGVKTAD FHVLRETHMT AILVEHGFMD 
SKTDLPYLKS DAYRKLCAES NVKSIAQMYG LKRKPAPKPV VKPAVSSDVF 




Chapter 4: PlyM30 (Not actively expressed) 
GenBank Accession Number: HM011618 
1017 base pairs; 338 amino acids; 36.89 kDa; Theoretical pI = 9.61 
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510) 
PG-1 binding domain (PF01471) 
ATGCGCTTAC TAAAAAATGG CACAAAAATA GGAAACGCCA CAGTAATTGT 
TGATATTGTG GACGGCGCAA ACAGAGAGAT TCGACCGCGC ACAAAAATGA 
ATCCGCGTTT CTTGACGGAC CACGACACGG GTAACTCGGG TAATGGCGCA 
GACGCGAAAA GTCATAATCG CTACATCCAC AACTTGGGCG ATAAGCTACC 
ACGCGACACA AGCCATATTT CCTGGCATGT AACTGTGGAT GAAAACTTCA 
TCATTCAACA TATCCCATTT GACGAGTGTG CTTATCATTG CGGCGACGGT 
TGGGCGACGA CTAGCGGGAA TCGCACAAGT ATCGGCATAG AGAAGTGCAT 
GCACAGAGGC GCGGATCGAA ATAAGATTGA GGCCAACGCG ATTGCGCTTT 
ATGCGTATCT AATGAAGGAA CTCAAAATAC CGATTACATC TGTACGCCCT 
CATCAGCATT GGAGCGGCAA ATACTGTCCA CAGTTGATAT TGAATCGGTA 
CGGTTCGTTT ACGCCATTCC GCAATAAGAT TGAAGCGGCG TTTAAAGGTG 
GCGCAGTAAC GGCAGCGAAG CCTTCCACAG TGAAGAGAGA CTACCTATTA 
GATGGCGATA CAGGCGCGGC GGTTAAAACG CTACAAAGCG AATTGAAACA 
AGCAGGTTTC TTACTATCTG TGGATGGCAT ATTCGGAAAA GGTACAGAGA 
CAGCGGTTAA GGCGTTTCAA CGTGCGAATG GATTAGCAGT TGATGGCGTG 
TTCGGAACGG GCTCACAGGC TAAACTCAAC GCAATACTGG CGAATCTGAA 
TAAGAAGCCG GTAGTTAAGC CGGCAGCGCC AACAAAACCA AAGGAGGAAT 
CCACAGTGGA GAAAACAAAA CAACCCTCAA AATGGGCAGA AGTGACGATT 
AAAGAAGCGG TGAAGATTGG TGTATCGGAC GGATCTCGCT TGCATGATAC 
AGTGACTCGT GAAGAATCAA TTGTAATCGC CATGCGCGCT GCAGGACTTG 
CGCCGAGACT TAAATAA 
 
MRLLKNGTKI GNATVIVDIV DGANREIRPR TKMNPRFLTD HDTGNSGNGA 
DAKSHNRYIH NLGDKLPRDT SHISWHVTVD ENFIIQHIPF DECAYHCGDG 
WATTSGNRTS IGIEKCMHRG ADRNKIEANA IALYAYLMKE LKIPITSVRP 
HQHWSGKYCP QLILNRYGSF TPFRNKIEAA FKGGAVTAAK PSTVKRDYLL 
DGDTGAAVKT LQSELKQAGF LLSVDGIFGK GTETAVKAFQ RANGLAVDGV 
FGTGSQAKLN AILANLNKKP VVKPAAPTKP KEESTVEKTK QPSKWAEVTI 




Chapter 4: PlyM31 (Not actively expressed) 
GenBank Accession Number: HM011619 
1074 base pairs; 357 amino acids; 38.61 kDa; Theoretical pI = 9.57 
N-acetylmuramoyl-L-alanine-amidase-Type 3 enzymatic domain (PF01520) 
PG-1 binding domain (PF01471) 
ATGGCAAAGA TTATGAATGA GCCGGGGCAC GGCAACAACA CATGGCCGCC 
AAGCAAAGGG GTGCGCGCAA GTGGTGGCGT TCCCGAAATG GCGGAGCATG 
ATTTTAACGC AGCGGTAGCA GATGAAGTGA ATCGCCTATT AAGCGGCAAG 
CTAACGACTT ATAGCGCACA GCCTAGTCGC GGCAAGGATG TTTCGCTAAC 
GACGCGCACG CGCCTATATA ATGAAGAGTT TCGCAAAGAT AAGAGCGCAA 
TTGGCTTCTC ACATCACGGA AACGCCAACG CTAACAAAGC GACAAAAGGT 
TTCGGTGTAT TCTACTGGGG CGGATCTGCA ACGGGTAAGA AGTTGGCGCA 
AATGCTTCTC GCGGCGTATA AAAAAGAATT CCCTGGCTAT CCGATTTGGG 
GCAGCGGGAT ATTCGAAAGT AAACGCGGAG ACTGGACAAA CTTTGCAATC 
CTGCGCGACA CGTCAGCGCC TTTCGTGTTA ATCGAGTGGG ATTTCTTTAC 
GAATGATGAA GCGCGTAAAC GGATGCTATC TACAGATTAT AGAAAGCGTT 
GCGGTAAAGT GGCAGCGAGT GTCGCGTGTG ATTGGTACGG TATTCCGTTT 
ACTGATTTCA CAGCAGCTAA ACCTGCGCCT TCCACAGTGA AGAGAGACTA 
CCTATTAGAT GGCGATACTG GCGCAGCGGT TAAAACGCTA CAAAGCGAAT 
TGAAACAAGC GGGTTTCTTA CTATCTGTGG ATGGCATATT CGGAAAAGGC 
ACAGAGACAG CGGTTAAGGC GTTCCAACGT GCGAATGGAT TAGCAGTTGA 
TGGCGTGTTC GGAACAGGCT CACAGGCTAA GCTCAACGCA ATACTGGCTA 
ATTTGAATAA GAAGCCGGTA GTTAAGCCTG CAGCGCCATC AAAACCAAAG 
GAGGAGTCCA CAGTGGAGAA AACAAACCAA CCCTCAAAAT GGGCAGAAGC 
GACGATTAAA GAAGCGGTGA AAATTGGTGT TACGGATGGC AGCAACTTAC 
ACGATCCAAT TACACGACAG GAAGCAATTG TGCTGGCGAT GCGTGCTGCA 
GGGCTTGCGC CAAAACTTAA GTAA 
  
MAKIMNEPGH GNNTWPPSKG VRASGGVPEM AEHDFNAAVA DEVNRLLSGK 
LTTYSAQPSR GKDVSLTTRT RLYNEEFRKD KSAIGFSHHG NANANKATKG 
FGVFYWGGSA TGKKLAQMLL AAYKKEFPGY PIWGSGIFES KRGDWTNFAI 
LRDTSAPFVL IEWDFFTNDE ARKRMLSTDY RKRCGKVAAS VACDWYGIPF 
TDFTAAKPAP STVKRDYLLD GDTGAAVKTL QSELKQAGFL LSVDGIFGKG 
TETAVKAFQR ANGLAVDGVF GTGSQAKLNA ILANLNKKPV VKPAAPSKPK 




Chapter 4: PlyM32 (Not actively expressed) 
GenBank Accession Number: HM011620 
423 base pairs; 140 amino acids; 15.78 kDa; Theoretical pI = 9.16 
N-acetylmuramoyl-L-alanine-amidase-Type 2 enzymatic domain (PF01510) 
No recognized binding domain 
ATGAGAAAAA TCAAGGAAAT AATAGTCCAT TGCTCTGCAA CGAGAGAAGG 
CAAGCCCTTC ACCGTTGCCG ATATTGAGCG TTGGCATCGG GAAAGAGGAT 
GGAAGGGCTG TGGCTATCAC TACGTTATCA CCCTTGACGG AAAGGTGGAG 
CAGGGCAGAC CAGAGCAGAT TGCTGGCGCA CATTGCTCTG GCAGAAACAG 
CGAGAGCATA GGCGTATGCT ACATCGGTGG ATGCGACCTC GTGGGCAAGA 
GCAAGGACAC ACGCACACCA GAGCAGAAGA AGGCAATGGT AACACTCATT 
CGTCAGCTCA TGCAGACACA CGGCATCAGC ATCAAGGATG TCCGCTGCCA 
TAATGAGTTC AGCACAAGGG CTTGCCCCAG TTTCTCTGTC CAGAAGTTGC 
ACAAGGAAAT ACTGGAAGGA TGA 
 
MRKIKEIIVH CSATREGKPF TVADIERWHR ERGWKGCGYH YVITLDGKVE 
QGRPEQIAGA HCSGRNSESI GVCYIGGCDL VGKSKDTRTP EQKKAMVTLI 










Chapter 5: PlySs1 
GenBank Accession Number: Not yet submitted 
Full-length construct: 1359 bp; 452 amino acids; 49.67 kDa; Theoretical pI = 6.87 
Truncated construct: 765 bp; 254 amino acids; 28.09 kDa; Theoretical pI = 7.7 
 
N-terminus: Pfam predicts an N-acetylmuramoyl-L-alanine-amidase-Type 5 
enzymatic domain (PF05382); it was experimentally verified, however, that this 
region actually possesses –D-glutaminyl-L-lysine endopeptidase activity against 
S. suis peptidoglycan. 
 
Dual CPL-7 binding domain (PF08230) 
C-terminus: Endo-beta-N-acetylglucosaminidase enzymatic domain (PF01832) 
 
ATGACAATCA ATCTTGAAAC ATCCATTCGT TGGATGAGCG ACCGTGTCGG 
CAAAGTCTCT TACTCAATGG ACTATCGTAA CGGTCCGAAT AGTTATGACT 
GCTCTAGTGC TGTATATTAT GCGCTAATGG CGGGTGGTGC AATTTCTGCA 
GGTTGGGCGG TTAACACTGA GTATATGCAT GACTGGTTGA TACGTAACGG 
ATATGTTTTG GTAGCTGAAA ATAAACCATT TAACGCTCAA AGACATGACG 
TTTGTATTTT GGGTAAACGT GGCTATTCGA GCGGAGCAGG TGGTCACGTC 
GTTATCTTTG TGGATAATGT TAATGTGATA CATTGTAACT ATGCACGTAA 
CGGAATTTCC ATTGATAATT ATAATCAAGT GCATCGTGGT ATGTATTACT 
ATCTATATCG CCCAGCAAAT CAACCCAGCA TCAGCAACAA ATCACTGGAT 
CAGCTTGTTA AGGAGACTTT GGCTGGGGTA CATGGCAACG GGGACACCCG 
TAAGGCAAGT CTTGGCAGTC AATACGAGGC TGTCATGGCG GTTATCAATG 
GCAAAGCTTC GGCAAGCGAG AAATCTGATG AGGAACTTGC TAGGGAAGTC 
TTAGCAGGTA AGCACGGGGC TGGAGAGGAC CGAAAACGGT CATTAGGACC 
ACGCTATGAG CCTGTTCAAG CCAAGGTCAA CGAATTGCTC AAGGCTAAGG 
AAAAACCGTC TGAGACGGCC AAAAATGAAC CACAGACGGT GCAATTCAAG 
GAGGACGGGG ACTTGTCTTT CAATGGTGCC ATTCTTAAGA AGTCTGTCCT 
CGAAATTATC CTGAAAAAGT GTAAAGAACA TGACATCTTA CCAAGCTATG 
CCCTAACTAT CCTACACTAT GAAGGGCTTT GGGGCACTTC TGCTGTCGGT 
AAGGCCGACA ACAACTGGGG CGGTATGACC TGGACTGGCC AAGGCAACCG 
TCCGAGCGGA GTAATTGTGA CTCAAGGTTT GGCTCGGCCA TCGAACGAGG 
GAGGCCACTA CATGCACTAT GCCACCGTGG ATGATTTCCT GACGGACTGG 
374 
 
TTCTACCTGC TTCGCAAGGA CGGGTCTTAC AAGGTATCTG GTGCATTGAC 
CTTCAGCGAG TCCATTAAGG GCATGTTCCA GGTTGGCGGA GCTAAATACG 
ACTATGCAGC CGCCGGCTAC GATAGTTACC TGGTCGGCGC CACTAGCAGG 
CTAAAAGCTA TCGAGTCCGA AAATGGCAGT CTGACACGGT TTGATGCCAC 
ATCAAATAAT GTCCATTCGG TTGACCCTGA TAAAATCTCT GTTGATATTG 
ACGGCATTGA AGTTACGATC AATGGTGTTG TCTACAAGCT GGAAAAGAAA 
CCAGTCTAA 
 
MTINLETSIR WMSDRVGKVS YSMDYRNGPN SYDCSSAVYY ALMAGGAISA 
GWAVNTEYMH DWLIRNGYVL VAENKPFNAQ RHDVCILGKR GYSSGAGGHV 
VIFVDNVNVI HCNYARNGIS IDNYNQVHRG MYYYLYRPAN QPSISNKSLD 
QLVKETLAGV HGNGDTRKAS LGSQYEAVMA VINGKASASE KSDEELAREV 
LAGKHGAGED RKRSLGPRYE PVQAKVNELL KAKEKPSETA KNEPQTVQFK 
EDGDLSFNGA ILKKSVLEII LKKCKEHDIL PSYALTILHY EGLWGTSAVG 
KADNNWGGMT WTGQGNRPSG VIVTQGLARP SNEGGHYMHY ATVDDFLTDW 
FYLLRKDGSY KVSGALTFSE SIKGMFQVGG AKYDYAAAGY DSYLVGATSR 
LKAIESENGS LTRFDATSNN VHSVDPDKIS VDIDGIEVTI NGVVYKLEKK PV 
 
**NOTE: The full-length gene/protein shown here is what was cloned during the 
initial functional screen of the S. suis 7711 genome.  For large-scale expression, 
purification, and functional analysis, a truncated construct was sub-cloned that 
omitted the C-terminal enzymatic domain.  The residues included in this 
construct are underlined above. 
375 
 
Chapter 5: PlySs2 
GenBank Accession Number: ZP_03625529 (from S. suis strain 89/1591) 
 
Originally annotated in GenBank as ―SH3-type 5 domain protein‖ 
738 base pairs; 245 amino acids; 26.06 kDa; Theoretical pI = 9.06 
CHAP enzymatic domain (PF05257) 
SH3-Type 5 binding domain (PF08460) 
ATGACAACAG TAAATGAAGC ATTAAATAAT GTAAGAGCTC AGGTTGGGTC 
CGGTGTGTCT GTTGGCAACG GCGAATGCTA CGCTTTGGCT AGTTGGTACG 
AGCGCATGAT TAGTCCGGAT GCAACTGTCG GACTTGGCGC TGGTGTGGGC 
TGGGTCAGCG GTGCAATCGG CGATACAATC TCTGCCAAAA ACATCGGCTC 
ATCATACAAC TGGCAAGCTA ACGGCTGGAC AGTTTCCACA TCTGGTCCAT 
TTAAAGCAGG TCAGATTGTG ACGCTTGGGG CAACACCAGG AAACCCTTAC 
GGACATGTGG TAATCGTCGA AGCAGTGGAC GGCGATAGAT TGACTATTTT 
GGAGCAAAAC TACGGCGGGA AACGTTATCC CGTCCGTAAT TATTACAGCG 
CTGCAAGCTA TCGTCAACAG GTCGTGCATT ACATCACACC GCCTGGCACG 
GTCGCACAGT CAGCACCCAA CCTTGCAGGC TCTCGTTCCT ATCGCGAGAC 
GGGCACTATG ACTGTCACGG TCGATGCTCT CAATGTTCGC AGGGCGCCAA 
ATACTTCAGG CGAGATTGTA GCAGTATACA AGCGTGGTGA ATCATTTGAC 
TATGATACTG TCATCATCGA TGTCAATGGC TATGTCTGGG TGTCTTACAT 
AGGCGGCAGC GGCAAACGTA ACTACGTTGC GACGGGCGCT ACCAAAGACG 
GTAAGCGTTT CGGCAATGCT TGGGGTACAT TTAAATAA 
 
 
MTTVNEALNN VRAQVGSGVS VGNGECYALA SWYERMISPD ATVGLGAGVG 
WVSGAIGDTI SAKNIGSSYN WQANGWTVST SGPFKAGQIV TLGATPGNPY 
GHVVIVEAVD GDRLTILEQN YGGKRYPVRN YYSAASYRQQ VVHYITPPGT 
VAQSAPNLAG SRSYRETGTM TVTVDALNVR RAPNTSGEIV AVYKRGESFD 
YDTVIIDVNG YVWVSYIGGS GKRNYVATGA TKDGKRFGNA WGTFK 
 
 
